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Eunice Ego Mgbeahuruike, Milla Stålnacke, Heikki Vuorela and Yvonne Holm
Antimicrobial and Synergistic Effects of Commercial Piperine and Piperlongumine in
Combination with Conventional Antimicrobials
Reprinted from: Antibiotics 2019, 8, 55, doi:10.3390/antibiotics8020055 . . . . . . . . . . . . . . . . 117
Graeme Hood, Kieran S. Hand, Emma Cramp, Philip Howard, Susan Hopkins 
and Diane Ashiru-Oredope
Measuring Appropriate Antibiotic Prescribing in Acute Hospitals: Development of a National 
Audit Tool Through a Delphi Consensus
Reprinted from: Antibiotics 2019, 8, 49, doi:10.3390/antibiotics8020049 . . . . . . . . . . . . . . . 129
Helene L. Robertsen and Ewa M. Musiol-Kroll
Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the
Development of New Antimicrobial Drugs
Reprinted from: Antibiotics 2019, 8, 157, doi:10.3390/antibiotics8040157 . . . . . . . . . . . . . . . 141
Danitza Romero-Calle, Raquel Guimarães Benevides, Aristóteles Góes-Neto 
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Treating infection is a key part of the work of most clinicians. Whilst new drug technologies
like biologics have begun a revolution in the treatment of cancer and autoimmune disease, there has
been a conspicuous absence of new classes of antibiotic over the last 30 years. This, coupled with the
mass use of antibiotics in farming and the continued emergence of resistant pathogens has created a
perfect storm, and antimicrobial resistance is now viewed as a global public health emergency [1,2].
Combating the threat posed by the failure of current antibiotics presents a unique need to co-ordinate
research and intervention policy across the spectrum of primary and secondary care, the private and
public sector, and public health alongside working with colleagues in agriculture and farming aiming
towards a “one health” approach. In this issue of Antibiotics, a variety of articles are presented that
cover the breadth of human research in this field from in vitro work on novel therapies to commentary
on public health strategies.
The emerging crisis of antibiotic resistance and paucity of novel therapies, has led to a resurrection
of historic drug development pipelines. Robertson and Musiol-Kroll [3] provide a comprehensive
account of the part actinomycetes have played in the history of antimicrobial therapy. The origins of
ß-lactams, macrolides, and tetracyclines (among others) lie in the exploration of these organisms in
the mid twentieth century and the article details their discovery and utility, as well as outlining the
potential discovery pipeline for future development of naturally occurring antimicrobials. Previously
discarded treatment options are also undergoing a resurgence. In their articles, Romero-Calle and
colleagues [4] and Fernandez et al. [5] discuss the potential of bacteriophages (bactericidal viruses) in
comprehensive summaries that discuss the history, mechanism of action, and current state of early
phase research of these therapies. Mgbeahurulike et al. [6] utilize another strategy for developing new
antimicrobial treatments by combining a novel synergistic compound with an established antibiotic.
They provide evidence in their in vitro work of the synergistic effect of the alkaloids piperine and
piplartin with rifampicin against Staphylococcus aureus. Infection caused by carbapenem-resistant
Enterobacteriaceae (CRE) provide a particular challenge to clinicians worldwide. Suay-Garcia and
Pérez-Gracia [7] provide a concise summary of the history, epidemiology and resistance mechanisms
of these pathogens, and outline the treatment strategies that may be employed to treat them. Old
(fosfomycin), newer (‘double carbapenem’), and novel (ceftazidime/avibactam) treatment strategies
are described, with a clear message that global cooperation is paramount to combating CRE.
Antimicrobial stewardship, including the prevention of inappropriate antibiotic prescribing is key
to preventing the continued rise and spread of resistant pathogens. However, there is currently no
international consensus on the definition or accurate quantification of the global burden of inappropriate
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prescribing. Hood and colleagues [8] provide commentary on some of the audit tools available in
Australia [9] and the USA [10] and present a novel approach, developed through an expert Delphi
process, that they aim to use in UK secondary care. Al-Hasan et al. [11] in their review, argue for a more
straightforward metric for antimicrobial stewardship performance–institutional antimicrobial use. In
primary care, Colliers et al. [12] present an analysis of the burden of infection and antibiotic prescribing
in out of hours contact between practitioners and patients in Belgium. They found that more than one in
five out of hours appointments resulted in an antibiotic prescription. They also found that out of hours
prescribing was often not in keeping with local guidelines. Sunde, Nygaard, and Høye [13] present
some of the challenges faced by General Practitioners when deciding whether to give antimicrobial
prescriptions, highlighting in their qualitative and quantitative study that patient expectations remain
a significant driver of prescribing for practitioners. Grigoryan and colleagues [14] present a qualitative
analysis of antimicrobial prescribing for perhaps one of the more common indications in primary care,
urinary tract infections. They include a report on a wide variety of resources used by practitioners
when making prescribing decisions, pointing out that stewardship interventions must consider where
and how practitioners seek information. Borek et al. [15] further describe some of the barriers to success
of antimicrobial stewardship interventions. They suggest some strategies, sourced from a stakeholder
engagement exercise, to improve the success rates.
For many clinicians, the threat or challenge of managing infection due to antimicrobial resistant
organisms is often focused on a single patient, ward or practice. In this issue, Holmes and Hughes
discuss the wider health economic implications of failing to act to combat resistant pathogens [16]. The
headline healthcare cost of no action, $100 trillion by 2050 [2], should prompt action from even the most
skeptical of policymakers. However, the authors provide insightful commentary on the challenges
in economic evaluation of interventions that may provide benefit to only individual patients or to
populations over a long time period. They argue succinctly that economic assessment must be paired
alongside evaluation of clinical efficacy of healthcare interventions to combat antimicrobial resistance, if
funds are to be targeted efficiently and effectively. More broadly, it is clear that antimicrobial resistance
is not an issue that is related to, or originates solely from humans. Although common sense dictates
that policy and interventions to combat antimicrobial resistance must be multi-faceted and include
stakeholders from public health, hospitals, and the community alongside colleagues from agriculture,
farming and veterinary medicine. Singh et al. [17] provide a commentary of the situation in Singapore,
pointing out that even in an economy with significant resource, combating antimicrobial resistance is
complex and challenging to coordinate. Their work, based on a qualitative analysis from stakeholder
interviews, highlights the need to understand and address cultural, social, and behavioral expectations
of antibiotic use, alongside implementing public health policy.
Articles on in vitro work by Vianna et al. [18] on antimicrobial efflux pumps and Costa et al. [19]
outlining the antimicrobial activity of silver camphro-imine complexes alongside work from Gavilán
et al. [20] on a novel and sensitive assay for detecting low levels of antibiotic in animal feed, complete
this innovative and exciting multi-disciplinary issue of Antibiotics.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Many antimicrobial stewardship (AMS) interventions have been implemented in England,
facilitating decreases in antibiotic prescribing. Nevertheless, there is substantial variation in antibiotic
prescribing across England and some healthcare organizations remain high prescribers of antibiotics.
This study aimed to identify ways to improve AMS interventions to further optimize antibiotic
prescribing in primary care in England. Stakeholders representing different primary care settings
were invited to, and 15 participated in, a focus group or telephone interview to identify ways to
improve existing AMS interventions. Forty-five intervention suggestions were generated and 31 were
prioritized for inclusion in an online survey. Fifteen stakeholders completed the survey appraising each
proposed intervention using the pre-defined APEASE (i.e., Affordability, Practicability, Effectiveness,
Acceptability, Safety, and Equity) criteria. The highest-rated nine interventions were prioritized as most
promising and feasible, including: quality improvement, multidisciplinary peer learning, appointing
AMS leads, auditing individual-level prescribing, developing tools for prescribing audits, improving
inductions for new prescribers, ensuring consistent local approaches to antibiotic prescribing, providing
online AMS training to all patient-facing staff, and increasing staff time available for AMS work with
standardizing AMS-related roles. These prioritized interventions could be incorporated into existing
national interventions or developed as stand-alone interventions to help further optimize antibiotic
prescribing in primary care in England.
Keywords: antimicrobial stewardship; antibiotic prescribing; primary care; implementation; behavior
change; stakeholder consultation
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1. Introduction
Conserving antibiotics by optimizing antibiotic prescribing to reduce the spread of antimicrobial
resistance is a key public health priority both globally and nationally in the UK [1–3]. In England, 81%
of antibiotics were prescribed in primary care in 2017 [4], and up to 23% of these are estimated to be
prescribed inappropriately, mostly (unnecessarily) for self-limiting respiratory tract infections (RTIs) [5].
While antibiotic prescribing in primary care in England reduced by 13.2% between 2013 and 2017 [4],
antibiotic use in the community is still higher than in several other European countries [6]. There is
also a considerable variation in antibiotic prescribing between general practices, with many practices
remaining high prescribers [7], and between practices and other types of healthcare providers in the
community (e.g., out-of-hours, urgent care) [4]. The variations in antibiotic use are not (fully) explained
by differences in patient characteristics, such as clinical presentation or prevalence of comorbidities [7,8].
Changing healthcare professionals’ (HCP) prescribing behaviors can help reduce antibiotic use
and many factors influencing antibiotic prescribing for RTIs in primary care have been identified [9–13].
A range of antimicrobial stewardship (AMS) interventions targeting HCPs have been developed, with
many shown effective in trials [14–16]. However, despite the recent decrease in antibiotic prescribing
and availability of AMS interventions, further optimizing and reducing inappropriate antibiotic use in
English primary care remains critical, especially among the higher prescribers. Further progress has
been included in the recent National Health Service (NHS) long-term plan [17] and is required to meet
the UK five-year target to reduce antibiotic prescribing in community by 25% by 2024 [2]. Behavioral
science evidence shows that to be effective, behavior change interventions need to target relevant
determinants of behavior and needs of the targeted population, and fit within the contexts where
they are implemented [18,19]. Thus, further improving antibiotic prescribing might involve adapting
and implementing effective AMS interventions that have not been yet widely used in England [14],
and/or addressing contextual and implementation-specific influences experienced by those using AMS
interventions [11].
A recent study aimed to explore nationally implemented AMS interventions in the UK and the
extent to which they target behaviors related to antibiotic use. Twenty-two interventions for primary
care prescribers and eight for community pharmacy staff were identified, targeting on average 5.8
HCPs’ behaviors [10]. A follow-up study identified barriers and facilitators to appropriate antibiotic
prescribing in primary care and found nine interventions evaluated in the UK and shown effective at
reducing antibiotic prescribing [11]; these included five research-only interventions [20–24] and four
nationally available interventions: communication skills training [25], FeverPAIN clinical score [26],
the TARGET toolkit [27], and the Chief Medical Officer’s letters with prescribing feedback to the
highest-prescribing practices [28]. Analyzing the behavioral content of the identified AMS interventions
and comparing the extent to which they address relevant behaviors and key barriers and facilitators led
to identification of potential changes to, or gaps to be addressed by, AMS interventions. However, such
theoretical analysis lacks the insight from the targeted population and intervention users, and does not
address factors related to context and implementation of interventions. Therefore, we aimed to build
on this recent research by consulting stakeholders (i.e., HCPs from general practices, out-of-hours,
community pharmacies and commissioning organizations in England) to: (a) identify barriers and
facilitators to optimizing antibiotic prescribing and implementing AMS interventions specific to their
settings, (b) generate suggestions for improvements of AMS interventions in their specific, primary care
settings in England, and (c) prioritize interventions (using pre-specified feasibility and acceptability
criteria). This paper reports the findings of this stakeholder consultation.
2. Results
2.1. Stakeholder Focus Group and Telephone Interviews
Twelve stakeholders attended the focus group and three participated individually by telephone.
Seven were representatives from Clinical Commissioning Groups (CCGs, i.e., organizations responsible
6
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for planning and commissioning of health care services for their local areas in England), three were
from NHS England, two from out-of-hours (OOH) organizations, one from a chain of community
pharmacies, and two were general practitioners (GPs).
In the first part, the stakeholders discussed barriers and facilitators to optimizing antibiotic
prescribing in primary care settings. These are summarized in Table 1 and reported in more detail in
Supplementary Materials (Boxes S1–S4). In brief, as key facilitators to optimizing antibiotic prescribing,
the stakeholders reported the availability of many AMS interventions, and awareness of healthcare
professionals of the need for appropriate and prudent antibiotic prescribing. As one of the key challenges
they reported a variation in use (and sometimes low uptake) of interventions between organizations
and HCPs. This was exacerbated by barriers including: limited dissemination of information about
specific interventions; insufficient time to engage with interventions (related to large workloads and
multiple competing priorities); lack of clarity on which interventions to engage with (influenced by a
perceived large number of interventions); insufficient initiatives with professionals collaborating across
networks (e.g., involving GPs, pharmacists, nurses) which fueled perceptions of ‘working in silos’.
In the second part of the consultation, the stakeholders identified challenges to implementing
specific current AMS interventions and made suggestions for improvements. These suggestions were
compiled, separately for each primary care setting, and are summarized in Table 1 (and reported in
more detail in Supplementary Materials, Boxes S1–S4). Key suggestions included: offering financial
incentives; mandating certain target behaviors (e.g., making AMS training a mandatory part of
professional development or appraisal); regularly auditing prescribing in all practices and of individual
prescribers and, based on this, providing interventions tailored to local contexts and individual
needs and addressing specific reasons for suboptimal prescribing; developing multi-professional
networks and learning groups to promote communication, collaboration and learning between different
professions (e.g., GPs, nurses, pharmacists); incorporating interventions nationally within existing
clinical systems; and using point-of-care (POC) diagnostics, such as C-Reactive Protein (CRP) tests
or throat swabs (although stakeholders expressed ambivalent views on these). No suggestions were
identified for walk-in/urgent care centers as no stakeholders were from this specific setting. However,
it was agreed that some of the suggested interventions may be relevant to this setting.
Table 1. Summary findings from stakeholder focus group and interviews.
Examples of Identified Facilitators (F) and Barriers (B)
Examples of Suggestions for Intervention Improvements or
New Interventions
Relevant to all settings
• F: Availability of many AMS interventions and guidelines.
• F: Consistency of AMS/antibiotic-related messages and advice
across HCPs and organizations.
• F: Knowing practice and prescribers’ prescribing rates and
resistance rates.
• B: Feeling of guideline ‘overload’ and lack of time to read them.
• B: Lack of clarity on which AMS interventions should be used;
variation in use of interventions across HCPs and organizations.
• B: Insufficient time, high workloads, and related
decision-making fatigue.
• B: Insufficient collaboration between professional networks
and organizations.
• Incentivizing or mandating engagement with AMS training and
other interventions.
• Making tools/interventions easy to use by incorporating them into
clinical systems.
• Making professional networks more multi-professional and
promoting multi-professional collaborations and learning.
• Providing better/easier access to data on prescribing data linked
with resistance data.
• Addressing primary care HCPs’ concerns about sepsis.
Relevant to general practice
• B: Prescribing antibiotics remaining to be seen as easier and
quicker than not prescribing (especially under time pressure).
• B: Prescribing antibiotics ‘just in case’ prior to limited access to
healthcare (e.g., before a weekend).
• B: Prescribers (e.g., locums) not using unique prescriber codes,
making it difficult to audit prescribing.
• Financial incentives for practices with antibiotic prescribing targets.
• POC CRP testing (but mixed views due to concerns about costs
and unintended consequences).
• Auditing prescribing in all practices and by all prescribers, with
feedback and tailored approaches to address specific issues.
• Peer review of prescribing in practices.
• Training patient-facing practice staff in signposting patients and
self-care advice.
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Table 1. Cont.
Examples of Identified Facilitators (F) and Barriers (B)
Examples of Suggestions for Intervention Improvements or
New Interventions
Relevant to out of hours (OOH)
• B: Lack of stable patient population.
• B: Prescribers not using unique prescriber codes.
• B: Lack of accountability for prescribing.
• B: Variation in awareness of local guidelines.
• B: Lack of/limited support from commissioners.
• B: Different clinical systems limiting access to patient records.
• Developing tools/system to enable/ automate prescribing audits
in OOH.
• Making AMS interventions (e.g., training) provided by
commissioners available and improving dissemination of
information about them to OOH staff.
• Improving induction of new prescribers in OOH to ensure
awareness of local guidelines.
Relevant to community pharmacy
• B: Variation in skills and experience between pharmacy staff, with
some having low confidence in providing self-care advice.
• B: Limited access to POC diagnostics across pharmacies and
concern about using them for financial benefit.
• B: Different computer systems limiting access to, and use of,
patient records.
• Providing training in giving self-care advice to improve skills and
confidence of staff.
• Providing access to POC diagnostics and training to help
pharmacy staff distinguish between serious and less serious illness
(thus improving confidence in giving self-care advice).
• Promoting use of patient records to identify potentially
inappropriate use of antibiotics.
2.2. Revising and Selecting Intervention Suggestions
Additional intervention components were identified based on available evidence on AMS
interventions shown to be effective in the UK [11]. In addition, steering group members and the
research team provided additional suggestions based on their experience and knowledge of current
national AMS policy. These were added to the list of suggestions made by the stakeholders. Altogether,
45 intervention suggestions were identified. Some involved modifications of existing interventions or
their implementation (e.g., relating to dissemination of information), whereas others involved new
intervention components (e.g., that could form a part of an existing intervention or be implemented as
a stand-alone intervention).
In order to identify which influences on antibiotic-related prescribing behaviors the suggested
interventions aimed to address, the interventions were mapped onto barriers and facilitators to
appropriate antibiotic prescribing. These influences were identified in the literature review [11] and by
the stakeholders. After revising and selecting intervention suggestions, 31 interventions were included
in an online survey comprising: seven suggestions potentially applicable to all settings, ten suggestions
specifically for general practice, nine for OOH, and five for community pharmacy. The full list of the
45 identified interventions is available in Supplementary Materials (Table S1), together with barriers
and facilitators that they addressed, source of how each intervention was identified, and indicating
which interventions were included in or excluded (with reasons) from the survey.
2.3. Stakeholder Survey and Prioritized Intervention Suggestions
Out of 40 stakeholders invited to complete the survey, 15 (38%) completed it. Seven respondents
indicated that they worked (or had expertise) in general practice, five in CCGs, four in OOH, three
in walk-in/urgent care centers, one in community pharmacy, and four in other settings (i.e., two
working across settings; one in community hospital; one in e-learning for healthcare professionals).
The respondents reported between 4 and 23 (mean 10.7) years of relevant experience. The APEASE
scores for each intervention and setting are reported in full in Supplementary Materials (Tables S2–S5).
Nine unique interventions were prioritized (Table 2). Three interventions were prioritized for
OOH and community pharmacy, and four were prioritized for general practice and walk-in/urgent
care centers (as two of the highest-scoring interventions for these two settings had even scores).
As some interventions were assessed for multiple settings, four interventions were prioritized for
multiple settings: ‘(2) Multi-disciplinary small group learning’ was prioritized for general practice,
walk-in/urgent care centers, and community pharmacy; ‘(3) Appointing AMS leaders’ for general
practice and OOH; ‘(7) Agreeing on a consistent local approach to antibiotics’ for walk-in/urgent care
8
Antibiotics 2019, 8, 207
centers and community pharmacy; ‘(8) Providing online AMS training to all patient-facing staff’ for
walk-in/urgent care centers and community pharmacy.
The lowest scoring intervention (with 22.7% of the maximum APEASE score) was ‘providing
diagnostic point-of-care CRP testing, including training in using it, interpreting the results and
maintaining the equipment’ in community pharmacy setting, which was assessed by only five out of 11
respondents as relevant to the setting, by two as practical and acceptable and by none as affordable. This
intervention was also rated as the second lowest for general practice (44% of the maximum APEASE
score), walk-in/urgent care centers (48.7%) and OOH (50%). Participants’ comments provided as free
text in the survey indicated that cost and funding, time to do the tests, and concern about over-use of the
tests by patients and clinicians were considered the main barriers to using this intervention; for example:
“Would need to have clear guidance and uptake would depend on who was funding [POC CRP tests].
Barriers to GP practices are cost of equipment and cost of tests, as well as time it takes to perform the
test when only have 5–10 min consultation and test takes a few minutes to perform so practical and
affordability issues are the main barriers.”
“Concerns [that POC CRP tests] may increase attendance to ‘get a test’. May involve clinicians
overly relying on a test which is not always accurate or there may be a time lag in the increase in CRP.
Time taken in consultation to administer test is a barrier and test strips are costly.”
The two second lowest scoring (with 33.3% of maximum APEASE score) interventions were also
in community pharmacy setting; although both were assessed by only three participants. One was
‘providing training and resources to structure the way(s) of asking patients the right questions about
self-limiting infections and identifying red flags to help decide what to advise patients’. In comments,
the participants suggested that: “this sort of training is available via CPPE, however uptake is voluntary”
and “this should already be done as part of the core community pharmacy contract.” The other intervention
was ‘promoting the use of patient records by pharmacists (e.g., by digital prompts) to review whether
antibiotics were prescribed appropriately’. Participants’ comments suggested that:
“At present community pharmacists do not have access to enough information to be able to do this
effectively. There may need to be specialist clinical training for community pharmacists to do this.”
“The relevance will depend on where the community pharmacist is in the patient pathway. If contractual
levers remain as is the community pharmacist may require remuneration.”
Other lowest scoring interventions (see a full list in Supplementary Materials) were: ‘providing
information on opening hours of all local healthcare services’ for general practice (31.8% of maximum
APEASE score) which was scored particularly low on ‘effectiveness’, and ‘co-organizing national AMS
events together with different professional networks’ for OOH and walk-in/urgent care centers (50%
and 38.5%, respectively) which was rated low on ‘affordability’.
9
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3. Discussion
The stakeholder consultation identified setting-specific barriers and facilitators to current antibiotic
optimization, and generated and prioritized suggestions for improvements of AMS interventions
in primary care in England. Stakeholders’ appraisal of relevance, feasibility and acceptability of 31
intervention suggestions led to nine interventions being prioritized across settings. These prioritized
interventions address some of the identified influences on antibiotic prescribing. They could be
incorporated as part of existing AMS interventions or further developed and implemented as
stand-alone interventions.
3.1. Implications within the Context of Current AMS Research and Practice
The interventions assessed and prioritized (or not) by the stakeholders build on AMS interventions
currently implemented in England [10] and effective interventions tested in UK-based research
studies [11]. How the 31 interventions fit with current research and practice, and how those prioritized
may be implemented, is discussed below and summarized in Table 3. Interventions are grouped by
intervention ‘type’, for ease of reference.
Improving engagement with AMS training and resources: There are many AMS interventions available,
including AMS training and resources tested and shown effective in trials [21,25,27]. For example, the
TARGET antibiotic toolkit (with training and resources primarily targeted at GPs) is available online [29]
and practice workshops promoting the TARGET resources were shown effective [27]. Similarly, the
STAR online communication skills training (with a practice seminar) was shown effective in a trial [25]
and is now available online on the clinical professional development website [30]. CCG professionals
report that HCPs are aware of, and promote or engage with, different AMS training and resources (such
as the TARGET toolkit), but time, reaching the correct people and lack of clarity on which online training
to promote were reported as the main issues with AMS education [31]. Similarly, the stakeholders in
our study identified improving engagement with AMS interventions as a challenge, influenced by lack
of time and priority, clarity on which interventions to use, incentives, and opportunities (e.g., protected
time, training for HCPs in organizations other than general practice). Current AMS interventions may,
at least in theory and research trials, facilitate change but improving the uptake of and engagement with
AMS interventions in the real world is critical to further optimizing antibiotic use. This may be facilitated
by the ‘train the trainers’ opportunities provided by the TARGET team [29] and by increasing numbers
of pharmacists appointed in primary care settings with AMS as part of their roles. The importance
of improving engagement with AMS training and resources was reflected by suggestions prioritized
by the stakeholders, such as organizing ‘(2) multi-disciplinary small group learning’ (that could be
delivered face-to-face, in addition to online resources, and focus on identifying challenges and solutions
specific to local contexts), ‘(8) providing online AMS training to all patient-facing staff’ (rather than,
as currently, targeting primarily GPs), and ‘(9) increasing staff time available for AMS work and
standardizing AMS roles’. Another suggestion to improve engagement with AMS training that was
made by the stakeholders but received medium APEASE score was to make the AMS training mandatory
in general practices.
11
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Enhancing prescribing data monitoring and feedback: Antibiotic prescribing data has been publicly
available and fed back to prescribers by a vast majority of CCGs for many years and interventions
involving prescribing feedback have been shown effective [24,28]. In contrast, detailed action planning
is rarely used (reported for only 16% of CCGs [31], often due to insufficient time for it [32]), as is feedback
on individual prescribing—both of these strategies were prioritized. Including them may enhance
the impact of monitoring of and feedback on prescribing by specifying and tailoring actions (setting
goals and/or ‘if-then’ plans) to address specific reasons for inappropriate antibiotic prescribing and by
activating individual accountability for prescribing. Based on available evidence from lifestyle-related
interventions, such behavioral regulation strategies (i.e., self-monitoring, especially when combined
with other ‘regulatory’ techniques such as goal-setting, problem solving or ‘if-then’ plans) and individual
tailoring can be effective behavior change techniques (e.g., [33,34]). Moreover, while monitoring/auditing
of, and feedback on, prescribing have likely contributed to reduced antibiotic prescribing in general
practice, the stakeholders reported barriers to using these strategies in OOH, such as lack of stable patient
population and different computer systems. Developing tools to enable and automate prescribing audit
and provision of individualized feedback might further optimize antibiotic prescribing in OOH.
Ensuring consistency in AMS approaches: The suggestion to ‘(7) agree on a consistent local approach
to antibiotics’ (prioritized for walk-in/urgent care centers and community pharmacies and also highly
scored for general practice and OOH) highlights the importance of consistency in managing infections
and reinforcing consistent messages to patients by different HCPs and across organizations. It could be
implemented by developing and agreeing within-and between-organization action plans or protocols,
for example, on using patient leaflets and other resources promoting messages about infection
prevention and self-care. The importance of consistency between HCPs in antibiotic prescribing and
the messages given to patients was also reflected in the following interventions prioritized by the
stakeholders: ‘(2) multidisciplinary small group learning’ and ‘(8) providing online AMS training to
all patient-facing staff’. Moreover, four interventions were prioritized for multiple settings (i.e., ‘(7)
agreeing on a consistent local approach to antibiotics’; ‘(2) multi-disciplinary small group learning’; ‘(8)
providing online AMS training to all patient-facing staff’; ‘(3) appointing AMS leaders’) and could
be considered for implementation across settings and by involving HCPs from different professional
networks. This could help promote a more integrated, system-wide approach to AMS [17]. Respondents
in a recent survey representing 99% of Clinical Commissioning Groups (CCGs) reported that AMS
training was targeted primarily at GPs, compared to 67% of CCG professionals reporting focus on
other prescribers, 42% on all practice staff and only 28% on OOH staff; consequently, a system and
practice-wide approach was one of the top suggestions for AMS training by the CCG professionals [31].
Finally, it may also be important to consider interventions that have not been prioritized by
stakeholders. Providing POC CRP tests was among the lowest-scoring suggestions in all settings.
The stakeholders considered it not affordable or practical to deliver. While POC CRP testing is supported
by examples of countries with low prescribing rates that routinely use it (e.g., Netherlands) and trial
evidence showing it as an effective and safe strategy to reduce antibiotic prescribing for RTIs in general
practice [14,35], it may not have sustained effects on prescribing behavior [36] and is often met with
mixed views on its usefulness and feasibility from HCPs [37,38]. Moreover, ‘co-organizing national AMS
events for participants from different professional networks to facilitate multi-disciplinary AMS work’
and ‘promoting the use of patient records by pharmacists to review whether antibiotics were prescribed
appropriately’ seemed to be considered by stakeholders as unaffordable; ‘providing information on
opening hours of local healthcare services’ (to reduce prescribing when concerned about limited access
to healthcare) was considered unlikely to be effective; and ‘providing training and resources to structure
the ways of asking patients the right questions about self-limiting infections and identifying red flags
to help decide what to advise patients’ in community pharmacy was seen as of low relevance. Our
findings suggest that these interventions might be less promising ways to optimize antibiotic use for
RTIs, at least as seen by the small number of stakeholders consulted in this study. Further research
may need to explore and identify ways to address barriers related to these interventions with a larger
14
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group of stakeholders and intervention users. In addition to the nine prioritized interventions and five
lowest-scoring interventions, there were also 17 other interventions included in the survey and another
14 suggestions that were not prioritized for inclusion in the survey (all available in the Supplementary
Materials) that could potentially be considered and refined.
3.2. Strengths and Limitations
This study was based on expert input from stakeholders and the study steering group, who
had practical experience and knowledge about national AMS interventions and policy. Views of
stakeholders and intervention users are critical, yet at times under-represented, in theoretical approaches
to developing and refining AMS interventions. Our study, focused on views of commissioners and
other key stakeholders, may help address this gap and provide some indication for future research on
implementation of AMS interventions. However, our findings need to be interpreted with caution.
The stakeholders were identified by the steering group members from their own professional networks,
and out of 40 stakeholders invited to the focus group and survey, only 15 responded. It is possible
that a larger number of stakeholders or intervention users might have generated suggestions for, and
prioritized, different interventions. The stakeholders had varied levels of experience and knowledge of
AMS interventions and different settings (with less experience specific to OOH, walk-in centers and
community pharmacies). This made it difficult to identify very specific improvements to current AMS
interventions and to capture a wider range of views from different organizations and settings. As the
study focused on stakeholders and interventions in England, the generalizability of the findings may
be limited beyond England.
4. Materials and Methods
The following steps were taken: (1) a stakeholder focus group and telephone interviews to identify
barriers and facilitators to appropriate antibiotic prescribing and to generate intervention suggestions;
(2) revision and selection of intervention suggestions; (3) a stakeholder survey to assess and prioritize
interventions according to pre-specified criteria of relevance, feasibility and acceptability. We focused
on interventions targeting HCPs’ antibiotic prescribing for RTIs in the following settings: general
practice, out-of-hours (OOH), walk-in/urgent care center, and community pharmacy. The study was
reviewed by the University of Oxford Clinical Trials and Research Governance team and classified
as service development, and as such it did not require research ethics review. Participants were free
to participate in any stage of the consultation and withdraw at any point without any consequences.
They were offered reimbursement of travel expenses but no payment for participation.
4.1. Stakeholder Focus Group and Telephone Interviews
Relevant stakeholders (including HCPs with expertise in and/or experience of antibiotic prescribing
in relevant settings) were identified by the study steering group members. The steering group included
experts in AMS with expertise in, and experience of, designing and implementing AMS interventions
and influencing national AMS policy in the UK. Identified stakeholders were invited by email to attend a
3-hour face-to-face focus group held at Public Health England premises in London. They were followed
up once in cases of non-response. Those who could not attend the focus group in person were invited
to a telephone interview.
The aims of the focus group were (a) to identify barriers and facilitators to appropriate antibiotic
prescribing and to implementing AMS interventions in relevant settings; and (b) to generate suggestions
for improvements of current AMS interventions and/or their implementation or for new interventions
addressing the identified barriers and facilitators. In the first part of the focus group, the stakeholders
were presented with barriers and facilitators identified from a literature review [11]. This was followed
by a discussion of stakeholders’ experiences and examples of these, and of any other influences on
antibiotic prescribing (especially in settings under-represented in the literature, such as community
pharmacy, OOH and walk-in centers). In the second part of the focus group, the stakeholders were
15
Antibiotics 2019, 8, 207
presented with examples of nationally available AMS interventions and/or interventions trialed in
research studies in the UK. This was followed by a discussion about stakeholders’ experiences of using
these interventions, any challenges to their use or implementation, and suggestions for improvements
and/or any new interventions.
The focus group discussions were facilitated by two researchers in a semi-structured way, which
included short presentations and general discussion, followed by more specific questions about
participants’ views, experiences and examples. A third researcher took detailed notes. The focus
group was audio-recorded and the recording was subsequently used to check the notes and add more
detail. Additionally, participants were provided with handouts including the information on barriers
and facilitators and AMS interventions identified in the literature, and with questions for discussion.
They could provide additional comments on the handouts and return them to the researchers. The
stakeholders interviewed by telephone were given information and asked questions in a similar format
to the focus group. Detailed notes were made on each telephone interview. All suggestions made during
the focus group, telephone interviews and on the handouts were collated and summarized. The summary
of notes was used to generate a list of barriers and facilitators and a list of intervention suggestions.
4.2. Revision and Selection of Intervention Suggestions for a Survey
Barriers and facilitators to appropriate antibiotic prescribing and effective research interventions
were identified in a literature review [11]); these were used to generate additional suggestions which
were added to the list of interventions identified by the stakeholders. The intervention suggestions
were divided into those potentially applicable to all settings or specific to each relevant setting. They
were mapped onto barriers and facilitators identified by the stakeholders and in a preceding literature
review [11].
The list of suggested interventions was reviewed by the researchers (AB, MW, STC, AS) and steering
group members (remaining authors) who provided feedback on and suggestions for rephrasing the
suggested interventions, and made additional suggestions that were added to the list of interventions.
To reduce a relatively large number of identified suggestions, the comments from the steering group
members (who have knowledge of existing AMS interventions and those currently in development)
were used to prioritize selection of interventions for the survey; suggestions were excluded if they were
considered unfeasible, already implemented, already under development, or insufficiently specific.
4.3. Stakeholder Survey and Prioritization of Interventions
An online survey was used for the stakeholders to assess intervention suggestions using the
APEASE criteria [39]: Affordability (is an intervention affordable?), Practicability (can it be delivered
easily?), Effectiveness (is it likely to be effective?), Acceptability (is it acceptable to staff?), Side effects and
safety (is it safe to implement?), and Equity (can it avoid inequalities in patient care?). The survey was
designed and delivered using online Survey Monkey software (www.surveymonkey.com). Stakeholders
identified by the steering group (those invited to the focus group) were invited by email, including a
brief description about the survey and a link to complete it online. Participants were sent one reminder;
responses were anonymous.
The survey asked about participants’ roles, work setting or expertise, and years of relevant
experience. Participants were then presented with interventions that could be potentially applicable
to all settings (i.e., general practice, OOH, walk-in/urgent care center, community pharmacy) and
suggestions specific to each setting: general practice, OOH, and community pharmacy. For each
suggestion, participants were asked to: (a) assess whether the intervention was relevant to the setting,
and, if yes, then (b) to assess it, for that setting, using the APEASE criteria.
Participants could skip questions and whole sections so the numbers of respondents that assessed
each intervention for each setting varied. We calculated the number of responses for each intervention
in each setting, the maximum possible APEASE score for each intervention/setting, and the actual
APEASE score for each intervention/setting. The percentage of the maximum possible APEASE score
obtained for each intervention/setting was calculated to allow comparison between interventions.
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In order to identify interventions which were rated highly, the following criteria were used to
prioritize interventions in each setting: (a) at least 50% of respondents for that question assessed the
intervention as relevant to that setting; and (b) intervention was scored as one of the top three (or four
in cases of equal scores) based on the percentage of the maximum APEASE score.
5. Conclusions
The study identified a number of barriers and facilitators to optimizing antibiotics and engaging
with AMS interventions, and possible ways in which current AMS interventions in primary care
in England could be optimized. Nine interventions were prioritized by stakeholders as relevant,
acceptable, affordable and feasible to implement in English primary care. They involve suggestions to
help improve engagement with existing AMS training and resources (e.g., by face-to-face small group
learning, tailoring AMS training to all patient-facing staff rather than prescribers only), enhancing data
monitoring and feedback (e.g., audit and feedback on individual’s prescribing, or developing tools
to automate prescribing audits), and promoting consistency in AMS approaches across healthcare
professionals and services (e.g., by agreeing consistent local approaches, upskilling all patient-facing
staff). These can be adapted and further developed as part of current AMS initiatives. Additionally,
stakeholders prioritized suggestions to incorporate AMS interventions into clinical systems at a national
level and enable sharing of patient information between general practice and OOH clinical systems.
Future work needs to also focus more on addressing particular barriers to engagement with specific
AMS interventions.
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Abstract: Antimicrobial resistance (AMR) is a global public health threat that warrants urgent
attention. However, the multifaceted nature of AMR often complicates the development and
implementation of comprehensive policies. In this study, we describe the policy context and explore
experts’ perspectives on the challenges, facilitators, and strategies for combating AMR in Singapore.
We conducted semi-structured interviews with 21 participants. Interviews were transcribed verbatim
and were analyzed thematically, adopting an interpretative approach. Participants reported that the
Ministry of Health (MOH) has effectively funded AMR control programs and research in all public
hospitals. In addition, a preexisting One Health platform, among MOH, Agri-Food & Veterinary
Authority (restructured to form the Singapore Food Agency and the Animal & Veterinary Service
under NParks in April 2019), National Environment Agency, and Singapore’s National Water Agency,
was perceived to have facilitated the coordination and formulation of Singapore’s AMR strategies.
Nonetheless, participants highlighted that the success of AMR strategies is compounded by various
challenges such as surveillance in private clinics, resource constraints at community-level health
facilities, sub-optimal public awareness, patchy regulation on antimicrobial use in animals, and
environmental contamination. This study shows that the process of planning and executing AMR
policies is complicated even in a well-resourced country such as Singapore. It has also highlighted
the increasing need to address the social, political, cultural, and behavioral aspects influencing AMR.
Ultimately, it will be difficult to design policy interventions that cater for the needs of individuals,
families, and the community, unless we understand how all these aspects interact and shape the
AMR response.
Keywords: Antimicrobial resistance; policy analysis; One Health; public health; Singapore
1. Introduction
Antimicrobial resistance (AMR) has gained considerable recognition as a major global public
health threat [1–4]. The impact of AMR has been described as a “doomsday scenario” where antibiotics
can no longer be relied upon and even minor infections could become untreatable and result in
severe morbidity, death and significant economic losses [1,4,5]. The World Health Organization
(WHO) released a Global Action Plan for AMR in 2015, setting out five strategic objectives to combat
AMR [2]. It also highlighted the importance of a “One Health” approach, requiring collaboration among
numerous sectors and actors including human and animal health, agriculture, finance, environment,
and well-informed consumers.
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Singapore is an island nation with a diverse population of 5.6 million people [6]. Public hospitals
cater for 80% of tertiary care services while private sector practitioners account for the majority (80%)
of primary care services [7]. There is a large, private animal health sector catering for companion
animals, but the agricultural animal health sector is small since Singapore has little local agricultural
production [8]. Food requirements are almost entirely supported by imports, which are regulated by
food laws focused on ensuring consistent foreign supply of food and agricultural products. Imported
food is strictly monitored by the Singapore Food Agency (SFA), while non-food related animal, plant
and wildlife management services are provided by National Parks Board (NParks) and Animal &
Veterinary Service (AVS) [9]. The National Environment Agency (NEA) and the Public Utilities Board
(now known as PUB, Singapore’s National Water Agency) overlooks the public health aspects of
environment [10,11].
In line with the Global Action Plan for AMR, Singapore launched its own National Strategic
Action Plan on AMR in November 2017 [12]. This multisectoral action plan was jointly developed by
the Ministry of Health (MOH), Agri-Food & Veterinary Authority (AVA) of Singapore (restructured
to form the SFA and the AVS under NParks in April 2019), NEA, and PUB. It sets a national One
Health framework to reduce the emergence and spread of drug-resistant microorganisms through
five core strategies: (1) Surveillance and risk assessment; (2) Research; (3) Education; (4) Prevention
and control of infection; and (5) Optimization of antimicrobial use. Chua et al. recently published a
paper on AMR in Singapore, detailing the changes in efforts against AMR in Singapore from 2008 to
2018 [13]. The paper mentioned that although a better understanding of AMR as a One Health issue
has developed, with significant efforts in improving antibiotic prescribing and controlling AMR in
Singapore, it was largely focused on the public hospital setting. Even then, a recent national point
prevalence survey conducted across 13 acute private and public hospitals in Singapore reported that
more than half the patients in acute hospitals were on at least one systemic antibiotic, a much higher
proportion compared to inpatients in European hospitals [14]. Based on the few published AMR
epidemiology papers, the actual impact on the control of AMR has been mixed, with better control of
methicillin-resistant Staphylococcus aureus (MRSA), coupled with an increase in resistant Gram-negative
bacteria in the hospitals and the community [15–18]. It has been suggested that more efforts are
required in the various sectors, especially the animal/farming and environment sectors, for better AMR
control [13].
The AMR issue has been described as a “wicked problem”, where there are many stakeholders
involved from the various sectors and several ways to frame the problem [19]. This results in a policy
arena where politics and conflict are very evident, and can potentially overwhelm policymakers in
devising plans to tackle AMR with a One Health approach. Insights into the policy process for AMR
will help to disentangle this complexity and provide a better understanding of support and opposition
by key stakeholders for alternative AMR mitigation policies [19]. To date, no qualitative study has
been conducted to analyze the factors that can aid in successful implementation of AMR policies in
Singapore. Therefore, the aim of our study is to discuss the facilitators and challenges to addressing
AMR and the dynamics in the policy process for AMR in Singapore via in-depth interviews. In this
study, we interviewed experts in human, animal, and environmental health from both public and
private sectors to gain their insights on the policy context, AMR awareness, its emergence in Singapore,
and steps taken to mitigate AMR generation and spread. We subsequently identified facilitators and
key challenges, and discussed proposed strategies for creating more awareness and combating AMR.
2. Materials and Methods
2.1. Data Collection
This qualitative study was conducted from September 2017 to May 2018. We used a purposive
sampling method to recruit informants in key roles across sectors relevant to the issue of AMR in
Singapore. Potential participants were identified from experts in the area of AMR in Singapore,
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and were approached for an in-depth interview via email explaining the purpose of research. A
total of 21 participants from within and outside Singapore were recruited in this study (Table 1).
The participants held expertise in human, animal, or environmental health and worked at either
ministry, healthcare institution, academia, or civil society. Most participants were from the human
health sector. We had difficulty recruiting participants from the environmental sector as potential
participants showed more reservation in accepting the invitation to be interviewed, perhaps based on
less knowledge about AMR. We were eventually able to recruit an academic and public health official
from the environmental sector.
Table 1. Participants’ characteristics according to profession and organization.
Sector Profession Count (n) Organization Count (n)
Human
Medical Practitioners 4 Government agency 3
Academics 3 Hospital (public and private) 6
Managers 6 Primary care 1
Animal
Academics 2 University 1
Laboratory Manager 1 Veterinary Clinic 2
Private practice 2 Government agency 2
Government agency manager 1
Environment
Policy maker 1 Government agency 1
Academic 1 University 1
International
WHO, NGOs, etc. 4
Total 21 Total 21
WHO =World Health Organization; NGOs = Non-governmental organizations.
Face-to-face in-depth interviews were conducted by three of the researchers (S.R.S., S.T.T. and
H.L.-Q.) in English. Among the interviewers, two were Research Associates and one was an Associate
Professor. All interviewers were trained in qualitative research. The interviews were conducted in a
quiet space at the preferred location of the participants. Each interview lasted an hour on average and
was audio-recorded. There were no repeat interviews. A semi-structured question guide was used to
explore the main areas of concern for the participants, in their fields and areas of interest. The question
guide was developed with questions focusing on participants’ experiences and perceptions of AMR
policy and practice including awareness, key challenges and facilitators in their particular area of
expertise, and possible strategies and solutions to address key challenges in the Singaporean context.
Participants were not remunerated for the interview.
2.2. Ethics
Ethical approval was obtained from the National University of Singapore Institutional Review
Board (NUS-IRB). Each participant was provided an information sheet stating the objectives and
methods of the research, at the point of recruitment. The confidentiality and anonymity of participants’
responses was also highlighted. Written consent was sought before the beginning of each interview,
requesting for permission to be audio-recorded and to be quoted anonymously in research outputs.
Participants could refuse any of these options, as well as any questions posed to them during the
interview itself. All participants were de-identified to maintain confidentiality.
2.3. Data Analysis
All interviews were transcribed verbatim and identifying data were removed from all research
documents to ensure confidentiality. QSR NVivo 11 software was used to organize and share the data
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among study team members. We used an interpretive approach which focuses on the participants’
perceptions and interpretations of the topic of discussion. Thematic analysis was used to inductively
identify themes from the data. We drew on techniques from the constant comparative method, such as
line by line analysis, naming each line and segment of data, and the use of subsequent interviews to test
preliminary assumptions. In addition, deviant cases were explored and examined [20,21]. The conduct
of the interviews and coding occurred concurrently to enable the researchers to determine when theme
saturation had been reached and to cease recruitment. Thematic saturation was established when the
research team discussed and agreed that no new themes were emerging from the data. To improve the
credibility of our findings, we conducted a member check at the final stage of manuscript preparation
to validate our interpretation of the data and to ensure an accurate representation of participant
perspectives. We were unable to contact a few of the participants as they have moved on to another
role and their contact information was not readily available. See Supplementary Materials for the
Consolidated criteria for Reporting Qualitative research checklist (COREQ form).
3. Results
We present our findings under five main themes identified from analysis of participants’ responses.
The first theme examines the policy context and discusses whether AMR as a policy issue is a priority in
Singapore. The second theme discusses the level of AMR awareness among policymakers, professionals,
and the general population. The third and fourth theme discusses the perceived facilitators and
challenges to combat AMR in the Singaporean context. Finally, the fifth theme reflects on the reported
strategies to increase awareness and combat AMR based on participants’ perceptions.
3.1. The Policy Context
Policymakers that participated in the study reflected on the importance of addressing infectious
diseases in the Singaporean context, especially after the outbreaks of severe acute respiratory syndrome
(SARS) and H1N1 influenza which took place in 2003 and 2009, respectively. As a physician highlighted:
“A lot of incidents drive behavior in Singapore, like for example SARS drove infection control
to the front of everything. If you speak to some people, (they) will say infection control
became prominent feature with SARS happening.” —I11, Human Health
In 2009, the MOH initiated the National Antimicrobial Taskforce (NAT) that helped lay down
the basics of mandatory surveillance, stewardship, and infection prevention principles in public
restructured hospitals. The NAT was tasked to formulate hospital programs and policies, as well as to
implement measure for monitoring and evaluation of these policies. It was later reorganized into the
National Antimicrobial Resistance Control Committee (NARCC) in 2014. Participants highlighted
that the strategy adopted to keep efforts sustainable was by working with people on the ground to
reinforce the implementation of these programs. The MOH’s knack for looking at global health issues
and comparing itself to other countries also helped in funding and formulation of AMR strategies.
The next quote highlights the ways in which the MOH operates including the dedicated funding for
antimicrobial stewardship programs:
“The Ministry keeps an eye out for how it compares itself to other countries. So that drives
their interest in looking at where we stand, how good, how bad ( . . . ) They directly fund
quite a lot of the manpower in the hospital systems, certainly for antimicrobial stewardship.”
—I02, Human Health
Participants also remarked that the ministry looked at other countries and international
organizations, such as the WHO and the European Union, for inspiration and implemented policies
relevant to the Singapore context.
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“What WHO or even the EU is recommending, ( . . . ) I have been trying to push for that.
We follow what others are doing, we don’t want to reinvent the wheel, so that we can then
compare ourselves.” —I07, Human Health
Participants credited the proactive Singaporean government with forming a One Health platform,
maintaining effective communication, and coordination between the agencies. One example of this
was the formulation of the National Strategic Action Plan on AMR that was released in 2017. Despite
establishing a One Health platform, participants suggested that the implementation of programs
against AMR would be more challenging. They stressed on the necessity of advocating the importance
of AMR to raise awareness.
“Bringing different people to the table in the first instance in Singapore is easy, for somebody
that is in charge ( . . . ). But at the end, ( . . . ) we need to get every single stakeholder to
believe in the topic. There’s a lot of sales or advocacy involved.” —I12, Human Health
3.2. AMR Awareness
Most participants recounted low awareness of AMR among Singaporeans. Furthermore, AMR
was identified as a recently coined term and many professionals including physicians were not familiar
with the term even though they were knowledgeable of the topic itself. The next quote is an example
of such reports:
“I guess AMR, this phrase ( . . . ) if you were to tell me it’s AMR, I would not know it’s
antimicrobial resistance.” —I01, Human Health
Participants also remarked there was low awareness of AMR both as a topic as well a term
among other One Health stakeholders including farmers and others within the environmental health
sector. When we contacted potential participants from the environment sector, very few agreed to
be interviewed since many reported not having conducted sufficient work related to AMR. The next
quote highlights the concerns expressed by an environmental health expert who was worried about
the lack of awareness among his colleagues at “the ground level”:
“At the ground level, they were saying, “What is AMR?” People don’t really know. ( . . . )
How do we address it? This is a difficult question.” —I09, Environment Health
Awareness was also perceived to be low in the general population as expressed by participants.
Timely awareness efforts by the academic sector had not yet reached the general population. Since
2016, Singapore has been actively participating in the annual World Antibiotic Awareness Week every
November, reaching out to the public at various public forums, hospitals and national libraries [22,23].
In 2017, the MOH and Health Promotion Board organized a social campaign focusing on the general
prevention of infection to fight the spread of infectious diseases such as influenza and hand, foot and
mouth disease [24]. This was closely followed by a “Use Antibiotics Right” campaign with the key
message that antibiotics do not work on viruses [25]. Despite these efforts many participants voiced
the lack of civil society or social groups movements to support the agenda of AMR in contrast to the
high HIV awareness in the early 90s. The following quote highlights the need to further develop health
promotion campaigns:
“I think we need people who can inform on public policy in a way that would make our
population understand. So we don’t have those communication agencies. I think we have
think tanks, right? And we have scientific groups. But we don’t quite have that translation
into a public health campaign.” —I02. Human Health
Some participants stated the importance of raising AMR awareness to counter its emergence.
It was suggested that by raising awareness of the topic and getting more funds to drive AMR programs
for the general population and stakeholders alike, AMR emergence could be tackled better.
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“The community somehow must come to feel that this is an important issue. And once they
do, then, you know, naturally, I think all the other pieces will fall into place. The politicians
will sing the same song. The private sector will start putting money into the issue.” —I06,
Animal Health
Most stakeholders considered AMR a significant threat to Singapore and global health, but they also
mentioned that it was not given the highest priority in the list of local healthcare challenges until
several outbreaks of healthcare-associated infection changed the perception of policymakers and
administrators with regards to its risk and standing. Until the early 2010s, issues such as ageing
population and chronic diseases were rated much higher in priority compared to infectious diseases.
“We had this roundtable discussion. Everybody, all the movers and shakers, public health
systems . . . and they were asked to state these priorities. And believe it or not, infection, the
scourge of infection wasn’t one of the top five.” —I02, Human Health
3.3. Challenges to Addressing AMR
3.3.1. Cultural Aspects Influencing AMR
There were many reports suggesting a lack of awareness of AMR from the public. Many participants
reiterated the fact that General Practitioners (GPs) may succumb to the pressure of demanding patients
to prescribe antibiotics even when they were not clinically indicated. The next quote highlights how
patients are “always asking for antibiotics”:
“Patients will always come in and ask for antibiotics. So I think it’s something that we should
control and not say that it all is well and then we ignore it. But like I said ( . . . ) I think the
awareness may not be strong enough for us to continue to pursue.” —I01, Human Health
It was also highlighted that there is a need for a firm drilling of infection prevention and control
practices right in formative years of training for all healthcare professionals. Healthcare professionals
needed to be more aware of and prioritize infection control, as it is not currently under “anyone’s radar
except for the people who do infection control”:
“As far as infection prevention goes, infection prevention and antimicrobial resistance is like
stepchild of everyone. Because it’s not in anyone’s radar except for people who do infection
control. So it’s about making it a culture in everyone’s mind, which is not an easy task.”
—I11, Human Health
3.3.2. Inadequate Infection Prevention and Control Measures
Inadequate infrastructure to facilitate optimal infection prevention and control measures was
the most commonly cited challenge in addressing AMR. Though infection prevention and control
efforts were highly regulated in both the public and private hospital settings, certain contextual factors
such as lack of sufficient single room facility were highly challenging to overcome. A few participants
mentioned that the design of hospital wards with one room having six beds or eight beds was not
conducive to prevent infections:
“It’s not really our fault. You are sitting here scolding us, that we have a lot of MRSA
but it’s because, it’s not poor infection control. You are making us take care of patients in
overcrowded hospitals. You know, it’s very different from the US or Europe where most of
their rooms are two-bedders. If you have a six-bedder, even if I wash my hands, the uncle
there who has a maid, and the maid is talking to the other maid and they all share, you know
. . . and it’s practically, it’s all crowded, all these infrastructure issues.” —I04, Human Health
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3.3.3. Lax Stewardship Policies in Private Health Sector
Overall, participants reported that guidelines and antimicrobial stewardship policies were better
established in public-sector hospitals and clinics than their private counterparts. Participants attributed
this to strict adherence to the guidelines in the public sector, as well as regular audits and monitoring
of antibiotic prescriptions by public-sector pharmacists. The following quote is an example of the
audits conducted in the public sector:
“If the pharmacy notice that the patient is coming back repeatedly with antibiotics, they will
alert the senior doctor to say that they’ve noticed that the doctor’s pattern tends to prescribe
a lot of antibiotics. At the same time, we also conduct audits annually on antibiotics usage.”
—I01, Human Health
In contrast, it was reported that private hospitals gave less priority to funding for infection control
and stewardship policies than public hospitals. The stewardship element was not strictly monitored in
the private hospitals and clinics, where it was reported that the MOH does not have so much leverage.
This was raised as a concern by some physicians and policymakers when discussing the extension of
AMR policies to the private sector:
“I feel, in the restructured setting, you know, it’s much more, I wouldn’t say easier may not
be the word, but maybe less challenging because it’s much more homogenous within that
institution and you only have to work in your institution whereas we have to work across all
these little and then we are spending a lot of time and cracking ourselves in bits and pieces
whereas it can all be done, you know, under one, I think, more harmonization, less bickering,
less fighting, and then we can get more funding.” —I18, Human Health
3.3.4. Defensive Medicine Practices and Expensive Diagnostics
Many participants mentioned that there were practical difficulties in being able to perform
adequate tests before dispensing or prescribing antibiotics. Hence physicians and veterinarians tended
to practice defensive medicine by prescribing broad-spectrum antibiotics.
“If you are not following the stories in Singapore, it’s not too long ago, you notice that
the doctors have been held a lot in, they are being suspended for not diagnosing a certain
condition ( . . . ) So, if you are going to hide under the umbrella of stewardship, are they
going to get bailed out? Is someone going to come and rescue them, you know? Pertinent
questions. It’s not that people want to practice defense medicine, but that is somehow being
construed or misconstrued from what is happening out there.” —I18, Human Health
Moreover, veterinarians emphasized that the high diagnostics costs were difficult to justify to pet
owners as the next quote exemplifies:
“Textbook always tells us to do so (diagnostics) before you start on any medication. But, in a
practical sense, hard to because how do I explain $60 more on top of what they are already
paying, for them to get a culture and sensitivity back before we give antibiotics?” —I17,
Animal Health
3.3.5. Disagreements between the Human and Animal Health Sectors
Stakeholders differed on their take as to what contributes more to AMR and ultimately which
policy may help in reducing it. Physicians reported being aware of the importance of antimicrobial
stewardship policies and infection prevention measures to control AMR, but were unsure if these
programs alone could alleviate AMR since they believed that AMR could also be generated by
antimicrobial use in animal farming as growth promoters. On the contrary, animal health experts
believed the animal food industry did not contribute much to the growing resistance since the volume of
antimicrobial used over the lifespan of livestock was very low. As reported by an animal health expert:
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“Even though the vets use a huge volume of antibiotic in farming, I think the quantity used
per animal over a period of time is way less than what we can get from human clinics. Way,
way less.” —I17, Animal Health
3.3.6. Need to Address the Prevention of AMR outside the Human Health Sector
Many participants also expressed that AMR in Singapore had so far only been addressed in
the hospital sector and not much had been done regarding the prevention of AMR in the animal
and environment health domains. It was also mentioned that within NAT most of its members and
emphasis was still focused on the hospital sector:
“It was still very much hospital-focused. The membership (in the National Antimicrobial
Taskforce) still basically comprised representatives of every public-sector hospital, and the
chairman and the members were still very much concerned about preventing the spread of
AMR organisms in hospitals.” —I07, Human Health
3.3.7. Contamination of Environment Serving as Breeding Sites for AMR
Environmental health stakeholders expressed the potential of AMR emergence from farms, the
community, and the environment as a whole. In general, the perception was that Singapore has not
established strategies to deal with environmental contamination. Untreated effluents from hospitals
was noted to serve as one of the potential threats in case of a sewage leak.
“The primary source for us ( . . . ) is, of course, our hospitals, also hospital effluents. We
know that there are very high concentrations of all these last resort antibiotics, especially
from the ICUs (Intensive Care Units) and all that, and it gets into the wastewater which
then goes into the sewerage system, all the way to the wastewater treatment plant.” —I14,
Environment Health
Also, there was a scope for improving the wastewater treatment standard to treat some antibiotic
residues so that they do not harbor AMR.
“Even if you look at the wastewater treatment plants, they’re not doing so well in removing
all the pharmaceuticals, all the antibiotics. Some can be removed very well, but some cannot.
And so, that means they will be discharged and be effluent.” —I14, Environment Health
Participants reported that antimicrobial laced water leeching in the environment served as
breeding sites for AMR as the next quote emphasizes:
“At the treatment end, there’s no problem because their treatment process is rigorous enough
to remove all these bugs and all that . . . But, of course, I think it’s more from the environmental
leakage (of antibiotics).” —I09, Environment Health
3.3.8. Vested Interests
In addition to the above factors, participants also hinted on the vested interest of different
stakeholders. For example, it was mentioned that private practitioners make substantial profits when
dispensing antibiotics as it added to their income.
“And by dispensing (antibiotics) they (GPs) are also getting the profits. So, there is already a
misaligned incentive.” —I04, Human Health
Also, some participants reflected on the vested interests of pharmaceutical companies in marketing
for higher sales of their antibiotics for their own profits.
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“There is a conflict of interest already, because, they (pharmaceuticals) are producing, they
are just selling to the farmers ( . . . ) in a way they are trying to encourage certain resistance.”
—I17, Animal Health
Animal health stakeholders expressed that the not so strict regulations on the import of newer
antibiotics with a broader spectrum of activity served as a leeway for some veterinarians to prescribe
them even when not clinically needed. Participants pointed out that the abuse of reserved antibiotics
favored acquisition of resistance genes by microorganisms, resulting in loss of antibiotic efficacy.
“There are those not very good ones out in the market that actually goes for the most exotic
antibiotics because they distinguish themselves in that sense. Some of them actually use
what I call the third-level antibiotic as a first line treatment which I personally don’t agree. Of
course, they charge exorbitant amount because it’s ‘special’ antibiotics.” —I17, Animal Health
In addition, owing to a small farming sector, existing veterinarians had limited expertise in
agriculture and aquaculture and hence farmers in Singapore were not mandated to attain prescription
for accessing antibiotics independently. Participants alluded that farmers not needing to consult a
veterinarian for a prescription for antibiotics served in the farmer’s interest.
“Vets were not familiar to treat fish, so farmers didn’t trust the vets to treat their fish, and
vets then became very unwilling to treat farm fish. That’s not changed very much, and there
are still issues in Singapore. For example, fish farmers can now buy any antibiotic they want
by themselves.” —I15, Animal Health
3.4. Facilitators to Addressing AMR
3.4.1. Leading Role of the MOH and Provision of Appropriate Funding
Singapore’s MOH was unanimously praised by all participants in its proactive approach towards
AMR and making way for changes amid very complex issues. It was mentioned that the MOH was
transparent and accountable and was operating an efficient public healthcare system in Singapore. Yet,
as a drawback some participants argued that having a system that relies too much on decisions made
at the highest political level makes the general population and service providers inert.
“That’s why I think in Singapore, unless it comes directly from the Prime Minister’s office, it
will never move anything.” —I11, Human Health
In terms of the resources made available to fund AMR programs, it was reported that MOH had
effectively funded AMR control programs and research in all public hospitals.
3.4.2. Trust in the Ability of the Government to Design Policies
Most participants affirmed that the Singaporean population and healthcare professionals bestow
trust in government programs and policies. The next quote highlights that whether participants agreed
or not with the proposed policy, there was a sense that the government is “trying to do a good thing”:
“When the Singaporean government gets into doing something, they tend to do it very
thoroughly. ( . . . ) You may not always agree with the strategy, but you have to give them
full marks for trying.” —I04, Human Health
In addition, a preexisting One Health platform among MOH, SFA, AVS, NEA, and PUB was
perceived to have facilitated the coordination and formulation of Singapore’s AMR strategies.
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3.4.3. Stewardship Programs
Laying the foundation of surveillance in public hospitals and making the data transparent was
appreciated by all participants. Participants also shared recent advances in the capacity to implement
stewardship and infection prevention and control policies among different Singapore institutions
including nursing homes.
“We are looking to reaching out to even nursing homes to provide that kind of bold infection
prevention, but also infection control.” —I03, Human Health
3.4.4. Setting up a Surveillance System
AMR indicators, segregated mainly into process and outcome indicators, were set up in the
public hospital surveillance system. Some of the process indicators were antimicrobial use for human
and animal health, and infection prevention and control measures such as hand hygiene in hospitals.
It was suggested that the Singapore government played a prime role in mandating the standardization,
transparency, and sharing of data with the NAT.
“We wanted to measure stuff in Singapore, but really to do that you really need the government
involved, ( . . . ) otherwise if it’s a voluntary basis, and there are certain biases about data.
Whereas if it’s systematic surveillance and it’s mandatory you get a more comprehensive
and representative sample.” —I04, Human Health
Participants mentioned that though the AMR surveillance indicators were defined and well set
up in the public hospital domain, surveillance needed to be at a national level, extended to private
hospitals, primary care and intermediate/long-term care facilities (GPs, community hospitals and
nursing homes), as well as animal and environment sectors.
“The indicators we sort of have been following is still hospital-based indicators. We don’t have
country-wide, AMR indicators which internationally people are talking about. For example,
we don’t know what is the level of antibiotic consumption at the country level, we don’t
know what, for example, when people are talking about “oh, for this bacterial infection, what
proportion of this bacterial infection is resistant to what antibiotics” you know? We haven’t
gone to measuring that kind of level.” —I07, Human Health
3.4.5. Highly Motivated Workforce
The motivation of the workforce was attributed to the competition, prestige, and reputation of the
workforce. In the hospital setting, metrics and outcomes of antimicrobial stewardship such as average
defined daily dose and percentage of appropriate antibiotics prescribed, and length of hospitalization
for each department are often reported and shared among the various departments within the hospital.
The transparency of data highly motivated the workforce to perform well in these benchmarking
exercises. The following quote is an example of such occurrence:
“More important I think is the peer pressure and peer standing. And when it’s made the
department target and communicated by the head of the department, no one wants to be the
worst department in the stats when they are shown up. So there’s lot of department pride
and that’s what drives stuff. Doctors are often competitive, some of the nurses too. And no
one wants to be the idiot that lets the team down.” —I03, Human Health
3.4.6. Research Excellence
Research in Singapore was unanimously considered to be well promoted and funded, albeit it
was also rated to be very competitive in terms of securing research funding. There was ongoing AMR
research including in the areas of surveillance, prevention of transmission, whole genome sequencing,
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among others. Of the various arms of AMR research, surveillance was considered to be one of the
main pillars in AMR research:
“One of the key reasons in the national action plan is research. And among the research
activities there have been sort of highlighted in terms of priority, is better surveillance.
You know, how to better measure the different perspectives and areas that we need to, outside
the hospitals: primary care, the community and understanding the sort of pathways of
antibiotic resistances, what is driving, the drivers of antibiotic resistance locally . . . ” —I07,
Human Health
3.4.7. Close Connections between Researchers and Policymakers
The researcher and academic participants mentioned that the government and ministry were very
tightly knit in Singapore. Leadership was very open and attentive to research findings that could be
translated into better health practices in Singapore. As the following quote highlights:
“There’s that translation angle number one. There is the One Health angle number two,
and then of course number three we also engage with basic science collaborators, to try to
understand the basic science mechanisms of this issue.” —I08, Human Health
3.4.8. Role of Singapore in Regional AMR
As AMR is a global health issue, participants remarked that Singapore alone could do very little
in controlling AMR as a whole. Despite all policies Singapore will not be untouched by rising AMR in
the region which can be ultimately transmitted via large imports of agricultural products and humans
travelling for trade and tourism. However, most participants mentioned that Singapore could play
a role by coordinating and sharing expertise with neighboring member states of the Association of
Southeast Asian Nations (ASEAN).
Many participants proposed the idea that Singapore can serve as a research hub owing to its
unique positioning and research capacity. Sharing innovative findings both on science, clinical practice
and exemplary policy implementation strategies could prove helpful to neighboring countries that
share some contextual factors with Singapore.
“It is an ideal geographic position as well as possibly a good political one with the recognition
by the west that Singapore is a high-income country as well as intellectually advanced.
That bridge between the west and low- and middle-income countries especially in the Asia
Pacific region could really be bridged by your university and your researchers.” —I20,
Human Health
A few ministerial participants affirmed Singapore’s role of coordinating regional efforts on AMR.
“What Singapore is trying to do is trying to harmonize efforts in the agriculture sector and
the livestock sector because these are under different ASEAN stream workgroups. So we
also work with FAO to coordinate these.” —I13, Animal Health
3.5. Strategies to Raise AMR Awareness and Combat AMR
3.5.1. Projecting AMR Costs
Participants articulated that highlighting the increasing cost of managing patients infected with
resistant organisms and the economic loss from AMR could be a potential way of drawing attention
to the topic and getting funds to drive programs. As specific examples, participants illustrated not
just the costs of treating resistant infections, but also the costs associated with implementing stricter
infection control measures.
Some participants believed that healthcare costs would increase due to AMR. These were attributed
to many reasons, one of which was the cost of more effective antibiotics required to treat infections
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with resistant organisms. Another prominent reason mentioned was the costs towards infection
prevention and control in healthcare settings. This was considered a necessary step to reduce the risk
of healthcare-associated infections, especially in the face of worsening AMR. The following factors
were suggested by one participant to prevent the spread of resistant pathogens and to cater to patients
harboring resistant or infectious organisms:
“That is going to jack up costs in all kinds of ways. Number 1, you are going to have to
pay for all those gowns, gloves, single rooms, for isolation, etc. Number 2 you need more
manpower, because suddenly a nurse is going to be slowed down right? Or a doctor. You
have to put on all this gear, you are going to be seeing fewer patients in the same amount of
time, just because of . . . it’s a bother.” —I04, Human Health
3.5.2. Push Forward AMR Agenda by Fear of no Treatment
Many participants believed that unless AMR’s potential damage to the population and the
economy is projected, people are not going to take AMR seriously. Some participants mentioned that
only a grave incident such as an AMR outbreak would be able to catch the attention of the general
public and extend the prevention efforts of AMR.
3.5.3. Building Communities of Practice
A few participants articulated that rather than forcing a top-down policy approach, AMR could
be better tackled by the sharing of best practices through communities of practitioners and creating
social movements to encourage and sustain behavior change.
“Practitioners come together to share best practices, through the ID networks, through the
hospital networks, through the volunteer networks, you know, build communities of practice
until this becomes a culture. And people are learning from each other ( . . . ) But whether it
gets done is a question of culture, a culture needs strategy every day ( . . . ) so you want to
do change, and you want to do large scale change and you want to sustain the change you
need to create a movement not a directive . . . I think it’s more important to you to create the
social movement around what that is, because if you are going to achieve this style change
of behavior you need a more behavioral approach to this problem not a clinical approach.”
—I05, Human Health
3.5.4. Engaging the Community and Public Campaigns on the Drivers of AMR
Participants reflected on the need to develop public campaigns to sensitize people to become
aware of and understand the fundamentals of programs and strategies against AMR. These include
stewardship, adherence to vaccination guidelines, better infection prevention and control practices in
hospitals as well as programs in the community. All these programs needed to take into account social,
behavioral, and cultural aspects to accommodate the needs and perceptions of the community.
“There is always a need to build a culture and to build a system for people to do the right
thing. And the same applies outside the hospitals. So I think you know the schools have
hand washing to teach the next generation.” —I05, Human Health
3.5.5. Increase Vaccination
Most participants asserted that one of the probable strategies to counter AMR was to increase
vaccination rates in children and adult population. However, increasing vaccination uptake will
uncover another set of issues including population awareness, behavior changes, funding for regular
vaccination, workforce to administer vaccination, and availability of vaccines.
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4. Discussion
This paper has discussed the challenges and facilitators to addressing AMR in a well-resourced
setting such as Singapore. Despite Singapore having an established One Health platform representing
all the different stakeholders; appropriate funding to address the response; existence of stewardship and
surveillance programs in public hospitals; an active program in research; and a motivated workforce;
most participants raised several challenges to address AMR efficiently. These included, among other,
vested interests among some stakeholders; disagreements between the human and animal health
sectors; low public awareness; the need to address prevention of AMR in the animal and environmental
sector; political and cultural aspects influencing AMR; and lax stewardship policies in the private sector.
Therefore, the results of this paper highlight how difficult it can be to address AMR, especially
when considering that Singapore has well-functioning stewardship programs, comprehensive hospital
surveillance systems, and some of the latest technologies and innovations to address it. The example
of AMR in Singapore brings to light the increasing need to address the social, economic, political,
cultural, and behavioral aspects influencing AMR rather than just focusing on the technical solutions.
Unless we understand how all these aspects operate and drive the response, it will be difficult to design
appropriate policy interventions. In the next paragraphs we provide an example of each of these aspects
to highlight their importance in the Singaporean setting. We address “the social” by analyzing how
AMR has been socially constructed in Singapore; we discuss the influence of “politics” by considering
power relations and governance approaches for the successful control of AMR; we address “behavioral
aspects” by analyzing vested interests; and we consider “cultural components” by exploring how
patients’ cultural beliefs influence antibiotic consumption.
First, it is important to understand how AMR has been socially constructed in Singapore and
how power relations operate between the different stakeholders. Wernli et al. distinguished five
different frames that map the global policy discourse on AMR [26]. These are: a One Health approach
combining in one paradigm human, animal, and environment health; a health security threat giving
rise to the global health security agenda; a healthcare policy issue with the dominance of the medical
profession; a development issue where it is considered that low-and-middle income countries drive
AMR; and an innovation issue with a focus on new diagnostics and antibiotics. Wernli et al. also
distinguish a set of actors and policies for each of the frames described. In the Singaporean context, it is
interesting to note that several frames coexist with their respective actors leading the selected frame.
First, it was reported that there is a One Health platform where all stakeholders meet. Second, there is
a strong healthcare policy frame as it was reported that Singapore’s AMR policies were largely driven
by a group of infectious disease clinicians. Third, AMR is also seen as an innovation issue where
researchers are working to identify novel solutions on all fronts. The results of this study suggest
that a deeper understanding is needed of the different power relations between these distinct groups
to ensure the successful implementation of policies designed to respond to the threat of resistance.
However, from our participants’ responses we can tentatively conclude that AMR is predominantly
seen as a biomedical problem within the context of healthcare facilities and within the pursuit of
clinicians controlling infectious diseases even when they still participate in the One Health platform.
It could also be argued that historically the emphasis on AMR has been biomedical because this is
where the health burden was seen and therefore where the expertise developed. This, however, does
not mean that other areas are not seen as important.
Second, considering governance approaches for the successful control of AMR requires a focus
on both whole of society and sector specific approaches [19]. This was detailed in a previous paper
where we proposed a new governance framework to investigate power relations and responses for
diverse stakeholders addressing AMR [19]. As Kickbusch mentioned, and further discussed in our
paper, recently there has been a diffusion of governance moving from a model dominated by the
state to a model co-produced by a wide range of actors [27]. As a result, Kickbusch has identified
five types of governance present in whole-of-government approaches. These include: (1) governing
among others by mixing regulation and persuasion; (2) by collaborating; (3) by engaging citizens;
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(4) through independent agencies and expert bodies; (5) and by adaptive policies, resilient structures,
and foresight.
In the Singapore setting, many participants highlighted the leading role of the MOH in regulating
the health sector, but acknowledged challenges in regulating the private and animal health sector.
These challenges present examples where governance structures will need to weigh up the balance
between regulation and persuasion as policy approaches. In the Singaporean context, differential
policies in the public and private human healthcare sectors, whether by design or practice, are likely
to be counterproductive, as patients use both sectors and the occurrence of resistant infections in
one sector has implications for the other. On the other hand, the agricultural sector in Singapore
is small and the availability of adequate veterinary expertise limited; imposing tight regulations
on antibiotic access in the absence of qualified prescribers is therefore challenging, and persuasive
strategies to reduce antibiotic use in this sector are likely to be more realistic, at least in the short term.
On their collaborative approach towards governance, many participants highlighted the One Health
platform as a good way of bringing stakeholders together. The good relationship between researchers
and policymakers was also emphasized via the many avenues for researchers to discuss and share
their research findings and discuss policy implications with policymakers. However, there were also
conflicts reported specifically between human and animal health experts. This was crystalized on
their different takes on what contributes more to AMR. Most physicians believed that antimicrobial
use in animal farming as growth promoters might be a more significant driver of AMR, as has been
explained by studies [28]. In contrast, animal health experts believed the animal food industry did not
contribute much to the growing resistance when compared to AMR infection rates in the health sector.
Finally, governing AMR through the engagement of citizens and civil society was not reported as a
strategy in Singapore. However, this is not unique to Singapore, as it is well recognized that globally
there has been a lack of engagement of civil society organizations in addressing AMR, especially when
comparing and contrasting to the high HIV involvement in the early 90s.
Third, the AMR policy context represents a policy arena where certain groups engage in “behaviors”
that might conflict with the overall goal of controlling AMR. Vested interests are more noticeable
than in other health policy areas since different professional groups coexist in the AMR policy arena
and there is substantial profit to be made from selling antibiotics [29,30]. In Singapore, vested
interests were mentioned among pharmaceutical companies in marketing for higher sales of their
antibiotics for their own profits; among private practitioners as they make substantial profits when
dispensing antibiotics; and among some veterinarians who prescribed antibiotics even when not
clinically needed. Our previous research in other settings (i.e., Pakistan and Cambodia) also suggested
several considerations and vested interests around antibiotic use which can hinder the control of
AMR in the human and animal health sectors [29,30]. For example, it was reported that among
doctors there are monetary incentives to prescribe certain antibiotics as these are often negotiated with
pharmaceutical companies. It was also recounted that a large proportion of the income at hospital level
and in pharmacies comes from prescribing antibiotics and as a result it might be difficult to introduce
stewardship programs to curb their prescription. While these reports were present in Cambodia and
Pakistan, they were absent in Singapore. Monetary incentives were not mentioned that often by our
participants and were absent at hospital level.
Fourth, many participants reported that “cultural aspects” and perception regarding medication
influenced patients’ requests for antibiotics, with patients requesting them, and GPs recognizing feeling
the pressure to prescribe them. Other research has found similar findings, with Lam et al. observing
that primary healthcare physicians over-prescribed antibiotics in order to satisfy their patients [31].
There were also reports suggesting a lack of awareness of AMR from the public and as a result, patients
continued demanding antibiotics even when they were not clinically indicated. This was also reported
in a Singaporean study that surveyed patients and found that most patients seeking primary health care
in Singapore were misinformed about the role of antibiotics, with poor knowledge being associated
with wanting antibiotics [32].
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To our knowledge, this is one of the first studies to explore the social, political, behavioral, and
cultural aspects influencing AMR in a well-resourced setting. A key strength of this study is that we
were able to gather the perspectives of multiple stakeholders in the human, animal, and environmental
sector. However, we had difficulty in recruiting participants from the environmental sector, and we
were only able to interview two participants. A limitation of this study is that participants could have
downplayed some of the challenges and some strategies that are considered key to address AMR could
have been missed. For example, the fact that Singapore has a well-functioning system for dispensing
antibiotics in the human sector, with antibiotics only available with a physician’s prescription, was not
mentioned as often as a facilitator as one might expect. This could be the case because it was already
taken for granted as it has been in existence for several years.
Finally, participants in this study were asked to describe the most important strategies to combat
AMR and to raise awareness among the population. The most often mentioned responses were: the
need to project AMR costs to draw more attention to the topic; pushing forward the AMR agenda by
fear of no treatment; creating a community of practice; considering the social aspects of AMR in order
to develop prevention efforts against AMR; engaging the community and public campaigns on the
drivers of AMR; and increasing vaccination rates in children and adult population. One important
step to realizing these strategies would be to have good quality data obtained from standardized
surveillance platforms at the national level. This will allow the conduct of outcome research, which can
eventually be translated into messages to increase awareness and to push forward the AMR agenda.
For example, Naylor et al. used a national mandatory surveillance database in England to quantify the
cost and mortality burden of Escherichia coli bacteremia, as well as the influence different resistances
have on them. Such findings will be useful for understanding the health and economic impact of
future trends in resistance, and for prioritization of funding and strategies to tackle the problem [33].
In addition, future research could focus on exploring further how the current Singapore National
Strategic Action Plan is being implemented; exploring in more detail the social, political, behavioral
and cultural components affecting AMR; and analyzing at greater length what type of AMR awareness
campaigns could be developed to reach the community and engage civil society organizations.
5. Conclusions
The process of designing and implementing AMR policies is complicated even in a country such as
Singapore, which has dedicated funding and has developed a multisectoral approach to address AMR.
This paper has highlighted the increasing need to address the social, political, cultural, and behavioral
aspects influencing AMR rather than just focusing on the technical solutions. Unless we understand
how all these aspects operate and drive the response, it will be difficult to design policy interventions
that produce the desired results and that cater for the needs of individuals, families, and the community
as a whole.
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Abstract: The basis of drug resistance in Mycobacterium abscessus is still poorly understood.
Nevertheless, as seen in other microorganisms, the efflux of antimicrobials may also play a role
in M. abscessus drug resistance. Here, we investigated the role of efflux pumps in clarithromycin
resistance using nine clinical isolates of M. abscessus complex belonging to the T28 erm(41) sequevar
responsible for the inducible resistance to clarithromycin. The strains were characterized by drug
susceptibility testing in the presence/absence of the efflux inhibitor verapamil and by genetic analysis
of drug-resistance-associated genes. Efflux activity was quantified by real-time fluorometry. Efflux
pump gene expression was studied by RT-qPCR upon exposure to clarithromycin. Verapamil
increased the susceptibility to clarithromycin from 4- to ≥64-fold. The efflux pump genes MAB_3142
and MAB_1409 were found consistently overexpressed. The results obtained demonstrate that the T28
erm(41) polymorphism is not the sole cause of the inducible clarithromycin resistance in M. abscessus
subsp. abscessus or bolletii with efflux activity providing a strong contribution to clarithromycin
resistance. These data highlight the need for further studies on M. abscessus efflux response to
antimicrobial stress in order to implement more effective therapeutic regimens and guidance in the
development of new drugs against these bacteria.
Keywords: efflux inhibitors; efflux pumps; erm(41); mutations; mycobacteria; verapamil
1. Introduction
Species belonging to the Mycobacterium abscessus complex are responsible for pulmonary and
extrapulmonary infections affecting mostly the skin and soft-tissues [1,2]. These species are estimated to
account for 5–20% of all nontuberculous mycobacteria (NTM) infections worldwide [3]. Nevertheless,
the incidence is likely underestimated due to the absence of compulsory notification in most countries.
The occurrence of outbreaks of M. abscessus (sensu lato) infections has been related to healthcare settings
and occurs mainly in immunocompromised patients [3,4].
M. abscessus complex comprises three subspecies: M. abscessus subsp. abscessus, M. abscessus
subsp. massiliense and M. abscessus subsp. bolletii [1,5]. The pattern of drug susceptibility differs
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according to the subspecies stressing the importance of their differentiation among the complex, as they
will respond differently to the therapeutic regimen [1,6–8]. Therapeutic regimens are based on a
macrolide, usually clarithromycin, an aminoglycoside, generally amikacin, and a β-lactam, imipenem
or cefoxitin [9,10]. M. abscessus subspecies differ on their antimicrobial susceptibilities, particularly to
macrolides, the first-line antibiotic for the treatment of these infections [10].
Macrolide resistance in M. abscessus can be due to mutations in the gene erm(41), encoding the
erythromycin ribosome methyltransferase Erm(41), and to mutations in the gene rrl, encoding the 23S
rRNA. M. abscessus subsp. massiliense has a non-functional Erm(41) [6,11,12]. Consequently, this gene
is not associated with clarithromycin resistance in this subspecies. On the contrary, M. abscessus subsp.
abscessus and M. abscessus subsp. bolletii have a functional Erm(41) protein. Mutations in the erm(41)
gene are the most common mechanism of resistance to clarithromycin in these subspecies [6,12–14].
Resistance to aminoglycosides is mainly associated with mutations in the rrs gene, encoding the
16S rRNA or aminoglycoside-modifying enzymes [15] and resistance to β-lactams occurs due to the
production of BlaMab, a chromosome-encoded Ambler class A β-lactamase [16].
Poor treatment outcomes of M. abscessus infections have been attributed to innate and acquired
drug resistance. Current treatment options are suboptimal and therapeutic options are limited [17,18].
M. abscessus is intrinsically resistant to several classes of antibiotics mainly due to the impermeability of
its cell membrane. Efflux activity has been proposed as a drug resistance mechanism in mycobacteria
where the induction of efflux pumps due to the exposure to non-inhibitory concentrations of antibiotics
is proposed as the first step of acquired drug resistance that leads to high-level chromosomal-
mutation-related resistance that may hamper the activity of several antibiotics [19,20]. Recently,
efflux activity has been correlated with clinical resistance to macrolides, aminoglycosides, bedaquiline,
and clofazimine also in M. abscessus [21–23]. Therefore, an alternative approach to overcome M. abscessus
drug resistance driven by efflux activity is the inhibition of efflux of antibiotics with the aid of efflux
inhibitors, compounds that are able to reduce the intrinsic resistance of the bacteria by increasing the
intracellular concentration of antimicrobial compounds [23]. Real-time fluorometric assays have been
used to detect and quantify increased efflux activity using fluorescent substrates, such as ethidium
bromide, which is capable of accumulating inside the bacteria in the presence of an efflux inhibitor and
this increased efflux activity has been correlated with clinically relevant antibiotic resistance [20,24–27].
The increasing number of infections caused by M. abscessus, together with the reduced therapeutic
options available, highlights the need to increase our knowledge on the mechanisms of drug resistance
in M. abscessus. Previous studies have shown that the inhibition of efflux activity by verapamil in
M. tuberculosis and M. avium complex can improve the activity of antimicrobial compounds [20,28–30].
In this study, we have evaluated the contribution of efflux to M. abscessus clarithromycin resistance
correlating the levels of resistance, in the presence and absence of verapamil, with the presence of
mutations in the clarithromycin resistance-associated genes, erm(41) and rrl. Furthermore, we have
investigated the role of increased efflux pump gene mRNA levels and the consequently increased efflux
activity in six M. abscessus strains when exposed to sub-inhibitory concentrations of clarithromycin as
one of the mechanisms contributing to inducible macrolide resistance.
2. Results
2.1. Phenotypic and Genotypic Characterization of the M. abscessus Strains
In this work, we studied four M. abscessus subsp. abscessus strains (three clinical isolates and
the ATCC19977T reference strain) plus three M. abscessus subsp. bolletii and three M. abscessus subsp.
massiliense clinical isolates from two geographically distinct origins, Brazil and Portugal. We used the
GenoType NTM-DR assay to determine the erm(41) sequevars and search for mutations in the rrl and
rrs genes (Table 1). We found that all the strains belong to the erm(41) T28 sequevar.
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Table 1. Phenotypic and genotypic characterization of the M. abscessus strains studied.
Strain Species/Subspecies
Genetic Background MICs (μg/mL), Day 3 *
CLA AMK Compounds
erm(41) rrl rs CLA AMK VP EtBr
MabATCC19977T M. abscessus subsp. abscessus T28 wt wt 2 (S) 16 (S) 1024 128
MabBR1 M. abscessus subsp. abscessus T28 wt wt 2 (S) 8 (S) 4096 256
MabBR2 M. abscessus subsp. bolletii T28 wt wt 1 (S) 4 (S) 1024 64
MabBR3 M. abscessus subsp. massiliense T28 A2059C wt 256 (R) 16 (S) 1024 32
MabPT1 M. abscessus subsp. abscessus T28 wt wt 0.25 (S) 4 (S) 1024 64
MabPT2 M. abscessus subsp. bolletii T28 wt wt 2 (S) 4 (S) 2048 128
MabPT3 M. abscessus subsp. massiliense T28 wt wt 0.5 (S) 4 (S) 1024 256
MabPT4 M. abscessus subsp. bolletii T28 wt wt 2 (S) 4 (S) 1024 128
MabPT5 M. abscessus subsp. massiliense T28 wt wt 1 (S) 4 (S) 1024 256
MabPT6 M. abscessus subsp. abscessus T28 wt wt 1 (S) 4 (S) 2048 64
* Ref [10]. AMK, amikacin; CLA, clarithromycin; EtBr, ethidium bromide; MIC, minimum inhibitory concentration;
R, resistant; S, susceptible; VP, verapamil; wt, wild-type sequence.
Clarithromycin and amikacin MICs are presented in Table 1. None of the strains presented
a multidrug-resistant phenotype, i.e., simultaneous resistance to clarithromycin and amikacin [14].
With regard to amikacin, all strains were susceptible to this antibiotic (breakpoint for resistance:
MIC ≥ 64 μg/mL) [10]. The susceptibility results were 100% concordant with those obtained with the
GenoType NTM-DR, i.e., no mutation was detected in the rrs gene associated with amikacin resistance.
Concerning clarithromycin, the results matched 100% with the results obtained with the GenoType
NTM-DR. Nine strains were susceptible to clarithromycin and one was resistant. The latter presented
an MIC of 256 μg/mL consistent with the presence of a mutation in the rrl gene (MIC ≥ 256 μg/mL) [10].
Next, we evaluated the presence of inducible clarithromycin resistance since all strains belong to
the erm(41) T28 sequevar (Table 2). According to the CLSI guidelines, macrolide inducible resistance is
defined as an increase in the MIC of clarithromycin from ≤2 μg/mL at day 5 to ≥8 μg/mL at day 14 of
incubation [10]. Of the 10 strains tested, only three presented an inducible resistance phenotype to
clarithromycin, namely two M. abscessus subsp. abscessus strains (ATCC19977T and MabPT6) and one
M. abscessus subsp. bolletii (MabPT2). No inducible resistance was found in the M. abscessus subsp.
massiliense isolates, as expected, since this subspecies harbors a non-functional Erm(41) protein.
Table 2. Analysis of inducible vs. non-inducible clarithromycin resistance in the M. abscessus
strains studied.
Strain
Mutations CLA MICs (μg/mL)
CLA Susceptibility Profile at Day 14 *
erm(41) rrl Day 5 Day 14
MabATCC19977T T28 wt 4 (I) 16 (R) Resistant Inducible
MabBR1 T28 wt 2 (S) 4 (I) Intermediate Non-inducible
MabBR2 T28 wt 16 (R) 256 (R) Resistant Non-inducible
MabBR3 T28 A2059C 256 (R) 256 (R) Resistant Non-inducible
MabPT1 T28 wt 0.25 (S) 2 (S) Susceptible Non-inducible
MabPT2 T28 wt 4 (I) 16 (R) Resistant Inducible
MabPT3 T28 wt 0.5 (S) 0.5 (S) Susceptible Non-inducible
MabPT4 T28 wt 16 (R) 64 (R) Resistant Non-inducible
MabPT5 T28 wt 1 (S) 1 (S) Susceptible Non-inducible
MabPT6 T28 wt 2 (S) 16 (R) Resistant Inducible
CLA, clarithromycin; I, intermediate; MIC, minimum inhibitory concentration; R, resistant; S, susceptible; wt,
wild-type sequence. * Ref. [10].
Of the 10 strains studied, two M. abscessus subsp. bolletii strains (MabBR2 and MabPT4) presented
increased resistance to clarithromycin after five days of incubation (Table 2) that, according to the CLSI
guidelines, could not be attributed to the presence of T28 nucleotide change, a finding indicating the
existence of another mechanism of resistance to clarithromycin. Since no mutations were found in the
rrl gene and active efflux has been associated with clarithromycin resistance in several microorganisms
including mycobacteria and M. abscessus [19–23,30,31], we continued the work with the evaluation
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of the presence of increased active efflux systems despite the presence of the T28 polymorphism.
For this purpose, we studied all strains to assess the contribution of active efflux to their macrolide
susceptibility phenotype.
2.2. Evaluation of the Synergistic Effect between Efflux Inhibitors and Clarithromycin
For these assays, we selected verapamil as reference efflux inhibitor since several works have
already shown that this is the most efficient efflux inhibitor for several mycobacterial species [20,23,28,29].
The MICs of verapamil are given in Table 1. The synergistic effect between verapamil and clarithromycin
and the modulation factor (MF) obtained for each combination are listed in Table 3.
Table 3. Minimum inhibitory concentration and modulation factor of clarithromycin in the presence of
verapamil for the M. abscessus strains in study.
Strain
MIC (μg/mL) (MF)
Day 3 Day 5 Day 14
CLA CLA+VP CLA CLA+VP CLA CLA+VP
MabATCC19977T 2 (S) 0.5 (S) (↓4) 4 (I) 1 (S) (↓4) 16 (R) 16 (R)
MabBR1 2 (S) 1 (S) (↓2) 2 (S) 2 (S) 4 (I) 4 (I)
MabBR2 1 (S) 0.25 (S) (↓4) 16 (R) 2 (S) (↓8) 256 (R) 128 (R) (↓2)
MabBR3 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R)
MabPT1 0.25 (S) 0.0625 (S) (↓4) 0.25 (S) 0.0625 (S) (↓4) 2 (S) 0.5 (S) (↓4)
MabPT2 2 (S) ≤0.0625 (S) (≥↓32) 4 (I) ≤0.0625 (S) (≥↓64) 16 (R) 16 (R)
MabPT3 0.5 (S) 0.0625 (S) (↓4) 0.5 (S) 0.25 (S) (↓2) 0.5 (S) 0.5 (S)
MabPT4 2 (S) 0.5 (S) (↓4) 16 (R) 4 (I) (↓4) 64 (R) 32 (R) (↓2)
MabPT5 1 (S) 0.5 (S) (↓2) 1 (S) 0.5 (S) (↓2) 1 (S) 0.5 (S) (↓2)
MabPT6 1 (S) ≤0.03125 (S) (≥↓32) 2 (S) 0.125 (S) (↓16) 16 (R) 8 (R) (↓2)
CLA, clarithromycin; I, intermediate; MIC, minimum inhibitory concentration; MF, modulation factor; R, resistant;
S, susceptible; VP, verapamil. In red are denoted the reductions of the MICs of clarithromycin in the presence of
verapamil corresponding to a MF ≥ 4.
As can be observed, the MIC of clarithromycin at day 3 and day 5 was significantly reduced
in seven of the 10 strains studied. Among the three remaining strains, MabBR1 and MabPT5 were
susceptible to clarithromycin and they do not present inducible clarithromycin resistance. Their MICs
decreased only two-fold in the presence of verapamil, which was not considered significant, and this
phenotype was maintained until day 14 of incubation. The third strain, MabBR3, harbors a mutation
in the rrl gene, which confers high-level resistance to clarithromycin and as expected no effect was
observed on the MIC of clarithromycin in the presence of verapamil. For the remaining seven strains,
the MICs of clarithromycin decreased in the presence of 12 the MIC of verapamil (determined for
each strain and presented in Table 1) by four-fold to ≥32-fold at day 3 and by four-fold to ≥64-fold
at day 5 (Table 3). At day 14, MabPT1 was the only strain for which the MIC of clarithromycin was
reduced by four-fold in the presence of verapamil. Moreover, the lack of effect of the efflux inhibitor
verapamil at day 14 is interpreted as the result of the emergence of other resistance mechanisms
during clarithromycin exposure, e.g., the development of mutations in target genes associated with
clarithromycin resistance such as the rrl, rplV or rplD, which will be analyzed in further studies.
These results showed that the synergistic effect of verapamil does not depend on the M. abscessus
subspecies studied nor by the presence of the T28 polymorphism in erm(41). This data demonstrates the
existence of efflux activity in these strains that can be reduced by verapamil. Altogether, these results
reveal, for the first time, that the inducible clarithromycin resistance in the strains assayed is also due
to increased efflux activity in spite of the inducible resistance via erm(41).
2.3. Assessment of Efflux Activity by Real-Time Fluorometry
After the demonstration of the synergistic effect between the efflux inhibitor verapamil and
clarithromycin, indirectly correlating efflux with resistance via the inhibitory effect of verapamil,
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we studied the presence of active efflux activity in these strains by real-time fluorometry using the
broad efflux substrate ethidium bromide in the presence of glucose as a source of metabolic energy and
in the presence and absence of verapamil. First, was determined the lowest concentration that causes
minimal accumulation of ethidium bromide, i.e., the concentration for which there is an equilibrium
between influx and efflux of the substrate (Figure 1A, Table 4).
Figure 1. Accumulation and efflux of M. abscessus. The figure shows one representative assay for each
subspecies, as follows: M. abscessus subsp. abscessus—MabPT1, M. abscessus subsp. massiliense—MabPT3,
and M. abscessus subsp. bolletii—MabBR2. (A) Accumulation of increasing concentrations of ethidium
bromide. The equilibrium concentration was determined for each strain as the concentration that
promoted a plateau of no more than 10% of relative fluorescence units during the 60 min of the assay
(black broken line) and is indicated in each graph by an arrow. The assays were performed in the
presence of 0.4% of glucose. (B) Accumulation of ethidium bromide in the presence of verapamil.
Each strain was tested at its equilibrium concentration (Table 4) in the presence and absence of 12 MIC of
verapamil (see Table 1 for MICs). The assays were performed in the presence of glucose. RFF, relative
final fluorescence. (C) Efflux of ethidium bromide. The strains were loaded with ethidium bromide at
the equilibrium concentration and efflux took place in the presence of glucose, which was inhibited by
verapamil at 12 MIC.
The lowest concentration that resulted in an equilibrium between the influx and efflux of ethidium
bromide (Ceq) for all the strains varied between 0.125 μg/mL to 0.5 μg/mL (Table 4).
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Table 4. Characterization of the M. abscessus strains according to their efflux capacity.
Strains CEq (μg/mL) RFFVP
MabATCC19977T 0.25 1.15 ± 0.03
MabBR1 0.125 0.78 ± 0.01
MabBR2 0.25 1.12 ± 0.06
MabBR3 0.125 0.19 ± 0.05
MabPT1 0.25 1.14 ± 0.01
MabPT2 0.25 0.63 ± 0.01
MabPT3 0.5 1.61 ± 0.05
MabPT4 0.125 1.61 ± 0.01
MabPT5 0.5 0.26 ± 0.00
MabPT6 0.25 1.64 ± 0.11
CEq, equilibrium concentration; RFF, relative final fluorescence; VP, verapamil
Next, we performed ethidium bromide accumulation assays in the presence of verapamil as a proof
of concept (Figure 1B) and determined the RFF indexes (Table 4). The RFF index reflects how efficient
verapamil is in promoting intracellular accumulation of ethidium bromide, in this case, in M. abscessus.
The results showed that verapamil is able to increase the ethidium bromide accumulation in all the
tested strains (Table 4) and at highly significant levels in six of the 10 strains studied. The RFF values
of these strains are in the same range varying between 1.12 to 1.64. Comparing the different subspecies,
no relevant differences were observed on the levels of ethidium bromide accumulation. These results
demonstrate that verapamil is able to promote intracellular accumulation of ethidium bromide on
M. abscessus evidencing that real-time active efflux is present in this species and can be inhibited
by verapamil.
To confirm that the efflux activity of these strains could be inhibited in the presence of verapamil
we performed efflux assays (Figure 1C). Analyzing the results of each strain and comparing the curves
corresponding to the strain in the presence of verapamil and glucose (orange) with the curve of the
strain in the presence of glucose but without verapamil (green), we conclude that ethidium bromide
efflux is inhibited by verapamil in the M. abscessus strains studied, strengthening the correlation
between active efflux and drug resistance in these strains.
2.4. Quantification of Efflux Pump mRNA Levels by RT-qPCR
To analyze the contribution of the overexpression of efflux pumps to clarithromycin resistance,
we selected three main efflux pump genes correlated with antibiotic-resistant phenotypes, including
macrolides, in mycobacteria and in particular in M. tuberculosis, as proof of concept [20,23,32], namely
MAB_3142 (homologue of M. tuberculosis p55), MAB_1409 (Rv1258c or tap-like) and MAB_2807 (efpA).
We chose two strains of each M. abscessus subspecies to analyze the changes in the mRNA transcriptional
levels after exposure to 12 of the respective MIC of clarithromycin. The relative mRNA transcription
levels were determined against the respective non-exposed strain (Figure 2).
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Figure 2. Relative quantification of efflux pump gene mRNA levels in the M. abscessus strains exposed
to clarithromycin. Strains were grown in MGIT medium for the MGIT 960 system in the presence of
half MIC of clarithromycin (see Table 1 for MICs). The relative expression of the efflux pump genes was
evaluated comparing the relative quantity of the respective mRNA in the presence of clarithromycin to
the respective unexposed strain. A level of relative expression equal to 1 indicates that the expression
level is identical to the non-exposed parental strain. Genes showing expression levels above four were
considered overexpressed (black dashed line in the graph).
Increased mRNA levels were detected in all strains with the sole exception of MabBR2. This strain
does not present overexpression of any of the three efflux pump genes studied nor erm(41). Comparing
these results with those obtained in the MICs assays, we noticed that MabBR2 was susceptible to
clarithromycin at day 3, with an MIC of 2 μg/mL. The concentration used for the analysis of efflux pump
mRNA levels was 1 μg/mL. Although there was a four-fold decrease in the MIC of clarithromycin in
the presence of verapamil at day 3, this effect may be attributed to a combined effect between the two
compounds and not exclusively to efflux pump overexpression at this time point. Moreover, MabBR2
does not have inducible clarithromycin resistance which is consistent with a non-expressed erm(41)
gene. Notably, at day 5 we noted a reversion of the phenotype from resistant to susceptible in the
presence of verapamil that may be attributed to the efflux activity due to the prolonged exposure to
clarithromycin. At day 14, no effect was seen in the presence of the efflux inhibitor, indicating that
the M. abscessus subsp. bolletii BR2 may have acquired other resistance mechanisms as a mutation
in the rrl gene that is associated with high-level clarithromycin resistance (MIC ≥ 256 μg/mL) [10].
Therefore, we studied another M. abscessus subsp. bolletii strain (MabPT4) to assess the contribution of
the subspecies to the response to clarithromycin exposure. In terms of antibiotic susceptibility in the
presence and absence of verapamil, the results are entirely equivalent between both strains (Table 3),
however, MabPT4 has the erm(41) gene overexpressed despite having a non-inducible phenotype
and shows borderline overexpression of the MAB_1409 (tap-like) gene (Figure 2). This result shows
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that erm(41) gene expression is not the sole cause of clarithromycin resistance in this strain. Efflux
activity is present in this strain (Table 4) representing a late stress response to clarithromycin exposure.
Concerning M. abscessus subsp. massiliense, we analyzed MabPT3 and MabPT5, both susceptible to
clarithromycin without inducible resistance consistent with the lack of expression of erm(41) encoding
a non-functional Erm(41) protein. Although susceptible, the MICs of clarithromycin decreased in the
presence of verapamil by four-fold in MabPT3 and two-fold in MabPT5 (Table 3). Both strains showed
overexpression of MAB_3142 and MAB_1409 (Figure 2). Comparing to the real-time efflux assays,
MabPT3 has increased efflux activity although MabPT5 showed lower efflux activity than MabPT3.
This result shows that efflux activity acts also as a first-line response in these M. abscessus subsp.
massiliense strains. Finally, we studied two strains of M. abscessus subsp. abscessus, namely MabBR1 and
MabPT6. MabBR1 showed intermediate resistance at day 14, and consequently, non-inducible resistance
to clarithromycin, whereas MabPT6 was resistant at day 14 through an inducible resistant phenotype
to this antibiotic. Comparing this data with the RT-qPCR assays, MabBR1 exhibited overexpression of
MAB_3142 and MAB_1409 efflux pump genes and, somehow unexpected, also erm(41). On the contrary,
MabPT6 that presents inducible resistance to clarithromycin, although at low levels (16 μg/mL), showed
no expression of erm(41). However, this strain shows overexpression of MAB_3142 and MAB_1409
efflux pump genes. Comparing with the real-time efflux assays, MabBR1 showed lower levels of efflux
than MabPT6, probably due to the presence of an overexpressed erm(41). No overexpression was
observed concerning the gene MAB_2807 for any of the six strains analyzed.
3. Discussion
Members of the M. abscessus complex are clinically important pathogens. At present, only few
antibiotics showed antimicrobial activity with clinical significance against this species, namely,
clarithromycin and amikacin, and either cefoxitin or imipenem. The main reasons commonly accepted
for this scarce therapeutic panel is the low permeability of M. abscessus complex cell wall, the presence
of mutations in the drug target genes and, in the case of clarithromycin, the presence of an inducible
erm(41) gene [14]. Recently, the hypothesis of efflux-mediated drug resistance has been appointed as a
putative contributor to drug resistance in M. abscessus [21,22].
All bacteria express efflux pumps. Efflux transporters are transmembrane proteins involved
in the extrusion of harmful compounds and cellular metabolites from the cells into the external
environment [33]. Indirectly, they are also involved in drug resistance by expelling antimicrobials,
reducing their intracellular concentration. Treatment failure has been mainly attributed to M. abscessus
belonging to the T28 sequevar [12,34,35]. Similar to what is observed in M. avium complex infections,
acquired resistance to clarithromycin also evolves rapidly during therapy in M. abscessus [36]. Therefore,
it is legitimate to raise the hypothesis of whether the overexpression of efflux pumps is also involved
in the resistance to clarithromycin even in the M. abscessus sequevar T28? Ongoing work showed
that resistance towards clarithromycin in M. avium results from the balance between the presence of
drug resistance-associated mutations and increased efflux activity. We also noticed that this increased
efflux activity was accompanied by the overexpression of several efflux pump genes upon exposure
to clarithromycin. Therefore, to answer this question, we investigated the contribution of efflux
transporters to the induced clarithromycin resistance in M. abscessus complex belonging to the erm(41)
T28 sequevar.
The strains were blindly selected in relation to their clarithromycin susceptibility status and
included a panel of nine clinical strains, comprising three isolates of each M. abscessus subspecies,
namely, subsp. abscessus, bolletii and massiliense. The M. abscessus subsp. abscessus ATCC19977T reference
strain was included as control. Firstly, we searched for mutations associated with clarithromycin
resistance the M. abscessus strains. We found that all belong to the erm(41) T28 sequevar which, at least
theoretically, is responsible for the inducible resistance to clarithromycin in M. abscessus [12,14]. One of
the strains harbors a mutation in rrl, and consequently, displays high-level resistance to clarithromycin,
and was used as mutation-driven resistance control. These initial results are in accordance with those
46
Antibiotics 2019, 8, 153
described in the literature that states that the majority of the M. abscessus strains are susceptible to
clarithromycin and resistance is acquired during treatment [1,14]. To test the role of the erm(41) T28
polymorphism in the induced resistance of the strains analyzed, we read the MICs at day 5 of incubation
and prolonged the incubation until day 14. Surprisingly, of the eight strains, only two clinical strains
and the reference strain showed induced resistance to clarithromycin, one M. abscessus subsp. abscessus
and the other M. abscessus subsp. bolletii. Interestingly, two M. abscessus subsp. bolletii strains were
shown to be already resistant to clarithromycin at day 5 and according to the CLSI guidelines, they do
not fit in the category of clarithromycin-inducible resistance. These results demonstrate that the T28
polymorphism in erm(41) is not the sole cause of clarithromycin-induced resistance in these M. abscessus
strains indicating the existence of another mechanism of resistance in this collection of strains.
We then studied the presence of active efflux activity in these strains through the determination
of the MICs of clarithromycin in the presence of the efflux inhibitor verapamil. The results obtained
supported our hypothesis that efflux is also involved in M. abscessus induced resistance to clarithromycin.
At day 3 and day 5, all the MICs of clarithromycin for all strains, with the sole exception of the strain
with the rrl mutation, could be reduced in the presence of the efflux inhibitor verapamil. In particular,
it was possible to reverse to clinically significant levels the resistance to clarithromycin at day 5 for four
strains, one from resistant to susceptible, one from resistant to intermediate and two from intermediate
to susceptible. After 14 days of exposure, no inhibitory effect was noted for these, meaning that
these strains may have acquired other mutational mechanisms of resistance, a subject that will be
addressed in subsequent studies. Concurrently with real-time fluorometric assays, using verapamil as
reference efflux inhibitor and ethidium bromide as substrate, we detected significant efflux activity
in the 10 strains, which could be inhibited in the presence of verapamil. It was also demonstrated
that this efflux activity does not depend on subspecies of the strains, as it was detected in all the
three subspecies, although at different levels, nor due to their phenotype since it was detected in
inducible and non-inducible clarithromycin resistance strains. These data demonstrated the presence
and importance of active efflux in M. abscessus strains resistant to clarithromycin, which could be
inhibited by verapamil.
Finally, to further analyze the contribution of the expression of efflux pumps to clarithromycin
resistance in these strains, three efflux pump genes, MAB_3142, MAB_1409 and MAB_2807, and the
erm(41) gene, were selected to examine changes in mRNA transcriptional levels after exposure to 12
MIC of clarithromycin determined for each of the six strains selected. We noted increased mRNA
expression levels of the efflux pumps MAB_3142 and MAB_1409 in four out of six of the strains and
found also erm(41) overexpression in two strains, one presenting inducible resistance while the other
does not have induced resistance to clarithromycin.
This exploratory study consolidates and strengthens the hypothesis that efflux activity plays a
role in M. abscessus intrinsic resistance to clarithromycin in strains belonging to the T28 sequevar and
that the inhibition of this efflux activity by compounds such as verapamil could potentiate the clinical
effect of clarithromycin, the most efficient antibiotic to treat M. abscessus infections, certainly reducing
or preventing the emergence of the, so far almost inexorable, acquired resistance to macrolides during
treatment against M. abscessus infections.
4. Materials and Methods
4.1. M. abscessus Complex Strains
The strains selected for this study are described in Table 1 and were isolated from Brazilian (BR) and
Portuguese (PT) patients. Brazilian clinical strains were granted by Fundação Oswaldo Cruz (Rio de
Janeiro, Brazil). The Portuguese clinical strains are part of the strain collection of the Mycobacteriology
Laboratory of the Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa (Lisboa,
Portugal). The strains were identified using the GenoType NTM-DR assay (Hain Lifescience, GmbH,
Nehren, Germany) according to the manufacturer’s instructions. Informed consent was not required
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for the present study since it corresponds to a retrospective study from which all patient identification
was unlinked from the results, and no patient information was collected. M. abscessus subsp. abscessus
ATCC19977T reference strain was obtained from the American Type Culture Collection (Virginia, USA)
and was included as a control strain.
4.2. Compounds and Reagents
Amikacin, clarithromycin, verapamil, ethidium bromide, dimethyl sulfoxide (DMSO), and glucose
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Clarithromycin was prepared in DMSO,
while the remaining drugs were prepared in sterile deionized water. Stock solutions were stored at
−20 ◦C. Working solutions of both antibiotics and ethidium bromide were prepared in Mueller–Hinton
broth (MHB; Oxoid, Hampshire, UK) on the day of the experiments. Löwenstein–Jensen medium,
Middlebrook 7H9, BBL OADC (oleic acid/albumin/dextrose/catalase) supplement and the mycobacteria
growth indicator tubes (MGITs) were purchased from Becton Dickinson (Diagnostic Systems, Sparks,
MD, USA).
4.3. Detection of Mutations Associated with Clarithromycin and Amikacin Resistance
Total DNA was extracted from clinical strains and the reference strain using the GenoLyse kit
(Hain Lifescience) according to the manufacturer’s instructions. The presence of mutations in rrl,
erm(41) and rrs were analyzed with the Genotype NTM-DR assay.
4.4. Susceptibility Testing
4.4.1. Growth of the Strains
All strains were maintained in MGITs tubes supplemented with 10% OADC. For minimum
inhibitory concentration (MIC) determination and synergism assays, the M. abscessus strains were
inoculated in Löwenstein–Jensen medium and incubated at 37 ◦C for three to five days.
4.4.2. MIC Determination of Compounds
For the determination of the MICs of the antibiotics, the efflux inhibitor verapamil and the
efflux substrate ethidium bromide, the inoculum of each strain was prepared by diluting the bacterial
cultures in MHB to a final density of approximately 105 cells/mL [37]. The MICs were determined
using a tetrazolium microplate-based assay (TEMA) [38] with small modifications. Briefly, aliquots
of 0.1 mL of inoculum were transferred to each well of the plate that contained 0.1 mL of each
compound at concentrations prepared from two-fold serial dilutions in MHB medium. Growth controls
(only inoculum without drug) and a sterility control (only medium) were included in each plate.
Two hundred microliters of sterile deionized water were added to the outer-perimeter wells of the
96-well plates to reduce evaporation of the medium during the incubation. The inoculated plates were
sealed in permeable plastic bags and incubated at 37 ◦C for three days. After this period, 10 μL of a
solution of 5×MTT/10%T80 (1:1) was added to each well and the plates incubated for four hours at
room temperature. The bacterial growth was registered for each well based on the MTT color change.
As the intensity of the color generated is directly proportional to the number of viable cells, a precipitate
of cells stained black can be observed in the bottom of the well. The MIC was defined as the lowest
concentration of compound that totally inhibited bacterial growth, i.e., no color change [39]. All assays
were performed in triplicate. For amikacin, the breakpoints used were: ≤16 μg/mL, susceptible;
32 μg/mL, intermediate; and ≥64 μg/mL, resistant. For clarithromycin at day 3, the breakpoints used
were: ≤2 μg/mL, susceptible; 4 μg/mL, intermediate and ≥8 μg/mL, resistant [10].
To evaluate clarithromycin induced resistance, the MIC determination of clarithromycin was
extended for 14 days. To do this, plates containing clarithromycin were prepared in quadruplicate to be
read at the following time points: 3, 5 and 14 days [14]. After each period of incubation, MTT was added
and the results read and interpreted as described above. Susceptible isolates at day 3 (MIC ≤ 2 μg/mL)
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and resistant at day 5 (MIC ≥ 8 μg/mL), were considered to have an inducible erm(41) gene [10]. All
assays were carried out in triplicate.
4.4.3. MIC Determination of Antibiotics and Ethidium Bromide in the Presence of Verapamil
The MICs of amikacin, clarithromycin, and ethidium bromide were determined in the presence
of verapamil. The assays were performed as described above with the exception that verapamil was
added to each well to a final concentration of 12 of the MIC. The results were read and interpreted as
described above. The modulation factor (MF) was calculated and used to quantify the inhibitory effect
of verapamil on the MICs of clarithromycin through the following formula: MF =MIC antimicrobial /
MIC antimicrobial + efflux inhibitor [40]. The MF reflects the reduction of the MIC values of a given
antimicrobial in the presence of an efflux inhibitor, being considered significant when MF ≥ 4 (four-fold
reduction) [41]. Each assay was carried out in triplicate.
4.4.4. Semi-Automated Fluorometric Method
The evaluation of efflux activity on a real-time basis was performed using a semi-automated
fluorometric method [26] with modifications [Machado et al., unpublished]. The M. abscessus strains
were grown in 10 ml of 7H9/10%OADC with 0.05% tyloxapol at 37 ◦C until they reached an OD600
of 0.8. For the accumulation assays, the cultures were centrifuged at 3500 rpm for three minutes,
the supernatant discarded and the pellet washed in 7H9. The OD600 was adjusted to 0.8 with 7H9.
In order to determine the concentration of ethidium bromide that establishes the equilibrium between
efflux and influx, aliquots of 0.05 mL of the bacterial suspension were added to 0.2 mL microtubes
containing 0.05 mL different concentrations of ethidium bromide that ranged from 0.625 μg/mL to
5 μg/mL with and without 0.4% glucose. The assays were conducted at 37 ◦C in a Rotor-Gene 3000
(Corbett Research, Sydney, Australia), using the 530 nm band-pass and the 585 nm high-pass filters
as the excitation and detection wavelengths, respectively. Fluorescence data were acquired every
60 seconds for 60 min. The selected concentration of ethidium bromide was further used for the
evaluation of the capacity of verapamil to retain ethidium bromide inside the cells. Verapamil was
tested at 12 MIC with and without 0.4% glucose and ethidium bromide at the equilibrium concentration
determined for each strain and the assays performed as described above. The inhibitory activity of
verapamil was determined through the determination of the relative final fluorescence (RFF) value
according to the following formula [42]: RFF = (RFtreated-RFuntreated)/RFuntreated. In this formula,
the RFtreated corresponds to the relative fluorescence at the last time point of ethidium bromide
accumulation curve (min 60) in the presence of verapamil, and the RFuntreated corresponds to the
relative fluorescence at the last time point of the ethidium bromide accumulation curve of the untreated
control tube. An index of activity above zero indicate that the cells accumulate more ethidium bromide
under the condition used than those of the control (untreated cells). Negative RFF values indicate that
the treated cells accumulated less ethidium bromide than those of the control condition [28,32].
For the efflux assays, the strains were exposed to conditions that promote the maximum
accumulation of ethidium bromide, i.e., ethidium bromide equilibrium concentration for each strain,
no glucose, presence of verapamil at 14 MIC, and incubation at 20
◦C for one hour [26]. Before incubation,
the cultures were centrifuged at 3500 rpm for three minutes, resuspended in 7H9, centrifuged again
and OD600 adjusted to 0.4. The suspension was incubated with ethidium bromide and verapamil under
the conditions described above. Aliquots of 0.05 mL of cells were transferred to 0.2 mL microtubes
containing 0.05 mL of verapamil at 12 MIC without ethidium bromide. Control tubes with only cells
and cells with and without 0.4% glucose were included. Fluorescence was measured in a Rotor-Gene™
3000 and data were acquired every 30 seconds for 30 min. Efflux activity was quantified by comparing
the fluorescence data obtained under conditions that promote efflux (presence of glucose and absence
of efflux inhibitor) with the data from the control in which the mycobacteria are under conditions of no
efflux (presence of an inhibitor and no energy source). Thus, the relative fluorescence corresponds
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to the ratio of fluorescence that remains per unit of time, relatively to the ethidium bromide-loaded
cells [27].
4.5. Efflux Pump Gene Expression
4.5.1. Sample Preparation
For the analysis of efflux pump gene expression, each strain was inoculated into 7H9 containing
10% OADC plus clarithromycin at 12 the MIC (see Table 1 for MIC values). The strains were then
incubated at 37 ◦C within the MGIT system until growth was achieved [20]. At this time point, samples
of each culture were taken for RNA extraction and RT-qPCR analysis.
4.5.2. RNA Extraction
Total RNA was isolated from the cells using the RNeasy mini kit (QIAGEN, GmbH, Hilden,
Germany) according to the manufacturer’s instructions with modifications [20]. Briefly, from a culture
with 100–200 GU (about 106–108 cells/ml), 1 ml aliquot was removed and centrifuged at 13,000 rpm
during 10 min. Then, 500 μL supernatant was removed and 1 mL of RNAprotect Bacteria Reagent
(QIAGEN) added. An enzymatic lysis step was carried out with lysozyme at 3 mg/mL (Sigma) for
10 min, followed by lysis in an ultrasonic bath at 35 kHz (Gen-Probe, CA, USA) during 15 min. The RNA
was purified using the RNeasy kit (QIAGEN) and treated with RNase-free DNase I (QIAGEN) during
2 h and 15 min by on-column digestion at room temperature to reduce the presence of contaminating
DNA. All RNA samples were stored at −20 ◦C until required.
4.5.3. RT-qPCR Assay
The relative expression level of mRNA of genes that code for membrane efflux transporters
in M. abscessus (MAB_2807, MAB_1409 and MAB_3142) and erm(41) was analyzed by RT-qPCR.
The normalization of the data was done using the M. abscessus 16S rDNA. The RT-qPCR procedure
was performed in a Rotor-Gene 3000 thermocycler and followed the protocol recommended for use
with the One-step NZY RT-qPCR Green kit (Nzytech, Portugal). The determination of the relative
mRNA expression level was performed using the comparative quantification cycle (Cq) method [43].
The relative expression of the genes analyzed was assessed by comparison of the relative quantity
of the respective mRNA in the presence of clarithromycin to the non-exposed culture, following the
same technical approach previously published [20]. Each culture was assayed in triplicate using total
RNA obtained from three independent cultures. A level of relative expression equal to 1 indicates that
the expression level was identical to the unexposed strain. Genes showing expression levels equal or
above four, when compared with the unexposed strain, were considered to be overexpressed [20].
5. Conclusions
The results obtained in this study provide evidence that efflux activity is an intrinsic characteristic
of M. abscessus clinical strains and is directly involved in clarithromycin resistance. Literature review
indicated that M. abscessus subsp. abscessus T28 and M. abscessus subsp. bolletii T28 are intrinsically
resistant to clarithromycin conferred by an altered Erm(41) methylase [1]. The change of cytosine by
thymine at position T28 on Erm(41) causes resistance to clarithromycin due to prolonged exposure
leading to treatment failure [12–14]. In our hands, the results obtained pointed out that erm(41)
expression is not the sole cause of the inducible clarithromycin resistance in M. abscessus subsp.
abscessus and M. abscessus subsp. bolletii T28 sequevars and that efflux pump overexpression has a
strong contribution to clarithromycin resistance acting both as a first-line response or a late response to
drug pressure. This study was designed as a proof of concept. Therefore, due to the small number of
strains studied, we could not generalize the results obtained here. Future work will include a higher
number of strains belonging to the three subspecies. Another limitation of this study, consequence of
the random selection of the strains, is the absence of strains from the C28 sequevar, which will be also
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studied further. Nevertheless, our results point out efflux as an important contributor to the emergence
of M. abscessus clarithromycin resistance and highlight the need of further studies on M. abscessus
senso lato efflux response to stress imposed by antimicrobials in order to implement more effective
therapeutic regimens and aid in the development of new drugs against these bacteria.
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Abstract: Hydroxide [Ag(OH)L] (L = IVL, VL, VIL, VIIL), oxide [{AgL}2}(μ-O)] (L = IL, IIL, IIIL,
VL, VIL) or chloride [AgIIL]Cl, [Ag(VIL)2]Cl complexes were obtained from reactions of mono- or
bicamphorimine derivatives with Ag(OAc) or AgCl. The new complexes were characterized by
spectroscopic (NMR, FTIR) and elemental analysis. X-ray photoelectron spectroscopy (XPS), ESI
mass spectra and conductivity measurements were undertaken to corroborate formulations. The
antimicrobial activity of complexes and some ligands were evaluated towards Candida albicans
and Candida glabrata, and strains of the bacterial species Escherichia coli, Burkholderia contaminans,
Pseudomonas aeruginosa and Staphylococcus aureus based on the Minimum Inhibitory Concentrations
(MIC). Complexes displayed very high activity against the Candida species studied with the lowest
MIC values (3.9 μg/mL) being observed for complexes 9 and 10A against C. albicans. A significant
feature of these redesigned complexes is their ability to sensitize C. albicans, a trait that was not
found for the previously investigated [Ag(NO3)L] complexes. The MIC values of the complexes
towards bacteria were in the range of those of [Ag(NO3)L] and well above those of the precursors
Ag(OAc) or AgCl. The activity of the complexes towards normal fibroblasts V79 was evaluated by
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Results showed that
the complexes have a significant cytotoxicity.
Keywords: silver complexes; camphorimine; anti-Candida activity; antifungals; antibacterials
1. Introduction
The resistance of microorganisms to conventional antimicrobials is presently a serious threat to
public health worldwide, representing a huge financial burden for public health systems. The group
of bacterial pathogens known as ESKAPE is of particular concern, which includes Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter spp. [1]. In addition, fungal infections, and notably candidiasis caused by members of
the Candida genus, are also of increasing concern worldwide. These infections range from superficial
infections to life-threatening disseminated mycoses [2,3]. Although Candida albicans remains the major
causative agent of candidiasis, there is an increase of the incidence of disseminated infections caused
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by C. glabrata, together with an increased resistance to antifungals among clinical isolates of this
species [4,5].
The increasing resistance of pathogenic microorganisms to existing antimicrobials has been
accompanied by a scarce increment in the number of alternative compounds commercially available,
due to the low interest shown by the pharma industry in the search and development of new
antimicrobials [6,7]. The present situation is an explosive combination of increasing resistance to
antimicrobials and the lack of investment in novel antimicrobials. Therefore, it is urgent to find novel
molecules with chemical characteristics different from those commercially available. Ideally, these
molecules should display new modes of action and point to new microbial targets [8]. Aware of
such a need, the scientific community has engaged in a search for novel antifungals alternative to
azoles, echinocandins, or polyenes [9], as well as for novel antibacterials as alternative to penicillins,
cephalosporin, tetracyclines, macrolides, quinolones or sulphonamides [10,11]. Consequently, many
new molecules with antimicrobial activity have been described, including peptides from a multitude
of species [12,13], natural extracts from plants, herbs, and spices [14], polymers modified with
antimicrobial functional groups [15], and metal-based molecules [16].
Complexes are feasible alternatives to the most used organic compounds, since the specific
properties of the metal site introduces steric and electronic characteristics relevant to switch distinct
mechanisms of action (e.g. electron transfer and redox processes) [17].
The design of complexes to tailor efficient antimicrobial agents requires that the metal and the
ligands are chosen according to the antifungal or antibacterial purpose, since the activity towards fungi
or bacteria is commonly different [18]. The choice of silver and copper as precursors for the synthesis
of complexes is attractive as these metals have been in use for thousands of years. For instance, silver
and copper vessels have been used for water and food preservation since the Persian kings due to their
antimicrobial properties [16].
Silver-based camphorimine complexes [Ag(NO3)L] emerged among the newly developed
molecules with strong antimicrobial potential, having excellent antifungal activity against several
pathogenic species of the Candida genus [18]. Despite the demonstrated efficacy of the developed
camphorimine complexes in inhibiting growth of C. glabrata, C. tropicalis, and C. parapsilosis, there was
no inhibition against C. albicans by silver nitrate camphorimine complexes [18], a drawback that has
now been reported to be surpassed by redesign of the complexes. The characteristics of the camphor
ligands to tune the properties, reactivity, and applications of the complexes was evidenced in former
work [19–22]. Therefore, a new set of camphorimine complexes was synthesized that exhibits very
high activity against C. albicans, highlighting the relevance of both the ligands (camphor derivatives)
and the co-ligands (NO3−, OH− or O2−) to achieve microbial growth inhibition.
2. Results
A new set of camphorimine silver complexes were synthesized using silver acetate (AgOAc) or
silver chloride (AgCl) as metal precursors to tune the properties and the antimicrobial activity of the
complexes. The objective was to keep the structure of the complexes while replacing the nitrate ion
by a less acidic anionic co-ligand (OAc− or Cl−), aiming to overcome the lack of antifungal activity
displayed by the nitrate complexes [Ag(NO3)L] towards C. albicans. The absence of antifungal activity
was accompanied by formation of silver nanoparticles (AgNPs) [18]. The acidic character of the nitrate
ion was hypothesized to favor the reduction processes mediated by a protein existing in C. albicans, but
not at other Candida species. Less acidic co-ligands (OAc−, Cl−) are expected to be less efficient in the
activation of AgNPs formation.
The low solubility of silver acetate (AgOAc) in solvents other than water requires that reactions
with camphor compounds are carried out in H2O/EtOH since the camphor derivatives used as ligands
are not soluble in H2O. Solutions of silver acetate in water have acidic character (pH ca. 4), consistent
with release of acetic acid (pKa = 4.76) [23] and formation of silver hydroxide (AgOH) or silver oxide
(Ag2O) solutions (Scheme 1).
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Scheme 1. Silver species in aqueous solutions of AgOAc.
Since different forms of silver species co-exist in solution, complexes with different metal cores
can be obtained, depending on the characteristics of the camphorimine derivatives (Figure 1) and the
experimental conditions.
Figure 1. Camphor derivatives used as ligands: (a) camphorimine and (b) bicamphor type.
Addition of the camphorimine (OC10H14NY, Figure 1a) or bicamphorimine compounds
(OC10H14N)2Z, Figure 1b) to the silver acetate solution increases the pH value to ca. 7–8, prompting
the formation of hydroxide or oxide silver complexes. The camphor mono imine ligands (IL-IIIL) favor
the formation of binuclear complexes with the two silver sites bridged by oxygen [{AgL}2(μ-O)] (1–3),
while IVL and the bicamphor ligands (VL–VIIL) prompt the formation of hydroxide type complexes
[AgL(OH)] (4–6,10) (Scheme 2).
 
Scheme 2. Types of complexes obtained from ligands IL–VIL (see Tables 1 and 2 for details).
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Table 1. Complexes obtained from reaction of Ag(OAc) with camphor ligands (L).
COMPLEX
LIGAND (L) IR (cm−1) a 13C NMR (δ ppm)
Y Z νC=O νC=N C=O C=N
[{AgIL}2(μ-O)] IL (1) NHCOOMe 1722 1649 (b)
[{Ag(IIL)}2(μ-O)] IIL (2) C6H5 1745 1652 207.4 173.3 c
[{Ag(IIIL)}2(μ-O)] IIIL (3) 4-CH3C6H4 1747 1653 206.8 171.9 d
[Ag(OH)(IVL´)] e IVL (4) 4-NH2C6H4 1733 1642 f 207.8 169.1 c
[{Ag(OH)}(VL)] VL (5) 4-C6H4 1754 1685 207.3 173.2 c
[{Ag(OH)}3(VIL)2] VIL (6) 3-C6H4 1751 1668 206.6 173.0 g
[Ag(OH)(VIIL)] VIIL (7) 4-(C6H4)2 1745 1660 206.7 172.5 g
a In KBr pellets. b Not soluble enough. c In CD3CN. d In MeOH-d4. e IVL´ = IVL·CH3COOH. f ν (O=CO), 1593,
1567 cm−1. g In CD2Cl2.
The absence of OH stretches in the IR spectra of complexes 1–3 (Table 1) support their formulation
as oxide rather than hydroxide complexes. The hydroxide complexes (4,5,7) fit in a 1:1 ligand to metal
ratio, consistent with a coordination polymer character. At complex 4 ([Ag(IVL´)(OH)]) the ligand
(Y=NH2) is protonated (IVL´ = IVL·HOOCCH3), as confirmed by elemental analysis and FTIR (Table 1)
through bands at 3455 and 3340 cm−1 (attributed to the OH− and NH4+ groups) and at 1593, 1567 cm−1
(attributed to the acetate (COO−) group). The metal to ligand ratio at 6 (3:2) differs from that of all the
other complexes, conceivably due to steric demands of the bicamphorimine ligand. All complexes (1–7)
were characterized by spectroscopic (FTIR, NMR) and analytical techniques. The relevant spectroscopic
characteristics are highlighted in Table 1 (see experimental section for further details). Complex 1 is
not sufficiently soluble to obtain NMR data, thus formulation was supported by X-ray photoelectron
spectroscopy (XPS).
2.1. Analysis of Complex 1 by XPS
Complex 1 was characterized by XPS. Besides the survey spectrum (not shown), the detailed
regions C 1s, N 1s, O 1s, and Ag 3d were analyzed and are shown in Figure 2.
Figure 2. Cont.
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Figure 2. XPS regions Ag 3d, N 1s, C 1s and O 1s for complex 1.
Ag 3d region displays a doublet with the main component, Ag 3d5/2, centered at 368.4 ± 0.2 eV
and the minor component, Ag 3d3/2, at a BE 6 eV higher. N 1s is fittable with a single peak centered at
399.9 ± 0.2 eV. C 1s was fitted with a main peak (used to correct all the binding energies for charge
accumulation effects) assigned to all the carbons just bound to other carbon atoms and/or hydrogen
atoms set at 285 eV. Other peaks at 285.6 ± 0.2, 286.6 ± 0.2, and 287.1 ± 0.2 eV are assigned to carbon
in C–N, in C–O and in C=O bonds, respectively. Finally, a peak at 288.8 ± 0.2 eV is assigned to the
urethane group (NHCOOMe) in the ligand and to the acetate group in the precursor. Quantitative
results are compatible with the coexistence of the complex and small amounts of the precursor (silver
acetate). Discounting the precursor contributions, computed atomic ratios for the complex give the
following values: Ag/N = 0.50, Ag/O = 0.29 and O/N = 1.75, fully consistent with the formulation
[{AgIL}2(μ-O)] (L = C10H18N2O3) proposed for 1.
2.2. Silver Chloride Derived Complexes
The solubility of silver chloride in common solvents is even lower than that of silver acetate,
however it is reasonably soluble in ammonia. Thus, the reactions of AgCl with the camphorimine
derivatives (L) were performed in NH3·H2O/EtOH. In such basic medium, silver oxide exists in solution,
thus accounting for the formation of the oxide complexes (3, 9, 10A). At [{Ag(NH3)}2(μ-VL)(μ-O)] (9),
ammonia (NH3) further acts as a co-ligand. Complex 3 is either obtained from reaction of ligand IIIL
with AgCl or Ag(OAc), in agreement with the formation of silver oxides either from silver acetate or
silver chloride under the experimental conditions used. By strict control of the order of addition of
AgCl to the solutions of ligands IIL and VIL, non-oxide complexes [Ag(IIL)]Cl (8) and [Ag(VIL)2]Cl (10)
were obtained. The cationic character of complex 10 was achieved by ESI-MS analysis. The ESI(+)/MS
spectrum for a solution of [Ag(VIL)2]Cl shows a group of peaks at m/z 915/317 (Figure 3), consistent
with the ionic complex [Ag(C26H32N2O2)2]+ formed by two neutral ligands and a silver cation, with
the characteristic isotopic distribution of silver-containing species (Figure 3, right upper insert).
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Figure 3. ESI (+) mass spectrum of a solution of [Ag(VIL)2]Cl (10) in acetonitrile. The insert shows the
theoretical isotopic pattern of the cation [Ag(VIL)2]+ i.e., [Ag(C26H32N2O2)2]+.
The cationic character of 8 was further confirmed through conductivity measurement
(138 Ω−1.cm2.mole−1) in acetonitrile. The value is within the range (120–160 Ω−1.cm2.mole−1) expected
for a 1:1 electrolyte [24]. Such as for the above complexes 1–7, the characterization of complexes 8–10A
was achieved by elemental analysis, FTIR and NMR. Some relevant spectroscopic details are displayed
in Table 2.
Table 2. Complexes obtained from reaction of silver chloride with camphor ligands (L).
COMPLEX
LIGAND (L) IR (cm−1) 13C NMR (δ ppm)
Y Z νC=O νC=N C=O C=N
[Ag(IIL)]Cl IIL (8) C6H5 1744 1651 207.5 173.2 a
[{Ag(IIIL)}2(μ-O)] IIIL (3) 4-CH3C6H4 1747 1654 206.8 171.9 b
[{Ag(NH3)}2(μ-VL)(μ-O)] VL (9) 4-C6H4 1744 1651 207.5 173.2 b
[Ag(VIL)2]Cl VIL (10) 3-C6H4 1750 1661 207.2 173.8 a
[Ag2(μ-VIL)(μ-O)] VIL (10A) 3-C6H4 1749 1660 207.3 173.9 a
a In CD3CN. b In CD2Cl2; From reactions of AgCl with ligands IL and IVL (Figure 1) no complexes could be obtained.
In the case of IVL, the hydrated ligand was recovered (IVL·H2O) from solution.
2.3. Antimicrobial Activity Assessment
The antimicrobial properties of the above complexes were assessed for C. albicans and C. glabrata,
as well as for the bacterial pathogens E. coli ATCC25922, S. aureus Newman, B. contaminans IST408 and
P. aeruginosa 477, based on the evaluation of the values of Minimum Inhibitory Concentration (MIC).
The selected bacterial strains represent pathogens of medical relevance, difficult to treat and eradicate
worldwide, mainly due to their resistance to multiple antibiotics. B. contaminans IST408 was isolated
from a Portuguese Cystic Fibrosis patient [24]. P. aeruginosa and S. aureus are members of the ESKAPE
group, responsible for many hospital- and community-acquired infections [1]. E. coli ATCC25922 is a
commonly used reference in antimicrobial activity assays. The antimicrobial activities of complexes 1,
4, and 5 were not assessed due to their low solubility (1) or stability (4, 5).
All the complexes essayed display anti-Candida activity that range from 15.6 μg/mL (1, 2, 6, 9, 10A)
to 125–250 μg/mL (8, 10). The antibacterial activity of the complexes (Table 3) ranged from 19 μg/mL (P.
aeruginosa, 2) to ≥112 μg/mL (6, 8, 10). The MIC values measured for the ligands (IIL, IIIL, VL and VIL)
display very high MIC values (≥500 μg/mL) consistent with their lack of antimicrobial activity.
60
Antibiotics 2019, 8, 144
Table 3. Biological values assessed for the camphorimine silver complexes.
Complex.













2 7.8 ± 0.1 15.6 ± 0.1 59.4 ± 0.3 47 ± 7 19 ± 3 125 7 ± 5
3 31.3 ± 0.1 31.3 ± 0.1 56 ± 5 78 ± 2 43 ± 11 58 ± 2 8 ± 5
6 7.8 ± 0.1 15.6 ± 0.1 125 125 60 ± 7 125 3 ± 1
7 15.6 ± 0.1 15.6 ± 0.1 54 ± 3 >125 61 ± 4 >125 12 ± 5
8 125 ± 1 250 ± 1 250 >250 112± 14 250 25 ± 14
9 3.9 ± 0.4 7.8 ± 0.1 32 ± 1 125 19 ± 3 125 2 ± 1
10 - - >250 >250 >250 >250 -
10A 3.9 ± 0.1 15.6 ± 0.1 52.2 ± 0.2 23 ± 3 43 ± 10 125 1.7 ± 0.9
Ag(OAc) >500 >500 30.9 ± 0.4 12 ± 2 16 ± 3 29.5 ± 0.1 0.6 ± 0.2
AgCl 500 ± 1 >500 14 ± 2 10 ± 1 12 ± 1 30 ± 2 >30
a IC50 values for 48 h incubation.
The MIC values (Table 3) show that the complexes are active against bacterial strains E. coli
ATCC25922, B. contaminans IST408, P. aeruginosa 477, and S. aureus Newman, although at relatively high
MIC values. In contrast, the MIC50 values obtained for the two Candida species are very low, thereby
showing that the complexes have higher antifungal than antibacterial activity. Although previous
work showed that silver camphorimine complexes [Ag(NO3)L] have high anti Candida spp. activity
(MIC50 2.0–15.6 μg/mL for C. parapsilosis) the complexes 2, 6, 9, 10A, display values (7.8 μg/mL, 9)
that are even lower than those formerly reported against C. glabrata (MIC50 ≥15.6 μg/mL) [18]. More
important, all complexes (except 8) are efficient against C. albicans, a feature not observed for the nitrate
complexes [Ag(NO3)L] [18]. So, by replacing nitrate by hydroxide or oxide co-ligands, we were able to
synthesize complexes that inhibit growth of C. albicans even more efficiently (MIC50 3.9 μg/mL; 9, 10A)
than C. glabrata. The lack of activity of [Ag(IIL)]Cl (8) towards the two Candida species and the bacterial
strains under study is attributed to its cationic character. Complex 10, which is also cationic, displays
a relatively low activity (Table 3). These results reinforce those previously obtained for the cationic
[Ag(OC10H13NOH)2]NO3 [19]. The ionic character of the complexes decreases their lipophilicity and
conceivably makes it more difficult for their penetration into the intracellular environment of Candida
spp. or bacterial cells, thereby reducing their activity.
In general, the complexes display both antibacterial and antifungal activities, although they
perform better as antifungals than as antibacterials. The MIC values show that some of the
complexes have very high antibacterial activity (40–60 μg/mL) and/or excellent antifungal activities
(4–8 μg/mL). Overall, the complexes perform better for Gram-negative (MIC 19–61 μg/mL) than
for Gram-positive bacteria (S. aureus Newman, 58–250 μg/mL). Complexes [{Ag(IIL)}2(μ-O)] (2) and
[{Ag(NH3)}2(μ-VL)(μ-O)] (9) display the highest activity against P. aeruginosa 477 (MIC, 19 μg/mL) while
complex [Ag2(μ-VIL)(μ-O)] (10A) displays the highest activity towards B. contaminans IST408 (MIC
23 ± 3 μg/mL). These complexes have in common a dinuclear character with the two metals sharing an
oxygen atom and camphorimine ligands that may prompt electron delocalization through the aromatic
ring. Such characteristics conceivably are not just circumstantial for their antimicrobial activity.
To obtain insights into the toxicity of the complexes towards mammalian cells, the IC50
measurements of representative complexes were evaluated towards V79 normal fibroblasts which are
cells commonly used to assess the toxicological effects of drugs [25]. Data shows that IC50 values of the
complexes are low and comparable or even lower than those of the MIC values obtained for fungi
(Table 3).
These results were not completely unexpected since fungi and mammalian cells are eukaryotes
and therefore some of the mechanisms by which the complexes exert toxicity against the Candida
spp. may be conserved in the mammalian cells [26]. This difficulty in achieving specificity is a
recognized challenge in the design of new compounds selectively targeting fungal cells. Future
work will focus on the design of silver camphorimine complexes with both reduced cytotoxicity and
enhanced antimicrobial activities.
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3. Materials and Methods
3.1. General Procedures
The camphorimines were obtained from camphorquinone by reaction with the appropriate amine
or hydrazine in ethanol using reported procedures [18,27–29]. In the case of air sensitive complexes,
Schlenk and vacuum techniques were used. Ethanol was purchased from Fisher Scientific, ammonia
from Sigma-Aldrich and acetonitrile from Carlo Erba. The amines and hydrazines were purchased
from Sigma-Aldrich and silver acetate and silver chloride from Merck.
The IR spectra were obtained from KBr pellets using a JASCO FT/IR 4100 spectrometer. The NMR
spectra (1H, 13C, DEPT, HSQC and HMBC) were obtained from MeOH-d4, CD3CN or CD2Cl2 solutions
using Bruker Avance II+ spectrometers (300 or 400 MHz). NMR chemical shifts are referred to
tetramethylsilane (TMS) (δ = 0 ppm).
The ESI mass spectrum was obtained on a LCQFleet ion trap mass spectrometer equipped with
an electrospray source (Thermo ScientificTM, Waltham, MA USA), operating in the positive ion mode.
The XPS data was obtained using a Kratos XSAM800 equipment.
Conductivity was measured in acetonitrile (1.0 × 10−3 M solution) at 25 ◦C using a CON 510
bench conductivity meter provided with a Conductivity/TDS electrode (code No. ECCONSEN91W/
35608-50, K = 1).
3.2. Synthesis
Complexes 1–7 were obtained from reaction of the suitable ligand with silver acetate (1:1). Air
was partially excluded by bubbling of nitrogen (3 minutes). The reaction mixtures were protected from
light to preclude reduction of Ag+ to Ag0. The typical procedure is described for 1. Complexes 8–10
were obtained from reaction of the suitable ligand with silver chloride (1:1). A typical procedure is
described for 8.
[{AgIL}2(μ-O)] (1)—A solution of the camphorimine OC10H14NNHCOOMe (IL, 72 mg, 0.35 mmol)
in EtOH (5 mL) was added to a suspension of Ag(OAc) (50 mg, 0.35 mmol) in H2O (5 mL) under N2.
The whitish suspension was stirred for ca. 1h. The slight suspension still remaining was then removed
by filtration and the solution was evaporated to dryness to yield the complex. Yield 55%. Elem. Anal.
(%) for Ag2C24H36N4O7. Found: C, 41.6; N, 7.9; H, 5.1; Calc.: C, 41.4; N, 7.5; H, 5.5. IR (cm−1): 1722
(C=O), 1649 (C=N), 1588 (O=COMe). 1H NMR (400 MHz, MeOH-d4, δ ppm): 4.56 (s, 3H), 3.81 (sbr,
1H), 1.88–1.81 (m, 2H), 1.54–1.44 (m, 2H), 1.18 (s, 3H), 1.04 (s, 3H), 0.85 (s, 3H). 13C NMR Decomposes
during acquisition.
[{AgIIL}2(μ-O)] (2)—OC10H14NC6H4 (IIL, 72 mg; 0.3 mmol) in ethanol (5 mL) and silver acetate
(50 mg; 0.3 mmol) in H2O (5 mL) were stirred for 4 h. Yield 74%. Elem. Anal. (%) for Ag2C32H36N2O3.
Found: C, 54.9 N, 3.5; H, 5.8; Calc.: C, 54.7; N, 3.8; H, 6.2. IR (cm−1): 1745 (C=O), 1652 (C=N), 1567
(CHarom). 1H NMR (300 MHz, CD3CN, δ ppm) 7.40 (t, J = 7.8 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.90 (d,
J = 7.5 Hz, 2H), 2.74 (d, J = 5.1 Hz, 1H), 1.90 (mc, 2H), 1.61 (mc, 2H) 1.04 (s, 3H), 0.97 (s, 3H), 0.86 (s,
3H). 13C NMR (300 MHz, CD3CN, δ ppm): 207.4, 173.3, 130.1, 126.0, 120.9, 59.0, 51.0, 45.3, 30.8, 24.8,
21.16, 17.6, 9.4.
[{AgIIIL}2(μ-O)] (3)—OC10H14NC6H4CH3-4 (IIIL, 76 mg; 0.3 mmol) in ethanol (5 mL) and silver
acetate (50 mg; 0.3 mmol) in H2O (5 mL) were stirred for 4 h. Yield 89%. Elem. Anal. (%) for
Ag2C34H42N2O3. Found: C, 55.3 N, 3.5; H, 5.9; Calc.: C, 55.0; N, 3.8; H, 5.7. IR (cm−1): 1747 (C=O),
1653 (C=N), 1565 (CHarom). 1H NMR (300 MHz, CD2Cl2, δ ppm): 7.24 (d, J = 7.5 Hz, 2H), 6.97 (d,
J = 7.5 Hz, 2H), 2.92 (d, J = 4.8 Hz, 1H), 2.36 (s, 3H), 2.3–1.9 (m, 2H), 1.6–1.5 (m, 2H), 1.61 (s, 3H) 1.07 (s,
3H), 0.98 (s, 3H), 0.87 (s, 3H). 13C NMR (300 MHz, CD2Cl2, δ ppm): 206.9, 174.2, 146.2, 138.6, 130.9,
123.2, 59.1, 52.2, 46.0, 31.3, 24.9, 21.3, 21.0, 17.4, 9.2.
Compound 3 can alternatively be obtained from reaction of AgCl (50 mg; 0.35 mmol in 5 mL
of ammonia 33%) with IIIL (89 mg; 0.35mmol in 5 mL EtOH) upon stirring overnight, filtration to
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eliminate residues of silver followed by solvent evaporation until precipitation which is then dried
under vacuum to obtain 3. The yield (60%) is lower than that in reaction of IIIL with Ag(OAc).
[Ag(IVL)(OH)]·CH3COOH (4)—OC10H14NC6H4NH2-4 (IVL, 46 mg; 0.18 mmol) in ethanol (3 mL)
and silver acetate (30 mg; 0.18 mmol) in H2O (3 mL). The solutions were degassed. The mixture was
stirred for 4 h under N2. Yield 57%. Elem. Anal. (%) for AgC18H25N2O4. Found: C, 49.3; N, 6.2; H,
5.4; Calc.: C, 49.0; N, 6.4; H, 5.7; IR (cm−1): 3454 (OH), 3339 (NH2), 1733 (C=O), 1625 (C=N), 1593
(CHarom), 1567 (O=CO), 1504 (NH2). 1H NMR (300 MHz, CD3CN, δ ppm): 6.93 (d, J = 8.6 Hz, 2H),
6.70 (d, J = 8.6 Hz, 2H), 4.30 (sbr, 2H) 2.98 (d, J = 4.7 Hz, 1H), 1–91–1.84 (m, 3H), 1.68–1.51 (m, 3H), 1.06
(s, 3H), 1.00 (s, 3H), 0.83 (s, 3H). 13C NMR (300 MHz, CD3CN, δ ppm): 207.0, 169.1, 161.3, 146.1, 139.8,
124.5, 115.3, 58.0, 51.0, 45.3, 30.8, 24.4, 20.9, 17.7, 9.2.
[{Ag(OH)(VL)] (5)—A solution of 4-C6H4(OC10H14N)2 (VL, 117 mg; 0.3 mmol) in ethanol (5 mL)
and silver acetate (50 mg; 0.3 mmol) in H2O (5 mL) were stirred for 5 h. The complex precipitates from
reaction mixture. Yield 54%. Elem. Anal. (%) for AgC26H33N2O3·H2O. Found: C, 57.2 N, 4.8; H, 6.1;
Calc.: C, 57.0; N, 5.1; H, 6.4. IR (cm−1) 1750 (C=O), 1649 (C=N), 1559 (CHarom). 1H NMR(300 MHz,
CD3CN, δ ppm) 6.98 (s, 4H), 2.86 (d, J = 4.9 Hz, 2H), 1.9 (mc, 3H), 1.05 (s, 6H), 0.99 (s, 6H), 0.86 (s, 6H).
13C NMR (300 MHz, CD3CN, δ ppm): 207.3, 173.2, 148.0, 122.4, 58.9, 51.2, 45.3, 30.9, 24.9, 21.2, 17.6, 9.4.
[{Ag(OH)}3(VIL)2] (6)—3-C6H4(OC10H14N)2 (VIL, 199 mg; 0.5 mmol) in ethanol (8.5 mL) was
added to a solution of silver acetate (95 mg; 0.5 mmol) in H2O (8.5 mL) and the mixture stirred
overnight. Yield 62%. Elem. Anal. (%) for Ag3C52H67N4O7 Found: C, 53.1 N, 4.3; H, 5.6; Calc.: C, 52.8;
N, 4.7; H, 5.7. IR (cm−1): 1751 (C=O), 1668 (C=N), 1566 (CHarom). 1H NMR (400 MHz, CD2Cl2, δ ppm):
7.34 (t, J = 7.9, Hz,1H), 6.68 (2d, J = 1.9 Hz, 2H), 6.34 (s, 1H), 2.77 (d, J = 4.4 Hz, 2H), 2.16–2.01 (m, 2H),
1.94–1.80 (m, 2H), 1.68–1.54 (m, 4H), 1.03 (s, 6H), 0.94 (s, 6H), 0.85 (s, 6H). 13C NMR(400 MHz, CD2Cl2,
δ ppm): 206.6, 173.0, 151.1, 130.1, 117.2, 111.4, 58.5, 50.6, 44.8, 30.5, 24.7, 21.1, 17.6, 9.2.
[Ag(OH)(VIIL)] (7)—VIIL (44 mg; 0.3 mmol) in ethanol (10 mL) was added to Ag(OAc) (100 mg;
0.6 mmol) in H2O (10 mL) and stirred overnight. Yield 88%. Elem. Anal. (%) for AgC32H37N2O3
Found: C, 64.0; N, 4.3; H, 6.1; Calc.: C, 63.6; N, 4.6; H, 6.2. IR (cm−1): 3421 (OH), 1745 (C=O), 1660
(C=N), 1566 (CHarom). 1H NMR (300 MHz, CD2Cl2, δ ppm): 7.65 (d, J = 8.1 Hz, 4H), 7.03 (d, J = 7.9 Hz,
4H), 2.89 (d, J = 4.5 Hz, 2H), 2.21–2.07 (m, 2H), 1.96–1.81 (m, 2H), 1.72–1.60 (m, 4H), 1.10 (s, 6H), 1.01 (s,
6H), 0.92 (s, 6H). 13C NMR (300 MHz, CD2Cl2, δ ppm): 206.7, 172.5, 149.3, 137.9, 127.8, 121.5, 58.4, 50.7,
44.9, 30.6, 24.7, 21.1, 17.7, 9.2.
[{AgCl(IIL)] (8)—To a solution of AgCl (50 mg; 0.35 mmol) in ammonia (33%,5 mL) a solution of
the ligand IIIL (84 mg; 0.35 mmol) in EtOH (5 mL) was added. N2 was then bubbled for a few minutes.
The mixture was stirred for 3 h at RT. The slight suspension was filtered off and the volume of the
solution was reduced until precipitation. Upon filtration the title compound was obtained and dried
under vacuum. Yield 59%. Elem. Anal. (%) for AgClC16H19NO. Found: C, 50.3; N, 3.6; H, 5.1; Calc.: C,
50.0; N, 3.6; H, 5.0. IR (cm−1): 1744 (CO), 1651 (CN), 1589 (CHarom). 1H NMR (400 MHzCD3CN, δ
ppm): 7.40 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.3 Hz 1H), 6.90 (d, J = 7.7 Hz, 2H), 2.74 (d, J = 4.3 Hz, 1H),
1.91–1.84 (m, 2H), 1.66–1.55 (m, 2H) 1.04 (s, 3H), 0.97 (s, 3H), 0.86 (s, 3H). 13C NMR(400 MHz, CD3CN,
δ ppm): 207.5, 150.9, 130.1, 126.0, 120.9, 58.9, 51.1, 45.2, 30.8, 24.8, 21.2, 17.6, 9.4.
[{Ag(NH3)}2(μ-VL)(μ-O)] (9)—A solution of the ligand VL (75 mg; 0.19 mmol) in EtOH (2.5 mL)
was added to a solution of AgCl (23 mg; 0.16 mmol) in ammonia (33%, 2.5 mL). The mixture was
stirred for 4 h at RT. Yield 69%. Anal. (%) for Ag2C26H38N4O3. Found: C, 46.4 N, 8.0; H, 5.3; Calc.: C,
46.6; N, 8.4; H, 5.7. IR (cm−1): 3341 (NH), 1753 (CO), 1621 (CN), 1595 (CHarom), 1505 (NH). 1H NMR
(400 MHz, MeOH-d4, δ ppm): 7.06 (s, 4H), 2.92 (d, J = 4.4 Hz, 2H), 2.29–2.17 (m, 2H), 2.02–1.93 (m,
2H), 1.75–1.56 (m, 4H) 1.09 (s, 6H), 1.07 (s, 6H), 0.83 (s, 6H). 13C NMR (400 MHz, MeOH-d4, δ ppm):
190.5, 169.8, 148.8, 125.4, 123.1, 116.2, 58.9, 49.5, 45.7, 31.3, 25.0, 21.3, 17.9, 9.3. There is evidence for two
isomers in solution that were not further investigated.
[AgCl(VIL)2] (10)—Solid AgCl (50 mg; 0.35 mmol) was added to VIL (137 mg; 0.35 mmol) in Et2OH
(5 mL) followed by addition of ammonia (33%, 5 mL). The mixture was stirred for 3 h. Yield 72%. Anal.
(%) AgClC52H64N4O4. Found: C, 65.9 N, 5.8; H, 6.8; Calc.: C, 65.6; N, 5.9; H, 6.8. IR (cm−1): 1750
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(CO), 1661 (CN), 1579 (CHarom). 1H NMR (400 MHz, CD3CN, δ ppm): 7.4 (t, J = 7.9 Hz, 1H); 6.7 (2d,
J = 7.9 Hz, 2H), 6.34 (m, 1H), 2.77 (d, J = 4.5 Hz, 2H), 1.04 (s, 3H), 0.98 (s, 3H), 0.87 (s, 3H). 13C NMR
(400 MHz, CD3CN, δ ppm): 207.2, 173.8, 152.1, 131.1, 111.3, 59.0, 51.2, 45.2, 30.8, 24.9, 21.2, 17.6, 9.4.
[Ag2(μ-VIL)(μ-O)] (10A)—Addition of VIL (137 mg; 0.35 mmol, 5 mL H2O) after complete
dissolution of AgCl (50 mg; 0.35 mmol) in ammonia (33%, 5 mL) followed by stirring overnight. Yield
56%. Anal. (%) Ag2C26H32N2O3·H2O. Found: C, 47.7; N, 4.5; H, 5.0. Calc.: C, 47.7; N, 4.3; H, 5.2. IR
(cm−1): 1749 (CO), 1660 (CN), 1579 (CHarom). 1H NMR (400 MHz, CD3CN, δ ppm): 7.43 (t, J = 7.9 Hz,
1H), 6.7 (dd, J = 1.7, Hz J = 7.9 Hz, 2H), 6.34 (m, 1H), 2.77 (d, J = 4.9 Hz, 2H), 2.12–2.03 (m, 2H), 1.91–1.75
(m, 2H), 1.64–1.56 (m, 4H), 1.04 (s, 6H), 0.98 (s, 6H), 0.87 (s, 6H). 13C NMR (400 MHz, CD3CN, δ ppm):
207.3, 173.9, 152.0, 130.9, 117.4, 111.3, 59.0, 51.1, 45.1, 30.8, 24.9, 21.2, 17.6, 9.3.
3.3. Antibacterial Activity Determinations
The antibacterial activity of compounds was assessed by determining their Minimal Inhibitory
Concentration (MIC) towards the Gram-positive Staphylococcus aureus Newman and the Gram-negative
Escherichia coli ATCC 25922, Pseudomonas aeruginosa 477 and Burkholderia contaminans IST408. These
bacterial strains are clinical isolates and were chosen as representatives of important bacterial
pathogens [1,25,30–32]. MICs were determined using Mueller Hinton Broth (MHB; Becton, Dickinson
and Company) as growth medium, based on microdilution assays, using previously described
methods [20,21]. In brief, a colony from a bacterial culture freshly grown in MHB solid medium was
transferred into MHB liquid medium and incubated for 4–5 h with agitation (250 rpm) at 37 ◦C. Bacterial
cultures were then diluted using fresh MHB to obtain ca. 106 colony forming units (CFUs) per mL. These
cultures were used to inoculate approximately 5 × 105 CFUs per mL in 96-well polystyrene microtiter
plates containing 100 μL of MHB supplemented with different concentrations of each compound,
obtained by 1:2 serial dilutions ranging 0.5 to 512 μg/mL. Stock solutions of compounds were prepared
with DMSO. After inoculation, microtiter plates were incubated at 37 ◦C for 20 h. Bacterial growth
was assessed by measuring the cultures optical density at 640 nm, in a SPECTROstarNano (BMG
LABTECH) microplate reader. Experiments were carried out at least four times in duplicates. Wells
containing 100 μL of 1× concentrated MHB and 100 μL of 106 CFUs per mL were used as positive
controls, while wells containing 200 μL of sterile MHB 1 × concentrated were used as negative controls.
3.4. Assessment of Complexes Anti-Candida Activity
The ability of the complexes 1–10A or of the ligands to inhibit growth of C. albicans or C. glabrata was
assessed using the highly standardized microdilution method recommended by EUCAST (European
Committee on Antimicrobial Susceptibility Testing). The MIC50 values were considered to be the
concentration of drug that reduced yeast growth by more than 50% of the growth registered in drug-free
medium [33]. The strains used in this work were C. albicans SC5314 and C. glabrata CBS138, largely used
as reference strains. Briefly, cells of the different species were cultivated (at 30 ◦C and with 250 rpm
orbital agitation) for 17 h in Yeast Potato Dextrose (YPD) growth medium and then diluted in fresh
Roswell Park Memorial Institute (RPMI) growth medium (Sigma) to obtain a cell suspension having
an OD530nm of 0.05. From these cell suspensions, 100 μL aliquots were mixed in the 96-multiwell
polystyrene plates with 100 μL of fresh RPMI medium (control) or with 100 μL of this same medium
supplemented with 0.98–500 μg/mL of the different compounds. As a control we also examined the
inhibitory effect of Ag(OAc) or of AgCl. After inoculation, the 96-multiwell plates were incubated
without agitation at 37 ◦C for 24 h. After that time, cells were re-suspended and the OD530nm of the
cultures was measured in a SPECTROstarNano (BMG LABTECH) microplate reader. The MIC50 value
was taken as being the highest concentration tested at which the growth of the strains was 50% of the
value registered in the control lane.
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3.5. Toxicity Assessment
The toxicity of the compounds was evaluated towards normal fibroblasts V79, obtained from the
American Type Culture Collection (ATCC). The cell lines were grown in Dulbeco´s Modified Eagle
Medium (DMEM) + Glutamax® medium supplemented with 10% Fetal Bovine serum (FBS) and
maintained in a humidified atmosphere at 37 ◦C using an incubator (Heraeus, Germany) with 5%
CO2. Cell viability was measured by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) assay, based on the conversion of the tetrazolium bromide into formazan crystals by living
cells which determines mitochondria activity [34]. For the assay, cells were seeded in 96-well plates at
a density of 104 cells per well in 200 μL medium and allowed to attach overnight. Complexes were
first diluted in DMSO to solubilize and then in medium to prepare the serial dilutions in the range
10−7–10−4 M. The maximum concentration of DMSO in the medium (1%) had no toxicity effect. After
careful removal of the medium, 200 μL of each dilution were added to the cells, and incubated for
another 48 h at 37 ◦C. At the end of the treatment, the medium was aspirated and 200 μL of MTT
solution (1.5 mM in PBS) was applied to each well. After 3 h at 37 ◦C, the medium was discarded
and 200 μL of DMSO was added to solubilize the formazan crystals. The cellular viability was
assessed by measuring the absorbance at 570 nm using a plate spectrophotometer (Power Wave Xs,
Bio-Tek). The IC50 values were calculated using the GraphPad Prism software (version 5.0). Results
are mean ± SD of at least two independent experiments done with six replicates each and represent
the percentage of cellular viability related to the controls (no treatment).
3.6. X-ray Photoelectron Spectroscopy
For X-ray photoelectron spectroscopy characterization (XPS), a XSAM800 XPS dual anode
spectrometer from KRATOS was used. The unmonochromatic Mg Kα radiation (main line at
hν = 1256.6 eV) was used. Operating conditions, data acquisition and data treatment are described
elsewhere [35]. For charge correction purposes, carbon bound to carbon and hydrogen in C 1s peak
was set to a binding energy (BE) of 285 eV. For quantification purposes, the following sensitivity factors
were used: 0.318 for C 1s, 0.736 for O 1s, 0.505 for N 1s, and 6.345 for Ag3d.
4. Conclusions
Silver hydroxide [Ag(OH)L] (L = IVL, VL, VIL, VIIL), oxide [{AgL}2}(μ-O)] (L = IL, IIL, IIIL, VL, VIL)
and homoleptic [AgIIL]Cl, [Ag(VIL)2]Cl camphorimine complexes were synthesized using Ag(OAc)
or AgCl as metal sources. The basic characteristics of the reaction medium prompted the formation
of hydroxide or oxide rather than acetate or chloride complexes. The selection of the camphorimine
ligands (L) that encompass mono- and bi-camphors, allowed the design of complexes with considerable
distinct electronic and steric properties and thus different biological activities.
In summary, the most relevant achievement of this study is that the new oxo and hydroxo silver
camphorimine complexes overreach the resistance of C. albicans. Additionally, the complexes reach
MIC50 values for C. glabrata even lower than those previously reported for the camphorimine nitrate
complexes [Ag(NO3)L]. In fact, the antifungal activity of the oxo and hydroxo silver camphorimine
complexes is even higher towards C. albicans than C. glabrata.
Author Contributions: Conceptualization, M.F.N.N.C., N.P.M., and J.H.L.; Experimental data acquisition, J.P.C.,
M.J.F.P., S.A.S., M.C.O., A.M.B.R., F.M., M.F.N.N.C.; methodology and data curation: all authors; writing—original
draft preparation, M.F.N.N.C., J.H.L., N.P.M., A.M.B.R., F.M.; writing—review and editing, all authors; funding
acquisition, M.F.N.N.C., N.P.M., J.H.L., F.M.
Funding: This research received no external funding.
Acknowledgments: Financial support by FCT-Fundação para a Ciência e Tecnologia through
projects ID/QUI/00100/2019, UID/BIO/04565/2019, UID/MULTI/04349/2019, Grant BL-CQE/2018-013, contract
PTDC/BIA-MIC/31515/2017 and Programa Operacional Regional de Lisboa 2020 (Project No. 007317) is gratefully
acknowledged as well as facilities from the NMR and Mass Spectra Networks (IST-UTL Nodes).
65
Antibiotics 2019, 8, 144
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E., Jr.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.;
Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America.
Clin. Infect. Dis. 2009, 48, 1–12. [CrossRef] [PubMed]
2. Lim, C.S.; Rosli, R.; Seow, H.F.; Chong, P.P. Candida and invasive candidiasis: Back to basics. Eur. J. Clin.
Microbiol. Infect. Dis. 2012, 31, 21–31. [CrossRef] [PubMed]
3. Witherden, E.A.; Shoaie, S.; Hall, R.A.; Moyes, D.L. The Human Mucosal Mycobiome and Fungal Community
Interactions. J. Fungi 2017, 3, 56. [CrossRef] [PubMed]
4. Pfaller, M.A.; Diekema, D.J.; Gibbs, D.L.; Newell, V.A.; Ellis, D.; Tullio, V.; Rodloff, A.; Fu, W.; Ling, T.A.;
Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance
Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole
as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2010, 48, 1366–1377. [PubMed]
5. Pfaller, M.A.; Diekema, D.J.; Turnidge, J.D.; Castanheira, M.; Jones, R.N. Twenty Years of the SENTRY
Antifungal Surveillance Program: Results for Candida Species From 1997–2016. Open Forum Infect. Dis. 2019,
15, S79–S94. [CrossRef] [PubMed]
6. Theuretzbacher, U. Future antibiotics scenarios: Is the tide starting to turn? Int. J. Antimicrob. Agents 2009,
34, 15–20. [CrossRef] [PubMed]
7. Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Rasool, M.H.; Nisar, M.A.; Alvi, R.F.;
Aslam, M.A.; Qamar, M.U.; et al. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist.
2018, 11, 1645–1658. [CrossRef] [PubMed]
8. Singh, S.B.; Young, K.; Silver, L.L. What is an “ideal” antibiotic? Discovery challenges and path forward.
Biochem. Pharmacol. 2017, 133, 63–73. [CrossRef]
9. Nett, J.E.; Andes, D.R. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.
Infect. Dis. Clin. N. Am. 2016, 30, 51–83. [CrossRef]
10. Etubu, E.; Arikekpar, I. Antibiotics: Classification and mechanisms of action with emphasis on molecular
perspectives. Int. J. Appl. Microbiol. Biotechnol. Res. 2016, 4, 90–101.
11. Kapoor, G.; Saigal, S.; Elongavan, A. Action and resistance mechanisms of antibiotics: A guide for clinicians.
J. Anaesthesiol. Clin. Pharmacol. 2017, 33, 300–305. [CrossRef] [PubMed]
12. Park, Y.-K.; Kyung-Soo, H. Antimicrobial Peptides (AMPs): Peptide Structure and Mode of Action. BMB Rep.
2005, 38, 507–516. [CrossRef]
13. Ghosh, C.; Sarkar, P.; Issa, R.; Aldar, J. Alternatives to Conventional Antibiotics in the Era of Antimicrobial
Resistance. Trends Microbiol. 2019, 27, 323–338. [CrossRef]
14. Singh, P.A.; Desai, S.D.; Singh, J. A Review on Plant Antimicrobials of Past Decade. Curr. Top. Med. Chem.
2018, 18, 812. [CrossRef] [PubMed]
15. Kenawy, E.R.; Worley, S.D.; Broughton, R. The chemistry and applications of antimicrobial polymers: A
state-of-the-art review. Biomacromolecules 2007, 8, 1359–1384. [CrossRef] [PubMed]
16. Lemire, J.A.; Harrison, J.J.; Turner, R.J. Antimicrobial activity of metals: Mechanisms, molecular targets and
applications. Nat. Rev. Microbiol. 2013, 11, 371–384. [CrossRef] [PubMed]
17. Liang, X.; Luan, S.; Yin, Z.; He, M.; He, C.; Yin, L.; Zou, Y.; Yuan, Z.; Li, L.; Song, X.; et al. Recent advances in
the medical use of silver complex. Eur. J. Med. Chem. 2018, 157, 62–80. [CrossRef]
18. Cardoso, J.M.; Guerreiro, S.I.; Lourenco, A.; Alves, M.M.; Montemor, M.F.; Mira, N.P.; Leitão, J.H.;
Carvalho, M.F.N. Ag(I) camphorimine complexes with antimicrobial activity towards clinically important
bacteria and species of the Candida genus. PLoS ONE 2017, 12, e0177355. [CrossRef]
19. Carvalho, M.F.N.; Leite, S.; Costa, J.P.; Galvão, A.M.; Leitão, J.H. Ag(I) camphor complexes: Antimicrobial
activity by design. J. Inorg. Biochem. 2019, 199, 110791. [CrossRef]
20. Leitão, J.H.; Sousa, S.A.; Leite, S.A.; Carvalho, M.F.N. Silver Camphor Imine Complexes: Novel Antibacterial
Compounds from Old Medicines. Antibiotics 2018, 7, 65. [CrossRef]
66
Antibiotics 2019, 8, 144
21. Cardoso, J.M.S.; Galvão, A.M.; Guerreiro, S.I.; Leitão, J.H.; Suarez, A.C.; Carvalho, M.F.N. Antibacterial
activity of silver camphorimine coordination polymers. Dalton Trans 2016, 45, 7114–7123. [CrossRef]
[PubMed]
22. Cardoso, J.M.S.; Correia, I.; Galvão, A.M.; Marques, F.; Carvalho, M.F.N. Synthesis of Ag(I) camphor
sulphonylimine complexes and assessment of their cytotoxic properties against cisplatin-resistant A2780cisR
and A2780 cell lines. J. Inorg. Biochem. 2017, 166, 55–63. [CrossRef] [PubMed]
23. Bordwell, F.G.; Algrim, D. Nitrogen acids. 1. Carboxamides and sulfonamides. J. Org. Chem. 1976, 41,
2507–2508. [CrossRef]
24. Geary, W.J. The use of conductivity measurements in organic solvents for the characterisation of coordination
compounds. Coord. Chem. Rev. 1971, 7, 81–122. [CrossRef]
25. Richau, J.A.; Leitão, J.H.; Sá-Correia, I. Enzymes leading to the nucleotide sugar precursors for
exopolysaccharide synthesis in Burkholderia cepacia. Biochem. Biophys. Res. Commun. 2000, 276, 71–76.
[CrossRef] [PubMed]
26. Doehmer, J. Predicting Drug Metabolism–dependent Toxicity for Humans with a Genetically Engineered
Cell Battery. Altern. Lab. Anim. 2006, 34, 561–575. [CrossRef] [PubMed]
27. Mazu, T.K.; Bricker, B.A.; Flores-Rozas, H.; Ablordeppey, S.Y. The Mechanistic Targets of Antifungal Agents:
An Overview. Mini-Rev. Med. Chem. 2016, 16, 555–578. [CrossRef] [PubMed]
28. Fernandes, T.A.; Mendes, F.; Roseiro, A.P.S.; Santos, I.; Carvalho, M.F.N. Insight into the cytotoxicity of
polynuclear Cu(I) camphor complexes. Polyhedron 2015, 87, 215–219. [CrossRef]
29. Carvalho, M.F.N.; Costa, L.M.G.; Pombeiro, A.J.L.; Schier, A.; Scherer, W.; Harbi, S.K.; Verfürth, U.;
Herrmann, R. Synthesis, structure, and electrochemistry of palladium complexes with camphor-derived
chiral ligands. Inorg. Chem. 1994, 33, 6270–6277. [CrossRef]
30. Denmark, S.D.; Rivera, I. Asymmetric Carboalkoxyalkylidenation with a Chiral Horner-Wadsworth-Emmons
Reagent. J. Org. Chem. 1994, 59, 6887–6889. [CrossRef]
31. Rice, L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE.
J. Infect. Dis. 2008, 197, 1079–1081. [CrossRef] [PubMed]
32. Sousa, S.A.; Feliciano, J.R.; Pita, T.; Guerreiro, S.I.; Leitão, J.H. Burkholderia cepacia Complex Regulation of
Virulence Gene Expression: A Review. Genes 2017, 8, 43. [CrossRef] [PubMed]
33. Arendrup, M.C.; Cuenca-Estrella, M.; Lass-Flörl, C.; Hope, W.; EUCAST-AFST. EUCAST technical note
on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum
inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect.
2012, 18, E246–E247. [CrossRef] [PubMed]
34. Van Meerloo, J.; Kaspers, G.; Cloos, J. Cell sensitivity assays: The MTT assay. Mol. Biol. 2011, 731, 237–245.
35. Carapeto, A.P.; Ferraria, A.M.; do Rego, A.M.B. Unraveling the reaction mechanism of silver ions reduction
by chitosan from so far neglected spectroscopic features. Carbohydr. Polym. 2017, 174, 601–609. [CrossRef]
[PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Assessing National Antimicrobial Resistance
Campaigns Using a Health Equity Assessment
Tool (HEAT)
Graeme Hood, Lina Toleikyte and Diane Ashiru-Oredope *
Public Health England, London SE1 8UG, UK
* Correspondence: diane.ashiru-oredope@phe.gov.uk; Tel.: +44-020-7811-7240
Received: 15 June 2019; Accepted: 14 August 2019; Published: 17 August 2019
Abstract: It has been widely recognised that a significant proportion of the world’s population suffer
inequalities in accessing high quality healthcare and wider services. Within healthcare, antimicrobial
resistance (AMR) is a global threat to public health affecting all healthcare systems and growing at
an alarming pace. To ensure that national AMR campaigns developed by Public Health England
are inclusive of all populations within the target audience a health equity assessment tool (HEAT)
was used. The project leads for each campaign completed the HEAT independently with a follow up
meeting with the study team to discuss and clarify the responses. A trend analysis was carried out
with common themes being used to provide recommendations. The campaigns have demonstrated
equality and diversity based on the requirements of the Equality Act 2010, particularly age, sex, and
race protected characteristics. Some notable results include the translation of website materials in
over 30 languages and reaching individuals in 122 countries. It was however noted that several of
the protected characteristics were not applicable. The continuous development of resources with
collaboration from a variety of diverse user groups would be advantageous towards aiding future
campaign reach. The use of the HEAT has demonstrated the ease and cost-effective way to assess
any health inequalities and would be a useful addition to antimicrobial stewardship and public
health campaigns.
Keywords: antimicrobial stewardship; health inequalities; health equity assessment tool; public health
1. Introduction
Research has shown that there are inequalities in accessing high quality healthcare across the
world, which affects a large proportion of people [1]. It has been estimated by the World Health
Organisation (WHO) that 400 million people do not have access to one of seven essential health services,
such as drugs and vaccines [2]. The variations in health inequalities have been reported both at a
national and at an international level with the average life expectancy in the UK (81.2 years) lower than
Japan (83.7 years) but higher than Sierra Leone (50.1 years) [1]. The health inequalities are classified as
unjust differences in health and wellbeing between different groups of people which are systematic
and avoidable and may be driven by (Supplementary Figure S1):
• Different experiences of the wider determinants of health or structural factors, for example the
environments, income or housing.
• Differences in health behaviours or other risk factors between groups, for example smoking,
diet, and physical activity levels have different social distributions. Health behaviours may be
influenced by wider determinants of health, like income.
• Unequal access to or experience of health and other services between social groups.
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The monitoring of health inequalities is important as it can identify progress linked to specific
health policies or programmes and help to focus interventions at the most disadvantaged cohorts of
the population. Through continual monitoring, the reduction or widening of health differences can
be highlighted [3,4]. To aid the assessment of health interventions, policies, programmes, services
and reduce health inequalities, specific assessment tools have been created such as the health equity
assessment toolkit (HEAT) that was developed by the World Health Organisation (WHO) between 2014
and 2016 [5]. The WHO HEAT is a software, that contains the WHO’s health equity monitor database,
supporting countries to assess inequalities within the country with over 30 indicators including
reproductive, maternal, new-born and child health and five dimensions of inequality (economic status,
education, place of residence, subnational region and child’s sex, where applicable) [5].
The reduction of health inequalities within England is a responsibility for Public Health England
(PHE), an executive agency of the UK Government [6]. To help the organisation assess the impact of
the public facing campaigns for health equity, PHE’s Health Inequalities team designed an internal
HEAT. The assessment consists of a series of questions, which are designed to support systematic
assessment of health inequalities related to work programmes, initiatives, policies and identify actions
that need to be taken to reduce any potential identified inequalities.
The HEAT was built on international experience from the WHO and the Ministry of Health in New
Zealand [5,7]. Unlike the WHO and New Zealand HEAT, the PHE tool considers the requirements of
the Equality Act 2010 and therefore the set protected characteristics (Box 1) in addition to inequalities.








• pregnancy and maternity
• marriage and civil partnership
As well as considerations about socio-economic differences, area variations by the deprivation
level (IMD), service provisions, urban/rural populations or in general and excluded and underserved
groups for example homeless people, people in prison, or young people leaving care were considered.
It also recommends five stages for the assessment which include prepare, assess, refine, apply
and review. Each assessment is likely to be iterative and can help areas continuously improve the
contribution of work streams to reducing health inequalities. There have been notable local results
within New Zealand from the application of this toolkit, including health promotion and health care
clinics in low decile schools; dental care for those on low incomes; free interpreter services; and
mobile Māori nursing services [8]. The WHO HEAT is pre-populated with the health equity monitor
database, allowing users to explore the situation in one setting of interest (e.g., a country, province,
or district) to determine the latest situation of inequality and changes in inequalities over time as
well as to benchmark settings/countries. The PHE and New Zealand tools can be considered quality
improvement tools for assessing and developing programmes, initiatives and policies.
It is important to use the HEAT to assess that the impact of public facing campaigns. The
development of an internal HEAT has helped PHE to assess such interventions and provides a
pragmatic and systematic set of steps for health policy makers to assess their initiative in relation to
health equity. The application of the toolkit can occur at different stages of the program or policy
development including the initial planning phase, the implementation stages or in the programme
review phase [7]. Within the development of proposals or policies, there can be a tendency to leave
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the target groups as wide as possible so that more people are included. However, this approach can
potentially result in the reduction of certain cohorts of the population that would benefit most from
the programme or policy. This can result in unintended and unanticipated health impacts on certain
population groups [9]. The use of HEAT can potentially help to reduce this unintended outcome for
which PHE has started to incorporate this toolkit within the assessment process of national campaigns.
The outcome of health equity assessments can inform decisions on how to build and strengthen policies,
programmes and future services that organisations provide [8]. The antimicrobial resistance team has
been one of the pioneers to adopt it within its campaigns.
Antimicrobial resistance (AMR) is a global threat to public health affecting all healthcare systems
and growing at an alarming pace [10,11]. The implementation of antimicrobial stewardship programmes
has been used within secondary care to help reduce this burden, with a focus on the UK Government
ambition to reduce inappropriate antibiotic prescribing [12]. An important element of these programmes
is the use of national campaigns to increase the overall reach. There is currently a lack of research
assessing the potential health inequalities within public facing antimicrobial stewardship campaigns.
The primary aim of this study was to assess whether the public facing AMR initiatives are reaching
a diverse population within England. The secondary aim included providing individual campaign
recommendations and general trend recommendations for the overall campaigns. Following a literature
review, the authors believe there is currently limited research available that specifically assesses health
inequalities related to AMR national campaigns.
National Campaigns
The following four national AMR campaigns run by Public Health England were assessed:
Antibiotic Guardian
As part of the European Antibiotic Awareness Week (EAAD), this campaign was launched in
September 2014. The aim was to increase commitment by healthcare professionals and members
of the public to reduce AMR, change behaviour and increase knowledge. This is done through a
pledge-based system where healthcare professionals and members choose a relevant pledge relating to
their practice or personal situation [13].
Target audience: Broad audience
e-Bug
This campaign was developed as a European Union project and created a junior and senior
school educational resource for teachers covering microbes, hygiene, antibiotics and the prevention of
infection. There is both a paper based educational pack along with a web site that hosts games for
young people and their families to play in the classroom or at home [14].
Target audience: School age children and teachers
TARGET (Treat Antibiotics Responsibly, Guidance, Education, Tools)
The TARGET antibiotics toolkit was developed by PHE in collaboration with the Royal College
of General Practitioners (RCGP) and other professional societies. The main aim of this campaign is
to improve antimicrobial prescribing in primary care through multiple channels such as guidance,
interactive workshops, patient facing educational and audit materials [15].
Target audience: Prescribing clinicians
Keep Antibiotics Working
This is a consumer-led campaign to help raise awareness of antibiotic resistance to members of
the public and highlight the dangers of not using antibiotics appropriately.
There are three main aims within this campaign—alert the public to the issue of AMR, reduce
public expectation for antibiotics and support change amongst healthcare professionals [16].
Target audience: Women aged 20–45 and Men and women aged 50+
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2. Results
The overall results assessing whether each protected characteristic as defined in the Equality Act
2010 was addressed by the campaign are summarised in Table 1.








Age All ages Ages 9–24 All ages Ages 20–45 and 50+
Sex All All All All




















Material designed for all
groups to understand
(C2DE inclusive)
Sexual Orientation N/A N/A N/A N/A
Gender












partnership N/A N/A N/A N/A
N/A—no data available.
2.1. Antibiotic Guardian
The overall reach of this campaign was found to be extensive with 122 countries having at least
one pledge [17]. This included the Antibiotic Guardian website currently being translated into 4
languages as well as English. When reviewing the population within England, it may be advantageous
to offer languages in line with the latest Census (e.g., 2011 Census in England and Wales showed 7.7%
of the population had another main language that was not English) [18]. The materials are open to
everyone who has internet access so can be accessed by a variety of local populations and specific
cultural groups. Further engagement and understanding of the culture of specific groups (e.g., Black,
Asian and minority ethnic (BAME) and travelling community) or those in deprived communities
would be beneficial to help promote the materials.
The Antibiotic Guardian campaign has now been embedded in the boy scouts to improve reach
within younger children, an addition within the equivalent guides would help provide this key resource
to more children.
The accessibility of information within the website is very good with an easy to use interface.
Supportive resources, via leaflets and videos, provide a platform for those that do not have internet
access. It could be beneficial to create and promote paper versions (PDF/word) of antibiotic guardian
pledges that can be used by local campaign leads so that individuals without the internet can also
pledge. The website supports a subtitle function on the home page video but a transcription of the
video would improve accessibility. Future interface designs of the website could be done in conjunction
with specific minority groups.
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2.2. e-Bug
The e-Bug focuses on the education element of infections within children, young people and
those hard to reach in the community. This interactive campaign has been translated into over 30
languages and has approved trainers throughout England, Wales and Northern Ireland which improves
accessibility for these resources. The e-Bug trainer events should be targeted at areas with greater
antibiotic use which have greater deprivation and ethnicity. It was found that all resources are freely
available to download and print from the internet. The resources are developed for a range of ages and
therefore abilities within the community. In the Beat the Bugs resources, each lesson plan has a range
of activities to suit a range of abilities. The antibiotic Beat the Bug resources include a specific patient
facing pictorial resource for the public with language or learning difficulties. There is an increased
awareness within the project team of pictorial and foreign language resources, with a commitment
to continue to reassess the language being used is inclusive of all, especially for disadvantaged and
minority groups. There is also an increase focus in the implementation of resources in deprived areas
using additional work force and targeted training to local clinical commissioning group staff.
An analytical review of the e-Bug website usage and views would help identify further
development and improvement to reduce health inequalities and could be beneficial.
2.3. TARGET
The TARGET resources were found to be easily accessible to all healthcare professionals via an
open access website. The distribution was extensive and resources can be accessed to permanent,
training or temporary general practitioners (GPs). This was also the case for the out of hour GPs,
though further publicity within this group would aid the reach. The use of community pharmacists in
promoting the use of TARGET resources would help improve reach to patients. The TARGET website
contains patient facing resources to share in consultations for respiratory tract infections (including
a pictorial version) and urinary tract infections for patients under and over 65 years. These patient
leaflets are available in the most common non-English languages spoken in the UK.
2.4. Keep Antibiotics Working
The quantitative research completed by the internal marketing team demonstrated a representative
sample of the population within England, however due to the size of the sample, it was not possible or
appropriate to break down the data by every protected characteristic. The choice of media via the TV
ensured the campaigned reached a broad cross section of the population. During the campaign period,
over 766,000 posters and leaflets were distributed to a range of partners including local authorities,
health care centres and housing associations with 92% of GP practices in England engaged [19]. Prisons
were also included within the distribution along with GPs who reach those from lower socioeconomic
backgrounds. The advertising featured red and white pills which have no gender or racial bias. All
campaign research, including campaign tracking, strategic and creative development research was
carried out across all socioeconomic groups. The campaign materials were designed for all groups to
understand and were C2DE—skilled working class, working class and non-working (the three lower
social and economic groups in a society) inclusive. It would be recommended to conduct a review
impact analysis of the campaign by age, sex and socioeconomic group, and where appropriate, change
the campaign strategy based on this evidence. It was noted that more data is required to change
the marketing or targeting specific populations but the use of advertising routes that are set up to
engage with minority groups (e.g. radio channels focusing on certain groups, promote in religious
areas, prisons) may be beneficial. It could be advantageous to translate resource leaflets into multiple
languages in line with latest national Census and local population.
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3. Discussion
The assessments highlight the diverse and inclusive nature of the four campaigns run by Public
Health England. There have been notable successes in reaching a wider audience such as 92% of GP
practices in England being engaged with the Keep Antibiotic Campaign. Interestingly, this wider reach
may have contributed to a positive impact on the intended behaviour, with 78% of the public stating
that they would be unlikely to ask their GP for antibiotics [19]. It is important to note that the reach of
a campaign on the population can also have an influence on healthcare professionals with 93% of GPs
saying they felt the materials supported them to say no to antibiotics when they were not needed [19].
As technology advances, it has been demonstrated that there is more of an emphasis being put on
the use of technology within healthcare over the last few years. It is vital that campaigns use this
to reach greater audiences but also remembering an ageing population who potentially do not have
access to technology or would prefer not to be contacted through this means. The use of paper-based
approaches are still of value and should be utilised to make sure it is inclusive of all.
The assessments were conducted by the project lead and team members which could cause bias
when completing the assessment. However, through the use of an independent study team who are
not actively involved within the projects, this was partially negated during the review meeting where
the member of the study team provided a focus on the context of each question and did not aid or
prompt the project lead around a particular response. It would be ideal to have an independent person
completing the assessment without the involvement of the project lead but due to the complexities of
the campaigns, specialist knowledge is required to provide meaningful results.
During the assessments, it became apparent that not all protected characteristics were appropriate
for each campaign, for example, the e-Bug where the target audience is children, the marriage and civil
partnership criteria for assessment was not applicable.
The way in which each campaign runs alongside each other is important with the integration and
collaboration being key to improving the overall AMR message. The involvement of a senior sponsor
of the proposed campaign during the review stage would aid this further integration and also make
sure that organisational oversight is achieved.
The use of behavioural insight teams can also play a significant part in helping change an
individual’s views when it comes to antibiotic use with a greater input in all campaigns would help
achieve a long-term improvement when the public use antibiotics.
One of the limitations of this study is that the analysed/numeric data from the national campaigns
are not presented. However, it is important to note that whilst these are not presented within the
manuscript, the data and evidence are an essential part of section A—prepare the health equities
assessment tool (HEAT) (S1). This study focuses its attention on the importance of national campaigns
considering and monitoring health inequalities in their development and revisions. This will ensure that
interventions do not widen health inequalities and also, they can be focused at the most disadvantaged
cohorts of the population.
To improve the output of future campaigns, further research on health inequalities and AMR is
needed. This would provide corresponding data to help tailor campaigns to specific individuals that
may not be reached. Of the limited data available, there have been significant findings, including
the increase of AMR among refugees and asylum seekers in high-migrant community settings [20].
This has highlighted where future policy could be implemented, but with this data being available it
can also contribute to the effectiveness of using the HEAT in other health economies. Although this
study only assessed each campaign once, the use of HEAT is an iterative process which can help to
continuously improve the contribution of campaigns to reduce health inequalities. To consider the
impact this assessment has in reducing health inequalities, a subsequent review is advised.
4. Materials and Methods
An internal HEAT (Supplementary Figure S1) developed by PHE was used. The project leads for
each campaign in England, UK were asked to complete the HEAT independently, over an eight-week
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period from October to November 2018, with input from their team members as required. There was a
100% (4/4) completion rate to the HEAT during the allocated period. An initial meeting was conducted
with the project lead and one member of the study team to discuss the rationale of the assessment
tool and explain how the tool should be used. The HEAT was sent to each project lead via email with
responses also returned in the same way. A follow up meeting between the same individuals was
arranged to discuss and clarify queries and to standardise the approach for each separate assessment.
This was done to be able to provide trend analysis over all the assessed campaigns. All the responses
were collated by one member of the study team with a summary of the responses being discussed with
the remaining members of the study team. The main focus of the overall analysis was assessing whether
each protected characteristic as defined in the Equality Act 2010 and is the focus of the PHE HEAT
was included within the individual campaigns. A trend analysis was carried out on all four campaign
assessments with common themes of the responses being used to provide recommendations for future
work. A common theme was confirmed if two or more of the campaign responses identified that theme.
A qualitative analysis was used to summarise each campaign against the protected characteristics.
An action plan for each project was developed inclusive of common themes but also of any specific
recommendations relevant to that campaign.
5. Conclusions
The use of the HEAT comes at a significant time when the threat of AMR is well publicised.
Making sure any stewardship campaign is as diverse and inclusive as possible is essential to improve
the reach of the target audience. The greater the reach, the more impact national campaigns have with
greater flexibility to make them accessible for a diverse population. To help tailor campaigns to hard
to reach groups, further research into health inequalities relating to accessing antimicrobials would
be beneficial. The assessment has shown to be an easy and cost-effective way to assess any health
inequalities within a campaign and could be a useful addition to local level stewardship programmes
that are trying to reduce the amount of inappropriate antimicrobial use. This systematic approach
helps facilitate opportunities to address any health inequalities that have been identified and can also
be applied to a range of services and programmes. The communication of information within diverse
populations is vital in reducing the burden of AMR and addressing health inequalities. To improve the
reach of this information, the use of HEAT is also vital.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/8/3/121/s1,
Figure S1: The PHE Health Equity Assessment Tool. * This assessment tool is currently a working draft that the
PHE’s Health inequalities team is planning to revise in line with stakeholder feedback.
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Abstract: Antimicrobial stewardship (AMS) interventions directed at general practitioners (GPs)
contribute to an improved antibiotic prescribing. However, it is challenging to implement and
maintain such interventions at a national level. Involving the municipalities’ Chief Medical Officer
(MCMO) in quality improvement activities may simplify the implementation and maintenance,
but may also be perceived challenging for the GPs. In the ENORM (Educational intervention in
NORwegian Municipalities for antibiotic treatment in line with guidelines) study, MCMOs acted as
facilitators of an AMS intervention for GPs. We explored GPs’ views on their own antibiotic prescribing,
and their views on MCMO involvement in improving antibiotic prescribing in general practice.
This is a mixed-methods study combining quantitative and qualitative data from two data sources:
e-mail interviews with 15 GPs prior to the ENORM intervention, and online-form answers to closed
and open-ended questions from 132 GPs participating in the ENORM intervention. The interviews
and open-ended responses were analyzed using systematic text condensation. Many GPs admitted
to occasionally prescribing antibiotics without medical indication, mainly due to pressure from
patients. Too liberal treatment guidelines were also seen as a reason for overtreatment. The MCMO
was considered a suitable and acceptable facilitator of quality improvement activities in general
practice, and their involvement was regarded as unproblematic (scale 0 (very problematic) to 10
(not problematic at all): mean 8.2, median 10). GPs acknowledge the need and possibility to improve
their own antibiotic prescribing, and in doing so, they welcome engagement from the municipality.
MCMOs should be involved in quality improvement and AMS in general practice.
Keywords: quality improvement; general practitioners; primary care; antibiotics; guideline
1. Introduction
The presence of antibiotic resistance is closely connected to the consumption of antibiotics, both at
a societal and an individual level, and most antibiotics consumed by humans are prescribed in primary
care [1]. Compared to other European countries, the use of antibiotics in Norwegian primary care is
relatively low, but there is still room for improvement [2]. Accordingly, in 2016 the Norwegian Ministry
of Health and Care Services published an action plan with the aim of an overall 30% reduction in the
use of antibiotics by 2020 [3].
As general practitioners (GPs) have a key role in regulating the amount of consumed antibiotics in
primary care, numerous antimicrobial stewardship interventions directed at GPs have been tried out.
In the Norwegian Rx-PAD (Prescription Peer Academic Detailing) study [4], effective strategies such as
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educational outreach visits [5] and audit and feedback [6] were combined, resulting in a relative reduction
in antibiotic prescribing of 9%, and an increased proportion of narrow spectrum antibiotic of 24%.
The participating GPs found the intervention acceptable [7], and especially valued that the
intervention was implemented by a peer GP and not by an external authority.
In Norway, GPs are mainly self-employed and have no clinical superiors. Professional autonomy
is highly valued [8]. The municipality, with which the GP has a contract to deliver primary care
services, has a legal responsibility to ensure quality improvement and patient safety measures for the
GPs [9]. However, how this responsibility should be interpreted and implemented is very unclear [10].
The Rx-PAD intervention was resource intensive, as it included training, travel expenses,
and payment for the GPs who acted as peer academic detailers. Hence, the intervention has
not been implemented as a freely available course for Norwegian GPs. The same is the case for
many antimicrobial stewardship interventions both in primary and secondary care. To overcome
these challenges, we developed the ENORM (Educational intervention in NORwegian Municipalities
for antibiotic treatment in line with guidelines) study [11], which aims at testing an antimicrobial
stewardship intervention that, if effective and acceptable, can be easily implemented throughout primary
care. The intervention; a 15-hour course consisting of 3 e-learning sessions and 3 Continuing Medical
Education (CME) group meetings where the GPs are to discuss their personal prescription reports,
is rolled out by a representative of the municipality, the Municipal Chief Medical Officer (MCMO).
In small municipalities, the MCMO post usually is a part-time position for a GP, while full-time
MCMO position is the norm in large municipalities. The ENORM intervention was tested in 30
randomly selected, medium-size (5.000–25.000 inhabitants), high-antibiotic-consumption Norwegian
municipalities between February 2017 and September 2018. The effect of the intervention will be
reported in a separate publication.
The aim of this study is to explore the GPs’ judgment of their own antibiotic prescribing, and their
views and attitudes toward MCMOs’ involvement in antimicrobial stewardship efforts toward GPs.
2. Results
2.1. Part 1—E-Mail Interviews
During our analysis, we defined three main themes: antibiotic prescribing, reduction, and quality
improvement.
2.1.1. Antibiotic Prescribing
The GPs were divided in their views of own antibiotic prescribing without medical indication.
Many stated that this was rarely or never the case. An equally common statement was that the GP
admitted to doing this on some occasions. A view was held that the correct prescription practice is not
easily defined:
“I don’t prescribe antibiotics without a medical indication, but here I mean there are grey areas of
right/wrong use, and not a black/white picture on indication.” (GP, board member)
Perceived pressure from patients was the most common explanation as to why the GPs prescribed
antibiotics without medical indication. While some GPs had recently experienced patients to be more
knowledgeable in their views on antibiotic use, the majority still experienced pressure from patients to
prescribe antibiotics. They expressed that this demand could be challenging to withstand. Fear of
under-treating, the patient’s strong opinion of the need for antibiotic treatment, and lack of time to
explain and convince the patient that the treatment is unnecessary, were pointed out as reasons for not
withstanding the pressure. Some pointed out patients’ lack of understanding the difference between
bacterial and viral infections, and a perception of antibiotics as an easy quick-fix.
Treatment guidelines were mentioned within the topic of reasons for antibiotic overuse. Some GPs
claimed that the actual guidelines on antibiotic use are an obstacle for reducing antibiotic prescribing,
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and pointed to several areas where they found that this was the case. Otitis, respiratory tract infections,
uncomplicated cystitis, and acne were some of the indications suggested for revision.
”I think (...) the indications are too spacious. We are over-treating when we follow guidelines.”
(GP with board membership)
2.1.2. Reduction
The GPs held that antimicrobial resistance is a serious threat, and they strongly agreed that
antibiotic use had to be greatly reduced. The GPs that reflected on their own ability to contribute to
reducing prescription rates were concerned about the goal being set too high. The majority stated that
they were unsure of their ability to cut their own prescription rates to match the 30% reduction goal set
by the Government. One GP stated that their prescription rate was at a level where 30% reduction
would not be a justifiable correction.
The GPs had several ideas on how to reduce antibiotic prescribing. Guideline revision, information
to the patients and public on antibiotic resistance, and the use of delayed prescribing were suggested.
Although most examples of ways to reduce antibiotic prescriptions were very specific, one GP had
thoughts on a more long-term measure:
“Make the GPs proud of their professional mandate, including their ability to single out the few
seriously ill patients who actually need antibiotics.” (GP with board membership)
This view was opposed by another GP who pointed out how their professional freedom is
rightfully challenged when matters of serious public concern are debated:
“As all my colleagues, I value my independence as a general practitioner, but certain cases
(like the problem of bacterial resistance) are too important not to manage centrally.” (GP without
board membership)
2.1.3. Quality Improvement
The GPs welcomed the MCMO as a facilitator of quality improvement activities in primary
care. It was described as a praiseworthy and reasonable use of the MCMO’s time, and an interesting
quality improvement approach. Some informants explicitly missed the municipalities’ engagement in
quality improvement.
“(If the municipality initiated quality improvement measures) I would probably faint by the
surprise of it. My municipality does nothing to improve the content of the primary care service.”
(GP with board membership)
A view was held that the MCMO would be in an appropriate professional position to initiate
quality improvement initiatives toward GPs.
“Professional independence is a sensitive topic for general practitioners. An arrangement like this
by the pharmacy, for an example, would end up wrong. A municipality doctor or infection doctor
would possibly be acceptable.” (GP without board membership)
2.2. Part 2—Online-Form Answers
2.2.1. Own Potential for Improvement
We received 132 answers to the question “What do you consider to be your potential for
improvement?” All respondents presented one or several specific goals for their antibiotic prescribing.
They pointed out specific diagnoses and age groups where they could reduce their use of antibiotics,
and considered tools to help them achieving their goals, such as enhanced consultation techniques.
Some of the respondents also set a time limit for when they should have reached their goals. Even though
the specificity and comprehensiveness of the answers varied, no respondents argued that they saw
small, or no, room for improvement.
79
Antibiotics 2019, 8, 120
2.2.2. The Municipal Chief Medical Officer’s Role
About 85% (112) of the 132 participants responded to the rating scale question “What is your
opinion on the Municipal Chief Medical Officer’s role in this course?” On the 11 points scale (0: very
problematic to 10: not problematic at all), the mean value was 8.2 (95% CI: 7.6–8.7), and the median
value was 10.
Twenty five percent (33) of the 132 participants responded to the open-ended question “Provide
comments on the Municipal Chief Medical Officer’s role.” Four respondents commented that their
MCMO did not have any role in the implementation of the ENORM course in their CME group, and five
respondents commented that they themselves were MCMOs, in addition to being GPs. The remaining
24 respondents all gave positive comments on the MCMOs role. Two main explanations were
identified: First, the participants appreciated having a designated course facilitator. They experienced
that the MCMO coordinated and structured the meeting, gave useful information and reminders, and
initiated valuable group discussions with relevant and relatable cases. Second, it was appreciated
that the MCMO engaged in the issue of antibiotic prescribing and set an example by recommending
national guidelines.
Some of the respondents commented that the MCMO also participated in the course as a GP,
or that they knew them as a GP, and that they considered the MCMO to be more a peer than a manager.
3. Discussion
3.1. Main Findings
The general practitioners in this study stated that there is an overuse of antibiotics in general
practice, and that the use should be reduced. Perceived pressure from patients, lack of time, fear of
under-treatment, and too liberal guidelines were pointed out as drivers of unnecessary antibiotic
prescribing. Both arguments that GPs themselves could bring about the needed reduction and that
external efforts were justified for GPs to reduce prescribing existed among the GPs. The Municipal
Chief Medical Officer (MCMO) was seen as a suitable and acceptable facilitator of quality improvement
activities in general practice. This view was supported by GPs taking part in the ENORM intervention,
facilitated by their MCMO.
3.2. Strengths and Limitations
This study has some limitations. The response rate on the open-ended questions was relatively
low in both part 1 (15% of invited GPs without board position) and part 2 (25% of participating GPs)
of the study. GPs with strong views on antimicrobial stewardship and GP’s autonomy, work frames,
and quality improvement may have been more inclined to participate, as suggested by the fact that
62% of GPs with board positions responded. However, the aim in qualitative studies is not to recruit a
representative sample of informants within the given population, but to explore existing views among
a variety of informants [12]. We find that the selection of GPs was diverse, including both opinion
leaders and GPs without any board membership, and we achieved variety with respect to geography,
gender, municipality’s size, and municipality’s antibiotic consumption.
Our selection of informants is quite small. In a paper on sample sizes in qualitative studies [13],
Malterud presents “information power” as a concept. Malterud suggests that the more relevant
information a sample holds for a study, the lower number of participants is needed. Our informants
may be considered to provide information of high value, as they included both potential participants
of a planned intervention and participants of the actual intervention.
The respondents gave relatively short answers to the open-ended questions, ranging from 1
to 180 words. As held by Meho [14], e-mail interviewing can be a viable alternative to face-to-face
interviews in qualitative research. The opportunity of easy outreach to informants over a large
geographic area was a great benefit in our study. The challenge of using this method, however, is the
less opportunity for continuous correspondence, and the information gathered is less in-depth than
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what could be expected in a face-to-face interview. We also experienced that some GPs agreed to
participate but did not respond when the e-mail with the actual interview was sent, suggesting that
e-mail interviews may be perceived as less binding than a face-to-face interview.
Due to the wording of the question “What do you consider to be your potential for improvement?”
respondents may have felt obliged to suggest such a potential, even if they found that there was no
need for improvement. Also, the respondents in part 2 had agreed to participate in a course facilitated
by the MCMO. GPs with negative views on such cooperation may have rejected the MCMOs invitation,
thus introducing a selection bias in this part of the study. However, no negative remarks regarding the
MCMOs’ involvement were expressed in part 1 of the study.
3.3. Results and Discussion
Many of the informants admitted to occasionally prescribing antibiotics without clinical
indication. Their reasons for doing so were to a large extent coherent with previous findings
on “non-pharmacological” antibiotic prescribing [15]: the lack of opportunity for continued care,
pressure from patients, and the GP’s uncertainty. However, the view that antibiotic overtreatment
may be due to adherence to guidelines is to our knowledge a new finding. GPs experience that
obligations to adhere to several single-disease guidelines may lead to polypharmacy and overtreatment
in multimorbid patients [16]. Especially, guidelines on prevention of cardiovascular disease are held to
be inadequate and cause overtreatment in primary care [17]. The existence of this view among GPs
when it comes to guidelines for antibiotic use may indicate that the guidelines could be stricter, but at
the same time it also indicates that there is a risk of under-treatment of infections in primary care.
The MCMO’s role as facilitator and organizer of quality improvement activities in general practice
was approved, both as a general idea among GPs not exposed to such activities, and based on the
experience of GPs taking part in the ENORM intervention. Previous research has demonstrated
the importance for GPs that quality improvement tutors are “one of them,” and independent of
health authorities [7]. The MCMO is indeed a representative of the health authorities, but to a large
extent, the participants regarded the MCMO as a peer, since many of them worked as both GP and
MCMO. Also, the MCMOs in the ENORM intervention seem to have acted as facilitators, organizers,
and initiators rather than experts or superiors.
There is an ongoing frustration among GPs, both in Norway and internationally, that GPs
are imposed an increasing number of tasks and obligations without corresponding financial and
organizational support [18,19]. The participants in our study valued the engagement from the
municipality, possibly indicating that quality improvement and antimicrobial stewardship are
perceived as necessary and wanted activities within general practice and not as obligations imposed
by external authorities.
Preliminary results from part 1 of this study have been utilized to develop and tailor the content
and implementation of the ENORM intervention.
4. Materials and Methods
This is a mixed-methods study combining quantitative and qualitative data from two data sources:
Part 1: E-mail interviews with a sample of GPs prior to the ENORM intervention.
Part 2: Online-form answers to closed and open-ended questions from GPs participating in the
ENORM intervention.
4.1. Part 1—E-Mail Interviews
4.1.1. Interview Guide
We developed a list of open-ended questions covering the themes—unnecessary antibiotic
prescribing, own potential for reducing antibiotic prescribing, and the MCMO’s potential role in quality
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improvement in primary care. The questions were piloted among three GPs and modified according to
the GPs’ comments (Supplementary File 1).
4.1.2. Selection and Recruitment
Two groups of informants were recruited:
(1) GPs who were considered to be opinion leaders among their peers, especially concerning
clinical practice and quality improvement; board members of the General Practitioners’ Association
(Allmennlegeforeningen), the Norwegian College of General Practitioners (Norsk forening for
allmennmedisin) and the General Practice committee for Quality and Patient Safety (Allmennmedisinsk
utvalg for kvalitet og pasientsikkerhet), a subcommittee of the Norwegian College of General Practitioners.
(2) GPs in high-antibiotic-consuming, medium-size (5.000–25.000 inhabitants) municipalities, aiming at
variety with respect to geography, gender, municipality size, and municipality antibiotic consumption.
Invitations were sent out by either mail or e-mail. GPs that consented to participate were sent the
questions by e-mail, and asked to reply to the e-mail. We aimed at about equal numbers of informants
in group (1) and (2), and continued to recruit GPs to group (2) until this was achieved. In group (1),
8 out of 13 GPs consented to participate, and in group (2), 7 out of 47 GPs consented to participate,
resulting in a total of 15 respondents. The interviews were performed between June 2016 and June
2017. None of the informants were exposed to the ENORM intervention.
4.1.3. Analysis
The e-mail answers were anonymized and then analyzed using systematic text condensation [20].
MS and SH read all the text thoroughly, and agreed upon a list of initial themes, resulting in a coding
frame. MS coded the text. The analysis followed four steps: (1) reading the complete material to obtain
an overall impression; (2) identifying units of meaning representing different aspects of antibiotic use
and antimicrobial stewardship efforts, and coding for these units; (3) condensing and summarizing
the contents of each of the coded groups; and (4) generalizing descriptions and concepts. MS and
SH read the condensates and agreed to the analysis. Illustrative quotes were translated into English.
The software tool NVIVO was used in the analysis.
4.2. Part 2—Online-Form Answers
4.2.1. Online Form
We developed an online form to be filled out by the participating GPs in the ENORM intervention
directly after the first group meeting. The form had three purposes—to register completion of each
participant’s group meeting, to aid as a quality improvement tool as part of a Plan-Do-Study-Act
(PDSA) cycle [21], and to register the participants views on the Municipal Chief Medical Officers’ role
in the intervention. Three of the online-form questions are used in this study:
• What do you consider to be your potential for improvement?
• What is your opinion on the Municipal Chief Medical Officer’s role in this course? (11-points
rating scale, from 0 (very problematic) to 10 (not problematic at all))
• Provide comments on the Municipal Chief Medical Officer’s role.
The first question was mandatory in order to register completion of the group meeting, while the
two other questions were optional. Hence, all GPs participating in the ENORM intervention were
asked to fill the online form.
4.2.2. Selection, Recruitment, and Analysis
MCMOs in the 30 ENORM intervention municipalities were informed that they belonged to
a high-antibiotic-consuming municipality, and invited to recruit their local GPs to participate in a
15-hour antibiotic-prescribing improvement course. MCMOs who were also GPs could participate
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alongside the other GPs in their municipality. Participating GPs gave written consent to analysis of
their online-form answers. By the end of the ENORM intervention in September 2018, 132 GPs had
completed the first group meeting, resulting in 132 online-form answers.
The material was analyzed in the same manner as described in Part 1. MMN and SH read through
all the responses, and MMN coded the text. The rating scale answers were analyzed using Microsoft
Excel 2016.
4.3. Ethics (Part 1 and 2)
All participants gave informed consent to the study. The ENORM project was presented for
the Regional Ethics Committee South/East (2016/1491/REK sør-øst C), which concluded that ethical
approval was not mandatory. Data protection was approved by NSD—Norwegian Centre for Research
Data (48136/3 and 50740/3).
5. Conclusions
GPs acknowledge the need and possibility to improve their own antibiotic prescribing. In doing
so, they welcome engagement from the municipality, and they find that the MCMO is a suitable and
acceptable quality improvement facilitator. MCMOs should be involved in quality improvement and
antimicrobial stewardship efforts in general practice.
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Abstract: Inappropriate choices and durations of therapy for urinary tract infections (UTI) are
a common and widespread problem. In this qualitative study, we sought to understand why
primary care providers (PCPs) choose certain antibiotics or durations of treatment and the sources of
information they rely upon to guide antibiotic-prescribing decisions. We conducted semi-structured
interviews with 18 PCPs in two family medicine clinics focused on antibiotic-prescribing decisions
for UTIs. Our interview guide focused on awareness and familiarity with guidelines (knowledge),
acceptance and outcome expectancy (attitudes), and external barriers. We followed a six-phase
approach to thematic analysis, finding that many PCPs believe that fluoroquinolones achieve more a
rapid and effective control of UTI symptoms than trimethoprim-sulfamethoxazole or nitrofurantoin.
Most providers were unfamiliar with fosfomycin as a possible first-line agent for the treatment of
acute cystitis. PCPs may be misled by advanced patient age, diabetes, and recurrent UTIs to make
inappropriate choices for the treatment of acute cystitis. For support in clinical decision making, few
providers relied on guidelines, preferring instead to have decision support embedded in the electronic
medical record. Knowing the PCPs’ knowledge gaps and preferred sources of information will guide
the development of a primary care-specific antibiotic stewardship intervention for acute cystitis.
Keywords: antibiotic stewardship; antibiotics; fluoroquinolones; guidelines; urinary tract infections
1. Introduction
Antimicrobial resistance is increasingly being recognized as one of the major threats to human
health globally [1]. The 2015 United States (U.S.) National Action Plan for Combatting Antibiotic
Resistant Bacteria set a goal to reduce inappropriate antibiotic use by 50% in outpatient settings [2].
Primary care providers (PCPs) constitute the largest proportion of antibiotic prescribers in the U.S.;
therefore, engaging these practitioners is essential to improving outpatient antibiotic stewardship [3].
In 2011, outpatient healthcare providers in the U.S. prescribed 262.5 million courses of antibiotics, with
the largest proportion (24%) being prescribed by family medicine physicians [3].
Most studies in outpatient settings have addressed implementing antibiotic stewardship for
upper respiratory infections, typically viral infections in which antibiotics are not indicated [4,5].
Few studies have addressed inappropriately prescribing for urinary tract infections (UTI) [6], one of
the top three diagnoses for which antibiotics are prescribed in outpatient settings [7]. The first-line
agents recommended by the updated 2010 Infectious Diseases Society of America (IDSA) guidelines to
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treat uncomplicated cystitis are nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin [8].
However, inappropriate choices and durations of antibiotic therapy for UTI are a common problem in
primary care [9–11]. Providers often choose fluoroquinolones as a first-line agent for uncomplicated
cystitis and prescribe antibiotics for longer than the guidelines’ recommended treatment duration [9,10].
Fluoroquinolone use is one of the factors that has led to the emergence and spread of multidrug-resistant
Escherichia coli (E.coli) strain sequence type 131 [12]. In addition, the U.S. Food and Drug Administration
(FDA) issued black box warnings for fluoroquinolones in 2016 [13] and 2018 [14,15] that fluoroquinolones
should not be used for uncomplicated UTIs in patients who have other treatment options. These
FDA warnings are based on studies indicating an association between fluoroquinolone use and
tendonitis and tendon rupture [16,17], QT-prolongation [18], dysglycemia [19,20], neuropathy [21–23],
and potentially aortic rupture [15].
Unfortunately, the 2010 IDSA guidelines had little impact on national outpatient national antibiotic
prescribing practices for UTI [24], with fluoroquinolones as the most commonly prescribed antibiotic
class in young women both before and after the release of the guidelines [24]. In order to design
an effective antibiotic stewardship intervention for outpatient UTI management, we first need to
understand why primary care providers are choosing certain antibiotics or certain durations of
treatment and what sources of information they rely on to guide their antibiotic-prescribing behavior.
To acquire these insights, we used qualitative semi-structured interviews to explore primary care
provider prescribing decisions for UTI.
2. Results
We interviewed 18 primary care providers working in two private academically affiliated family
medicine clinics. We reached data saturation after 13 interviews with our homogeneous sample [25,26].
Our thematic analysis identified seven themes related to providers’ prescribing decisions for
acute cystitis (Figure 1). The themes were mapped to the Cabana framework for understanding the
barriers to physician adherence to clinical practice guidelines [27]. Four of these themes reflected
factors influencing antibiotic prescribing decisions for acute cystitis, two themes described the sources
of information they rely upon to guide antibiotic-prescribing decisions, and one theme explored the
perceptions of antibiotic resistance in providers’ practices.
 
Figure 1. Mapping of the identified themes to the Cabana framework.
2.1. Theme 1: Perceived Effectiveness and Efficiency were Common Reasons for Choosing Fluoroquinolones
Most providers reported that they would prescribe trimethoprim-sulfamethoxazole (TMP-SMX)
or nitrofurantoin in the case scenario; however, the treatment duration suggested was sometimes longer
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than recommended by the guideline. Specifically, the preferred treatment duration of nitrofurantoin
was 7 days instead of the guideline recommendation of 5 days among approximately half of the
providers who selected this medication as their first choice for treatment. The suggested duration of
TMP-SMX was 5 days instead of the guideline recommendation of 3 days among a few providers who
selected this medication as a first choice, though most providers correctly chose a guideline concordant
with the 3-day duration. Relatively few providers chose fluoroquinolones in the case scenario, though
a third listed fluoroquinolones second among their top three choices of antibiotics most frequently
prescribed for uncomplicated cystitis in response to a different question. In all quotations below,
alias initials of providers were included to indicate that the quotations presented come from a variety
of participants.
Common reasons given for why providers might choose fluoroquinolones included prescribing
familiarity, “I think a lot of it has to do with familiarity and comfort.” (DS); perceived effectiveness, “No
matter what kind of bacteria it is, it would be responsive to Cipro.” (WC); short course of treatment,
“In most instances, I just choose Cipro, and it’s easy; it’s for three days.” (WC); broad-spectrum
coverage, “Ciprofloxacin is a very strong antibiotic, and it is broad-spectrum.” (JG); and previous
patient experience, “If the patient had reported that Cipro had worked well before for them in the past,
that might be a consideration.” (SL). Providers also expressed confidence in the ability of ciprofloxacin
to kill a wide range of bacteria, reporting, for example, “Physicians don’t want the patient to have a
treatment failure and come back in for a second antibiotic.” (AA).
2.2. Theme 2: Factors Influencing Providers’ Choice of Antibiotics and Treatment Duration
Providers described multiple considerations when choosing the best antibiotic for acute cystitis.
These considerations included allergies, patient sex, pregnancy, patients’ past experience with the
antibiotic, familiarity with the antibiotic, previous antibiotic susceptibilities, older age, shorter treatment
duration and better compliance, frequency of UTI, presence of diabetes, and cost of antibiotics. A few
providers mentioned the potential effect of fluoroquinolones on tendons. For example, one provider
noted, “There is concern about the fluoroquinolones and their effect on tendons, but I don’t know
whether it’s a media sort of blown up case of concern or whether it’s real.” (MB). Another provider
described various factors affecting their choice of antibiotic for particular patients, “Age, whether
or not they have frequent UTI, maybe information from their previous urine cultures which shows
sensitivities.” (AA).
When the interviewer asked probing questions about the treatment of older patients, some
providers mentioned that they would be more likely to choose ciprofloxacin and a longer duration of
treatment, while others mentioned that the management of UTI would not change. Similarly, when
questioned about recurrent UTIs and the management of diabetic patients with UTI, some providers
reported that they would go with “a stronger, broad-spectrum antibiotic such as ciprofloxacin” (BC)
and a longer treatment duration. When questioned about male UTIs, providers emphasized the need
to rule out a sexually transmitted infection and recommended a treatment duration of up to 14 days.
2.3. Theme 3: Providers’ Mixed Assessments of Nitrofurantoin
Few side effects, low cost, and good tolerance were mentioned by the majority of providers as
the benefits of nitrofurantoin, with providers giving such responses as, “Nitrofurantoin, it is one of
my “go to”. It is a good medication for uncomplicated cystitis.” (JQ). However, many providers also
mentioned that nitrofurantoin is not as “strong” and not as “quick” as fluoroquinolones. One provider
explained, “We have a patient population that wants their symptoms to be resolved immediately.
Therefore, nitrofurantoin is not a good choice as it is bacteriostatic, and I want to make sure the patient
is satisfied and just want to give them something that will resolve symptoms faster.” (BC).
A few providers were concerned about birth defects based on published case-control studies [28,29],
while others thought nitrofurantoin is much safer than TMP-SMX or fluoroquinolones for pregnant
women with UTIs, reporting, for example, “It’s one of the ones I use the most, especially in women of
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childbearing age.” (AV). Provider-reported drawbacks included concerns about lung problems with
prolonged use, “When I was on the pulmonary rotation, they were talking about the risk of nitrofurantoin
causing pulmonary fibrosis, and I’ve never forgotten that.” (JS), as well as contraindication in patients
with low creatinine clearance or in older patients in general, “It’s on the Beers list.” (AA).
2.4. Theme 4: Unfamiliarity with Fosfomycin as a Treatment Option
Most providers were unfamiliar with fosfomycin as a possible treatment option for cystitis,
although it is a first-line agent per guidelines [8]. Providers gave such responses as, “I don’t use
fosfomycin. I’ve read about it maybe once or twice.” (AV) and “I don’t think one can use it in the United
States. I’ve never seen anyone try it, and I’ve never looked into it.” (WC). One provider reported
having had a patient who had been prescribed fosfomycin by an infectious disease specialist.
2.5. Theme 5: Reliance on Easily Accessed Sources for Clinical Decision-making
In terms of sources of support for clinical decision-making, few providers directly relied on
guidelines. Instead, many reported that they use clinical decision support resources, such as UpToDate,
accessed through the institution’s electronic health record, “I use UpToDate. That’s simple. I can
click from Epic, so it’s right there on my chart. [I’m] talking to the patient, and I just click and pop it
up.” (AZ) or through a mobile phone app for staying informed about new information on antibiotics,
“I use UpToDate. I have the app on my phone, so I am always searching.” (BC). A few providers
mentioned publications such as Prescriber’s Letter and resources available from the American Academy
of Family Physicians.
2.6. Theme 6: Lack of Specific Recall of Guidelines on Treatment of Uncomplicated Cystitis
Only two providers mentioned the IDSA guidelines, though most respondents reported varying
degrees of familiarity with unspecified guidelines, saying, for example, “I think I am reasonably
up-to-date.” (SC), “I guess I would be fairly familiar.” (JQ), and “It’s been about 10 years since I
reviewed the guidelines.” (AV). A few providers acknowledged limited recall of the details of any
guidelines regarding the treatment of uncomplicated cystitis, as indicated in the following statements:
“Not very. There’s very little reason in something as simple as acute cystitis for me to go searching out
the guidelines.” (MB), “Try to stay away from Cipro first line. That’s about all I remember.” (DT), and
“I have to admit I’m not particularly conversant. I will usually look at UpToDate and just refresh my
memory.” (JS).
2.7. Theme 7: Differing Perceptions of Antibiotic Resistance as a Problem in Providers’ Own Practices
When discussing the extent to which antibiotic resistance is a problem in their own practices,
providers had widely differing opinions, ranging from little or no resistance, “I have never noticed
resistance within my practice.” (GS), to clear, affirmative responses, “Yes, based on cultures, I have had
patients who have had organisms identified that have a pretty concerning resistance profile.” (DS).
Some providers expressed uncertainty regarding the extent of antibiotic resistance, for example, “It
is so hard for me to predict what’s going to be resistant.” (EJ), while others indicated a need for an
antibiogram. One provider stated, “I don’t know if there’s actually resistance in this area or not. It
would be nice to get, like, a report to say that.” (AA).
3. Discussion
In our study PCPs’ antibiotic choices and durations in the case scenario of acute uncomplicated
cystitis were generally in line with the guidelines’ recommended first-line therapy. Most providers
correctly chose TMP-SMX or nitrofurantoin for the treatment of uncomplicated cystitis in the case
scenario. However, ciprofloxacin was often the second antibiotic mentioned when providers responded
to the question about the top three most frequently prescribed antibiotics for uncomplicated cystitis.
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A number of providers chose treatment durations longer than the guideline recommendations. In
particular, many were unaware that the current recommended duration of therapy for nitrofurantoin has
been reduced to 5 days [8] compared with the 7-day duration in the previous 1999 IDSA guideline [30].
We found that many PCPs believe that fluoroquinolones are more likely to achieve rapid
and effective control of UTI symptoms than TMP-SMX or nitrofurantoin. This finding is in line
with a previous qualitative study on the effects of knowledge, attitudes, and practices of PCPs on
antibiotic selection [31]. Belief that broad-spectrum antibiotics may be more likely to cure an infection
was the main reason for a lack of adherence to the guidelines [31]. However, clinical trials have
shown that fluoroquinolones are comparable with first-line recommended agents in both clinical
and microbiological efficacy in UTIs [32]. Although fluoroquinolones are highly efficacious for
uncomplicated cystitis if the uropathogens are susceptible, increasing resistance rates may hamper
the effectiveness of fluoroquinolones for empirical antibiotic use. Fluroquinolone resistance increased
dramatically in recent years, with >10–30% of community-associated Enterobacteriaceae being
quinolone resistant in many parts of the United States and with even higher rates (>50%) in other
parts of the world [33]. Furthermore, fluoroquinolones have been moved to the last class of agents
(after β-lactams) and should be used only when no other oral options are available because of three
warnings from the U.S. FDA that the risk for serious harms outweighs the benefits for patients with
uncomplicated UTIs [13–15]. Of note, the initial warning preceded our interviews by approximately
a year.
In our study, PCPs’ prescribing decisions took into account multiple factors in determining the best
course of treatment for patients with acute cystitis such as pregnancy, patients’ past experience with a
specific antibiotic, previous antibiotic susceptibilities, frequency of UTI, older age, and presence of
diabetes. Some PCPs chose a longer duration of treatment when the patient was older or had diabetes.
These results are consistent with our previous observational database study, performed in the same
setting, showing that older age and the presence of diabetes were independent, significant predictors of a
longer treatment duration for UTIs [10]. Older women were also more likely to receive fluoroquinolones
for uncomplicated UTIs in a study on national antibiotic prescribing trends in outpatient settings in the
U.S. [9]. Advanced age, diabetes, and recurrent UTIs may be cognitive biases that drive inappropriate
antibiotic use for uncomplicated UTI. Treatment recommendations for otherwise healthy older women,
with or without diabetes, are similar to those for younger women [34–36]. Similarly, antibiotic choice
and duration for sporadic and recurrent UTIs are not different. Broadening the antibiotic spectrum
or lengthening the treatment course have not been proven efficacious and elicit concern for potential
harm to the individual and the community [37].
Another condition that triggered uncertainty for choosing the right antibiotic among the PCPs was
UTI in pregnancy. Some were concerned about the association between the use of nitrofurantoin and
birth defects reported in case-control studies [28,29]. However, no relationship between nitrofurantoin
use and birth defects was observed in a recent large cohort study [38]. An alternative first-line antibiotic
that can be used in pregnancy is fosfomycin. However, PCPs in our study were not familiar with
fosfomycin as a possible treatment option for cystitis, although it is a first-line agent per IDSA guidelines.
The fact that our providers did not seem to be aware of fosfomycin as a first-line recommended
antibiotic for uncomplicated UTI was not surprising. Fosfomycin was not prescribed in any visits for
UTIs in our previous database study [10], and it was prescribed in less than 0.1% of all visits in a recent
study of national antibiotic prescribing practices for UTIs in the U.S. [24]. Some of the reasons may be
that susceptibility to fosfomycin is not included in the reports received by the providers from the lab, as
well as insurance barriers and higher cost of fosfomycin compared with other UTI-relevant antibiotics.
Primary care physicians increasingly have multiple and sometimes conflicting guidelines [39]
for patient care and are challenged to maintain the knowledge base represented by the array of
guidelines for common problems. In a nationally representative sample of family physicians, Wolff
and colleagues [40] found that time constraints, concern for patient well-being, and consideration
of particular circumstances were all potential obstacles to guideline adherence; such concerns (e.g.,
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compliance concerns, patient preferences, and previously reported side effects) were noted by the
physicians interviewed for the current study. Likewise, nearly half of our study sample thought it
would be useful to have guidelines as a component of an electronic medical record, implying that
speed and ease of access are important to them. Most providers interviewed were unable to quote
from guidelines presented in monograph form but reported routinely accessing various electronic
media (e.g., UpToDate or Family Practice Notebook) for prescribing support.
Although most of the primary care providers were concerned about antibiotic resistance in their
practice, some did not consider antibiotic resistance to be a problem in their own practice, citing
greater resistance problems in inpatient settings or in non-UTI conditions. Likewise, in a Swedish
qualitative study, providers were aware of antibiotic resistance but thought of it as a national problem
that does not concern their own practice [41]. Some of our interviewed providers indicated a need for
an antibiogram specific to their setting to guide their empiric choices and a tool that can help predict
the risk of resistance in a specific patient. Unfortunately, an outpatient-specific antibiogram is not
available for the participating clinics, and we suspect that few settings have an outpatient-specific
antibiogram [42,43].
The main limitation of our study is the relatively small sample size. However, we performed this
qualitative study in a preparatory phase of a stewardship intervention and included all PCPs working
in two clinics. As with any qualitative study, the results are not meant to be generalizable. In particular,
our findings may not be generalizable to public clinics or clinics that are not academically affiliated. Our
findings represent an in-depth exploration of the attitudes and beliefs of the study sample. However,
findings are transferable as the issues we identified have been seen in other settings [9,31,41]. We are
using these findings to develop provider-focused materials for a subsequent clinic-based intervention
designed to support providers in their efforts to reduce the risks of drug resistance, to minimize serious
side effects, and to enhance overall patient care.
Our findings highlight the necessity of providing point-of-care information for primary care
providers from a trusted and easy to access source. This information will help providers to choose the
right antibiotic with the right duration, a fundamental aspect of antimicrobial stewardship for UTI.
4. Materials and Methods
4.1. Ethics
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of Baylor College of Medicine on 7 February 2019 (H-38265).
4.2. Setting and Participants
We selected individual interviews as the data collection strategy most appropriate for our research
objectives of exploring individual prescribing decisions. Individual interviews allow for in-depth
data collection and minimize the potential influence of group interaction or seniority and supervisory
relationships that could have been introduced with focus groups. In addition, individual interviews
allowed a much greater flexibility with scheduling, making it more feasible to reach and engage
participants. We conducted brief (30 minutes or less), individual, semi-structured interviews with 18
primary care providers (15 family medicine physicians and three physician assistants) in two private,
academically affiliated family medicine clinics in a large urban area between late July 2017 and early
November 2017. Both clinics utilize Epic Electronic Health Records. The characteristics of our study
sample are described in Table 1.
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Physician assistant 3 (17)
Years in practice
Fewer than ten years 9 (50)
10–20 years 3
Over 21 years 6
Board certified in Family Medicine 14






a One physician was board certified in Internal Medicine.
On average, 19,777 patients attend 3248 appointments at these clinics each month. Patients in both
clinics are predominantly female (58%) and white (54%). Fluoroquinolones were the most common
antibiotic class prescribed (51.6%) for uncomplicated UTI, and 75% of all prescriptions were longer
than the recommended duration in these clinics in our previous study in the period of 2011–2014 [10].
4.3. Interview Guide Development
The concepts included in our interview guide were based on the Cabana framework for
understanding barriers to physician adherence to clinical practice guidelines [27]. According to
this framework, three factors affect physician compliance with evidence-based guidelines: knowledge,
attitudes, and external factors. Our interview guide (Figure 2) focused on the following issues:
awareness and familiarity with the guidelines (knowledge), acceptance and outcome expectancy
(attitudes), and external barriers. To assess awareness and familiarity, we included the following
questions: “How familiar are you with any guidelines on the treatment of uncomplicated cystitis?”,
“What do you recall about these guidelines?”, and “Do these guidelines apply to your practice?”.
To assess the acceptance and outcome expectancy, we asked probing questions about the treatment of
recurrent UTIs and situations in which the patients were older, diabetic, or male. To help elucidate
external factors that might be driving treatment decisions, we included a clinical vignette about a
patient who had a diagnosis of acute uncomplicated cystitis and asked the participants to explain their
rationale for antibiotic choice and treatment duration and some reasons other primary care providers
might prescribe a fluoroquinolone for this condition.
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Figure 2. Sample interview questions.
The interview guide also included questions about clinical and nonclinical factors influencing
antibiotic choice and treatment duration, such as patient comorbidities or expected patient compliance.
We asked open-ended questions about providers’ experience with the specific antibiotics and their
preferred sources of support for clinical decision making. We also asked whether they perceived
antibiotic resistance to be a problem in their practices. Before starting the study, we pilot-tested our
interview guide with two primary care providers at another institution and adapted the guide as per
their suggestions.
4.4. Interview Procedures
Primary care providers were recruited by the research team during a weekly clinic meeting
and provided an overview of the study. After these meetings, individual follow-up recruitment
emails were sent by the research interviewer, a doctoral level social psychologist with substantial
experience in conducting qualitative interviews (SN). If providers were interested in participating, the
interviewer negotiated a convenient time for the session before or after regularly scheduled patient care
responsibilities. At the meeting, the interviewer responded to any additional questions or concerns
and obtained consent to participate. All invited providers agreed to participate and received a U.S. $20
gift card for their participation. Each individual participated only once.
4.5. Data Collection and Analysis
To protect participant confidentiality, the interviewer asked each participant to select an alias,
which we designated by initials during the interview and in the resulting transcripts. The interviews
were digitally recorded and transcribed verbatim by professional medical transcriptionists. The
interviewer listened to all recordings to verify the accuracy of the transcripts before entering them
into NVivo 10 software, a qualitative analysis package (QSR International, 2014) that facilitates the
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management of qualitative data. Based on a preliminary review of the transcripts and the aims of the
study, we determined that the interview questions and subsequent probes provided an appropriate
outline for the initial identification of key themes [44,45].
Two authors (LG and SN) met regularly to read, code, and discuss the transcribed interviews,
maintaining a shared consensus on the coding process. We elected to focus on the explicit content of
providers’ reported experiences and perspectives [46]. Overall, we followed the six-phase approach to
thematic analysis described by Braun and Clark [47], a sequential but flexible set of guidelines that
encompasses familiarization with the data; initial coding; searching, reviewing, and defining themes;
and finally, integrating the analytic narrative and data extracts by incorporating illustrative quotes
from providers into the description of the final themes [44,47]. Although our sample size was limited
to the total number of providers in the clinic setting, we judged that the last 5 to 6 interviews coded
were redundant to those previously coded, in repetition without an expansion of the themes, and were
confident that data saturation for this sample had been reached [25].
5. Conclusions
Our qualitative analysis found that many PCPs believe that fluoroquinolones achieve more rapid
and effective control of UTI symptoms than trimethoprim-sulfamethoxazole or nitrofurantoin. The
majority of the providers were unfamiliar with fosfomycin as a possible treatment option for cystitis,
although it is a first-line agent per guidelines. For recurrent UTI, older patients, or those with diabetes,
some providers reported that they would go with “a stronger, broad-spectrum antibiotic such as
ciprofloxacin” and longer treatment duration. For support in clinical decision making, few providers
relied on guidelines, preferring instead to have decision support embedded in the electronic medical
record. Understanding primary care providers’ clinical challenges and knowing their preferred sources
of information will enable us to develop a primary care-specific antibiotic stewardship intervention for
acute cystitis.
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Abstract: Outpatient antibiotic use in Belgium is among the highest in Europe. The most common
reason for an encounter in out-of-hours (OOH) primary care is an infection. In this study, we assessed
all consultations from July 2016 to June 2018 at five OOH services. We described antibiotic prescribing
by diagnosis, calculated disease-specific antibiotic prescribing quality indicators’ (APQI) values and
critically appraised these APQI. We determined that 111,600 encounters resulted in 26,436 (23.7%)
antibiotic prescriptions. The APQI diagnoses (i.e., bronchitis, upper respiratory infection, cystitis,
tonsillitis, sinusitis, otitis media, and pneumonia) covered 14,927 (56.7%) antibiotic prescriptions.
Erysipelas (1344 (5.1%)) and teeth/gum disease (982 (3.7%)) covered more prescriptions than sinusitis
or pneumonia. Over 75% of patients with tonsillitis and over 50% with bronchitis, sinusitis, and
otitis media were prescribed an antibiotic. Only for otitis media the choice of antibiotic was near
the acceptable range. Over 10% of patients with bronchitis or pneumonia and over 25% of female
patients with an acute cystitis received quinolones. The APQI cover the diagnoses for only 57% of
all antibiotic prescriptions. As 5.1% and 3.7% of antibiotic prescriptions are made for erysipelas
and teeth/gum disease, respectively, we propose to add these indications when assessing antibiotic
prescribing quality in OOH primary care.
Keywords: antibiotics; out-of-hours care; primary care; quality of care; quality indicators;
practitioners cooperative
1. Introduction
Antibiotic use in Belgium is among the highest in Europe, especially in ambulatory care,
and thus the risk for antimicrobial resistance is high [1]. The European Surveillance of Antimicrobial
Consumption (ESAC) [2] project has developed a set of 21 disease-specific antibiotic prescribing quality
indicators (APQI) to assess the quality of antibiotic prescribing in primary care [3]. These APQI have
been adopted in several evaluations of antibiotic prescribing in Europe [4–6].
Out-of-hours (OOH) care covers a large part of hours during a week. In Belgium, but also
in the rest of Europe, the on-going establishment of large-scale general practitioner cooperatives
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(GPCs) represents one of the most important developments for primary OOH health care. The most
common reason for an encounter in Flemish (Northern part of Belgium) OOH primary care is an
infection [7]. Many infections are self-limiting and no antimicrobial treatment is necessary. However,
in our qualitative work general practitioners (GPs) describe the difficulties they encounter in OOH
care not to prescribe antibiotics relating to contextual factors such as a larger uncertainty due to an
unknown patient, type of patients (e.g., children, elderly, Non-Native Speakers, . . . ), workload, and the
lack of diagnostic tools or follow-up. They have a feeling that their professional identity is different
compared to in-hours care [8,9]. However, previous research in Belgium showed similar APQI values
for in- and out-of-hours care, using the data of a singular general practitioner cooperative (GPC)
from 2004–2009 [4], which is similar to findings in Norway and Sweden [10,11]. In the Netherlands,
research showed higher prescribing rates in OOH care but with equal or even better quality compared
to in-hours care [12]. In the United Kingdom, researchers found an increase in antibiotic prescribing
in OOH primary care in contrast to in-hours care, however, this study did not explore the quality of
the prescriptions [13,14]. Moreover, in Danish OOH care, antibiotics are the most prescribed drugs,
but there was no evaluation on the quality of prescribing [15].
Therefore, the objective of this study is to assess the quality of antibiotic prescribing in OOH
primary care to inform the implementation of future interventions to improve the antibiotic prescribing
quality in this specific setting [16]. More specifically, we aim to describe antibiotic prescribing in Belgian
OOH primary care by indication, assess its quality by updating values for ESAC’s disease-specific
APQI [3] and critically appraise these APQI [4].
2. Methods
2.1. Database and GPCs
Data were extracted from the Improving Care and Research Electronic Data Trust Antwerp
(iCAREdata) database, a research database of linked data on OOH primary care [17,18]. On a weekly
basis, routine clinical data and patient characteristics are automatically collected from GPCs, emergency
departments (EDs) and pharmacists’ electronic records completed during OOH-care. For this study
we only used data from GPCs.
iCAREdata currently covers nine GPCs, that cover a population of 1,127,153. Only data from five
GPCs were withheld for this study, because of the level of completeness of their data and availability
at the start of the study. Together, they cover a population of around 811,000 inhabitants (11% of the
Flemish population; i.e., the Northern Dutch speaking part of Belgium). The characteristics of these
five GPCs are presented in Table 1. Because of a lack of registration of home visits in OOH care, only
data from consultations at the GPC itself were used.
Table 1. Characteristics of the five general practitioner cooperatives (GPCs) providing data for this study.
GPC Population Number of GPs Rural/Urban
Antwerp-East 148,366 112 Urban
Antwerp-North 141,110 119 Urban/rural
Antwerp-Centre 185,358 171 Urban
Tienen 84,430 80 Rural
Zuiderkempen 251,833 270 Rural
Total 811,097 752
2.2. Study Setting
Since the beginning of the year 2000, Belgian OOH care is increasingly being organized in GPCs
in regions that typically cover 80–180 GPs. All practicing GPs in such an area are obliged to participate
in this service following a rotation-based system of being ‘on call’ during the weekends in their own
region and they work in shifts of on average 12 h. GPCs are mostly organized in a fee-for-service
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system. There are 80–180 GPs per GPC. Belgian GPs do not have a gatekeeper function. There is
free access to primary, secondary, and tertiary care. They use an electronic medical health record
to register every patient contact. The software can differ depending on the GPC, but diagnoses
are always selected using Thesaurus terms in the Belgian Bilingual Biclassified Thesaurus (3BT).
By selecting a diagnosis in 3BT, an International Classification of Primary Care (ICPC-2-R) code is
automatically linked [19]. Prescriptions are registered using the database of the Belgian Centre for
Pharmacotherapeutic Information [20], which is linked to the Anatomical Therapeutic Chemical (ATC)
classification system [21,22].
2.3. Data Analysis
Data extraction was done using Microsoft SQL server 2012. We performed descriptive analyses
using Microsoft Excel 2016. Data from 1 July 2016 until 30 June 2018 were included.
2.3.1. Antibiotic Prescribing by Indication
To describe antibiotic prescribing by indication, first we only analyzed all antibiotic prescriptions
(ATC code J01: antibacterials for systemic use) delivered during the consultations in five GPCs during
a two-year timeframe and linked them with the diagnosis that was registered in the electronic medical
health record.
2.3.2. Quality of Antibiotic Prescribing: Disease-Specific APQI
Second, we used information on all encounters to assess the quality of antibiotic prescribing using
the disease-specific APQI introduced by ESAC (European Surveillance of Antimicrobial Consumption
project) in 2007 [3]. The seven most common indications for antibiotic prescribing are in descending
order: acute bronchitis (ICPC code R78), acute upper respiratory tract infection (RTI) (R74), cystitis/other
urinary infection (UTI; U71), acute tonsillitis (R76), acute/chronic sinusitis (R75), and acute otitis media
(H71). For pneumonia (R81), values of three valid APQI were calculated:
a = the percentage of patients with age and/or gender limitation (see legend Table 3) prescribed
an antibiotic;
b = a and receiving the guideline recommended antibiotic;
c = a and receiving quinolones.
We compared them with the findings of an earlier study with data from 2004–2009 from one GPC [4].
2.3.3. Critical Appraisal
We evaluated if APQI is a sufficient method when describing the quality of antibiotic prescribing
in OOH care. We used and adapted the concept of drug utilization 90% (DU90%) [23], which analyzes
the number of drugs accounting for 90% of drug use. We used it to see if using APQI-diagnoses covers
90% of all antibiotic prescriptions.
2.4. Ethics
The study was approved by the Ethics Committee of the Antwerp University Hospital/University
of Antwerp (reference number 17/08/089), and registered at clinicaltrials.gov (NCT03082521). The study
was approved by the scientific advisory board of ICAREdata and the different GPCs.
3. Results
From 1/7/2016 until 30/6/2018, 26,436 antibiotic prescriptions were registered in 111,600 visits
(excluding home visits) covering a population of 811,097 persons.
For 93.65% of the prescriptions, a diagnosis was registered in the same consultation. A diagnosis
was missing for 1612 (6.35%) antibiotic prescriptions.
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3.1. Antibiotic Prescribing by Indication
Table 2 shows the number of prescriptions linked to the ICPC chapters. Of them, 44% of the
prescriptions are linked to diagnoses related to respiratory infections, 13% to urinary tract infections,
12% skin infections, 11% ear infections, and 6% digestive infections. Other diagnoses represent less
than 5% of the prescriptions and are grouped in other diagnoses.
Table 2. Number of antibiotic prescriptions in a two-year time frame linked to diagnostic group (total
patient contacts (excluding home visits) = 111,600).







Other diagnoses (A, Y, L, X, B, F, W, K, P, N, T) 2179 8%
TOTAL 26,436 100%
ICPC: International Classification of Primary Care; R: respiratory; U: urinary; S: skin; H: ear; D: digestive; A: general
and unspecified; Y: Male genital system; L: Musculoskeletal; X: female genital system and breast; B: blood forming
organs, lymphatics, spleen; F: eye; W: pregnancy, childbirth, family planning; K: circulatory; P: Psychological; N:
neurological; T: endocrine, metabolic and nutritional.
3.2. The Quality of Antibiotic Prescribing
Table 3 shows the results of the quality appraisal using APQI. We complemented this table with
similar indicators for erysipelas and dental abscess, because they both cover respectively 5% and 4%
of antibiotic prescriptions. There are not yet quality indicators for these two indications [24], but we
chose to use following age limitations: older than one year for erysipelas and older than 18 year
for dental abscess. Overall, for all conditions the percentage of antibiotics prescribed for common
conditions exceed the upper limit (i.e., 20% for otitis media, upper RTI, sinusitis and tonsillitis, and
30% for bronchitis). Despite the fact that the highest amount of prescribed antibiotics are linked to
upper RTI (Table 3), indicator 2A shows that 30% of patients diagnosed with upper RTI receive a
prescription. Of the patients diagnosed with tonsillitis, 77% received an antibiotic prescription. For the
latter two conditions, the use of the recommended antibiotics is less than 10% (3% for upper RTI and
6% for tonsillitis). For most other conditions, the use of recommended antibiotics ranges from 40–46%
(40% for sinusitis, 42% for bronchitis, 42% for teeth/gum disease, erysipelas, and 46% for pneumonia).
For cystitis and otitis media, the use of recommended antibiotics is higher, 69% and 74% respectively.
No conditions reached the goal of 80–100%. Comparing these results with the APQI OOH study from
2004–2009, there is an improvement in choosing the recommended antibiotic. (otitis media: 42%→
74%; acute sinusitis: 23%→ 40%; cystitis 40%→ 69%; bronchitis 34%→ 42%). Other values are in the
same range as in 2004–2009 (Table S1 in the online Supplementary Materials).
For four conditions, the 5% upper limit of quinolone use was exceeded, i.e., in ascending order
sinusitis (7%), bronchitis (11%), pneumonia (15%), and cystitis (25%).
GPs can choose to enter a symptom diagnosis. (such as fever, cough, etc.), but only
3.8% of all antibiotic prescriptions are linked to this type of diagnosis (Table S2 in the online
Supplementary Materials).
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Table 3. Quality appraisal using disease-specific antibiotic prescribing quality indicators (APQI)




% of Patients Receiving the
Guideline Recommended AB
% of Patients Receiving
Quinolones
(<20%) (>80%) (<5%)





30 [15–41] 3 [2–7] 2 [0–2]
R75 Acute sinusitis 51 [39–57] 40 [35–51] 7 [2–9]
R76 Acute tonsillitis 77 [65–87] 6 [3–15] 1 [0–1]
(<30%) (>80%) (<5%)
R78 Acute bronchitis 69 [58–75] 42 [37–54] 11 [5–15]
(>80%) (>80%) (<5%)
R81 Pneumonia 80 [70–85] 46 [42–62] 15 [2–20]
U71 Acute cystitis 91 [77–95] 69 [64–77] 25 [18–32]
(? > 80%?) (>80%) (<5%)
S76 Erysipelas 80 [64–83] 44 [36–59] 1 [0–2]
(? < 30%?) (>80%) (<5%)
D82 Teeth/gum disease 67 [53–72] 42 [38–52] 1 [0–2]
ICPC: International Classification of Primary Care; AB: antibiotics; (): the acceptable range []: variation between the
individual GPCs; R78: patients aged between 18 and 75 years with acute bronchitis/bronchiolitis; R74: patients older
than one year with acute upper respiratory infection; U71: female patients older than 18 years with cystitis/other
urinary infection; R76: patients older than one year with for acute tonsillitis; R75: patients older than 18 years with
acute/chronic sinusitis; H71: patients older than two years with acute otitis media/myringitis; R81: patients aged
between 18 and 65 years with pneumonia; S76: patients older than one year with erysipelas; D82: patients older
than 18 years with teeth/gum disease.
3.3. Critical Appraisal of APQI to Describe Antibiotic Prescribing Quality in OOH Care
In 31,596/111,600 consultations, a diagnosis covered by APQI or erysipelas or dental abscess
was made in OOH. Detailed diagnoses linked to antibiotic prescription are shown in Table 4.
Most prescriptions are linked to upper respiratory tract infections (13%), followed by prescriptions
for acute cystitis (12%), acute tonsillitis (9%) acute bronchitis (8%), and acute otitis media (8%).
Most antibiotic prescriptions for skin infections are made for erysipelas (5%). Sinusitis, teeth/gum
disease and pneumonia represent 4%, 4%, and 3% of the total of antibiotic prescriptions, respectively.
When only using APQI diagnoses, 57% of antibiotic prescriptions are covered. When including
erysipelas and teeth/gum disease, these nine diagnoses represent 66% of all antibiotic prescription.
DU90% normally describes the number of drugs. When applying this concept on the coverage of
indications, we do not reach 90% of all antibiotic prescriptions. The 220 other diagnoses represent in
total 28% of the prescriptions but represent less than 3% each.
Table 4. Total antibiotic prescriptions and percentage linked to the diagnosis in a two-year time frame.
(total patient contacts (excluding home visits) = 111,600).
ICPC-Code Label Total Prescriptions Percentage
R74 † Acute upper respiratory tract infection 3564 13%
U71 † Acute cystitis 3068 12%
R76 † Acute tonsillitis 2294 9%
R78 † Acute bronchitis 2223 8%
H71 † Acute otitis media 2129 8%
missing Diagnosis missing 1612 6%
S76 Erysipelas 1344 5%
D82 Teeth/gum disease 982 4%
R75 † Acute sinusitis 965 4%
R81 † Pneumonia 684 3%
Other diagnoses Group of diagnoses representing lessthan 3% each 7571 29%
Total 26,436 100%
† Diagnosis used in antibiotic prescribing quality indicators (APQI).
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4. Discussion
4.1. Main Findings
Although most respiratory tract infections are self-limiting and usually caused by viral pathogens,
at least half of the patients diagnosed with acute otitis media, sinusitis, tonsillitis, and bronchitis receive
a prescription for an antibiotic at the GPC. Patients diagnosed with acute tonsillitis receive in 77% of
the cases an antibiotic. Only for patients diagnosed with acute upper respiratory tract infection is the
proportion of antibiotic prescriptions lower, but still higher than acceptable (30% while the acceptable
range is between 0–20%). For nearly all indications the recommended type of antibiotics, according
to the guidelines, are not prescribed apart from for otitis media, which is almost within the accepted
range. Quinolone use is outside the acceptable range for following respiratory infections: sinusitis
(7%), bronchitis (11%), and pneumonia (15%), which is in line with previous studies. The highest
proportion of quinolones are still found among antibiotics prescribed for female patients with acute
cystitis (25%). Looking at the total amount of antibiotic prescribing, we noticed a high number of
prescriptions for erysipelas and dental problems, again with a high prescribing rate of non-guideline
recommended antibiotics. There is not yet an acceptable range of prescribing determined for these two
conditions. We suggest an acceptable range for the recommended antibiotic of more than 80% and
respectively >80% and <30% of total antibiotic prescribing for erysipelas and teeth/gum disease.
For acute tonsillitis and acute upper respiratory tract infection, the very low percentage of
recommended antibiotics (6% and 3%, respectively, acceptable range 80–100%) can be explained by the
frequent unavailability of small spectrum penicillin in the Belgian pharmacies, therefore GPs most often
choose to prescribe amoxicillin as an alternative (63% and 66% of all antibiotic prescriptions for upper
RTI and tonsillitis respectively are for amoxicillin, see Tables S2 and S3) [4]. It is likely that conditions
with recommended use around 40–44% (40% for sinusitis, 42% for bronchitis, 43% for teeth/gum
disease, and 44% for erysipelas and 46% for pneumonia) are of more interest to policy makers, as for
these conditions the GP decides to deviate from the guidelines mostly in favor of a broader spectrum
antibiotic e.g., amoxicillin with clavulanic acid instead of amoxicillin alone). More detailed research is
needed to identify appropriate use of broader spectrum antibiotic (e.g., treatment failure of initiated
small spectrum antibiotic) versus inappropriate use driven by other factors such as lack of knowledge
of the guideline, disagreement with the guideline, etc. [8]. These factors have been suggested as drivers
for the use of quinolones for respiratory tract infections [25].
In Belgium, since 1 May 2018, the conditions for the reimbursement of quinolones and
fluoroquinolones have been changed. These antibiotics are no longer reimbursed for the treatment of
respiratory tract infections or uncomplicated urinary tract infections. Immediately after 1 May 2018,
this measure seemed to have had an effect on quinolone prescribing [26]. However, whether or not this
effect is causal and whether this trend will continue will be further monitored and analyzed using
iCAREdata [17,18].
We have used the disease-specific APQI to describe the quality of antibiotic prescribing during
OOH care. In our study, all seven diagnoses included in these APQI represent a considerable proportion
of the total antibiotic use. In addition, we noticed that a substantial number of antibiotic prescriptions
was also linked to two other diagnoses, i.e., erysipelas, dental problems (erysipelas (ICPC S76),
and teeth/gum disease (ICPC D82), the latter most often representing a dental abscess based on notes
review in a sample of the data. Therefore, we propose to add these two diagnoses (ICPC codes) when
assessing the quality of antibiotic prescribing in OOH care. Further validation and more studies
are necessary to confirm their relevance. However, when using these nine indications, only 66% of
antibiotic prescriptions are covered and it could be argued that this is not enough to describe antibiotic
quality. In accordance with the DU90% [23] concept, it would be more relevant to use indicators to be
able to describe 90% of prescriptions. Dolk et al. found that the majority of antibiotic prescriptions
in English primary care were for infections of the respiratory and urinary tracts, followed by skin
infections and only a small number for dental problems [27].
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According to the Belgian antibiotic guidelines, the primary treatment of acute dental problems is
dental care by a dentist [28]. However, patients with acute tooth ache often visit the GPC to seek help
during weekends and receive antibiotics. This has also been shown in previous studies in the UK [29].
GPs feel that general practice is not the best setting for managing dental problems [30] and one could
argue whether or not the care for dental problems falls within the remit of GPs. Access to dental care
during the weekends is limited, but patients should be redirected to these services.
APQI’s were calculated for 1 GPC from data from 2004 to 2009. In the current study, with five GPCs
(including the one GPC that was used in the 2004–2009 APQI OOH study) we noticed similar results in
the percentage of patients who received an antibiotic, but an improvement in choice of antibiotics.
4.2. Strengths and Limitations
We have used electronic data that were routinely registered by GPs in their electronic health
record for each patient contact. We used these observational routinely collected data retrospectively
and GPs had no knowledge of an ongoing study. We included five GPCs (rural as well as urban GPCs)
covering a large population that reflects the general population in Flanders (Belgium). Only GPCs
with complete datasets were included. All GPs of the region are obliged to participate in the OOH care.
Therefore, maximal coverage of GPs is guaranteed. In this way, we were able to achieve high validity
and completeness of the data.
The use of electronic primary care databases such as iCAREdata can produce valid APQI
values [4]. These values were originally developed for primary care, but not specifically for OOH care.
Previous research showed minimal differences in antibiotic prescribing between in and out of hours
care [4]. The quality of the data depends on the quality of the registrations by the GPs. We suspect
that these APQI values give an incomplete picture of antibiotic prescribing. Antibiotics prescriptions
linked to a symptom diagnosis, i.e., coding the diagnosis with a code for reasons for encounter such
as fever, ear ache, cough, sore throat, etc., were not included in calculating APQI values. However,
Flemish GPs not often register symptom diagnoses [7]. Indeed, when looking at the total number
of antibiotic prescriptions, only a small percentage was made for symptom diagnosis. Handwritten
prescriptions are still possible at the GPC, but are discouraged. Diagnosis shifting is possible as well,
i.e., registering an incorrect diagnosis to justify a prescription [8]. Every prescription made by a GP
is registered, and no difference is made between an immediate or a delayed prescription in the data.
Although delayed prescriptions will add to the quantity of antibiotic prescribing, we know that around
40–60% of patients will collect their antibiotic anyway [31–34]. We register antibiotic prescribing and
not antibiotic consuming or adherence to the prescribed course [31].
4.3. Implications for Practice and Future Research
Feedback of APQI values could serve as benchmarks of (in)appropriate prescribing. Each GPC
could compare their antibiotic prescribing quality with the range of acceptable use to help quantify the
magnitude of inappropriate prescribing in OOH primary care. It gives the opportunity to focus on the
specific challenges in every organization and to work on prescribing more accurately.
These data could inform future tailored interventions to improve the quality of antibiotic
prescribing in OOH primary care, such as we plan to do in the BAbAR project [16], and may also
be used to monitor effects of other interventions to improve quality of care at the level of GPCs [35].
However, these indications do not cover all antibiotic prescribing.
5. Conclusions
Flemish GPs too often prescribe antibiotics for self-limiting infections in OOH primary care and
do not choose the guideline recommended antibiotics. When using disease-specific APQI to define
the quality of antibiotic prescribing in OOH care, we suggest to calculate indicator values for two
additional disease entities, since a substantial amount of antibiotics are also prescribed for dental
abscess and erysipelas.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/8/2/79/s1:
Table S1: Average value (%) for the disease-specific antibiotic prescribing quality indicators over a six-year period
from 1 January 2004 to 31 December 2009 during out-of-hours vs. value (%) for the disease-specific antibiotic
prescribing quality indicators over a two-year period from 1 July 2016 to 30 June 2018, Table S2: Number of
antibiotic prescriptions in a 2 year time frame linked to symptom diagnosis * (total antibiotic prescriptions =
26,436), Table S3: Number of antibiotic prescriptions in a 2 year time frame linked to ICPC code R74, Table S4:
Number of antibiotic prescriptions in a 2 year time frame linked to ICPC code R76.
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Abstract: Administration of florfenicol and thiamfenicol through medicated feed is permitted within
the European Union, always following veterinary prescription and respecting the withdrawal periods.
However, the presence of low levels of florfenicol, thiamfenicol, and chloramfenicol in non-target
feed is prohibited. Since cross-contamination can occur during the production of medicated feed
and according to Annex II of the European Regulation 2019/4/EC, the control of residue levels of
florfenicol and thiamfenicol in non-target feed should be monitored and avoided. Based on all the
above, a sensitive and reliable method using liquid chromatography tandem mass spectrometry was
developed for the simultaneous detection of chloramfenicol, florfenicol, and thiamfenicol at trace
levels in animal feed. Analytes were extracted from minced feed with ethyl acetate. Then, the ethyl
acetate was evaporated, the residue was resuspended in Milli-Q water and the extract filtered.
The method was in-house validated at carryover levels, with concentration ranging from 100 to
1000 μg/kg. The validation was conducted following the European Commission Decision 2002/657/EC
and all performance characteristics were successfully satisfied. The capability of the method to detect
amfenicols at lower levels than any prior perspective regulation literature guarantees its applicability
in official control activities. The developed method has been applied to non-compliant feed samples
with satisfactory results.
Keywords: non-target feed; florfenicol; thiamfenicol; chloramfenicol; HPLC–MS/MS; validation; swine
1. Introduction
Globalization permits food produced in one country to be sold in other countries, sometimes on
an intercontinental level. However, globalization also contributes to competition between production
companies. The final goal of any type of business is to have low production cost and high benefits.
Low production cost is very important in food of animal origin, for which farmers fight with
animal disease. The use of certain veterinary medicine is permitted to control, prevent, and treat
illness. The most employed medicines, in this case, include antibiotics and antiparasitic agents.
Antimicrobial medicines are sold as premixes, oral powders, oral solutions, injections, intramammary
preparations pastes, oral pastes, boluses and intrauterine preparations [1]. Fenicols (chloramfenicol,
thiamfenicol, and florfenicol) belong to this group of antibiotics; however, even if chloramfenicol is
very effective on a broad spectrum, it is prohibited in food-producing animals within the European
Union [2]. On the other hand, thiamfenicol and florfenicol can be administrated through feed,
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but always respecting the withdrawal periods. Regulation 2019/4/EC [3] includes these two antibiotics
as an active substance for medicated feed and also in Annex II of the Regulation, indicating that
cross-contamination level should be investigated during the production of medicated feed.
Techniques such as phase sorptive extraction [4], indirect competitive enzyme-linked
immunosorbent assays [5], molecularly imprinted solid-phase extraction [6], high performance
liquid chromatography (HPLC) with ultraviolet (UV) detection [7], capillary electrophoresis [8],
and QuEChERS [9] were employed for amfenicol analysis.
The European Decision Commission 2002/657/EC states that positive samples need to be confirmed
with confirmatory methods, and that HPLC–MS/MS is a good technique for confirmatory methods [10].
The use of HPLC–MS/MS has been reported for amfenicol analysis in food matrices. However, when
compared with other antibiotics, such as tetracyclines, sulfonamides or penicillin, there are few methods
available for amfenicols. According to the ESVAC 2015 report, these three groups of antibiotics (tetracyclines,
sulfonamides, and penicillin) accounted for approximately 70% of the total sales of antibiotics in the
European Union. The reported HPLC–MS/MS methods include one described by Van de Riet et al.
(2013) [11] for chloramfenicol, thiamfenicol, and florfenicol in fish muscle, one developed by Barreto et al.
(2016) [12] to detect the same amfenicols in poultry, swine, bovine, and fish muscle, another published by
Anderson et al. (2016) [13] for florfenicol and thiamfenicol in white-tailed deer, one described for detection
in milk and honey [9], and the most recent one reported for detection in egg [14].
Regarding feed samples, Pietroń et al. (2014) [15] reported an HPLC–UV method for the
quantification of florfenicol and thiamfenicol in medicated feed. Later, in 2017, a similar method was
reported, but the feed extract was purified by thigh layer chromatography (TLC) (Yang et al., 2017) [16].
For residue levels of amfenicols in feed, the technique most frequently employed is HPLC combined
with different types of mass spectrometry. Between 30 and 300 active compounds (veterinary drugs,
pesticides, and others) can be identified with low limits of detection (20 μg/kg). However, some of
these methods are for screening [17–21] while others purify the extract with primary secondary amine
(PSA) [22] or solid-phase extraction (SPE) [23].
To the best of the authors’ knowledge, no method has been found in the scientific literature that is
capable of analyzing all three amfenicols (chloramfenicol, thiamfenicol, and florfenicol) at the residual
levels that fulfill the requirements of the European Commission Decision 2002/657/EC. Therefore, the aim
of this research article is to report a simple extraction protocol followed by HPLC–MS/MS detection of
amfenicols in feed samples from different animal species.
2. Results
The objective of this article is to describe a simple extraction protocol and an HPLC–MS/MS
method to confirm the presence of amfenicols in feed samples at trace levels.
Figures 1 and 2 show multiple reaction monitoring (MRM) transitions of the different analytes in
blank feed samples and in the same blank feed samples spiked with amfenicols to a final concentration
of 100 μg/kg.
2.1. HPLC–MS/MS Conditions
Standard solutions of 1 μg/mL of florfenicol, thiamfenicol, chloramfenicol, and chloramfenicol-d5
were employed to optimize their detection by the MS. The objective was to achieve a high signal
intensity of representative ions through modifications in parameters such as curtain gas, ion spray
voltage, source temperature, and curtain gas flow. Once precursor ions were selected for each amfenicol
and optimized by manual tuning, automatic optimization was conducted (Table 1). This process
permitted the evaluation of parameters such as entrance potential, collision cell potential, collision
energy, and collision cell exit potential for four representative production ions. From these four
ions, two were selected to conduct MRM analysis. Amfenicols were ionized by employing negative
electrospray, due to the chemistry of the molecule; this ionization mode has been previously employed
by other researchers in this field [14,17–24]. Acetonitrile was the first tested organic solvent as it is
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preferential to methanol. Acetonitrile was combined with water and buffers (ammonium acetate,
ammonium formate, and ammonium hydroxide), resulting in a good intensity signal. The best
resolution between peaks and signal intensity was obtained with the combination of acetonitrile and
water with ammonium formate and 0.1% of formic acid.
 
Figure 1. The total ion chromatogram (TIC) of a blank feed sample.
 
Figure 2. MRM chromatograms of feed samples spiked with amfenicols at the validation level of
200 μg/kg.
Table 1. Retention time (Rt), cone voltage (CV), collision energy, and precursor and product ions
employed for ion identification.
Tetracycline Rt (min) m/z Transition CV Collision Energy
Chloramfenicol 6.71 320 > 151 46 26
Chloramfenicol 320 > 120 46 32
Thiamfenicol 5.93 353 > 184 56 20
Thiamfenicol 353 > 79 56 27
Florfenicol 6.57 335 > 185 61 23
Florfenicol 335 > 79 61 23
Chloramfenicol-d5 6.69 325 > 157 41 32
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Following the requirement of the Decision 2002/657/EC, four identification points were achieved
with the use of two MRM transitions for each amfenicol and the internal standard (IS). While both
MRM transitions gave identification information, quantification was implemented from the MRM that
gave the higher signal to noise ratio (S/N). The ions selected for chloramfenicol and florfenicol were also
employed by Cronly et al. (2010) [25] and by Shinoda et al. (2011) [26] for detection in feed matrices.
Similar results occurred between the selected ion for florfenicol and the work described by Shinoda et al.
(2011) and Cronly et al. (2010), though the latter reference does not include florfenicol in its method.
The same ions have also employed in other type of matrices, such as wastewater [27], manure [27],
poultry tissues [28], pork, porcine liver, porcine kidney, beef, bovine liver, fish, chicken [29], milk,
and honey [9]. The chromatography separation was performed with various C18 columns, including
LiChrospher, Symmetry Shield RP18, ZORBAX Eclipse Plus, XTerra C18, and Hypersil C18-BD. For the
present work, Sunfire C18 columns were selected.
2.2. Extraction
Independently of the matrix, most methods described in the scientific literature employ ethyl
acetate to extract amfenicols [12,24,28,30]. Xiao et al. (2015) also employed ethyl acetate for poultry
tissue but with a pressurized liquid extraction system [28]. Acetone and dichloromethane were selected
by Van de Riet et al. (2013) to extract the drugs from fish muscle [11]. Acetonitrile with formic acid
was employed by Boix et al. (2014) in feed samples and water combined with buffered acetonitrile
by Leon et al. (2016) also for feed samples [21]. More sophisticated extraction techniques, such as
QuEChERS, were employed by Liu et al. (2016) for milk and honey [9]. An immunoaffinity column was
used by Luo et al. (2010) [31] for swine muscle and imprinted polymer by Ge et al. (2010) for animal
tissue [6]. For the extraction of trace-level amfenicols from feed samples, 2 mL of water and 5 mL of
ethyl acetate were employed with satisfactory results. However, after shaking for 20 minutes and
centrifugation for the separation of the different phases, only 2 mL of the organic layer was evaporated.
The evaporation of greater volumes (3, 3.5, and 4 mL) was investigated to increase the limit of detection
(LOD), however, a higher matrix effect was observed, and the idea discarded.
2.3. Method Validation
The research group has developed, validated, and published various methods for the analysis of
trace levels of veterinary drugs (coccidiostats, sulfonamides, and other antibiotics) in animal food and
feed samples [32–35]. Validation for this type of sample and the matrix has typically been conducted
following the European guideline (Decision 2002/657/EC) [10], which permits method implementation
and comparisons in EU reference laboratories.
The Decision 2002/657/EC indicates that when no certificate reference material is available, trueness
of measurements is assessed through recovery of additions of knowns amount of the analytes to a
blank matrix. For amfenicols, recoveries were between −20% and +10% for the three investigated
analytes (Table 2).
As with recovery, the precision under conditions of repeatability and reproducibility were
evaluated using a standard addition method. Precision values were within the range provided by the
European Decision; they ranged from 12% to 21% for chloramfenicol, 6.5% to 22% for thiamfenicol,
and 12% to 19% for florfenicol. Currently, the presence of residue of amfenicols in non-target feed is
prohibited; therefore, CCα and CCβ were calculated through employing formula for non-permitted
substances. After peak identification, the area was plotted against the added concentration. CCα
was the corresponding concentration at the y-intercept plus 2.33 times the standard deviation of the
within-laboratory reproducibility. Similarly, for CCβ calculation, the peak area was plotted against the
added concentration, and the CCα plus 1.64 times the standard deviation of the within-laboratory
reproducibility of the mean measured content at the CCα equals the CCβ (2002/657/EC). While CCα
values were 108, 140, and 110 μg/kg for chloramfenicol, thiamfenicol, and florfenicol, respectively,
CCβ values were 116, 180, and 122 μg/kg for chloramfenicol, thiamfenicol, and florfenicol, respectively.
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For the selected analytes, the S/N at the CCα was around 100; values for LOD and limit of quantification
(LOQ) were calculated with the feed samples spiked with amfenicols. Results indicated that the LOD
and LOQ values could reach 50 μg/kg. However, to further validate the method, validation was
conducted at 200 μg/kg to confirm satisfactory S/N at the CCα level of each compound and to fulfill
the EU requirements.
The technique itself is very selective/specific as it uses an MRM detection mode; the use of two MRM
transitions reduces the detection of other interfering peaks. Selective/specific proxies were investigated
with 20 blank feed samples for different animal species. The same 20 samples were spiked at 100 μg/kg
with amfenicols and other antibiotics (sulfadiazine, trimethoprim, tetracycline, and ciprofloxacin).
Both the absence of interfering peaks at the Rt of the amfenicols in the two MRM transitions of each
analyte and the correct identification of the analytes demonstrate the selectivity/specificity of the
developed method.
Table 2. Recovery (%), repeatability (CV%), reproducibility (CV%), CCα (μg/kg), CCβ (μg/kg), LOD








(n = 18) CCα CCβ LOD LOQ
Chloramfenicol
100 81 21 16 108 116 25 40
200 88 12 16
300 89 15 19
Mean 86 16 17
Tiamfenicol
100 81.41 6.5 22.35 140 180 75 100
200 97.69 12.58 21.61
300 103.83 18.97 21.98
Mean 94.31 12.69 21.98
Florfenicol
100 96.61 14.64 18.77 110 122 50 75
200 94.680 12.97 12.32
300 90.342 13.22 15.22
Mean 93.88 13.61 15.44
2.4. Real Sample Collection and Analysis
Interlaboratory studies gave satisfactory results indicating the reliability and applicability of the
developed method. Furthermore, the presence of the three amfenicols was investigated in 30 feed
samples from feed mills. Florfenicol was the only amfenicol detected, and it was detected in one
individual sample at a concentration of 0.36 mg/kg. This sample belonged to a group of four samples
used to monitor florfenicol carryover after the production of a bath of medicated feed with 80 mg/kg of
florfenicol. These results indicated that florfenicol carryover may occur during the manufacture of
medicated feed and should be investigated in more detail. None of the samples collected from pig
farms gave positive results.
3. Materials and Methods
3.1. Chemicals, Reagents, and Stock Solutions
Florfenicol, thiamfenicol, chloramfenicol, and chloramfenicol-d5 (purity > 98%) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Chloramfenicol-d5 was employed as internal standard (IS).
Ethyl acetate and acetonitrile was obtained from Scharlau Chemie (Barcelona, Spain), and formic acid
and ammonium acetate (purity >99% for analysis) were obtained from Acros Organics (Geel, Belgium).
Purified water was prepared in-house with a Milli-Q water system from Millipore (Bedford, MA, USA).
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Nitrogen gas was generated using an in-house nitrogen generator from Peak Scientific Instruments,
Ltd (Chicago, IL, USA).
In 20 mL volumetric flasks, 20 ± 0.01 mg of each analyte (florfenicol, thiamfenicol, chloramfenicol,
and chloramfenicol-d5) were precisely weighed to prepare stock solutions of individual compounds in
acetonitrile (to yield a final concentration of 1 mg/mL; the purity was considered when calculating
specific concentrations). To prepare the intermediate stock solution (10 μg/mL), the individual solutions
were mixed and diluted with acetonitrile. Each day, a working stock solution (1 μg/mL) was freshly
prepared by diluting the intermediate stock solution with acetonitrile. All standards solutions were
stored in the dark at −18 ◦C for no longer than three months.
3.2. Conditions for HPLC–MS/MS Analysis
The HPLC–MS/MS analyses were performed using a 1100 HPLC from Agilent Technologies
(Waldbronn, Germany) attached to a QTRAP 2000™MS from Applied Biosystems/MDS-Sciex (Toronto,
Canada). The software Analyst 1.4.1 from Applied Biosystems (Toronto, Canada) was employed to
control the system.
The analysis of the extracts with amfenicols was achieved with a Sunfire C18 (3.5 μm 2.1 ×
150 mm) HPLC column from Waters (Milford, PA, USA), water with formic acid (185 μL), and 370 μL of
ammonium formate (6.3% in water; mobile phase A), and acetonitrile (mobile phase B). Mobile phase
components A and B were freshly prepared with each batch of sample. The solvents were mixed at a
constant flow rate of 250 μL/min, the column temperature was maintained at 50 ◦C, and the injection
volume was 40 μL. The gradient program was as follows: 0 min, 90% A; 1 min, 50% A; 5 min, 20% A;
7 min, 90% A; 17 min, 90% A.
The MS analysis was performed using negative electrospray ionization mode (ESI). The dwell
time was 150 ms between transitions. The system uses nitrogen as nebulized gas set up at 50 psi for ion
source gases 1 and 2. The source temperature was 475 ◦C, the ion spray voltage was −4500 V, and the
curtain gas flow was 25 psi. Analytes were identified by retention time (Rt) and two multiple reaction
monitoring (MRM) transitions. Table 1. compiles the MS parameters employed for the identification of
each analyte.
3.3. Sample Extraction
To confirm the absence of chloramfenicol, feed samples were sent to an accredited laboratory.
Once the results were obtained, these samples were employed as blank feed samples to prepare
matrix-matched calibration.
Quantification of the analytes was performed with matrix-matched samples spiked with the
analytes at concentrations of 100, 200, 300, 400, and 1000 μg/kg. Samples were ground on a Minimoka
GR-020 grinder (Lleida, Spain), and 1 g was transferred to a 15 mL Falcon conical-bottom tube.
Then, 2 mL of Milli-Q water and 5 mL of ethyl acetate were added to the tube. The mixture was mixed
with an IKA Minishaker MS2 (Staufen, Germany) for 20 s, shaken for 30 min at 200 rpm on a New
Brunswick Scientific G25 orbital shaker (NJ, USA), and centrifuged at 7000 rpm for 10 minutes on
a Kokusan H-103N centrifuge (Tokyo, Japan). Then, a volume of 2 mL was transferred to a conical
glass tube and evaporated to dryness with a stream of nitrogen on a TurboVap® II evaporator from
Zymark (MA, USA). The dry residue was dissolved in 500 μL of Milli-Q water, filtered with a GHP
Acrodisc syringe filter (0.2 μm; Waters Corporation, MA, USA), and transferred to an HPLC amber vial
with an insert. The extract was stored at −20 ◦C until analysis, which was conducted within a day.
Figure 1 shows the total ion chromatogram (TIC) of a blank feed sample, and Figure 2 shows MRM
chromatograms of feed samples spiked with amfenicols at the validation level of 200 μg/kg.
3.4. Method Validation
Linearity range, recovery, precision (repeatability and reproducibility), selectivity/specificity,
limit of detection (LOD), limit of quantification (LOQ), decision limit (CCα), and detection capability
112
Antibiotics 2019, 8, 59
(CCβ) of the developed method were obtained, along with validation of the method. The validation
was conducted following the criteria included in the Commission Decision 657/2002/EC. Blank feed
samples were spiked with the amfenicols at 100, 200, 300, 400, and 1000 μg/kg for linearity verification.
Calibration curves were prepared over four different days; for each day, peak area was correlated
against analyte concentrations for linear regression analysis. The accuracy of the method could not be
determined as certified reference materials were no available. Therefore, trueness and precision were
obtained with blank feed samples spiked at 100, 200, and 300 μg/kg. Six replicates of each concentration
were extracted and analyzed on the same day to obtain intra-day precision (repeatability). The same
procedure was repeated over three different days for inter-day precision (reproducibility).
The selectivity/specificity was evaluated with blank feed samples spiked and non-spiked with
amfenicols at the validation level (100 μg/kg). The different feed samples were provided by the
manufacturers. Selectivity/specificity was evaluated with feed samples for different animal species
(swine, poultry, and cattle).
3.5. Sample Collection and Analysis
Feed producers provided non-targeted feed samples (n = 30) to the laboratory. Four of these
samples belonged to a feed mill and were collected after being manufactured in the same production line
of medicated feed and after the cleaning batches to evaluate carryover contamination. The other feed
samples were collected in pig farms and were feed employed for pig crowing. Once in the laboratory,
all samples were ground and keep in plastic bottles in the dark until analysis. Interlaboratory samples
from 2018 RIKILT proficiency tests were also conducted.
4. Conclusions
The article describes a simple a rapid confirmatory method based on HPLC–MS/MS for the
simultaneous identification and quantification of residue of chloramfenicol, thiamfenicol and florfenicol
in non-target feed. Since the method was validated following the EU guidelines and fulfilled
the requirements of the Decision, the method can be applied by different laboratories, including
reference laboratories.
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Abstract: Microbial resistance to currently available antibiotics is a public health problem in the
fight against infectious diseases. Most antibiotics are characterized by numerous side effects that
may be harmful to normal body cells. To improve the efficacy of these antibiotics and to find an
alternative way to minimize the adverse effects associated with most conventional antibiotics, piperine
and piperlongumine were screened in combination with conventional rifampicin, tetracycline, and
itraconazole to evaluate their synergistic, additive, or antagonistic interactions against Staphylococcus
aureus, Pseudomonas aeruginosa, and Candida albicans. The fractional inhibitory concentration index
was used to estimate the synergistic effects of various combination ratios of the piperamides and
antibiotics against the bacterial and fungal strains. Both piperine and piperlongumine showed
synergistic effects against S. aureus when combined at various ratios with rifampicin. Synergistic
interaction was also observed with piperine in combination with tetracycline against S. aureus, while
antagonistic interaction was recorded for piperlongumine and tetracycline against S. aureus. All the
piperamide/antibacterial combinations tested against P. aeruginosa showed antagonistic effects, with
the exception of piperine and rifampicin, which recorded synergistic interaction at a ratio of 9:1
rifampicin/piperine. No synergistic interaction was observed when the commercial compounds were
combined with itraconazole and tested against C. albicans. The results showed that piperine and
piperlongumine are capable of improving the effectiveness of rifampicin and tetracycline. Dosage
combinations of these bioactive compounds with the antibiotics used may be a better option for the
treatment of bacterial infections that aims to minimize the adverse effects associated with the use of
these conventional antibacterial drugs.
Keywords: piperine; piperlongumine; antibacterial; antifungal; synergy
1. Introduction
Infectious diseases caused by bacteria and fungi are one of the leading causes of death
worldwide [1–3]. The emergence of multidrug resistance in microbes and the nonavailability of
antibiotics to combat and treat microbial infections have led to a constant search for new antimicrobial
agents from natural sources. Previous research has shown that about 13 million deaths are recorded
throughout the world each year as a result of bacterial and fungal diseases that are often caused by
multidrug-resistant pathogens [4,5]. Natural products of plant origin include novel therapeutic and
highly effective antimicrobial agents [6,7]. In clinical practice, one of the leading new advances in the
fight against microbial resistance is antimicrobial combination therapy [8–10]. Alternatively, bioactive
compounds from natural sources could also be screened for leads to the discovery of new antibiotics
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to combat microbial resistance [5,11,12]. The mode of activity of antimicrobial combination therapy
in antimicrobial treatments differs from that of the same individual antibiotics when administered
as single drugs [8,13]. Bioactive compounds and extracts from plants can also potentiate the effect of
antimicrobial drugs, thereby acting as antibiotic adjuvants [5,11]. Another strategic approach to the
fight against multidrug-resistant bacteria in clinical practice is to deactivate the resistance mechanism
of the bacteria to the existing antibiotics. In addition, pharmacological studies have shown that
synergistic interaction is necessary and could greatly enhance the activity of antimicrobial compounds
with moderate or weak activity. Thus, these bioactive plant compounds can serve as inhibitors against
multidrug-resistant pathogens [5,14].
Piperine (1) and piperlongumine (2) are novel alkaloids found in most Piper species.
Piperlongumine (2), also known as piplartin, is a piperamide compound found in Indian long
pepper Piper longum L. [15]. It is a bioactive compound of clinical importance that is active against
multidrug-resistant pathogens such as Pseudomonas aeruginosa (Schroeter) Mogul and Staphylococcus
aureus Rosenbach [16]. Piperine (1) is a piperamide compound found in Piper guineense Schumach.
& Thonn., black pepper Piper nigrum L., and other Piper species [17–19]. The chemical structures
of piperine and piperlongumine are shown in Figure 1. Previous research has shown that piperine
is a potent antibacterial agent acting as an inhibitor of the efflux pump of S. aureus [20,21]. Recent
pharmacological research on piperine and piperlongumine [22–25] led us to hypothesize that these
piperamide compounds may potentiate the antibiotic effect of some conventional antimicrobials,
thereby acting as antibiotic adjuvants.
 
Figure 1. Chemical structures of piperine and piperlongumine.
The aim of this study was to investigate the in vitro antimicrobial effects of piperine and
piperlongumine when used in combination at various ratios with some conventional antimicrobials
(tetracycline, rifampicin, and itraconazole) against P. aeruginosa, S. aureus, and Candida albicans. It was
aimed at evaluating whether piperine and piperlongumine interact synergistically when combined with
tetracycline, rifampicin, or itraconazole at various ratios. This is the first report on the synergistic activity
of piperlongumine in combination with conventional antimicrobials. The study of the synergistic
interaction of these piperamide compounds with conventional antibiotics may aid in addressing the
problem of microbial resistance and provide new strategies for improving the use of antibiotics in the
treatment of infectious diseases. Piperine and piperlongumine as antibiotic adjuvants may help to
reduce the adverse effects associated with these conventional antibiotics.
2. Results
To evaluate an alternative way to fight multidrug-resistant pathogens and to minimize the adverse
effects associated with most conventional antibiotics, piperine and piperlongumine were screened
singly and in combination with conventional antimicrobials to determine their synergistic, additive,
or antagonistic interactions against S. aureus, P. aeruginosa, and C. albicans (Table 1, Figures 2 and 3).
The aim was to investigate the synergistic effects of piperine and piperlongumine when used singly
and in combination with conventional antimicrobials against S. aureus, P. aeruginosa, and C. albicans.
S. aureus, P. aeruginosa, and C. albicans are pathogens that are capable of causing systemic infections
in humans. As such, 90–95% of S. aureus strains are resistant to most conventional antibiotics [8,26].
The fractional inhibitory concentration (FIC) index was used to determine the synergistic interaction
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between the commercial piperamides and the antimicrobials. The FIC index method is one of the most
accurate means for determining synergistic interactions when two inhibitors are studied in various
combinations [27,28]. A synergistic effect was observed when the FIC index value of the compound of
interest was ≤ 0.5 [26]. Previous research has also shown that the ratio of combination of two inhibitors
could influence the degree of their interaction, such that the interactions could vary depending on the
ratio by which the two inhibitors are combined [28].
Table 1. Inhibition zone diameters (mm) of the antibacterial and antifungal effects of piperine,
piperlongumine (P. longumine), rifampicin, tetracycline, itraconazole, and 70% ethanol tested
individually against Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans, using the agar
diffusion method.
Bacteria/Fungi Piperine P. longumine Tetracycline Rifampicin 70% Ethanol Itraconazole
S. aureus 15.2 ± 0.31 12.4 ± 0.31 49.1 ± 0.32 47.2 ± 0.17 NA NP *
P. aeruginosa 14.4 ± 0.33 11.5 ± 0.33 34.6 ± 0.33 30.3 ± 0.33 NA NP *
C. albicans 16.5 ± 0.31 18.2 ± 0.31 NP * NP * NA 15.2 ± 0.33
NA, not active; *, not performed. The inhibition zone diameters (mm) represent the means of three replicates (n = 3)
± the SEM (standard error of the mean).
 
Figure 2. Inhibition zone diameters (mm) of the antibacterial and antifungal effects of piperine and
piperlongumine combined at various ratios with rifampicin/itraconazole against S. aureus, P. aeruginosa,
and C. albicans, using the agar diffusion method. Rif, rifampicin; Itr, itraconazole; piper, piperine; p.long,
piperlongumine; 200 μL of the piperamide/antimicrobial combinations were applied in the wells.
The results of the first preliminary agar diffusion method performed singly on the piperamide
compounds and antibacterials against S. aureus showed that the inhibition zone diameters of
tetracycline, rifampicin, piperine, and piperlongumine were 49.1 mm, 47.2 mm, 15.2 mm, and
12.4 mm, respectively (Table 1). Preliminary agar diffusion screening was also performed on the
various piperamide/antimicrobial combinations to ascertain the five best combinations to screen for the
minimum inhibitory concentrations (MICs) and FIC index calculations for synergistic or antagonistic
evaluations (Figures 2 and 3).
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Figure 3. Inhibition zone diameters (mm) of the antibacterial effects of piperine and piperlongumine
combined at various ratios with tetracycline against S. aureus and P. aeruginosa, using the agar
diffusion method. The inhibition zone diameters (mm) are the means of three replicates (n = 3).
P.lon, piperlongumine; tet, tetracycline; piper, piperine.
The MICs of the various combinations were evaluated (Table 2) to obtain the values used in
calculating the FIC indices.
Table 2. Minimum inhibitory concentrations (MIC, μg/mL) of piperine and piperlongumine combined
at various ratios with rifampicin (rifam), tetracycline (tetracy), itraconazole (itracon) against S. aureus,
P. aeruginosa, and C. albicans.
Ratioof Antibiotics/Compound S. aureus P. aeruginosa C. albicans
Rifam + piperine 1:9 7.8 15.6 NP*
Rifam + piperine 3:7 1.9 15.6 NP *
Rifam + piperine 5:5 3.9 62.5 NP *
Rifam + Piperine 7:3 1.9 62.5 NP *
Rifam + piperine 9:1 7.8 15.6 NP *
Rifam + piperlongumine 1:9 7.8 31.2 NP *
Rifam + piperlongumine 3:7 125 15.6 NP *
Rifam + piperlongumine 5:5 3.9 15.6 NP *
Rifam + piperlongumine 7:3 62.5 15.6 NP *
Rifam + piperlongumine 9:1 62.5 7.8 NP *
Tetracy + piperine 1:9 7.8 62.5 NP *
Tetracy + piperine 3:7 3.9 31.2 NP *
Tetracy + piperine 5:5 0.97 15.6 NP *
Tetracy + piperine 7:3 1.9 7.8 NP *
Tetracy + piperine 9:1 7.8 7.8 NP *
Tetracy + piperlongumine 1:9 31.2 31.2 NP *
Tetracy + piperlongumine 3:7 3.9 7.8 NP *
Tetracy + piperlongumine 5:5 3.9 15.6 NP *
Tetracy + piperlongumine 7:3 1.9 7.8 NP *
Tetracy + piperlongumine 9:1 62.5 7.8 NP *
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Table 2. Cont.
Ratioof Antibiotics/Compound S. aureus P. aeruginosa C. albicans
Itracon + piperine 1:9 NP * NP * 3.9
Itracon + piperine 3:7 NP * NP * 3.9
Itracon + piperine 5:5 NP * NP * 7.8
Itracon + piperine 7:3 NP * NP * 7.8
Itracon + piperine 9:1 NP * NP * 15.6
Itracon + piperlongumine 1:9 NP * NP * 31.2
Itracon + piperlongumine 3:7 NP * NP * 7.8
Itracon + piperlongumine 5:5 NP * NP * 7.8
Itracon + piperlongumine 7:3 NP * NP * 3.9
Itracon + piperlongumine 9:1 NP * NP * 31.2
Piperine only 3.9 15.6 7.8
Piperlongumine only 15.6 31.2 3.9
Rifampicin only 1.97 0.48 NP *
Tetracycline only 0.97 0.97 NP *
Itraconazole only NP * NP * 15.6
The MIC values represent the means of triplicates. Only five combinations were tested for MIC. *, not performed.
Rifampicin and tetracycline were combined at various ratios with piperine and piperlongumine
and tested against S. aureus. For piperlongumine, a synergistic effect was observed at a ratio of 5:5
with rifampicin against this bacterium (Table 3). This result demonstrates that the pharmacological
interaction between a bioactive compound and a conventional antimicrobial can be affected by the ratio
and concentration at which the two are combined. However, antagonistic interactions were observed
between piperlongumine and tetracycline at all the combination ratios tested against this bacterium
(Table 3).




S. aureus P. aeruginosa C. albicans
Rifam + piperine 1:9 5.9 (AT) 33.5 (AT) NP *
Rifam + piperine 3:7 0.2 (S) 33.5 (AT) NP *
Rifam + piperine 5:5 3.9 (AT) 8.0 (AT) NP *
Rifam + piperine 7:3 1.2 (I) 5.0 (AT) NP *
Rifam + piperine 9:1 12.6 (AT) 0.4 (S) NP *
Rifam + piperlongumine 1:9 4.4 (AT) 66.0 (AT) NP *
Rifam + piperlongumine 3:7 39.0 (AT) 33.0 (AT) NP *
Rifam + piperlongumine 5:5 0,5 (S) 1.5 (I) NP *
Rifam + piperlongumine 7:3 17.0 (AT) 2.0 (I) NP *
Rifam + piperlongumine 9:1 17.0 (AT) 1.0 (I) NP *
Tetracy + piperine 1:9 10.0 (AT) 68.0 (AT) NP *
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S. aureus P. aeruginosa C. albicans
Tetracy + piperine 3:7 4.5 (AT) 32.0 (AT) NP *
Tetracy + piperine 5:5 0.3 (S) 0.7 (A) NP *
Tetracy + piperine 7:3 2.4 (AT) 0.7 (A) NP *
Tetracy + piperine 9:1 12.1 (AT) 1.5 (I) NP *
Tetracy + piperlongumine 1:9 34.1 (AT) 33.1 (AT) NP *
Tetracy + piperlongumine 3:7 4.1 (AT) 8.2 (AT) NP *
Tetracy + piperlongumine 5:5 1.1 (I) 2.5 (AT) NP *
Tetracy + piperlongumine 7:3 0.9 (A) 1.5 (I) NP *
Tetracy + piperlongumine 9:1 48.9 (AT) 1.5 (I) NP *
Itracon + piperine 1:9 NP * NP * 0.8 (A)
Itracon + piperine 3:7 NP * NP * 1.2 (I)
Itracon + piperine 5:5 NP * NP * 4.0 (AT)
Itracon + piperine 7:3 NP * NP * 3.0 (AT)
Itracon + piperine 9:1 NP * NP * 4.0 (AT)
Itracon + piperlongumine 1:9 NP * NP * 10.1 (AT)
Itracon + piperlongumine 3:7 NP * NP * 0.7 (A)
Itracon + piperlongumine 5:5 NP * NP * 1.3 (I)
Itracon + piperlongumine 7:3 NP * NP * 1.0 (I)
Itracon + piperlongumine 9:1 NP * NP * 12.0 (AT)
The activity is expressed as the fractional inhibition concentration (FIC) index, which is calculated from the MIC
of the various piperamide/antimicrobial combinations. The FIC index interactions were defined as: FICI ≤ 0.5,
(S) synergy; >0.5 to ≤1.0, (A) additive; >1.0 to ≤2.0, (I) indifferent; and >2.0, (AT) antagonistic [26]. *, not performed.
3. Discussion
3.1. Antibacterial Synergistic Effects of Piperine and Piperlongumine against S. aureus
For piperine, the FIC index value of rifampicin and piperine against S. aureus in this study
showed synergistic interaction at a ratio of 3:7 (Table 3). A synergistic effect was observed between
piperine and rifampicin and between piperine and tetracycline, as shown in Table 3. Rifampicin
is an antibiotic that is often used in the treatment of systemic bacterial infections in antimicrobial
therapy, and this antibiotic is characterized by numerous adverse effects when used consecutively for
10–14 days [29,30]. A formulation containing a fixed-dose combination of rifampicin and piperine
(rifampicin 200 mg + piperine 10 mg) has been approved in India to minimize the adverse effects
associated with the use of conventional rifampicin in the antimicrobial treatment against Mycobacterium
tuberculosis [30]. Our results show here that piperine could be a compound leading to the discovery of
new antibacterial drugs with minimum adverse effects. We observed that piperine and piperlongumine
are capable of improving the effectiveness of rifampicin and tetracycline. We suggest, therefore, that
dosages of combinations of these bioactive compounds with antibiotics could be a better option for the
treatment of bacterial infections than the conventional antibiotics which often show problems with
multidrug-resistant pathogens. Our study demonstrates that a combination of antibacterial (rifampicin
and tetracycline) with piperamide compounds (piperine and piperlongumine) could lead to minimal
systemic toxicity to normal cells during antimicrobial treatments.
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3.2. Antibacterial Synergistic Effects of Piperine and Piperlongumine against P. aeruginosa
Preliminary agar diffusion assays performed individually with piperamides and antibiotics
against P. aeruginosa (Table 1) showed that the inhibition zone diameters of tetracycline, rifampicin,
piperine, and piperlongumine were 34.6 mm, 30.3 mm, 14.4 mm, and 11.5 mm, respectively. When
the MIC of the various combinations was determined, the FIC index calculations showed mainly
antagonistic interactions between the piperamides and the antibiotics against P. aeruginosa, with
the exception of the 9:1 ratio of the piperine/rifampicin combination, which showed synergistic
activity (Table 3). P. aeruginosa is a Gram-negative pathogenic bacterium that causes systemic
infections in immunocompromised individuals and is often associated with antibacterial resistance [31].
For piperlongumine, no synergistic effect was observed in any of the antibiotic combinations (rifampicin
and tetracycline) against P. aeruginosa, although additive and antagonistic interactions were observed.
The results of tetracycline/piperlongumine and rifampicin/ piperlongumine combinations tested at
various ratios demonstrated no synergistic effects between tetracycline and piperlongumine as well
as between rifampicin and piperlongumine against P. aeruginosa. These results suggest that piperine
and piperlongumine may not improve the effectiveness of tetracycline against P. aeruginosa infections.
Indeed, appropriate measures should be taken to avoid too heavy a consumption of herbal drugs or
foods rich in piperine and piperlongumine when undergoing antimicrobial treatment with tetracycline
against diseases caused by P. aeruginosa.
For piperine, a synergistic interaction with rifampicin was observed for a rifampicin/piperine
combination at a ratio of 9:1 against P. aeruginosa, while antagonistic or additive interactions were
observed for the other combinations tested. Piperine was previously tested for its immunomodulatory
activity in enhancing the efficacy of rifampicin in a murine model of M. tuberculosis infection, thereby
acting in synergy with rifampicin to improve its therapeutic efficacy [32]. However, the synergistic
efficacy recorded in our study for a rifampicin/piperine combination showed that the efficacy could be
influenced by the ratio of the combination, i.e, the synergistic, additive, or antagonistic interactions
were greatly dependent on the ratio between rifampicin and piperine.
3.3. Antifungal Synergistic Effects of Piperine and Piperlongumine against C. albicans
When preliminary agar diffusion assays were performed singly on the piperamides and
itraconazole against C. albicans, the inhibition zone diameters of piperine, piperlongumine, and
itraconazole were 16.5 mm, 18.2 mm, and 15.2 mm, respectively (Table 1). The results of the FIC
index evaluations of the various combinations showed additive or antagonistic interactions (Table 3).
No synergistic effects were recorded in our study against C. albicans. C. albicans is an opportunistic
pathogen that is responsible for most yeast infections in humans [33]. These results demonstrate
that piperine and piperlongumine cannot improve the effectiveness of itraconazole, and thus herbal
formulations made from these bioactive compounds should be avoided while undergoing treatments
for yeast infections.
4. Materials and Methods
4.1. Sources of Antibiotics and Commercial Compounds
Analytical-grade commercial piperlongumine (≥ 97.0% purity) and piperine (≥ 97.0% purity) were
purchased from TCI Europe N.V. (Zwijndrecht, Belgium). Tetracycline hydrochloride (Sigma-Aldrich,
St. Louis MO, USA), rifampicin (Sigma-Aldrich), and itraconazole (Sigma-Aldrich) were the antibiotics
used in the investigation. The selection of tetracycline, rifampicin, and itraconazole was based on their
activity against bacterial and fungal strains in a previous study [34]. S. aureus American Type Culture
Collection ATCC 25923, P. aeruginosa ATCC 27853, and C. albicans ATCC 10231 cultures used in this
investigation were obtained from the Division of Pharmaceutical Biosciences, Faculty of Pharmacy,
University of Helsinki, Finland. The bacterial strains were selected because they are significant human
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pathogens capable of causing life-threatening nosocomial infections [35,36], while C. albicans, on the
other hand, causes fungal diseases in humans [37].
4.2. Preparation of Piperine, Piperlongumine, and Antimicrobials
Each of the commercial piperamides (piperine and piperlongumine) was prepared to a final
concentration of 5 mg/mL (stock solution) in 70% ethanol and tested in the initial screening. An initial
stock solution of 5 mg/mL was prepared for each of the antibiotics (tetracycline, rifampicin, and
itraconazole). Piperine and piperlongumine were also prepared in combination with tetracycline,
rifampicin, or itraconazole at various ratios according to the method of Van Vuuren et al. [10].
The combinations/dilutions were prepared at nine different ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3,
8:2, 9:1 as follows: rifampicin/piperlongumine, rifampicin/piperine, tetracycline/piperlongumine,
tetracycline/piperine, itraconazole/piperine, and itraconazole/piperlongumine.
4.3. Agar Disk-Diffusion Method
The agar disk-diffusion method was applied for the initial screening of the nine combination
ratios according to the method of the Clinical and Laboratory Standards Institute [38]. Sterile Petri
dishes (∅ = 14 cm, VWR International Oy, Helsinki, Finland) were used for the screening. For the
antibacterial screening against S. aureus and P. aeruginosa, 25 mL of sterile base agar (Antibiotic agar
No. 2, Difco, VWR) was applied as a bottom layer into the sterile Petri dishes, using a sterile serological
pipet (Falcon; BDLabware Europe) and allowed to solidify. Thereafter, 25 mL of isosensitest agar
(OXOID, ThermoFisher Scientific, Waltham, MA, USA) was applied as the top layer. For the antifungal
screening, 25 mL of sterile base agar (Antibiotic agar No. 2, Difco VWR) was applied as a bottom layer
into the sterile Petri dishes and 25 mL of Saboraud agar (OXOID, ThermoFisher Scientific, Basingstoke,
United Kingdom) was applied as the top layer. The agar in the Petri dishes was allowed to solidify
and then stored at +4 ◦C. The screening was initiated with the inoculation of the bacterial strains or
C. albicans onto solid nutrient or Saboraud agar slants that were incubated overnight for the bacterial
strains and 48 h for the fungus at +37 ◦C. Viable bacterial and fungal cultures from the agar slants
were used to prepare an inoculum for the test. Bacterial and fungal specimens from the agar slants
were transferred into 2 mL of a 0.9% (w/v) sodium chloride (NaCl) solution in a sterile glass tube,
using a sterile inoculation loop. In all, 1 mL of the suspension was transferred into another sterile
glass tube, and the absorbance was measured at 625 nm (UV–Visible Spectrophotometer, Pharmacia
LKB-Biochrom 4060; Pfizer Inc., New York, NY, USA). The other milliliter of the suspension (sterile part)
was diluted with the 0.9% NaCl solution so that the absorbance at 625 nm became 0.1 (this suspension
contained approximately 1.5 × 108 colony-forming units (CFUs)/mL). In all, 200 μL of this diluted
bacterial or fungal suspension were spread evenly on each Petri dish and left to dry for several seconds
with the lid open. A sterile cork borer (11 mm diameter) was used to make six equidistant holes on
the agar surface of the Petri dishes. A total of 200 μL of the 5 mg/mL concentration of each of the
piperamides and 200 μL of the 10 mg/mL antimicrobial were carefully pipetted into the holes; 70%
ethanol was used as the solvent control. The first screening of the combined samples was done in
the same manner as described above for the agar diffusion method, and the various inhibition zones
were recorded. The Petri dishes were transferred to the cold room and incubated at +4 ◦C for 1 h.
Thereafter, they were incubated at +37 ◦C, overnight for the bacterial strains and 48 h for the fungal
strain. The diameters of the zones of inhibition were measured with a caliper under a Petri dish
magnifier and expressed as the mean of the diameters of three replicates ± the standard error of the
mean (SEM).
4.4. Microdilution Method for Minimum Inhibitory Concentration Estimation
The MIC was estimated for the five best combinations of each piperamide/antimicrobial. The MIC
was taken as the lowest concentration of the piperamide/antimicrobial resulting in the inhibition of
at least 90% of the growth of the bacterial or fungal strain. The MIC values were determined using
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a microdilution turbidimetric broth method based on the guidelines of the Clinical and Laboratory
Standards Institute [38]. For MIC evaluation, two-fold serial dilutions from 2500 to 9.75 μg/mL
were prepared in sterile Mueller–Hinton broth (bacterial strains) and Saboraud broth (C. albicans) for
each of the piperamide/antimicrobial combinations. The commercially pure compounds, piperine
and piperlongumine (5 mg/mL concentrations in 70% ethanol), were two-fold serially diluted in
Mueller–Hinton broth for the bacterial strains and Saboraud broth for the fungal strain. Tetracycline,
rifampicin, and itraconazole were similarly diluted in Mueller–Hinton broth or Saboraud broth from
125 to 0.48 μg/mL, respectively; 96-well microtiter plates (Nunc, Nunclone; Nalge Nunc International,
Roskilde, Denmark) were used for the tests. The bacterial or fungal cultures were inoculated in
5 mL of Mueller–Hinton broth and grown for 24 h at +37 ◦C for the bacterial strains or in 5 mL
of Saboraud broth and grown for 48 h at +37 ◦C for C. albicans before the test. Absorbance of
1 mL of the overnight bacterial culture was measured for turbidity at 625 nm, using a UV–Visible
Spectrophotometer type 1510 (ThermoFisher Scientific). The absorbance was adjusted to 0.1 at 625 nm
(approximately 1.0 × 108 CFUs/mL). A total of 100 μL of this suspension A625 = 0.1 was further
diluted a hundredfold to obtain a working suspension or inoculum containing 1.0 × 106 CFUs/mL.
In all, 100 μL of this inoculum and 100 μL of each of thepiperamide/antimicrobial combinations and
solvent controls were introduced into the 96-well microtiter plates. Each well therefore contained
5 × 105 CFUs/mL. The growth control (GC) wells contained only the bacterial suspension, and the
test (T) wells contained the piperamide/antimicrobial + bacterial suspension. Moreover, negative
control wells were prepared for each piperamide/antimicrobial combination ratio tested, and these
wells contained the piperamide/antimicrobial combinations at different ratios and the broth only.
The microwell plates were incubated for 24 h in an incubator coupled to a shaker at+37 ◦C. The turbidity
of the wells at 620 nm was recorded using a Victor 1420 spectrophotometer (PerkinElmer (Wallac Oy),
Turku, Finland). The tests were done in triplicate, and the percentage growth was expressed as the
mean of these triplicates ± the SEM.
4.5. Fractional Inhibitory Concentration Index
The FIC index was used to estimate the synergy [5,26]. For the FIC index calculation, the MIC
values of five combinations of each piperamide/antimicrobial at different ratios were used to calculate
FIC (A) and FIC (B), using the equation below:
The FIC values were calculated as follows:
FIC(A) = MICvalueo f combinedpiperamideandantimicrobialMICvalueo f antimicrobialalone
FIC(B) = MICvalueo f combinedpiperamideandantimicrobialMICvalueo f piperamidealone
FICindex = FIC(A) + FIC(B)
A FIC index value ≤ 0.5 was interpreted as synergy. The FIC index was calculated on the basis of
the above-mentioned equation, in which the FIC index = X + Y and the interactions are defined as:
FIC index ≤ 0.5, synergy; > 0.5 to ≤ 1.0, additive; > 1.0 to ≤ 2.0, indifferent; and > 2.0, antagonistic [26].
5. Conclusions
Piperine and piperlongumine are possible antibiotic adjuvants that should be applied in drug
discovery for use as effective antibacterial treatments. The synergistic efficacy of piperlongumine and
piperine in combination with rifampicin has shown that these two piperamides are bioactive scaffolds
that could aid in fighting against multidrug-resistant pathogens, thereby improving the effectiveness
of rifampicin in the treatment of infectious diseases. Our results show that the synergistic efficacy
of piperamide compounds is dependent on the concentration and ratio of the combination. This
indicates that the use of piperine and piperlongumine may minimize the adverse effects associated with
conventional tetracycline and rifampicin and improve the effectiveness of these antibiotics. However,
the antagonistic effects observed with the commercial compounds/antibiotics used against P. aeruginosa
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in this study demonstrate that appropriate caution should be taken to avoid the consumption of herbal
drugs made from Piper species during antibacterial treatment therapies against P. aeruginosa infections.
We suggest that piperine and piperlongumine could be considered as therapeutic bioactive compounds
for antibacterial drug discovery. Further studies should be conducted on the mode of activity of the
synergistic interaction between piperamides and antibiotics.
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Abstract: This study developed a patient-level audit tool to assess the appropriateness of antibiotic
prescribing in acute National Health Service (NHS) hospitals in the UK. A modified Delphi process
was used to evaluate variables identified from published literature that could be used to support
an assessment of appropriateness of antibiotic use. At a national workshop, 22 infection experts
reached a consensus to define appropriate prescribing and agree upon an initial draft audit tool.
Following this, a national multidisciplinary panel of 19 infection experts, of whom only one was
part of the workshop, was convened to evaluate and validate variables using questionnaires to
confirm the relevance of each variable in assessing appropriate prescribing. The initial evidence
synthesis of published literature identified 25 variables that could be used to support an assessment
of appropriateness of antibiotic use. All the panel members reviewed the variables for the first round
of the Delphi; the panel accepted 23 out of 25 variables. Following review by the project team, one of
the two rejected variables was rephrased, and the second neutral variable was re-scored. The panel
accepted both these variables in round two with a 68% response rate. Accepted variables were used
to develop an audit tool to determine the extent of appropriateness of antibiotic prescribing at the
individual patient level in acute NHS hospitals through infection expert consensus based on the
results of a Delphi process.
Keywords: Antimicrobial resistance; antibiotics; antimicrobial stewardship; inappropriate prescribing;
days of therapy; Start Smart then Focus
1. Introduction
Antimicrobial resistance (AMR) is a global threat to health affecting all healthcare systems
and growing at an alarming pace [1,2]. In the UK an increase in annual secondary care antibiotic
consumption by 4.8% (measured as defined daily doses (DDD) of antibiotics per 1000 inhabitants
per day) was reported in England between 2013 to 2017 [3]. Optimising prescribing, through the
development and implementation of antimicrobial stewardship (AMS) programmes is a key area
of the UK five-year AMR strategy [4]. An important element of these programmes is assessing
the quality of antimicrobial prescribing. Several countries now use European Centre for Disease
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Prevention and Control (ECDC) point prevalence survey (PPS) of healthcare-associated infections
and antimicrobial use protocol to identify targets for quality improvement and evaluate antimicrobial
stewardship programmes [5]. Surveillance data collected via PPS provide useful information for
assessment of the burden of antimicrobial prescribing, however, the method has limited capacity to
assess the appropriateness of prescribing in the absence of more complete individual patient-level
clinical data [6]. An adaptation of the ECDC point prevalence survey tool was developed by infection
experts in Australia to better measure prescribing quality; this tool performed well in validation,
inter-rater reliability testing, and user feedback [7]. The Centers for Disease Control and Prevention
(CDC) in the US have also published an audit tool to evaluate the quality of inpatient antibiotic
prescribing with similar positive feedback [8]. These tools share common themes in their evaluation
of appropriateness, such as use of individual patient clinical data and indication to aid the auditor’s
judgement of appropriateness. Two important limitations of existing audit protocols remain evident:
Firstly, application of a broad definition of inappropriateness that includes a range of prescribing
quality indicators (such as prompt intravenous-to-oral switch and appropriate dosing) that do not
predict overall consumption of antibiotics; and secondly, an inability to specifically quantify the
scale of inappropriate prescribing directly resulting from unnecessary doses administered. An ability
to quantify the proportion of antimicrobial consumption that is unnecessary will allow healthcare
organisations and governments to determine targets for a reduction in antimicrobial consumption.
This will limit avoidable selection pressure for AMR and can be achieved without compromising
patient safety. In addition, whilst PPS can provide a rich data source due to the fact they require a
point-in-time assessment, it is not possible to measure the total duration of antibiotic use for patients
assessed as part of a PPS. The national audit tool designed for NHS hospitals described in this report
aims to support a focussed patient-level assessment of the appropriateness of antibiotic prescribing in
secondary care.
It is not currently possible to estimate with any certainty the proportion of antimicrobial prescribing
in English hospitals that is inappropriate, as electronic prescribing data directly linking hospital
prescriptions to clinical data are still not widely available. A key study aim was to develop and
validate a patient-level audit tool that could support estimation of the number of days of antibiotic
therapy that auditors considered non-essential and therefore potentially avoidable. The proportion
of inappropriate antibiotic prescribing can be represented as non-essential days of therapy (DOTs)
expressed as a percentage of total days of therapy. The goal of the audit tool was to collate variables
that would support assessment of those aspects of prescribing most relevant for selection pressure and
resistance. If successful, this would allow the UK to potentially set goals for reduction of antibiotic
consumption in hospitals that are safe and achievable. A secondary aim included creating an audit
tool that helped minimise subjectivity in order to standardise the assessment of appropriateness by
prompting auditors to consider certain critical information in order to support their decision.
2. Results
2.1. Defining Appropriateness
Defining the gold standard for appropriate antibiotic prescribing is challenging due to the
inherently subjective nature of evaluating quality in prescribing. An initial list was compiled to
incorporate elements of high-quality prescribing identified by opinion leaders in the field, the UK
Government Scientific Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare
Associated Infection (APRHAI) and a workshop including 22 infection experts convened to define
appropriate antibiotic prescribing. The collated list (Table 1) sets out many elements of antibiotic
prescribing that may be considered in an assessment of appropriateness.
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No antibiotic if not indicated
(no reasonable evidence of infection) Unnecessary antibiotic exposure selects for avoidable resistance [9–11].
√
Indication documented Good practice for continuity of care but of uncertain relevance to resistance.
√
Appropriate specimens taken for
microscopy, culture, and sensitivity
(MC&S)—blood cultures and suspected
site of infection
Important for establishing evidence of infection and for targeting appropriate
therapy but requires manual audit and >50% of cultures are negative [12,13].
√
No allergy or contra-indication
to treatments Important patient safety consideration but not relevant for resistance. ×
Prompt administration of first dose Important patient safety consideration in cases of severe sepsis but ofuncertain relevance to resistance. Already captured by national sepsis audits. ×
Treatment regimen adequate to cover
most likely pathogens
Meta-analysis of RCTs reports increased risk of mortality if initial regimen
inadequate [14]. Relevance to resistance uncertain.
√
*
Treatment regimen not unnecessarily
broad spectrum




No redundant agents in
treatment regimen Unnecessary antibiotic exposure selects for avoidable resistance [9–11].
√
Treatment regimen compliant with
local/national guideline or
justified deviation
Validity dependent upon quality of local guideline. Relevance to
resistance uncertain. ×
Treatment regimen cost-effective Not relevant to resistance. ×
No underdosing
Limited evidence from modeling suggests that low doses may select
resistance in pneumococci [18] but underdosing unlikely to be a problem in
NHS hospitals due to pharmacist and nurse intervention.
×
No overdosing Important patient safety consideration but likely to reduce rather thanincrease risk of selecting resistance [19–24]. ×
Correct route of administration Relevant for efficacy, length of stay, and risk of line infection but of uncertainrelevance to resistance. ×
Prompt appropriate source control Subjective assessment. Of uncertain relevance to resistance. ×
No missed doses or delayed doses Of uncertain relevance to selection of resistance. ×
Therapeutic drug monitoring (TDM) for
narrow therapeutic index drugs
Important primarily for patient safety (but also for efficacy); of uncertain
relevance to resistance. ×
THEN FOCUS
Prompt discontinuation of antibiotics if
alternative diagnosis established and
infection excluded
There is RCT evidence that unnecessary continuation selects for
multi-resistant organisms [25–27].
√
Appropriate broadening of spectrum in
response to MC&S results
This may necessitate an increase in broad-spectrum agent use if indicated by
MC&S results. Failure to adjust ineffective treatment to MC&S results is
associated with a higher risk of mortality [27].
√
*
Appropriate narrowing of spectrum in
response to MC&S results
Evidence largely from observational studies suggests that de-escalation to
narrow-spectrum agents is safe when patients are improving clinically and a
plausible pathogen has been identified [28].
√
*
Prompt referral to outpatient parenteral
antibiotic therapy OPAT services for
suitable patients
Relevant for length of stay and risk of healthcare-associated infection (HCAI)
but of uncertain relevance to resistance. ×
Prompt switch from IV to oral route of
administration when safe and effective
Relevant for length of stay and risk of line infection but of uncertain
relevance to resistance. ×
Antibiotic plan documented in the notes Good practice for continuity of care but of uncertain relevance to resistance. ×
No unjustified prolonged duration
of treatment
There is evidence from RCTs and observational studies that unnecessarily
prolonged duration selects for multi-resistant organisms [25,26,29]. Can only
be audited at the end of therapy.
√
* Prescribing elements relating to antibiotic spectrum; deprioritised for audit tool prototype
It could reasonably be argued that each of these elements is relevant to efficacy, safety,
and improving patient outcomes, and critical to the assessment of appropriateness of prescribing.
However, the APRHAI committee took a view that improvement in performance against certain
elements would be less likely to impact upon the overall consumption of antibiotics and, consequently,
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would be less likely to impact upon antibiotic resistance. Three aspects were therefore given ultimate
priority as most relevant to identifying avoidable selection of resistance within the UK hospital setting:
• Prescribing an antibiotic for a patient in the absence of (documented) evidence of bacterial infection.
• Prescribing a critical broad-spectrum antibiotic to patients in the absence of a (documented) rationale.
• Continuing an antibiotic prescription beyond the course length recommended in local or national
guidelines, in the absence of a (documented) rationale.
2.2. Initial Draft of Audit Tool
A consensus emerged from the one-day workshop that existing antibiotic prescribing guidelines
for acute hospitals often do not suggest clinical thresholds for initiating or stopping antibiotics. This
means there is a lack of consistency between hospitals in assessing whether antibiotics are indicated
and for how long. There was also general agreement that antibiotic consumption data alone were not
sufficient to determine the proportion of prescribing that is inappropriate. This was further complicated
by the failure of hospital-level antibiotic consumption data to account for patient acuity and hospital
case mix. The workshop group arrived at the conclusion that an individual patient audit by an infection
specialist was required to establish with greater certainty the current proportion of prescribing that is
inappropriate. This process was anticipated to be less vulnerable to case mix or speciality bias. It was
agreed that a patient-level audit tool would be sent for expert elicitation via a Delphi process.
2.3. Round 1 Delphi
The response rate to the initial survey was 100% (19/19), taking on average 32 minutes to complete.
Of the first-round responders, 42% (8/19) were specialist antimicrobial pharmacists, 21% (4/19) were
infectious disease doctors or medical microbiologists, 16% (3/19) were general medical doctors, and the
remaining 21% (4/19) were antimicrobial stewardship nurses. The majority (14/19) of participants in
round one had over five years’ experience and practice in antimicrobial stewardship and infection.
When asked what proportion of inpatients prescribed antibiotics should be audited to provide
reasonable confidence of the overall assessment of the appropriateness of antibiotic prescribing in
secondary care, 79% (15/19) expressed the view that either 5–10% or 10–25% of inpatients on antibiotics
would be an adequate sample size to represent the entire hospital patient population. The panel
members were also asked at what frequency would it be necessary and reasonable to repeat an audit
assessing appropriate antibiotic prescribing; 89% (17/19) indicated annually and 11% (2/19) stated every
three years would be sufficient. Twenty-three of the 25 variables were scored as relevant or highly
relevant for assessing appropriateness for one or more of the main decision points (Supplementary
Materials, Table S1) and were therefore accepted following Round 1. One variable, “documentation of
pre-72-hour review”, was rejected by the expert panel in Round 1 as not relevant to the assessment
of appropriateness at any of the main decision time points. A neutral consensus was reached by the
expert panel for the variable “presenting complaint”; this was subsequently rescored in the second
round. The first variable was renamed to “review of antibiotic prescription within 72 h” to remove the
requirement for formal documentation of the review and presented for scoring in the second round.
The project team was reluctant to remove this variable due to the potential value it brings in predicting
unnecessarily prolonged treatment courses.
2.4. Round 2 Delphi
Out of the nineteen respondents (from Round 1) who were invited to participate in Round 2
the response rate was 68% (13/19). The same distribution of healthcare professionals participated in
Round 2 with 69% (9/13) having over 5 years’ experience and practice in antimicrobial stewardship and
infection. The neutral variable “presenting complaint” was rescored, with 85% (11/13) of respondents
indicating this was considered relevant to assessing appropriate prescribing. A consensus was reached
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when the expert panel members were asked to score the renamed variable “review of antibiotic
prescription within 72 h” with this being accepted by the panel (Figure 1).
Figure 1. Overall Delphi results.
The majority (9/13) of respondents reported that there were local guidance or supportive tools
available to help clinicians stop antibiotic therapy safely. Where not available, three of the four
respondents agreed that such guidance would be helpful.
2.5. Feasibility
Eight of the 19 original panel members agreed that the audit tool was fit for purpose, 32% (6/19)
expressed a neutral view, and 5 panel members disagreed (5/19) including one panel member stating
they were unable to assess this question. The participants were asked if the time taken to complete the
audit tool is a worthwhile investment of NHS resources for the benefit of patient safety and public
health, with 43% (8/19) agreeing that it is, 21% (4/19) having a neutral view, 26% (5/19) disagreeing,
and 10% (2/19) being unable to assess this.
3. Discussion
An audit tool consisting of 25 variables to support assessment of the appropriateness of antibiotic
prescribing in secondary care has been developed. The prototype audit tool was reviewed by
19 multi-disciplinary infection specialist health professionals through a two stage modified Delphi
process and all 25 variables were accepted by specialists as relevant or very relevant to the aim of the
audit following rewording of just one variable.
The response rate of participants within the Delphi process was seen to reduce between rounds
one and two. A systematic review of 31 studies indicated that the median response rate of a Delphi
process does reduce by 2% from the first to the last round of Delphi processes [30], however even with
reminder e-mails our response reduced by 32% from round one to two, so this could be interpreted as
introducing potential bias. The Delphi process occurred during winter months which can operationally
be a busy time for NHS hospitals. This could have been a contributing factor in the reduced response
rate seen over the two rounds.
The inclusion of acuity scores within the audit tool was to help support the auditor in assessing
appropriateness of antibiotics by highlighting the severity of the acute health status which could
be as a result of a likely infection. The supportive use is important as a low acuity score does not
rule out infection, but merely indicates no severe or deteriorating condition or a lesser probability
of organ failure. Evidence from a multi-centre study of adult emergency departments in the UK
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reported a positive predictive value for National Early Warning Score (NEWS) ≥3 of 20% for mortality
or ICU admission [31]. It was therefore considered reasonable to assess what proportion of patients
treated with antibiotics either have NEWS ≥3 or localised evidence of infection at an anatomical site.
An abbreviated version of the Sequential Organ Failure Assessment (SOFA) score, quick SOFA (qSOFA),
was assessed in almost 75,000 adult patients hospitalised with suspected infection [32]. The predictive
validity of the qSOFA score for in-hospital mortality was found to be statistically greater than the
SOFA or systemic inflammatory response syndrome (SIRS) scores, supporting its use as a prompt
to consider possible sepsis [32]. Applying qSOFA score ≥2 during emergency department or ward
stay as a prediction tool for in-hospital all-cause mortality had a negative predictive value of 97% in
adult patients with clinical suspicion of infection in a recent multi-centre study including 27 French
emergency departments [33]. A qSOFA score at a threshold of 2 or more may be considered by some
clinicians to be a reasonable tool for differentiating patients in whom immediate broad-spectrum
antibiotics are justified, given the associated in-hospital mortality of 24% [33].
During the second round of the Delphi process the panel did not accept that formal documentation
of a pre-72-hour review was relevant. The panel did however accept that whether a pre-72-hour review
took place was relevant, irrespective of documentation (e.g., prescription changed but no corresponding
entry in the medical notes) for the purposes of assessing appropriateness of antibiotic prescribing.
In the absence of a pre-72-hour review, it is likely that patients for whom diagnostic tests support an
alternative diagnosis to infection are likely to continue antibiotics longer than necessary. This variable
is also important due to the potential value it brings to predicting unnecessarily prolonged treatment
courses, and it is part of ongoing quality improvement work within English hospitals, so the indicator
was reworded for Round 2. Secondary healthcare quality improvement work within England has
focussed on reducing total antibiotic consumption as well as obtaining evidence of antibiotic review
within 72 h of commencing an antibiotic [34].
The addition of separate questions to explore individual views on inappropriate prescribing
within secondary care was used as it was not possible to estimate a sample size, because the proportion
of non-essential DOTs was unknown. Delphi participants were asked what proportion of patients on
antibiotics required auditing to give them assurance on appropriateness of antibiotic prescribing for
their hospital.
The expert panel members were invited to estimate the feasibility and likely value of the audit tool;
this saw 26% of the expert panel disagreeing with statements that the audit tool was fit for purpose
or a worthwhile investment of NHS resources. This finding was surprising given the high degree of
consensus over the relevance of individual variables for supporting the assessment of appropriateness
and was not explored in more detail. It may reflect a perception of futility that a simple audit tool could
not sufficiently capture the complexity of an episode of infection to enable a reproducible assessment
of appropriateness. A pilot study of the audit tool to test the reliability of the instrument is clearly a
prerequisite before more widespread adoption.
3.1. Study Strengths and Limitations
Strengths of this project include the development of an audit tool through a consensus of a
multi-disciplinary team of experienced infection specialists working in hospital clinical practice.
The authors believe the developed audit tool is the first of its kind internationally that can specifically
quantify the scale of inappropriate prescribing directly resulting from unnecessary doses being
administered. The audit tool was designed to minimise the burden of data collection by limiting
the items of data collected to only those considered relevant or highly relevant to the specific aim of
evaluation of appropriateness of prescribing at three critical prescribing decision time points. The audit
tool also narrows the focus of the audit to evaluate only those elements of prescribing associated
with unnecessary antibiotic doses and therefore likely to be most relevant to the selection of resistant
microorganisms: whether an antibiotic is indicated at the start of treatment, whether treatment beyond
72 h is justified, and whether treatment beyond a standard course length is appropriate.
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The potential to collect more detailed clinical information to explore the subjective decision that
the auditors would take was advantageous. Standardisation of the assessment process may be aided
by the inclusion of objective variables to capture evidence of infection or sepsis, along with markers of
severity including qSOFA score, NEWS, C-reactive protein (CRP), and white blood cell count.
The potential limitations of the audit tool include the time needed to collect data and risk of
subjectivity in assessment which are inherent limitations of this approach, however a balance is
struck between the value of detailed patient-level data to robustly answer the important question
of appropriateness set against the use of a standardised data collection tool to minimise variability
in assessment. There was also limited opportunity for experts to consider variables not included
in the tool, such as medical imaging and urine dipstick tests. Presenting an increased number of
potentially relevant variables such as antibiotic dose and route of administration may have provided
greater opportunity to discriminate between the perceived value of different variables for estimating
non-essential doses. Whilst a relatively small sample of experts participated in the Delphi process,
an important limitation, it is worth noting that 22 experts participated in the workshop to define
appropriate antibiotic prescribing and develop the initial audit tool cascaded for the Delphi consensus.
Subsequent piloting of the audit tool will need to include ongoing evaluation of the strengths and
weakness of the tool and inform iterative improvements. The minor changes to the audit tool as a
result of this Delphi process provide reassurance that extensive revision of the tool was not required,
however a higher number of experts participating would have provided greater assurance of a reliable
rating for each of the variables assessed.
Since admission and discharge dates were not included in the tool it was not possible to determine
at which point during their admission a patient receives antibiotics and therefore whether a patient is
receiving treatment for a healthcare-associated infection or community-acquired infection unless this
is stated explicitly by the auditor. This was identified by the project team as a priority to capture in
future versions of the audit tool.
The use of a web-based Delphi process limited opportunity for qualitative feedback from a
face-to-face discussion and may have contributed to the lower response rate for Round 2. The selection
of expert panel members was via national infection networks and only one healthcare professional also
participated in the previous workshop that convened to define appropriate prescribing. To help reduce
potential bias, all participants were blinded to who participated in the expert panel with individual
correspondence being sent.
The use of the developed audit tool is for active treatment and does not assess long-term and
peri-operative surgical prophylaxis antibiotics. An adaptation could be made to the audit tool in order
to assess these groups of patients. Finally, the developed audit tool was prioritised for antibacterial
agents only but could also be adapted for antifungal and antiviral agents.
3.2. Future Work
Piloting the audit tool within NHS hospitals to assess usability and operability is the next
step. This would also provide additional insight and development of the tool and mitigate against
the limitations of the small consensus panel. The resource burden of data collection and whether
there is variation between hospitals that use electronic systems or paper-based processes needs to
be quantified. Although it is anticipated that the use of electronic systems should be faster than
paper-based prescribing, ease of access to information for each variable may vary. Piloting the audit
tool within 5 to 10 hospitals could provide a preliminary assessment of non-essential days of antibiotic
therapy prescribed to inform the sample size calculation for a definitive study. Recruiting a mixture
of hospital types (teaching, district and specialist) will be important to assess the practicality of the
developed audit tool. The balance between the amount of information being collected with the time
taken to collect the data in a busy operational hospital will be crucial.
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4. Materials and Methods
4.1. Part 1: Development of the Audit Tool
Evidence synthesis of published literature and international guidance contributed to the
development of the initial prototype audit tool to try and quantify and identify inappropriate
antimicrobial prescribing. The initial prototype audit tool then underwent preliminary feasibility
testing at one acute teaching hospital in Southampton, England. This was conducted by a specialist
pharmacist supported by a medical microbiologist, with a focus on evaluating the operability of the
audit tool. After a subgroup of the UK government APRHAI scientific advisory committee drafted
standards to define appropriate prescribing in secondary care a finalised prototype audit tool was
created [4]. The subgroup discussed aspects of auditing including frequency, intensity, resourcing,
and mechanism of data collection including feedback and reporting processes.
To elicit further expert opinion, a one-day workshop was held on 6 March 2017 with infection
experts including secondary care clinicians (10/22), pharmacists (9/22), a nurse, an academic,
and a medical director to explore views on the appropriateness of prescribing within hospitals.
The project team including two pharmacists of the antimicrobial resistance programme at Public
Health England and three national antimicrobial pharmacists met to discuss the workshop findings
and updated the audit tool accordingly. Elements of the audit tool that were intended to support
the assessment of appropriateness of antimicrobial prescribing were termed “variables” for the
purposes of the validation process. The selection of variables to include in the audit tool was based on
discussions within the antibiotic prescribing quality subgroup of APRHAI, iterative e-mail feedback
from co-authors, and prototype audit tool testing in Southampton.
To support the auditor in their assessment of the severity of infection and deterioration as a result
of a likely infection the National Early Warning Score (NEWS) and quick sequential organ failure
assessment (qSOFA) score were incorporated into the audit tool [32,35]. A threshold NEWS value of
3 or above has been proposed as a suitable trigger to systematically screen for sepsis or septic shock in
patients with suspected infection in a United States Emergency Department (ED) population with a
reported negative predictive value of 99.5 (95% CI 97.8–99.9) [36].
4.2. Part 2: Validation of the Audit Tool
Between October and December 2017, a RAND-modified Delphi process was conducted to validate
each individual variable within the audit tool. A multi-disciplinary expert panel of infection and public
health specialists was recruited via e-mail through national infection and microbiology networks and
asked to assess the relevance of each variable against a five-point Likert Scale [37]. The relevance was
assessed in relation to three main decision time points during a course of antibiotic therapy:
• Initiation (was the antibiotic indicated and necessary at the start date?);
• Early post prescription review (was the antibiotic continued after infection was ruled out?);
• End of therapy (was the antibiotic continued beyond the standard duration?).
Non-essential days of antibiotic therapy were included with potential reasons as follows:
(1) antibiotic not indicated/unnecessary at start date; (2) unexplained continuation of antibiotic
after infection ruled out; and (3) unexplained continuation of antibiotic beyond standard duration.
The standard duration was defined by individual hospitals as identified in local antibiotic guidelines.
A separate questionnaire was sent to the Delphi participants to explore individual views on
inappropriate prescribing within secondary care.
The expert panel participated in two rounds. Invitation via e-mail was sent to 19 participants
before the first round. The online survey SelectSurvey.net was used in each Delphi round with
participant reminder e-mails sent periodically. The results were discussed within the project team after
the first round and the aggregated scores were shared with the participants prior to the second round.
Each of the 25 variables was assessed for its relevance against the three main decision time points.
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Qualitative feedback was reviewed by one project team member and common themes reported for
discussion with the full project team. The threshold for accepting a variable was met if the median
score was “relevant” or “very relevant” for assessing appropriateness at any one of the three decision
time points. A variable was rejected if the median score for all three of the critical decision points was
“irrelevant” or “very irrelevant” with a neutral score being rescored in the second round to provide a
definitive response. The rewording of questions between each round occurred by the project team and
was presented to the participants from Round 1 for Round 2. After completing both rounds of the
Delphi process the accepted variables were incorporated into a finalised audit tool (Supplementary
Materials, Figure S1).
4.3. Statistics
Data were summarised using non-parametric descriptive statistics which are considered suitable
to measure consensus and stability in Delphi studies [38] and due to the number of Delphi participants.
The median and percentage “relevant” and “highly relevant” responses for each of the variables in
relation to each decision time point was calculated using univariate analysis.
5. Conclusions
In summary, the RAND-modified Delphi process has provided face validity of this audit tool and
selection of critical variables that can be used to support the assessment of inappropriate antibiotic
prescribing. The feedback from expert panel members helped shape development of the audit tool
and provides an important endorsement from practising healthcare professionals within and outside
the NHS. This audit methodology will help hospitals identify the location, extent, and nature of
inappropriate antibiotic prescribing and provide evidence to drive local antimicrobial stewardship and
focus targeted training to specific areas of improvement.
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Abstract: Actinomycetes are remarkable producers of compounds essential for human and veterinary
medicine as well as for agriculture. The genomes of those microorganisms possess several sets of genes
(biosynthetic gene cluster (BGC)) encoding pathways for the production of the valuable secondary
metabolites. A significant proportion of the identified BGCs in actinomycetes encode pathways for
the biosynthesis of polyketide compounds, nonribosomal peptides, or hybrid products resulting from
the combination of both polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs).
The potency of these molecules, in terms of bioactivity, was recognized in the 1940s, and started
the “Golden Age” of antimicrobial drug discovery. Since then, several valuable polyketide drugs,
such as erythromycin A, tylosin, monensin A, rifamycin, tetracyclines, amphotericin B, and many
others were isolated from actinomycetes. This review covers the most relevant actinomycetes-derived
polyketide drugs with antimicrobial activity, including anti-fungal agents. We provide an overview
of the source of the compounds, structure of the molecules, the biosynthetic principle, bioactivity and
mechanisms of action, and the current stage of development. This review emphasizes the importance
of actinomycetes-derived antimicrobial polyketides and should serve as a “lexicon”, not only to
scientists from the Natural Products field, but also to clinicians and others interested in this topic.
Keywords: actinomycetes; bioactivity; antimicrobials; polyketides; polyketide synthases; biosynthesis
1. Introduction
More than 70 years has passed since the discovery of the first antibiotics from actinomycetes.
Although some of the high G+C (bacteria with high guanine- (G) and cytosine- (C) content in their
genomes) [1,2], Gram-positive bacteria of the order Actinomycetales and their products have been
studied in depth, they remain one of the most important sources of secondary metabolites, including
the naturally-derived antimicrobial drugs (e.g., β-lactams, tetracyclines, rifamycins, macrolides,
aminoglycosides, and glycopeptides). In the past, the producers of valuable bioactive compounds were
mainly isolated from soil samples and either directly or indirectly, using culture filtrates or extracts,
subjected to susceptibility testing (diffusion method) (Figure 1). Recent advances in different disciplines
of science, such as robotics [3], biology [4], chemistry [5–7], genetics [8], and/or bioinformatics [9] has
extended the spectrum of methodology applied to the isolation and identification of actinomycetes and
the produced metabolites. In addition to technical innovations which, for example, enable sampling of
unexplored and difficult to access environments, Next Generation Sequencing Technologies (NGST)
and genome mining facilitate accurate and cost-effective sequencing of actinomycetes genomes and a
fast identification of genes encoding the proteins of the secondary metabolite biosynthetic machineries
(biosynthetic gene clusters, BGCs). In the past two decades, hundreds of actinomycetes genomes have
been sequenced and many of them have been fully annotated. The analysis of the data has demonstrated
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Antibiotics 2019, 8, 157
that a significant portion of the BGCs are associated with polyketide synthase (PKS) and nonribosomal
peptide synthetase (NRPS) pathways, indicating that polyketides, nonribosomal peptides, and their
hybrid compounds are the major secondary metabolites of actinomycetes [10,11]. The biosynthesis
of both, polyketides and nonribosomal peptides, involves multifunctional megaenzymes referred as
PKSs and NRPSs, respectively (Section 2). Despite the fact that polyketides are assembled according to
a similar biosynthetic principle, a wide variety of chemical structures are found in the producer strains.
This structural diversity is mainly accomplished through the different architecture and specificity of the
PKSs, variation of the building blocks for the polyketide chain biosynthesis, and post-PKS modification
reaction. Consequently, it is expected that the chemical arsenal provided by polyketide pathways
encompasses molecules targeting various cellular compartments or interacting with distinct sites of
the same target. Indeed, polyketide drugs such as erythromycins and rifamycins have a different
mode of action. The antimicrobial drug-target interactions and their effects are well described [12–14].
In general, the four major mode of actions (MOAs) include interference with cell wall synthesis
(e.g., penicillins), interference with nucleic acid synthesis (e.g., rifamycins), inhibition of metabolic
pathways (e.g., sulfonamides), and inhibition of protein synthesis (e.g., erythromycins) [15,16]. A fifth
MOA has been identified for the polymyxins and colistin, which disrupts the bacterial cell membranes
by increasing membrane permeability [17].
Figure 1. The process of drug development.
Based on the success of antimicrobial drugs during the “Golden Age” of antibiotic discovery
(1940s–1960s) some experts were confident that “the tide had turned” in the war against pathogens
causing severe infections. However, microbes develop the ability to resist the effects of an antibiotic
whenever the dose of the drug is too low to eliminate the whole population of the pathogen (minimum
bactericidal concentration (MBC)) and thus, antibiotic resistance developed shortly after the drugs
were applied [18–24]. Resistance to antibiotics arises from chromosomal mutations or acquisition of
genetic elements encoding resistance genes (horizontal gene transfer). Several resistance mechanisms
have been reported [25–27]. The most frequent resistance mechanisms are exported through the efflux
pumps, degradation or inactivation of an antibiotic, and modification or alteration of the cellular target
of the antibiotic [15,28]. Furthermore, the overuse and misuse of antimicrobial drugs have promoted
and accelerated the spreading of antibiotic resistance (e.g., methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE)). New resistance mechanisms are constantly being
reported, and transmission elements are identified on a regular basis [29]. According to the World
Health Organisation (WHO), antimicrobial resistance is widely regarded as one of the greatest global
challenges to humanity (estimated 10 million lives a year by 2050) [30]. Thus, guidelines and initiatives
are being put forward in order to limit the further spread of antimicrobial resistance [31]. Some of these
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initiatives include the development of vaccines, faster diagnostic tests to ensure appropriate antibiotic
administration, and immune-based therapies [32]. These measures could provide promising solutions
for prevention of infections however, once infection occurs in a human host, antibiotics remain the
choice of treatment for bacterial and fungal infections. Therefore, the need for new antibiotic classes
and improvement of the old compounds remain more important than ever. Unfortunately, discovery of
novel antibiotic classes is halted by the low return on investment, forcing companies to abandon their
discovery platforms. According to an issue brief of The Pew Charitable Trusts from March 2019 [33],
out of the roughly 38 companies currently invested in antibiotic clinical development, only four of
these are multinational pharmaceutical companies. Furthermore, 90% of the current products in
development are studied by small pharmaceutical or biotech companies, which are ill-equipped to
deal with the expense of possible setbacks, delays or even rejections, which are often faced in clinical
trials [34].
Since polyketide-derived antimicrobials have had a historical significance in human therapy,
this group of compounds remain important for continuation of research aiming at: the identification of
new structures and activities, the biosynthesis and/or chemical semi-synthesis for discovery of novel
derivatisation routes, and finally, at understanding of resistance mechanisms to overcome this obstacle.
In this review, we focus on the therapeutically relevant polyketide drugs which were derived from
actinomycetes. We describe compounds active against microbial pathogens, including pathogenic
fungi and bacteria, their biosynthesis in the natural producer, and the most recent results on
production optimization and derivatisation attempts. This review should serve as a “lexicon” of
actinomycetes-derived antimicrobial polyketides, not only to scientists from the Natural Products field,
but also to clinicians and others interested in this topic.
2. The Biosynthetic Assembly Lines
The biosynthesis of polyketides and nonribosomal peptides requires the PKS and NRPS enzymatic
machineries. PKSs are grouped into type I, II, and III, and can be iterative (type I, II, III) or modular
(type I) [35–39]. The diverse polyketide assembly lines have been previously reviewed [7,40–43].
Here, we introduce types of PKSs that are represented in this review.
The modular type I PKSs can give rise to large, complex polyketides. A “minimal PKS module”
is composed of three essential domains; the acyltransferase (AT), the ketosynthase (KS), and the
acyl carrier protein (ACP). The AT domain selects and loads the building blocks onto the activated
ACPs, while the KS domain catalyses the decarboxylative Claisen-like condensation of the newly
loaded unit and the already existing polyketide chain. The β-keto-processing of the generated chain is
accomplished by optional domains, such as the ketoreductase (KRs), the dehydratases (DHs) and/or
the enoyl reductases (ERs). The final chain termination and release of the polyketide intermediate
from the PKS is facilitated by the thioesterase (TE) domain, often found as the “last domain” in the
multimodular PKS.
Type II iterative PKSs are responsible for the biosynthesis of aromatic polyketides [44–46].
The overall architecture of this type of PKSs appears simpler than the one of complex modular PKSs,
as they only require the presence of three enzymes, the KSα, KSβ (also referred to as chain elongation
factor (CLF)), and an ACP. During elongation, a thioester is bound to the ACP while the KSαKSβ
complex orchestrates chain extension with malonyl-CoA units exclusively. The BGCs of type II PKSs
often contain additional genes encoding cyclases (CYCs) and KRs, which act as chaperones and reductive
enzymes to ensure the correct cyclisation of the polyketide precursor, respectively. Finally, the presence
of aromatases (AROs) leads to the biosynthesis of aromatic ring systems. The iterative type I PKS [47,48]
work in a similar fashion as the iterative type II PKSs [44]. However, the bacterial iterative type I PKSs
only facilitate the biosynthesis of small aromatic polyketides [35,49].
NRPSs display a similar architecture to modular type I PKSs and function in an analogous
manner [39,50]. The selection and loading of the building blocks (proteinogenic or non-proteinogenic
amino acids) onto peptidyl carrier proteins (PCPs) of NRPSs is catalysed by an adenylation (A) domain,
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resulting in an amino acid–PCP–thioester. A condensation (C) domain attaches the amino acid to the
so-far synthesised peptide (chain elongation). Modifications, such as epimerisation or N-methylation at
the peptide chain may occur due to the activity of the optional epimerisation (E) and methyltransferase
(MT) domain, respectively. The peptide chain is released from the NRPS by a TE domain. In the case
of hybrid PKS/NRPS structures [51], the transfer of the growing precursor chain between the different
megaenzymes might require additional enzymes. However, this remains speculative and requires
deeper investigation.
3. Clinically-Relevant Polyketide Derived Antibiotics
3.1. Erythromycin and Derivatives
The history of the macrolide erythromycin began in 1949 with a soil sample, collected in Iloilo City,
(Iloilo, Philippine Islands) by Dr. Abelardo Aguilar, who sent the sample to Lilly Research Laboratories,
where the soil-dwelling bacterium Saccharopolyspora erythraea (formerly known as Streptomyces erythreus)
and the antibiotic erythromycin were isolated [52]. Inspired by the name of the place from which the
soil sample was collected, erythromycin was launched by Eli Lilly Co. in 1952 as Ilosone (also Ilotycin)
(Table 1) for treatment of respiratory tract infections, skin infections, and Legionnaire’s disease.
The antibiotic erythromycin is composed of a 14-membered lactone, erythronolide B, to which two
deoxysugars l-mycarose and α-d-desosamine are attached [53,54] (Figure 2). The BGC of erythromycin
remains one of the most-studied in terms of the type I PKS [55–58]. The precursor erythronolide B
is generated by the modular type I deoxyerythronolide B synthase (DEBS), composed of the three
enzymes DEBS 1–3, encoded by the genes eryAI–eryAIII (Figure S1). The PKS complex contains
six modules, which are responsible for the initial loading of propionyl-CoA, the six steps of chain
elongation with methylmalonyl-CoA as extender units, modification of the growing polyketide chain
by reductive domains, and finally chain release and cyclization by the TE domain in DEBS 3 [57,59,60].
The hydroxylation of the released aglycone is catalysed by the cytochrome P450 enzyme EryF, resulting
in the intermediate erythronolide B. The glycosyltransferases EryBV and EryCII/EryCIII attach the
sugar structures, derived from thymidine diphosphate (TDP)-l-mycarose and TDP-d-desosamine,
which leads to the production of erythromycin D. Erythromycin D is further converted to erythromycin
B or C, which are the substrates for erythromycin A. Erythromycin B is formed whenever the
methyltransferase EryG is acting on erythromycin D. In the case where the molecule erythromycin D is
modified by the monooxygenase EryK, erythromycin C is produced as an intermediate.
Although the strain produces a mixture of erythromycins, erythromycin A was the most abundant
and biologically active compound [61]. Erythromycin shows activity against many Gram-positive
and some Gram-negative bacteria, including Haemophilus influenzae, S. aureus, Streptococcus pyogenes,
Streptococcus pneumoniae, Legionella pneumophila, Neisseria gonorrhoeae, and Mycoplasma pneumonia [61,62].
The antibiotic interacts with the large 50S subunit of the prokaryotic ribosomes and inhibits the protein
biosynthesis [63,64]. More specifically, the antibiotic binds to the exit tunnel and blocks its large subunit
whereby the elongation of the nascent peptide chain is stalled. This stalling leads to the premature
dissociation of the peptidyl-transfer RNA (tRNA) from the ribosome [64,65]. As the inhibition occurs
directly after initiation of protein synthesis, the nascent polypeptide chain remains short, however,
the length size is determined by binding of the macrolide structure to the complex. Consequently,
the size and conformation of erythromycin play a crucial role in the bioactivity of the molecule [66].
In case of erythromycin A, binding to the 50S subunit leads to dissociation and accumulation of
peptidyl-tRNAs with six, seven, or eight amino acid residues. This accumulation causes depletion of
the free tRNA pool, whereby protein biosynthesis is inhibited [65].
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Figure 2. Structures of the two natural substances erythromycin A and spiramycin, and the
semi-synthetic derivatives of erythromycin, including clarithromycin, azithromycin, roxithromycin,
telithromycin (Ketek), solithromycin, and nafithromycin.
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In order to improve the chemical, microbiological, and pharmacokinetic properties of macrolides,
a lot of effort was put into the production of semi-synthetic and synthetic derivatives [63,170,171].
Some of the most successful semi-synthetic derivatives produced from erythromycin include
the 14-membered clarithromycin and roxithromycin and the nitrogen-containing 15-membered
azithromycin (Figure 2) [73,74]. Clarithromycin (trade name: Biaxin, Table 1) and roxithromycin
(not commercially available, Table 1) were discovered in the 1980s in screening programs aiming at
identification of erythromycin A variants with improved acidic stability and oral availability [74,75,172].
The pharmacokinetic profiles of erythromycin A and clarithromycin (6-O-methylerythromycin A
derivative, Taisho Pharmaceutical Co.) are similar however, due to the methylation in clarithromycin,
the antibiotic displays an increased and more stable absorption [62]. At a Croatian pharmaceutical
company PLIVA, chemists succeeded in producing a range of novel erythromycin derivatives based
on chemical modification of an erythromycin A oxime. One of the analogues was roxithromycin
which contains a N-oxime side chain on the macrolactone ring [76,77,172]. However, since the general
pharmacokinetic properties of roxithromycin are similar to those of erythromycin A, the search for more
active and stable derivatives continued and ultimately, azithromycin (trade name: Zithromax, Table 1),
which was the first azalide, was discovered [172,173]. Azithromycin (also CP 62,993 or XZ-450) differed
from the other erythromycin derivatives due to its nitrogen-containing macrolactone ring [78,172,173].
In addition to its high stability and sustained tissue concentrations, azithromycin also had an extended
activity spectrum, covering both Gram-positive and Gram-negative bacteria associated with respiratory
tract infections [62,78,79,172]. Interestingly, azithromycin was the first derivative identified with a
MOA different to that of erythromycin. Similar to other macrolides, azithromycin binds to the 50S
ribosomal subunit. However, instead of one molecule, as it is the case for example for erythromycin,
two molecules of azithromycin bind simultaneously to the 50S ribosomal subunit [174].
Another class of interesting semi-synthetic erythromycin A derivatives are the ketolides,
which were developed as a part of a rational drug design approach [80,81,175]. Telithromycin
(also HMR 3647) (Figure 2, Table 1), with the trade name Ketek, was the first ketolide introduced
into clinical practice. The main difference between ketolides and other semi-synthetic erythromycin
A derivatives is the exchange of the mycarose sugar moiety with a 3-keto group. Furthermore,
telithromycin contains a large aromatic N-substituted carbamate side chain to which an imidazo-pyridyl
group is attached at position C11/C12 of the aglycone structure [175]. Telithromycin was not
only more stable than some of the other semi-synthetic erythromycin A derivatives under acidic
conditions, the ketolide also retained activity against erythromycin resistance isolates of S. aureus and
S. pneumonia [80]. It was suggested that the exchange of the sugar with a 3-keto group is the reason
for the lack of macrolide–lincosamide–streptogramin B (MLSB) resistance against ketolides [176].
Furthermore, telithromycin binds to prokaryote ribosomes with ten-times higher affinity than
erythromycin A [177]. Unfortunately, shortly after its introduction into the clinics, severe side
effects were reported (“Ketek effects”). These included visual disturbance and hepatic failure [82].
As the reports of fatal liver failures in patients receiving Ketek increased, the US Food and Drug
Administration (FDA) withdrew the approval of the drug for simple infections in 2007 [73].
Since many pharmaceutical companies were in possession of large macrolide and ketolide
libraries, screening for novel macrolide drug candidates continued. Two novel ketolides, solithromycin
(trade names: CEM-101 and T-4288) and nafithromycin (trade name: WCK 4873) were identified and
used for treatment of community-acquired bacterial pneumonia (CABP) (Figure 2, Table 1) [73,83,84].
Solithromycin is metabolically stable and shows potency against CABP-associated bacteria and the
Gram-negative pathogen N. gonorrhoeae, which is the causative agent of gonorrhea. However, the future
of solithromycin is currently less certain. Despite promising phase III study results, the US FDA
rejected the approval of the drug for treatment of CABP in 2016, stating their concerns for the lack of
sufficient safety studies addressing the risk of hepatotoxicity [34].
At present, nafithromycin is the only ketolide in global clinical development [85]. The compound
has been enrolled in a phase II clinical study for treatment of CABP. The structure of nafithromycin
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(Figure 2) differs from other ketolides. Instead of a carbamate at position C11/C12, nafithromycin
contains a lactone group. In addition, the backbone of the side chain is differentiated by amino
group and methyl group substituents. Finally, the side chain is attached at another position of the
pyridine [73].
Erythromycin remains one of the best-studied 14-membered macrolides however, other naturally
occurring macrolide antibiotics have been reported. These include oleandomycin (Streptomyces antibioticus,
1954), megalomicin (Micromonospora megalomicea, 1968), and pikromycin (Streptomyces venezuelae,
1951) [67,178,179], of which only oleandomycin made it into the clinics. Oleandomycin displays lower
in vitro activity against S. aureus and Streptococcus spp. than erythromycin A [180]. However, scientists
working at Charles Pfizer and Company claimed that the derivative sigmamycin (Table 1), a 2:1 mixture
of tetracycline and oleandomycin, showed synergic effect on 22 S. aureus isolates, which were otherwise
resistant to the two individual antibiotics [68]. Since other groups failed to reproduce the original findings,
sigmamycin was removed from the market in the early 1970s [69].
Another naturally occurring macrolide is the 16-membered spiramycin (trade name: Rovamycin)
(Figure 2, Table 1), which was discovered in 1954 from culture of Streptomyces ambofaciens, [70,71,181].
This was just two years after the discovery of erythromycin and due to a number of studies reporting
better in vitro antimicrobial activity of erythromycin A compared to spiramycin, the latter never
made it to clinical development in the US [72]. Although spiramycin is not commercially available
in the US, pregnant women, suspecting an infection with the protozoan parasite Toxoplasma gondii,
can request spiramycin for free from the US FDA after a consultation. The details are described in
other comprehensive reviews [182,183].
Macrolide antibiotics such as erythromycin and its derivatives remain some of the most successful
antibiotics in human therapy [73]. In addition to their application in treatment of common respiratory,
genital, and skin infections, the overall properties of erythromycin and its derivatives still favour
their use. These properties include, but are not limited to, good oral availability, narrow spectrum
of activity, and a strong safety profile [73]. Furthermore, this compound class represents a safe and
efficient alternative to patients suffering from allergies to penicillins [184].
3.2. Tylosin
The antibiotic tylosin (Figure 3, Table 1) was discovered in a preliminary screening by Denny and
Bohrer in 1959 (Washington Research Laboratory, Washington, DC, USA) and later produced by Eli Lilly
and Company in Indianapolis, Indiana (trade names: Tylocine, Tylan, tylosin tartrate) [86,185–188].
Tylosin was obtained from a fermentation culture of Streptomyces fradiae which was originally
isolated from a soil sample collected in Thailand [86,189]. The compound is also produced by
other streptomycetes strains such as Streptomyces rimosus [190] and Streptomyces hygroscopicus [191],
however, S. fradiae remains the preferred choice for industrial fermentation of tylosin.
The naturally-derived tylosin is a mixture of the four 16-membered macrolide antibiotics tylosin
A, B, C, and D [86,188,192–195]. Although tylosin A is found in highest concentration in the mixture
(80–90%), tylosin B (desmycosin), tylosin C (macrocin), and tylosin D (relomycin) are also believed to
contribute to the overall bioactivity of tylosin [195]. The structure of tylosin A (Figure 3) is a 16-atom
polyketide lactone with the three deoxyhexose sugars d-mycaminose, mycinose (6-deoxy-d-allose),
and l-mycarose attached [87].
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Figure 3. Structures of tylosin A and the four semi-synthetic derivatives tilmicosin, tildipirosin,
tulathromycin, and gamithromycin.
The biosynthetic pathway of tylosin has been studied in detail [87,196–200]. With a size of ~85 kb,
the tylosin (tyl) gene cluster occupies 1% of the entire genome of S. fradiae. Sequencing of the tyl gene
cluster has revealed 13 genetic loci, tylA through tylM. These genes encode the PKS megaenzyme
complex (TylGI–TylGV) for the assembly and cyclization of the precursor tylactone (Figure S2),
proteins responsible for the biosynthesis of mycaminose, mycarose, and mycinose, hydroxylases,
a methyltransferase, a reductase, and finally proteins involved in resistance and regulation.
The biosynthesis of the tylosin polyketide chain is initiated by the loading of methylmalonyl-CoA to the
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first module in TylGI. The polyketide chain is extended by the attachment of four methylmalonyl-CoA,
two malonyl-CoA, and one ethylmalonyl-CoA [88,201–204]. The TE-catalysed release of the aglycone
and cyclisation of the structure yields the 16-atom tylactone, which is further modified at C20 and C23
by the two cytochrome P450 hydroxylases TylI and TylHI, respectively. The resulting intermediate
tylonolide is then glycosylated through the attachment of the deoxyhexose sugars d-mycaminose,
mycinose, and l-mycarose by TylMII, TylN, and TylCV, respectively [87,199,200,205] (Figure S2).
Finally, to yield tylosin A, TylE and TylF modify the mycinose through the O-methylation of the C2′′′
and C3′′′ positions in the sugar. The remaining genes found in the tyl gene clusters encode ancillary
proteins (crotonyl-CoA carboxylase/reductase (CCR), MetK, and, MetF), regulators (TylP, TylS, TylQ,
TylU, TylR (TylT)), and proteins involved in resistance (TlrB–TlrD) [87].
Similar to other macrolides, tylosin inhibits protein biosynthesis in prokaryotes by binding
to the large 50S subunit [88,89,185]. Poulsen et al. have shown that the disaccharide
d-mycaminosyl-l-mycarose at the C5-atom in tylosin affects the binding of the molecule to the
ribosome complex [206]. As opposed to erythromycin A (Figure 2), in which tri- and tetrapeptides are
still released from the ribosome upon binding of the macrolide, for tylosin the C5-disaccharide extends
binding of the macrolide to the ribosome, only allowing formation of dipeptides [206,207].
The antibiotic tylosin is approved exclusively for veterinary use. It is applied to treat
leptospirosis, mycoplasmosis, and respiratory tract infection, caused by Gram-positive bacteria,
including Streptococcus spp., Staphylococcus spp., Clostridium perfringens, and Mycoplasma spp. [208].
Historically, tylosin has been used as feed additive for cattle to prevent the development of liver
abscesses and for swine as a growth promoter.
Tylosin remains a valuable antibiotic for use in veterinary medicine. However, derivatives of
the native compound have been introduced in clinical practice as well. One such molecule is the
semi-synthetic derivative tilmicosin, which has an extended antimicrobial spectrum compared to
tylosin [90,91]. Tilmicosin displayed activity against Pasteurella multocida and Pasteurella haemolytica,
and is important for treatment of bacterial pneumonia in young cattle. In addition, tilmicosin has shown
improved activity against P. multocida in chickens. Tilmicosin is available under different trade names
(Table 1), including Pulmotil and Micotil (Elanco Animal Health (https://www.elanco.com/), previously
owned by Eli Lilly Company) and as Tilmovet (Huvepharma (https://www.huvepharma.com/)).
Other semi-synthetic tylosin derivatives, which have been approved for treatment of respiratory
diseases in animal production, include the 16-membered macrolide tildipirosin (trade name: Zuprevo)
and the two 15-membered macrolides, tulathromycin (trade name: Draxxin), as well as gamithromycin
(trade name: Zactran) (Figure 3, Table 1) [92–95].
In most cases, the 16-membered macrolides have less in vivo efficacy than the 14- and 15-membered
macrolides. This is due to the fact that the side chains are metabolised and the generated products
have a decreased activity compared to 14- and 15-membered macrolides.
3.3. Monensins
The polyether ionophore monensin A (Figure 4, Table 1) (trade names: Coban, Rumensin, and
Monensin) is another example of antibiotics being particularly important for veterinary medicine.
The compound was identified in fermentation cultures of Streptomyces cinnamonensis and reported
for the first time in 1967 as monensic acid by the Lilly Research Laboratories and the Department of
Biochemistry of Indiana University School of Medicine [96,209]. In the natural producer, a mixture
of monensin-like agents (monensin A, B and C) is synthesised, however, monensin A is the main
constituent of this product (Figure 4). Monensin A is composed of five rings to which seven methyl,
one ethyl, one carboxyl, and one hydroxyl group are attached [96]. Monensin B and C vary from
monensin A by their side groups. In monensin B, the ethyl group on C16 is replaced by a methyl group,
whereas in monensin C the methyl group at C2 is replaced by an ethyl group [210–212]. The carboxyl
and hydroxyl groups can interact through hydrogen bonds, whereby a pseudocyclic conformation
of monensin is formed (Figure 4). This results in an oxygen-containing center, which is selective for
151
Antibiotics 2019, 8, 157
cations. Due to these conformational changes of monensin, an exterior composed of alkyl groups,
which render the molecule hydrophobic and capable of passing the lipid bilayer of cell membranes, is
built. The ionophore monensin A is able to bind monovalent metal cations such as Li+, Na+, K+, Rb+,
Cs+, and Ag+. However, the compound prefers sodium cations for the formation of the ion–ionophore
complex, which facilitates cation transport across cell membranes. This disturbs the natural Na+/K+
concentration gradient in Gram-positive bacteria causing death of the cell [97,210,213–216].
 
Figure 4. The structures of monensin A and monensin A in complex with sodium (Na+) ion.
The genome sequencing of the producer and understanding the biosynthetic pathway of monensin
have been crucial for optimizing the production of monensin in S. cinnamonensis. Sequence analysis
of the 97 kb BGC of monensin (mon) has revealed a modular type I PKS, encoded by the genes
monAI–monAVIII [98,217] (Figure S3). The first step in the assembly of the polyketide backbone is the
loading of the “initiation module” of MonAI with malonate, which is derived from a malonyl-CoA
starter unit. Twelve “downstream” extension modules in the PKS complex MonAI–AVIII catalyse the
loading and condensation of additional four acetate, one butyrate, and seven propionate molecules,
leading to the biosynthesis of the monensin polyketide chain. Since no TE domain is present in MonAVII,
the release of the monensin intermediate must be facilitated by TEs acting in trans. Originally, it was
assumed that either MonAIX and/or MonAX, which show homology to TEs involved in rifamycin,
tylosin, and erythromycin biosynthesis [98], catalyse this reaction. Later, the enzyme MonCII, previously
assigned as an epoxide hydrolase, was proposed as a putative novel TE, which might be responsible
for the release of the monensin polyketide chain from the PKS assembly line [218]. The additional
genes found in the mon gene cluster encode enzymes involved in isomerisation, epoxidation (MonCI),
hydroxylation (MonBI, MonBII, and MonD), and methylation (MonE) of the structure to the final
product monensin A [98,219]. Finally, the mon gene cluster includes three regulator genes, monH, monRI,
and monRII, and the gene monT, which encodes an efflux protein, believed to confer self-resistance to
the host [98,217,220,221].
Monensin A is used as a coccidiostat (inhibitor of coccidiosis) in poultry and as a non-hormonal
growth promoter for cattle in the beef and dairy industry [97,210]. In addition, it was suggested that
monensin A might also improve food metabolism in ruminants. Therefore, the feed additive Rumensin,
which contains 6.6% monensin, was introduced for cattle to improve the composition of the intestinal
bovine microbiota, reducing lactic acid formation, and ultimately leading to faster growth of cattle [99].
In 1971, monensin A was the first ionophore to be approved as a veterinary medicine.
Two additional ionophore antibiotics lasalocid and salinomycin have subsequently been approved.
Lasalocid, originally identified from fermentation broth of Streptomyces lasaliensis, was introduced in
1977 as a coccidiostat for poultry (trade name: Avatec) and later in 1982 as growth promoter for cattle
(trade name: Bovatec). Salinomycin (trade name: Bio-Cox), produced by Streptomyces albus, received its
approval as a coccidiostat for chickens in 1983 [210,222–224].
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Given the nature of their applications, ionophore antibiotics have been subjected to increased
concerns with regards to the association between their misuse as feed additives and development
of resistance. However, studies on ionophore resistance in ruminal bacteria indicate that instead
of resistance occurring as a result of mutations or horizontal gene transfer, it is more a matter of
physiological selection [225]. Since ionophore antibiotics are restricted to only a few animal species
and have never been used in human medicine, it appears that the risk of cross-resistance is rather low.
Little is known about resistance development in bacteria subjected to ionophores. Based on in vitro
and in vivo experiments several ionophore resistance mechanisms have been suggested. Those include
the hypothesis of a proton-translocating enzyme which might counteract ionophore-dependent ion
flux [226,227], the cell wall model of ionophore resistance [228–230], and the theory of extracellular
polysaccharides (biofilm) [225], such as glycocalyx produced by ruminal bacteria. As no clear
indications of resistance development and spreading have been reported, it is likely that the use of
ionophore antibiotics as feed additives will continue [225].
3.4. Tiacumicin
In the 1980s, scientists working at Abbott Laboratories were screening soil samples for novel
microbes with antimicrobial activities. In a soil sample from Hamden, Connecticut, USA, the novel
Gram-positive bacterium Dactylosporangium aurantiacum subsp. hamdenensis subsp. Nov. AB718C-41
(NRRL 18085) was isolated based on its activity against MRSA. After scaling up the production, six novel
compounds were isolated known collectively as the tiacumicins [100,231]. Structure elucidation of
the tiacumicins further revealed a shared 18-membered macrolactone, which differed between the
analogues based on the types of modification to the macrocyclic ring and the number and esterification
pattern of the sugar groups attached. Out of the six compounds produced, tiacumicin B (Figure 5) was
found in largest quantities [100].
Figure 5. Structure of tiacumicin B.
The tiacumicin (tia) biosynthetic gene cluster of the original producer strains D. aurantiacum subsp.
hamdenensis NRRL 18,085 was elucidated by Xiao and co-workers in 2011 based on sequence analysis
and gene knockout studies [101]. The data revealed the presence of 50 open reading frames (ORFs)
spanning an 110,663 bp DNA region. Additional sequence analysis has shown that 31 of the originally
identified 50 ORFs are directly involved in tiacumicin biosynthesis. The remaining 83 kb DNA region
includes genes encoding enzymes responsible for polyketide backbone assembly, sugar biosynthesis,
glycosylation, halogenation, methylation, hydroxylation, epoxidation, and resistance determinants.
The four genes tiaA1 through tiaA4 encode the multimodular type I PKS responsible for the assembly
of the central aglycone tiacumicinone (Figure S4) [101,232]. After loading of the starter unit propionate,
additional three malonates, four methylmalonates, and one ethylmalonate are condensed to the
polyketide chain. Several genes are encoded in the tia BGC, which could provide the precursors for
the polyketide. The synthesis of isobutyryl-CoA, propionyl-CoA, and acyl-CoA might be catalysed
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by TiaC and TiaD. Furthermore, the propionyl-CoA carboxylase encoded by tiaL might catalyse
the formation of methylmalonyl-CoA from propionyl-CoA, and the CCR encoded by tiaK could be
responsible for provision of the ethylmalonyl-CoA subunit [233]. Upon reaching the TE domain in
module eight of TiaA4, the polyketide chain is released and cyclised, yielding the tiacumicinone
precursor (Figure S4). An additional TE TiaE, which shows homology to the type II TE NysE involved
in nystatin biosynthesis, is found in the tia BGC. Since these type II TEs are believed to act as repair
enzymes, removing aberrant PKS precursors, TiaE has been hypothesized to have a similar role
in tia biosynthesis [101,234]. Tiacumicinone undergoes several modifications including C18 and
C20 hydroxylations, which are catalysed by the two cytochrome P450 enzymes TiaP1 and TiaP2,
respectively, and the attachment of the rhamnose sugars at position C11 and C20, catalysed by the two
glycosyltransferases TiaG1 and TiaG2 (Figure S4). The sugars are further modified. First, to yield the
final 4-O-isobutyryl-5-methyl-β-rhamnose at position C11, the sugar C-methyltransferase TiaS2 and
O-acyltransferase TiaS6 incorporate the methyl and isobutyryl moieties, respectively. The sugar at
C20 also undergoes several modifications. The synthesis of the homo-orsellinic moiety is believed
to be catalysed by an iterative type I PKS TiaB based on a propionyl-CoA starter unit and three
malonyl-CoA extender units [101]. The transfer of the aromatic moiety to the C20 sugar could then
be facilitated by the acyltransferase encoded by tiaF (Figure S4). Further modifications to the sugar
are achieved by the actions of TiaS5, responsible for the 2′-O-methyltransferase reaction leading to
2-O-methyl-β-rhamnose and, finally, the dihalogenase TiaM, which is responsible for attachment of two
chlorine atoms to the homo-orsellinic acid. Within the tia cluster, genes encoding proteins putatively
involved in regulation and resistance are also found. This includes the putative LuxR class regulator
TiaR1 and the putative ArsR family transcriptional regulator TiaR2, of which only the function of
TiaR2 has been experimentally verified [101]. Since the ΔtiaR2 mutant strain produced slightly higher
levels of tiacumicin than the wild type strain, the regulator might act as negative regulator in tia
biosynthesis. TiaT1 through TiaT4 show homology to membrane proteins and ATP-binding cassette
(ABC) transporter and therefore, have been hypothesized to be involved in export of tiacumicin.
However, genetic and biochemical studies are necessary to clarify their role in the biosynthesis of
tiacumicin [101].
Coincidentally, in the same year as the tiacumicins were discovered and reported, a Japanese
group, led by Satoshi Omura, reported the discovery of the antibiotics clostomicins, produced by
Micromonospora echinospora subsp. armenica subsp. Nov [235]. Structure comparisons not only revealed
tiacumicin B and clostomicin B1 to be identical, but also that a third antibiotic, lipiarmycin A3,
discovered in 1975 from culture of Actinoplanes deccanensis A/10655, shared the same structure [231,236].
Ultimately, only tiacumicin B went through to further clinical studies. Although originally identified for
its activity against MRSA, promising in vivo potency against Clostridioides (formerly Clostridium) difficile
in animal models directed the development of tiacumicin B towards a narrow spectrum antibiotic for
treatment of clostridia [233]. The antibiotic was approved by FDA in 2011 under the generic name
fidaxomicin and trade name Dificid (Table 1) for treatment of C. difficile infections (CDI), which remains
one of the main causes of hospital-acquired diarrhoea [233]. At the time, Dificid was regarded as an
alternative to vancomycin, which was used to treat CDI. One of the major drawbacks of vancomycin
is its broad-spectrum and bacteriostatic activity which promote reoccurrence of CDI. In contrast,
fidaxomicin is a bactericidal, narrow-spectrum antibiotic and has been found to not only reduce
recurrence of CDI but also promote survival of commensal gut microbes and prevent the development
of colitis [102,237]. In addition, fidaxomicin is administered orally with no reports of resistance
development in C. difficile isolates. In a recent US-based national survey, 1889 C. difficile isolates
were collected from the stool of patients infected with the pathogen over the period of 2013 to 2016.
The isolates were screened for susceptibility against fidaxomicin and showed that fidaxomicin MIC50
(maximum inhibitory concentration of an antibiotic, at which 50% of the isolates are inhibited) and
MIC90 (maximum inhibitory concentration of an antibiotic, at which 90% of the isolates are inhibited)
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values toward C. difficile had not changed over the time period [238]. However, the fact that fidaxomicin
was only recently introduced to the clinics stresses the need for continuous surveillance [238].
Recently, the MOA of tiacumicin B has been further clarified based on the cryogenic electron
microscopy (cryo-EM) structure of Mycobacterium tuberculosis RNA polymerase (RNAP) holoenzyme
in complex with lipiarmycin A3 [103]. Although the target of fidaxomicin was already known to be the
bacterial RNAP [239], the recent findings could show the binding of the antibiotic to be specific for the
RNAP clamp. Upon binding of fidaxomicin, the RNAP is trapped in an open-clamp conformation,
which prevents the simultaneous engagement of the −10 and −35 elements needed for transcription
initiation. Furthermore, since the binding sites of fidaxomicin do not overlap with those of other known
RNAP inhibitors, including rifamycin and sorangicin, the risk of cross-resistance is lowered [103].
At the moment, fidaxomicin is the only substance approved for human therapy within the
tiacumicin-like compounds. However, the advanced information on the structure activity relationship
(SAR) of fidaxomicin might trigger a more rational structure-based design of drug analogues in the
future [103].
The knowledge obtained from studies on the tia gene cluster aided the design of a
dihalogenase-deficient ΔtiaM mutant strain, which produced 14 tiacumicin congeners of which
11 were novel derivatives [240]. Based on minimum inhibitory concentration (MIC) tests, tiacumicin
congener 3 displayed higher potency against Bacillus thuringiensis (MIC = 0.5 μg/mL), Micrococcus
luteus (MIC = 1 μg/mL), and Enterococcus faecelis (MIC = 4 μg/mL) compared to all other congeners and
the parent compound tiacumicin B. Interestingly, in addition to its lack of chlorine atoms, congener
3 contained a propyl group on the aromatic ring. The four-fold antibacterial activity increase of congener
3 compared to tiacumicin B was putatively assigned to the structural change in the aromatic ring. In the
future, this knowledge could provide the foundation for further gene manipulations, which would
result in generation of novel tiacumicin derivatives with improved antibacterial activities [240].
Furthermore, these derivatives might also provide more cost-effective alternatives to fidaxomicin,
the price of which remains a major point of criticism [241].
3.5. Rifamycin and Derivatives
Rifamycins (Figure 6) belong to the class of ansamycin antibiotics. This group of compounds is
distinguished by a cyclic structure bridged at two nonadjacent positions by an aliphatic chain [104,105].
This basket or handle-like architecture gave rise to the naming ansamycins (Latin: ansa = handle).
Ansamycins comprise a range of different substances. In the following, we cover rifamycin and its
derivatives, which collectively belong to the group of naphtalenes-ansamycins.
The history of this class of compounds started in 1959 with the isolation of the naturally-derived
rifamycins, a complex mixture of several congeners produced by Streptomyces mediterranei [106].
More detailed studies on morphology, cell wall composition, and phage susceptibility resulted
in re-classification of the strain, first as Nocardia mediterranei, and later as Amycolatopsis
mediterranei [105,242]. Structure elucidation has revealed common architectures of the complex
of rifamycins, which include a 17-membered aliphatic chain and a C–O bond linking the benzene ring
to the chain [243] (Figure 6). In the initial attempts to separate and isolate each of the congeners from the
fermentation broth of A. mediterranei, only rifamycin B, which constitutes 5–10% of the mixture, could
be purified [244]. Since the substance was the least active congeners in the mixture, further studies were
necessary to identify the more potent substances. One of the breakthroughs came with the elucidation
of four additional rifamycin intermediates, including rifamycin S, L, O, and SV [105,245,246].
155
Antibiotics 2019, 8, 157
 
Figure 6. Structures of the two naturally derived substances rifamycin B and rifamycin SV and the
semi-synthetic derivatives rifampicin, rifabutin, rifapentin, and rifamixin. Additionally, the structure
of the natural substance kanglemycin A isolated from Nocardia mediterranei var. kanglensis 1741-64
is included.
Using the sequence encoding RifK (3-amino-5-hydroxy benzoic acid synthase (AHBA synthase))
in the natural producer as a probe, the BGC of rifamycin was isolated from a cosmid library of
A. mediterranei [107]. The gene cluster stretches over a 95 kb DNA region and contains 34 genes
encoding all structural, modification, resistance, export, and regulatory elements. The assembly of
the polyketide chain is governed by the modular type I PKS, encoded by the five genes rifA through
rifE (Figure S5). Since the loading module within RifA contains domains with homology to A and T
domains of NRPSs, the rifamycin assembly line is a hybrid PKS/NRPS [247]. The starter and extender
units involved in the formation of the polyketide has been identified [248]. This includes the atypical
starter unit AHBA, of which biosynthesis is orchestrated by enzymes encoded by rifG through rifN.
The shikimate-related pathway of aromatic biosynthesis leading to the formation of AHBA was
elucidated based on gene inactivation and heterologous expression [248]. Upon loading of AHBA,
the polyketide chain is further elongated by the ten extender modules, which facilitate the addition
of eight acetate and two propionate extender units [107,108]. The rifamycin PKS does not encode a
typical TE domain. Instead, downstream of rifE, the gene rifF which shares homology to an arylamine
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N-acetyl-transferase is located. The role of RifF in chain release and macrolactam ring closure has been
confirmed through an in-frame deletion, in which the ΔrifF mutant lost its ability to produce rifamycin
B and instead accumulated shorter open-chain ketides [249]. An additional TE encoded by rifR has
been identified in the rifamycin gene cluster [250]. However, since the ΔrifR and ΔrifF+ΔrifR mutants
showed identical production profile, in which the same aberrant open-chain polyketides were detected,
it was concluded that RifR is directly involved in the release of polyketide precursors from the assembly
line. Furthermore, closer examinations of the PKS intermediates produced by the ΔrifF mutant revealed
that while the tetraketide contained an unmodified aromatic chromophore, the pentaketide through the
decaketide contained the bicyclic naphthoquinone moiety [251]. This indicated that naphthoquinone
ring closure must occur while the polyketide chain is still attached to the PKS. This hypothesis was
later confirmed based on the genetic studies of rif19, which encodes a 3-(3-hydroxyphenyl)propionate
hydroxylase-like protein [252]. It was concluded that Rif19 catalyses the naphthoquinone ring closure,
which occurs between module three in RifA and module four in RifB (Figure S5). Upon its release from
the PKS, the polyketide precursor undergoes a series of post-modifications, including dehydrogenation
at the C8 and hydroxylation of the C34, which results in the formation of one of the early intermediates
in the post-modification pathway, namely rifamycin W [252,253]. The conversion of rifamycin W to
rifamycin B involves the formation of the intermediate rifamycin SV (Figure S5) [105,252]. The final
steps in the conversion of rifamycin SV to rifamycin B, through the intermediates rifamycin S, L, and O,
have only recently been elucidated based on in vitro assays with the cytochrome P450 enzyme Rif16
and the two-subunit transketolase Rif15 (Figure S5) [254].
Additional genes encoding enzymes involved in regulation, export, and self-resistance have been
identified in the rifamycin BGC. This includes the LuxR family regulator RifZ, which acts as an activator,
and the TetR-family transcriptional regulator RifQ, which is a repressor of rifamycin biosynthesis
in A. mediterranei [255–257]. The repressor RifQ is feedback-regulated by rifamycin B, the product
of the rifamycin gene cluster in A. mediterranei. When a threshold concentration of rifamycin B is
reached intracellularly, the substance interferes with the binding of RifQ to the promoter region of rifP,
which encodes a membrane protein, whereby export of the antibiotic is initiated [258].
The importance of the rifamycins in human therapy is evident from their strong activities against
a wide range of Gram-positive bacteria and to a lesser extent, some Gram-negatives. The reason
for the higher MIC of Gram-negatives is most likely due to a reduced penetration of the rifamycins
through the outer membranes of Gram-negatives [258]. The rifamycins remain the first-line treatment
of tuberculosis (TB) caused by M. tuberculosis and for treatment of non-tuberculous mycobacterial
infections [105,119,244]. Collectively, the rifamycins interact with the bacterial DNA-dependent RNAP
whereby transcription is blocked.
As previously mentioned, rifamycin B itself displays modest bioactivity and therefore, the need
for derivatisation of the scaffold is necessary to produce rifamycin analogues with improved activity
and availability. In fact, from the naturally derived rifamycins, only rifamycin SV has been introduced
in human therapy. With a strong bioactivity against Gram-positives, including M. tuberculosis,
and moderate activity against some Gram-negatives [244], rifamycin SV was introduced into the
clinic in 1963 as a topical and parental agent. Extensive semi-synthesis efforts on rifamycins
delivered several clinically relevant compounds. Using information gained from SAR studies,
the first series of rifamycin analogous were generated based on substitutions at the C3/C4 positions
in the aromatic moiety of the intermediate 3-formyl rifamycin SV. One of the resulting substances,
3-(4-methyl-piperazinyl-iminomethyl) rifamycin SV, coined rifampicin (Figure 6), displayed strong
bioactivity against Gram-positive bacteria, including M. tuberculosis and Neisseria species, and modest
activity against Gram-negatives [105,110]. Just as importantly, rifampicin was fat-soluble and could
be administered orally. Ultimately, rifampicin (trade names: Rifadin and Rimactane) (Table 1) was
introduced for human therapy in 1968 in Italy and in 1971 in the US, and has since then been an
important agent in treatment of TB, leprosy, and other mycobacterial infections [243]. Additionally,
rifampicin has also been an important substance for determining the MOA of rifamycins. Based on the
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3.3 Å crystal structure of the RNAP core of Thermus aquaticus complexed with rifampicin, Campbell and
co-workers determined the binding of the antibiotic to the β subunit within the DNA/RNA channel.
This binding resulted in the physical blockage of the channel for the elongating RNA, when the
transcripts reach a size of two to three nucleotides in length [111]. Determining the MOA of rifampicin
also aided in understanding the high frequency of resistance development in rifamycin sensitive
microorganism. Since pathogens can develop resistance to rifampicin with a rate of 10−8 to 10−9
per cell division, the application of the antibiotic is restricted to combination therapy, in which the
antimycobacterial agent isoniazid is often used together with rifampicin, or used only in severe cases
of TB infection [105]. The high rate of resistance is most commonly associated with the acquisition of
mutations in the rpoB gene, which encodes the β subunit in the RNAP, whereby the binding affinity of
the enzyme to the antibiotic is lowered. The rpoB gene is highly conserved in prokaryotes, however,
pathogens acquire different levels of mutations in their respective rpoB genes, and consequently the
level of resistance also can vary amongst isolates. For clinical isolates of M. tuberculosis, the three
amino acids S411, H406, and D396 (T. aquaticus numbering) are most often mutated. Mutations at these
positions in the RNAP core influence the hydrogen bonds formed between the hydroxyl groups on C8
and C21 of rifampicin, which interact with S411 and with H406 and D396, respectively [105,111].
Additional rifamycin analogues obtained through the derivatisation efforts on rifamycin SV have
made it through to the clinics (Figure 6). One of these analogues is the 3-(((4-cyclopentyl-1-piperazinyl)
imino) methyl) rifamycin S, also known as rifapentine (trade name: Priftin) (Table 1). Rifapentine
was discovered during the initial derivatisation efforts on the C3/C4 aromatic moiety in rifamycin SV.
The analogue was approved for treatment of TB in 1998 and similar to rifampicin can be administered
orally [115,259]. Unfortunately, isolates which are resistant to rifampicin display cross-resistance to
rifapentine, which has limited the application of the antibiotic.
The two rifamycin analogues rifabutin (trade name: Mycobutin) and rifaximin (trade names:
Normix, Rifacol, Xifaxan) were approved for human therapy in 1992 and 2004, respectively
(Table 1) [243]. Rifamixin ((4-deoxy-4)-methylpyrido [1),2)-1,2]imidazo-[5,4-c]rifamycin SV) is
non-systemic and can reach high concentrations in the gastrointestinal (GI) tract, enabling its application
for treatment of traveller’s diarrhoea caused by enteropathogens, including Escherichia coli [116].
More recently, rifaximin has been further implicated in the treatment and prevention of various
GI diseases, including inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
Although the continuous administration of rifaximin has raised concerns for selection of resistance and
undesirable disruption of the gut microbiota, several studies have shown that rifaximin may promote
a healthy gut microbiota [117,260,261]. The beneficial effects of the antibiotic are lost quickly after the
treatment with rifaximin was terminated which probably limits its application as a preventive agent for
GI-associated diseases [118]. Only recently, an alternative antibiotic combination has been approved
by the US FDA for the treatment of traveller’s diarrhoea. The oral formulation developed at Cosmo
Pharmaceuticals N.V. (Ireland) is based on the unique combination of rifamycin SV together with the
MultiMatrix (MMX®) technology, which ensures colonic delivery of the antibiotic [109]. Based on
in vitro studies, rifamycin SV MMX® (trade names: Aemcolo and Relafalk) (Table 1) was found
to exhibit antibacterial activity against most enteropathogens associated with traveller’s diarrhoea.
Moreover, in later phase III clinical studies, the oral substance was well-tolerated in patients undergoing
treatment and could shorten the duration of non-dysenteric traveller’s diarrhoea [109].
The semi-synthetic derivative rifabutin (4-N-isobutylspiropiperidylrifamycin S) was approved for
human therapy due to its inhibitory activity against a number of rifampicin-resistant M. tuberculosis
clinical isolates in addition to its well-documented activity against Mycobacterium avium and
M. intracellulare (also referred to as Mycobacterium avium-intracellulare complex (MAC)) [112,113].
MAC infection frequently occurs in patients with acquired immunodeficiency syndrome (AIDS)
and when administered prophylactically as a 300 mg daily dose, rifabutin significantly reduces the
incidence of MAC bacteraemia. However, due to the risk of cross-resistance between rifampicin and
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rifabutin in M. tuberculosis isolates, rifabutin is restricted to MAC patients and for newly diagnosed
and multidrug-resistant TB in Europe [114].
During the derivatisation of rifamycins, modifications to the ansa bridge often led to compounds
with lowered activities [262]. Recently, the natural ansamycin antibiotic kanglemycin A, which has
an altered ansa chain, was found to maintain potency against rifampicin-resistant bacterial isolates,
including multidrug-resistant M. tuberculosis (Figure 6). Kanglemycin A was originally isolated
from Nocardia mediterranei var. kanglensis 1741-64 in 1988, however, the MOA of the compound was
only recently elucidated. Based on the crystal structure of the RNAP-promoter complex of Thermus
thermophiles with kanglemycin A, it became evident that the sugar (β-O-3,4-O,O′-methylene digitoxose)
and acid (2,2-dimethyl succinic acid) moieties on the ansa bridge in the molecule increase the binding
surface of the antibiotic with the RNAP. Furthermore, the additional interaction of the sugar group of
kanglemycin A was hypothesized to limit the frequency of resistance development as this would require
two simultaneous mutations in the binding pocket of the RNAP [119,120]. Although kanglemycin A
(Table 1) itself has not been introduced to the clinics, its discovery might open up for future structural
derivatisation efforts in which the ansa bridge might prove to be a valuable “target” for generating
new synthetic ansamycin antibiotics with improved bioactivities.
3.6. Tetracyclines
The tetracycline group of antibiotics covers a variety of natural and semi-synthetic compounds.
There are three naturally derived tetracyclines that have been described in detail and have formed
the basis for 2nd and 3rd generation tetracycline derivatives. The three natural substances include
chlortetracycline (trade names: Aureomycin, Table 1) discovered from the fermentation broth of
Streptomyces aureofaciens in 1948 [125], oxytetracycline (trade name: Terracycline, Table 1) found
in the broth of Streptomyces rimosus in 1950 [121], and finally tetracycline, which was discovered
as a fermentation product of Streptomyces viridofaciens and the two aforementioned strains [263]
(Figure 7). Based on the structural elucidation of the three compounds, which revealed a characteristic
DCBA naphthacene tetra-cyclic core (Figure 7), the agents later became descriptively known as the
tetracyclines [264]. Within the group of tetracyclines, tetracycline represents the simplest of the
structures, whereas chlortetracycline and oxytetracycline contain modifications at the core cyclic
structure. While chlortetracycline contains a chlorine atom at the C7 atom in ring D, oxytetracycline
instead harbours a hydroxyl group at the C5 position in ring B.
The biosynthesis of chlortetracycline and oxytetracycline follows a similar logic and in the
following, we focus on the biosynthetic principle of the latter compound. The BGC of oxytetracycline
covers a 21.2 kb DNA region in S. rimosus and contains 21 ORFs encoding structural, modification,
resistance, and regulatory elements [265]. The biosynthesis of oxytetracycline starts with the assembly
of the polyketide precursor by the type II minimal PKS encoded by the genes oxyA through oxyC
(Figure S6). More specifically, the KSα (OxyA) and KSβ (OxyB) form the heterodimer responsible for
chain elongation, while the ACP (OxyC) provides the extender units. An interesting feature of the
natural tetracyclines is the unusual starter unit, malonamate, giving rise to the amide group on ring
A in the naphthacene core [122,265]. The gene encoding the enzyme responsible for the provision
of this starter unit has been identified as oxyD, which is located immediately downstream of the
minimal PKS-encoding genes oxyA through oxyC in the oxytetracycline gene cluster in S. rimosus.
The protein sequence of OxyD shows homology to the ATP-dependent class II asparagine synthases
and it is believed to catalyse the transamination of malonate to yield malonamate [266]. Once attached
to the minimal PKS, the malonamate is condensed with eight additional malonates, giving rise to
the amidated decaketide backbone, which is released from the megaenzyme and further processed
by AROs and CYCs encoded by genes in the oxytetracycline gene cluster (Figure S6). Based on the
heterologous expression of the extended minimal PKS of oxytetracycline (OxyABCD) in Streptomyces
coelicolor CH999, three enzymes have been identified and assumed to play a role in the correct cyclisation
of the polyketide precursor [267]. This includes the NADPH-dependent KR OxyJ, which catalyses the
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C9 reduction in ring D, the two-component CYC/ARO OxyK which is responsible for closing the first
ring (ring D), and the CYC OxyN, catalysing the ring closure of the second ring (ring C). An additional
putative CYC, encoded by oxyI, has been identified in the oxytetracycline gene cluster, however, since
the heterologous expression of OxyABCDJKNI displayed a profile similar to that of OxyABCDJKN,
it was concluded that OxyI is not directly involved in cyclisation of the third or fourth ring (ring B and
A, respectively). Instead, closing of these two rings is believed to occur spontaneously [268].
 
Figure 7. Structures of the naturally derived chlortetracycline and oxytetracycline and their
semi-synthetic derivatives doxytetracycline, minocycline, tigecycline, omadacycline, and sarecycline.
Eravacycline and TP-271 are fully synthetic tetracycline analogues.
160
Antibiotics 2019, 8, 157
Upon ring closure, the stable intermediate pretetramid is formed, which undergoes a series
of modification reactions, of which the actual sequence remains to be clarified [269] (Figure S6).
The modification of pretetramid involves a C6 methylation in ring C, which is catalysed by
the S-adenosyl methionine (SAM)-dependent methyltransferase OxyF, yielding the intermediate
6-methylpretetramide. In the next step, the dihydroxylation of C4 and C12a in ring A, yielding the
substance 4-keto-anhydrotetracycline, is catalysed by the two oxygenases OxyL and OxyE. While OxyL
can give rise to both hydroxylations, OxyE only catalyses the addition of the hydroxyl group at the
C4 position. The reason for the extra function of OxyE seems to be a matter of increasing the rate of
the enzymatic reaction [268]. The further conversion of 4-keto-anhydrotetracycline is achieved first
by the actions of the aminotransferase OxyQ, yielding the intermediate 4-amino-anhydrotetracycline,
which then serves as a substrate for the SAM-dependent methyltransferase OxyT, catalysing a
N, N-dimethylation that gives rise to anhydrotetracycline. The final enzymatic reactions leading to
formation of oxytetracycline from anhydrotetracycline was recently elucidated by Wang and co-workers
(Figure S6) [270]. In this study, OxyS was confirmed to catalyse the two sequential hydroxylations of
C6 and C5 in ring C and B, respectively. Furthermore, OxyR was shown to act as a F420-dependent
reductase, which is responsible for the final C5a−C11a reduction affording oxytetracycline (Figure S6).
In the case of chlortetracycline, an additional gene, ctcP, encoding a flavin-dependent halogenase,
has been identified in the chlortetracycline BGC in S. aureofaciens [126]. CtcP yields the final product
chlortetracycline based on the halogenation at position C7 in ring D (Figure S6). In addition to structural
and tailoring genes, the BGCs of chlortetracycline and oxytetracycline include additional genes involved
in resistance (otrA and otrB) and regulation (otcG and otcR). In the case of the oxytetracycline BGC,
the two genes otrA and otrB, which encode proteins responsible for host resistance, are found at the
flanking regions of the actual gene cluster. Based on sequence similarity, OtrA shows homology to TetM
and is believed to provide resistance to S. rimosus by binding the ribosome and competing with the
produced oxytetracycline. OtrB encodes a membrane protein and ensures the efflux of oxytetracycline
from the cell [269,271]. The genes for the regulators OtcG and OtcR are also present in the flanking
regions of the oxytetracycline BGC in S. rimosus [269,272,273]. OtcG, is a LuxR family transcriptional
activator which was shown to provide positive regulation of oxytetracycline biosynthesis since an
inactivation of otcG resulted in a mutant strain producing 40% less oxytetracycline than the wild type
strain S. rimosus [272]. The overexpression of otcG did not yield a significant increase in production of
oxytetracycline. OtcR was assigned to a Streptomyces antibiotic regulatory protein (SARP) activator of
the oxytetracycline in S. rimosus [273]. Since a deletion of otcR completely abolished oxytetracycline
production in the producer strain, the authors tested whether its overexpression would result in
increased yields of the antibiotic. Indeed, the introduction two additional copies of otcR, under the
control of a SF14 promoter, in S. rimosus increased the yields of oxytetracycline to 6.24 g/L (6.49 times
higher than the yields of the parental strain) [273].
Tetracyclines are broad-spectrum antibiotics with activities against a range of microorganisms,
including Gram-positive and Gram-negative bacteria, chlamydiae, mycoplasmas, and protozoan
parasites [123]. They act as bacteriostatic drugs by binding to the 30S subunit of the prokaryote
ribosome in a reversible fashion whereby protein synthesis is inhibited [132]. Furthermore, crystal
structures of tetracycline in complex with both, the 30S subunit and 70S ribosome of Thermus thermophiles,
have expanded the knowledge of the MOA of tetracyclines [124,274]. Based on the first X-ray structure
of Brodersen et al., the primary binding site of tetracycline (Tet1) was found to be located between the
head and shoulder of the 30S subunit, just above the transfer RNA (tRNA) binding site. When binding
the A site, tetracycline act as a physical barrier for aminoacyl-tRNA so that the peptide chain cannot
be elongated and protein synthesis is stalled [123,274]. Furthermore, the oxidised hydrophilic part
of the tetracyclines appear to provide the main chemical interactions with the 16S ribosomal RNA
(rRNA) and therefore, they are most important for the binding [275]. Another interesting property of
the tetracyclines is their ability to chelate ions (Mg2+). In addition to the hydrogen bond interactions
between the hydrophilic side of tetracycline and the nucleotides on the 16s rRNA, the Mg2+ ions,
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coordinated by ring A of tetracycline, seem to further strengthen the binding to the ribosome [274].
The ion chelating properties of tetracyclines also explain their broad spectrum, including activity
against Gram-negatives. In order to enter the periplasm of Gram-negatives, tetracycline forms a
complex with Mg2+ allowing the antibiotic to pass through the porins of the outer membrane. To diffuse
through the cytoplasmic membrane, tetracycline dissociates from Mg2+ enabling its passage through
to the cytosol. The chelating complex is restored inside the cytosol [132].
The emergence of tetracycline resistance in clinical isolates has led to many studies to clarify the
driving forces behind it. To date, four mechanisms by which bacteria acquire resistance to tetracyclines
have been identified. These include active efflux of the antibiotic, ribosomal protection proteins,
antibiotic modification, and alteration of the antibiotic target site, i.e., the ribosome. More information
on the basis behind these individual resistance mechanisms can be found elsewhere [123,127,132].
The discovery of the naturally derived tetracyclines immediately triggered studies on improving
the overall performance of the antibiotics. This resulted in the so-called 2nd generation tetracyclines,
two of which, doxycycline and minocycline (Figure 7), were marketed in 1967 and 1972,
respectively [123]. The discovery of doxycycline was based on the structural observations that
the C6 hydroxyl group of tetracyclines greatly impact the stability of the molecules while antibacterial
properties are not affected [128]. Consequently, derivatisation at this site of the molecule was
conducted. The first attempt to alter the functional group at the C6 position in oxytetracycline
gave rise to 6-methylene-5-hydroxytetracycline (methacycline), which was further modified to
6-deoxy-5-hydroxytetracycline, later named doxycycline (trade name: Vibramycin, Table 1). On the
other hand, minocycline was the result of studies on biogenesis mutants of S. aureofaciens, the producer
of chlortetracycline [129]. Here, scientists working at the former Lederle Laboratories succeeded
in isolating the precursor C6-demethyl-C7-chlorotetracycline (demeclocycline), which gave rise to
the C6-demethyl-C6-deoxytetracycline (sancycline) precursor, that ultimately was converted to the
final substance 7-dimethylamino-6-demethyl-6-deoxytetracycline (minocycline, trade name: Minocin,
Table 1) [130,131]. Both doxycycline and minocycline are lipophilic molecules, which allow for oral
absorption and thereby extend their applicability in the human therapy. Furthermore, they display
improved antibacterial activities compared to tetracycline, including potent activities against
Gram-negative bacteria such as E. coli and Pseudomonas aeruginosa and against the Gram-positive
bacteria S. aureus and E. faecalis [127]. The importance of their introduction in human therapy was
further strengthened by their activities against tetracycline-resistant isolates.
To ensure the continuous potential of the tetracyclines, a second round of derivatisation efforts,
aiming at discovering novel tetracycline analogues with activities against both susceptible and
tetracycline-resistant isolates, was initiated in the 1990s [123]. These efforts gave rise to the so-called
glycylcyclines, also referred to as the 3rd generation tetracyclines, including tigecycline, omadacycline,
and sarecycline (Figure 7) [127,133]. Tigecycline (trade name: Tygacil) was the first of the 3rd generation
tetracyclines and was the result of the derivatisation of minocycline (Table 1) [134]. Compared to its
precursor, tigecycline contains a N-alkyl-glycylamido group at position C9 in ring D. This structural
modification resulted in a ~10–100-fold improved binding of tigecycline to the ribosome when compared
to tetracycline [127,134]. Based on the crystal structure of T. thermophilus 70S ribosome bound to
tigecycline, it has been shown that while the derivative binds the 30S subunit in the same manner
as tetracycline, the interaction of tigecycline with the ribosome is greatly improved based on its
additional tert-butylglycylamido group [274]. In cell-free translation assays tigecycline was capable
of retaining its binding to the ribosome in the presence of the two resistance determinants TetM and
TetO, confirming the activity of the derivative against tetracycline-resistant clinical isolates, which had
acquired resistance based on ribosome protection proteins [135]. Tigecycline was approved by the
US FDA in 2005 [132]. The current major limitation of tigecycline is its poor oral bioavailability and
consequently the antibiotic is administered intravenously, giving rise to nausea and vomiting in the
majority of patients [276].
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Three additional 3rd generation tetracycline analogues have been approved by the US
FDA for various applications in human therapy. Two of these, omadacycline (trade name:
Nuzyra) and eravacycline (trade name: Xerava), bear a C9 substitution on ring D and have
been licensed as broad-spectrum antibiotics, while the third, sarecycline (trade name: Seysara),
was developed specifically as a narrow-spectrum tetracycline antibiotic for treatment of acne (Table 1).
Omadacycline is an aminomethylcycline derivative of minocycline, which was isolated based on
its superior activity against tetracycline-susceptible and -resistant bacteria, lack of toxicity, and
the oral bioavailability [136,137,264]. Additionally, omadacycline shows improved activity against
Gram-positive isolates compared to tigecycline and superior activity against Gram-negatives compared
to eravacycline. This improved activity is believed to be a consequence of the C7 dimethylamino
group and the C9 aminomethyl moiety in ring D of the molecule, since these modifications allow the
antibiotic to evade the most common resistant determinants of efflux and ribosome protection [276].
The antibiotic was approved by the US FDA in October 2018 for the treatment of acute bacterial skin/skin
structure infections, caused by a variety of bacteria, including methicillin-susceptible and -resistant
strains of S. aureus, and for treatment of CABP, caused by S. pneumonia and methicillin-susceptible
S. aureus [138]. Furthermore, omadacycline is currently undergoing safety and efficacy studies for its
use in treatment of uncomplicated urinary tract infections. Eravacycline, developed at Tetraphase
Pharmaceuticals, Inc., varies from the other clinical available 3rd generation tetracycline analogues
with its fluorine atom at the C7 position and a pyrrolidinoacetamido group on the C9 of ring D
(Figure 7) [139,140]. It displays activity against both Gram-positives and Gram-negatives and has been
approved by the US FDA for treatment of infections caused by multidrug-resistant microorganisms,
including carbapenem-resistant Enterobacteriaceae, MRSA, VREs, and extended spectrum β-lactamase
(ESBL)-producing Enterobacteriaceae [141]. Following the same logic as for tigecycline and omadacycline,
the altered functional groups on this fully synthetic tetracycline derivative was designed to evade
tetracycline resistance determinants, which is evident from the retained activity of eravacycline against
TetM-protected E. coli cells tested in an in vitro transcription/translation assay [140]. An additional
fully synthetic tetracycline derivative, named TP-271 (Table 1), is currently being investigated by
Tetraphase Pharmaceuticals, Inc. for its activity against pathogens causing CABP, anthrax, tularemia,
and bubonic plague [143,144]. Similar to eravacycline, TP-271 is TetM-insensitive and can be used as
an agent for bacterial isolates with this type of acquired resistance [143]. According to the pipeline
of Tetraphase Pharmaceuticals, TP-271 is currently in phase I clinical testing [145]. The latest 3rd
generation tetracycline to be approved by the US FDA, is the sarecycline, an aminomethylcycline with
the unique and stable methoxy(methyl)aminomethyl modification at position C7 in ring D. Unlike the
other tetracyclines, sarecycline has been approved as a narrow-spectrum antibacterial agent for the
treatment of moderate to severe acne vulgaris caused by Cutibacterium acnes (formerly Propionibacterium
acnes). Sarecycline was developed to meet the need for a safe treatment regime against acnes vulgaris,
while simultaneously limiting resistance development of C. acnes [142].
3.7. Streptogramins
The group of streptogramins is an important class of antibiotics given their chemical complexity
and potent antibacterial activity. They are composed of a mixture of two chemically unrelated
substances, known as type A and type B streptrogramins, which are produced by the same host in a
70:30 ratio, respectively [277,278]. Streptogramin A and B, produced by Streptomyces graminofaciens,
were the first in the group of streptogramin antibiotics to be discovered and provided the name for
the substance class [279]. Following their discovery in 1953, several additional streptogramins were
identified, some of which include mikamycin from Streptomyces mitakaensis [280,281], griseoviridin
and viridogrisein from Streptomyces griseoviridis [282], as well as virginiamycin from Streptomyces
virginiae [283]. Out of these substances, virginiamycin has had significant impact on veterinary
medicine. Since its discovery, virginiamycin (trade names: Staphylomycin and Stafac) has been used
all over the world in animal production as a disease control agent and feed additive for swine, poultry,
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and cattle. However, due to scientific concerns of resistance transmission between animals and humans,
the use of drugs containing virginiamycin as a feed additive in Europe has been forbidden since
1999 [284]. Pristinamycin (Figure 8) is a close structural relative to virginiamycin. The antibiotic was
first isolated from Streptomyces pristinaespiralis, which produces the two substances pristinamycin
IIA and pristinamycin IA in the ratio 70:30 [146,147]. Within the group of streptogramins, the two
natural substances virginiamycin and pristinamycin and the semi-synthetic quinupristin–dalfopristin
substance mixture (trade name: Synercid) (Figure 8, Table 1) have been subject to the most studies and
will be the focus of this section. Since virginiamycin and pristinamycin share a common biosynthetic
logic (Figure S7), only pristinamycin with its significant role in human medicine will be described.
 
Figure 8. Structures of the two naturally derived antibiotics pristinamycin IA and pristinamycin IIA
and their two respective semi-synthetic analogues quinupristin and dalfopristin.
The biosynthetic gene cluster of pristinamycin remains one of the largest bacterial antibiotic
clusters identified, covering a DNA region of 210 kb [148]. Within this region, 45 genes, covering a 120 kb
region, are involved in the biosynthesis, regulation, and resistance of pristinamycin. Pristinamycin
II is synthesised by a hybrid PKS/NRPS complex responsible for the assembly of the starter unit
isobutyryl-CoA with six malonyl-CoA extender units and the amino acids glycine, serine, and proline
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(Figure S7). The assembly starts at SnaE1, which ensures the successful loading of isobuturyl-CoA
followed by its extension with two malonyl-CoA and glycine. The following four modules in SnaE2
and SnaE3 attach additional four malonyl-CoA extender units to the growing chain. In between the
genes for the two megaenzymes SnaE2 and SnaE3, snaG through snaL are located. Together their
respective enzymes are believed to be responsible for the C12 methyl group in pristinamycin II [148].
Downstream of snaL, the gene for the hybrid PKS/NRPS SnaE4 is located that is responsible for
attachment of serine before transferring the precursor chain to the final module. The last NRPS module
of SnaD, including the TE domain is responsible for the attachment of proline to the polyketide-hybrid
chain and the release and cyclisation of the precursor chain. An interesting feature of the PKS is its lack
of AT domains. Sequence analysis of the BGC and phylogenetic analysis of discrete ATs suggested that
similar to the trans-AT KirCI, which is involved in kirromycin biosynthesis [285], SnaM also groups in
the clade of discrete ATs of trans-AT-PKSs [148,286]. This indicates that SnaM might be responsible for
an in trans loading of malonate units to assemble the pristinamycin II polyketide chain.
Pristinamycin I is synthesised from the NRPS encoded by genes snbA, snbC, and snbDE,
which ensures the successful condensation of the four non-proteinogenic amino acids
3-hydroxypicolinic acid, l-aminobutyric acid, 4-N, N-dimethylamino-N-methyl-l-phenylalanine
(DMAPA), 4-oxo-l-pipecolic acid, l-phenylglycine, and the two proteinogenic amino acids l-threonine
and l-proline (Figure S7). Through the actions of the TE domain in the C-terminal of SnbDE,
the precursor is released from the NRPS and cyclised. Additionally, 12 genes are involved in
pristinamycin I biosynthesis through their synthesis of the amino acid precursors. This includes hpaA
for 3-hydroxypicolinic acid, pipA and snbF for 4-oxo-l-pipecolic acid, and papA/B/C/M for DMAPA
biosynthesis. For the non-proteinogenic amino acids, sequence analyses identified pglA through pglE
to be involved in their biosynthesis [148]. Furthermore, within the 210 kb DNA region, several genes
encoding regulatory elements have been identified [287,288]. Knowledge of the complex regulatory
network behind pristinamycin I and II biosynthesis have fed metabolic engineering approaches in
order to improve yields in the natural host [289,290]. In the study of Li and co-workers, the team
systematically manipulated the cluster-situated genes spbR and papR1 through papR6 and found the best
production enhancement of pristinamycin IIA when deleting either papR3 or papR5 and overexpressing
both papR4 and papR6. Surprisingly, strains overexpressing the major SARP activator PapR2 resulted
in lowered pristinamycin production which could indicate a maximum threshold concentration of
pristinamycin IIA in S. pristinaespiralis [290].
When applied separately as therapeutics, the type A and B streptogramins only provide a
bacteriostatic effect. In combination, the two antibiotics act in a synergetic manner leading to a
bactericidal activity against susceptible pathogens. Streptogramin antibiotics are active against a range
of Gram-positive bacteria, including the severely resistant pathogens MRSA, vancomycin-resistant
S. aureus (VRSA), E. faecium strains, and drug-resistant S. pneumonia. Activity against Gram-negative
bacteria is mostly restricted to pathogens causing upper respiratory tract infection, including H. influenza,
Haemophilus parainfluenzae, M. pneumonia, and Moraxella catarrhalis [150,277,278]. The synergistic activity
of the type A and B streptogramins can be explained from the unique MOA, in that both antibiotics
bind to the prokaryotic 50S ribosomal subunit however, at separate sites. The type A substances inhibit
the early phase of protein elongation through their binding to the A and P sites on the 23S rRNA,
thereby preventing the attachment of tRNA at each site [149,278]. Type B streptogramins also bind to
the P site on the ribosome however, inhibit the late stage of polypeptide chain elongation by binding the
exit tunnel of the ribosome. As a result, elongation of the nascent polypeptide chain is prevented and
incomplete peptide chains are released from the complex. While the MOA of type B streptogramins
is similar to that of erythromycin and related macrolides, the MOA for the type A streptogramins
is similar to that of chloramphenicol. Furthermore, it has been shown that the binding of group A
streptogramins to the P site leads to conformational changes in the subunit, which increases the affinity
to the ribosome of the type B streptogramins. Even upon dissociation of the type A substances from the
ribosome, the increase of ribosome affinity for type B streptogramins remains, explaining the synergetic
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effect of the mixture [291]. Recently, the crystal structure of the 50S ribosomal subunit from Deinococcus
radiodurans in complex with Synercid (quinupristin/dalfopristin, Figure 8) has expanded our knowledge
on the binding of streptogramins antibiotics to the ribosome [151]. Firstly, the two streptogramins share
direct contact with a single nucleotide A2062 (E. coli numbering) through hydrophobic interactions
and hydrogen bonds. This leads to conformational changes at A2062 whereby the binding of both
antibiotics is strengthened. Secondly, an additional conformational change occurs when dalfopristin
(type A) binds to the peptidyl transferase center (PTC) in that the universally conserved nucleotide
U2585 is rotated to point away from the tunnel of the PTC. The altered conformation of U2585 in the
PTC is stabilised by hydrogen bonds and might explain the post-antibiotic effect of streptogramin A
antibiotics, in which protein synthesis is still inhibited after treatment with the antibiotic has been
terminated [151].
To date, several resistance mechanisms against streptogramin antibiotics have been proposed.
Some of these include target modification, drug inactivation, drug efflux, and impermeability [278,292].
Excellent reviews exist detailing the mode of drug resistance [292–294]. Briefly, a common resistance
mechanism developed towards macrolide antibiotics is ribosomal target modification. This antibiotic
resistance is encoded by the erythromycin-resistance methylase (erm) genes, which can mono- or
dimethylate an adenosine residue of the 23S rRNA of the ribosomal 50S subunit [295]. Methylation
changes the conformation of the ribosome and collectively causes resistance towards antibiotics of the
MLSB group. Additionally, the pathogen can develop resistance by drug inactivation through
acetyltransferases (targets type A) and hydrolases (targets type B) or by drug efflux, encoded
by genes such as msrA/B, mefA, lsa, and vga [294,296,297]. Resistance against streptogramins
depends on the substance type. Type B streptogramins, which shares properties with erythromycin,
are classified as MLSB antibiotics, which suffer from cross-resistance between each other. Type A
streptogramins instead show cross-resistance with lincosamides and pleuromutilins and group in the
lincosamide–streptogramin A–pleuromutilin (LSAP) antibiotics. Since bacterial isolates with lowered
susceptibility towards the synergetic mixture have already been isolated, it is evident that caution
should be taken when administering these drugs. In order to reduce the risk of resistance towards this
important class of compounds, streptogramins are classified as drugs of last resort [278].
Due to its hydrophobic nature, pristinamycin (Table 1) is administered orally, which limits its use
in paediatrics and intensive care [152,278]. To solve the issue of bioavailability, medicinal chemists
employed by the French chemical and pharmaceutical company Rhône-Poulenc Rorer worked on
synthesising novel pristinamycin derivatives with improved water solubility. Their attempts proved
successful and in 1999 the US FDA approved the antibiotic Synercid (Table 1), which is a 70:30 mixture
of the two semi-synthetic derivatives dalfopristin (type A) and quinupristin (type B), for treatment
of bacteraemia caused by VRE and skin/skin structure infections caused by methicillin-susceptible
S. aureus and S. pyogenes [152,153,278]. Information on the synthesis of dalfopristin and quinupristin
(Figure 8) remain scarce. From the published structures, it is known that quinupristin is the result
of derivatisation of pristinamycin IA at position five of the 4-oxo pipicolic acid residue and that
dalfopristin is generated based on the substitution of pristinamycin IIA with a 2-diethylaminoethane
thiol [292].
Synercid suffers from its own limitations, including a high treatment price and the risk of infusion
site thrombosis in addition to myalgias and arthralgias [154]. A more recent example of a semi-synthetic
pristinamycin derivative is NXL-103 (Table 1), which is a 70:30 mixture of flopristin (type A) and
linopristin (type B) [154,155]. As opposed to Synercid, NXL-103 is administered orally thereby avoiding
the complication associated with intravenous therapy. Additionally, NXL-103 has been shown to
possess an improved activity against multiple Gram-positive isolates when compared to Synercid [155].
With its expanded activity against clinical Gram-positive isolates such as MRSA, methicillin-resistant
Staphylococcus epidermidis, and VRE, NXL-103 could provide an additional treatment option to the
current drugs on the market. However, since the report of phase II clinical trials in 2010, to the best of
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our knowledge, no new information on NXL-103 exists and the drug made no progress towards its
introduction into the market [154].
4. Other Clinically Relevant Polyketide-Derived Antimicrobials
4.1. Nystatin A1
The antifungal polyene macrolides are characterised by a large macrolactone ring containing 20 to
40 carbon atoms connected by a series of conjugated double bonds, an exocyclic carboxyl group, and a
mycosamine sugar. Several compounds belonging to this group have been studied in detail, including
candicidin, nystatin, amphotericin, and pimaricin (also referred to as natamycin) [298,299] (Figure 9).
In this review, we focus on nystatin A1, amphotericin B, and pimaricin/natamycin, since these are the
drugs still used in the clinic.
 
Figure 9. Structures of the three antifungal compounds nystatin A1, amphotericin B, and pimaricin
(also referred to as natamycin).
The first polyene macrolide was discovered in 1950 by E.L. Hazen and R.F. Brown from the New
York State Department of Health and was the initially named fungicidin [156,300]. The compound was
discovered from Streptomyces No. 48240 isolated from a soil sample collected at a farm owned by H.
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Nourse. Later, the strain was renamed S. noursei and the compound name changed from fungicidin to
nystatin [157]. With the advances in analytical separation techniques it became evident that nystatin
was a mixture of three components, namely nystatin A1, A2, and A3. Nystatin A1 was the major
component in the fermentation mixture [301]. So far, S. noursei remains the commercial strain for
production of nystatin, however, other strains, including Streptomyces fungicidicus ATCC 27,432 [302]
and Streptomyces albulus ATCC 12,757 [303], have also been identified as nystatin producers.
Nystatin A1 (brand names: Mycostatin and Nystop) (Table 1) is composed of a 38-membered
macrolactone ring which includes sets of two and four conjugated double bonds separated by one
saturated bond (Figure 9). Similar to other polyene macrolides, nystatin contains a mycosamine sugar
attached to the aglycone ring in addition to an exocyclic carboxyl group (Figure 9) [299,304].
The aglycone macrolide of nystatin (Figure 9) is assembled from one acetyl-CoA starter unit
and further extended through condensation with three methylmalonyl-CoA and 15 malonyl-CoA
extender units (Figure S8). The assembly of the nystatin precursor is governed by a type I PKS,
composed of a total of one loading and 18 extender modules, which are all encoded in the six genes
nysA, nysB, nysC, nysI, nysJ, and nysK [158]. The TE domain found at the C-terminal of module 18 in
NysK is responsible for chain termination and cyclisation, forming the aglycone precursor of nystatin.
Immediately downstream of nysC, the gene nysE is located. NysE displays protein similarity to TEs
found in Streptomyces venezuelae and Streptomyces fradiae, however, the role of the enzyme has not been
experimentally verified. It is postulated that this additional TE enzyme, like in the case of erythromycin
and tylosin biosynthesis, acts as a “proof-reading” enzyme to avoid stalling at the PKS. Additional
genes found in the nystatin gene cluster include the two P450 monooxygenases, encoded by nysL and
nysN, which are responsible for the C10 hydroxylation and C16 methyl group oxidation, respectively.
The role of NysN has been confirmed based on genetic inactivation. The ΔnysN mutant lost the ability
to produce nystatin A1, and instead the analogue 16-decarboxy-16-methyl nystatin was isolated from
the culture broth [160].
The biosynthesis and transfer of the mycosamine sugar to the aglycone of nystatin are carried
out by three enzymes encoded by nysDI, nysDII, and nysDIII [158]. Specifically, the biosynthesis
of the sugar is believed to be facilitated by the aminotransferase NysDII and the guanosine
diphosphate (GDP)-mannose-4,6-dehydratase NysDIII, while the attachment of mycosamine at C19 of
the nystatin aglycone is thought to be catalysed by the glycosyltransferase NysDI. Furthermore, it has
been postulated that mycosamine is synthesised from a GDP-mannose instead of deoxythymidine
diphosphate (dTDP)-glucose [298].
Two ATP-binding cassette (ABC) transporter-encoding genes nysG and nysH are located at the
border of the nystatin gene cluster [305]. Since mutants in either of the two genes displayed similar
phenotypes, NysG–NysH is thought to be part of the same transporter. Furthermore, four genes
nysRI through nysRIV encoding regulator proteins have been identified and their role clarified in the
nystatin gene cluster [299,306]. NysRIV is most likely directly controlling the expression of nystatin
biosynthesis genes. More information on the regulation governing nystatin biosynthesis in S. noursei
can be found elsewhere [299,306].
Nystatin A1 is primarily used as a topical agent e.g., in treatment of mucous membrane candidiasis
caused by members of the yeast-like family Candida [307]. As it is the case for most polyenes, nystatin has
a low water solubility and shows detectable toxicity, which restricts its application in human therapy.
The explanation for the toxicity is found in the MOA shared among the polyenes. In general, the MOA
of polyenes is based on their interaction with sterols in eukaryotic cell membranes, resulting in pores
and increase membrane permeability for ions and small molecules, which is usually lethal for the
cell [159]. Although nystatin displays a higher selectivity toward the ergosterol found in fungal cell
membranes, it can also interact with the cholesterol of mammalian cells membranes, which is limiting
its use for human therapy. Taken together, due to its undesired toxicity, low solubility, and lower
antifungal potency than that of amphotericin B, the application of nystatin as human medicine remains
restricted [160,308].
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With the elucidation of the gene cluster responsible for the biosynthesis of the polyene macrolides
candicidin, pimaricin, amphotericin, and nystatin it has become evident that the overall organisation
of these cluster is highly similar [298]. This logic was utilised to design a polyene-specific polymerase
chain reaction (PCR)-guided genome screening approach to screen for novel polyene-producing
actinomycetes [309]. Using the sequence of a cytochrome P450 hydroxylase gene, which is similar
between polyenes, the authors could identify and later confirm the presence of a Nystatin-like
Pseudonocardia Polyene (NPP) gene cluster in the rare actinomycete Pseudonocardia autotrophica [310].
Structural analysis of NPP revealed an aglycone identical to that of nystatin however, with a modified
sugar residue (a unique disaccharide moiety; mycosaminyl-(α1-4)-N-acetyl-glucosamine) [311].
Compared to nystatin A1, NPP A1 displayed a 300-fold increase in water solubility, 10-fold reduced
hemolytic activity, but also ~50% lower antifungal activity against Candida albicans. The issue of lowered
bioactivity was later solved through the manipulation of the ER domain in module five (ER5) of the NPP
biosynthetic cluster [312]. Deleting this gene disables the reduction at the C28–C29 unsaturated bond in
the aglycone of NPP A1 hence, generating a heptaene instead of the original tetraene. The new derivative
NPP B1 displayed in vitro and in vivo activity against C. albicans and improved hemolytic activity
compared to amphotericin B. However, the production yields of NPP B1 in the pathway-engineered
strain (P. autotrophica ER5 mutant) were extremely low. In an attempt to solve this issue, the P. autotrophica
ER5 mutant strain was subjected to N-methyl-N′-nitro-N-nitrosoguanidine (NTG) iterative random
mutagenesis [312]. The resulting mutants were screened in zone-of-inhibition agar plug assays in
which the mutant strain 3R-42 produced the largest inhibition zone. The transcriptional analysis
further revealed a general up-regulation of the NPP biosynthetic genes in the 3R-42 mutant compared
to the original ER5 mutant. Based on this observation, the authors introduced a second copy of each
putative regulatory gene into the chromosome of the 3R-42 mutant strain and could determine a final
NPP B1 production of 31.6 mg/L [312], which was a substantial increase in comparison to the 0.77 mg/L
NPP B1 produced by the original ER5 mutant.
Additionally, studies on the biosynthesis of nystatin itself also open up for the discovery
of novel derivatives with improved properties. In fact, based on genetic engineering of the
nystatin gene cluster, Brautaset and colleagues obtained seven nystatin derivatives with altered
exocyclic carboxy groups and polyol regions [160]. The mutational studies were based on
the already obtained S. noursei mutant strain GG5073SP, in which the ER5 was deleted. This
mutant produced a heptaene nystatin analogue, named S44HP. The introduction of a CL346AS
mutation in the nysN of GG5073SP resulted in the mutant BSM1 and the isolation of a novel
compound. Its structure was confirmed as 16-decarboxy-16-methyl-28,29-didehydro-nystatin (BSG005)
by nuclear magnetic resonance (NMR) analysis. The authors also succeeded in generating a mutant
strain, BSM3, which in addition to the mutation in nysN also was disrupted in the dehydratase
(DH) domain in module 15, located in NysJ. The mutant strain BSM3 produced the analogue
5-oxo-5-deoxy-16-decarboxy-16-methyl-28,29-didehydro nystatin (BSG020). Both BSG005 and BSG020
display improved toxicities and comparable antifungal activities against disseminated candidiasis in a
mouse model when compared to amphotericin B and thus, represent promising candidates for the
development of new antifungal drugs [160]. The derivatives have not yet been introduced for human
therapy however, based on information obtained from the homepage of the Swedish biotech company
Biosergen AS, the company has selected the BSG005 candidate for further preclinical and clinical tests
(Table 1) [161].
4.2. Amphotericin B
The antifungal polyene macrolide amphotericin B (trade names: Fungizone and Amphocin) was
first discovered together with amphotericin A in the 1950s in the fermentation broth of soil-derived
Streptomyces nodosus [162]. While amphotericin A contains a tetraene chromophore, amphotericin B
possesses a heptaene (Figure 9).
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The BGC of amphotericin B has been fully sequenced. The sequence analysis revealed that the
cluster organisation is similar to the BGC of nystatin [313]. The polyketide chain is biosynthesised by
an assembly line involving one loading (encoded by amphA) and 18 extension modules (encoded by
the five genes amphB, amphC, and amphI through amphK) (Figure S8). Assembly of the precursor
on the amphotericin PKS is initiated by the loading of a malonyl-CoA starter unit which is further
elongated by additional 15 acetate and nine propionate extender units (Figure S8) [163]. In the last
module, encoded by amphK, a TE domain is responsible for chain termination and release from the PKS.
Two putative cytochrome P450 enzymes AmphL and AmphN are possibly involved in the modification
of the amphotericin B structure. While AmphL most likely catalyses the C8 hydroxylation in the
macrolactone, AmphN may facilitate the oxidation of the methyl group on C16 to yield a carboxyl
group. Targeted deletion of amphN resulted in a S. nodosus mutant strain producing a amphotericin
analogue in which the exocyclic methyl group is retained [314]. The fact that the antifungal activity
of this analogue was unchanged, and the haemolytic activity reduced compared to amphotericin B,
makes the derivative an interesting candidate for clinical studies.
Additional modification of amphotericin is facilitated by the glycosyltransferase, encoded
by amphDI, which is responsible for the attachment of the mycosamine to the aglycone core of
amphotericin [313,314]. The biosynthesis of the mycosamine is believed to be catalysed by a
GDP-mannose-4,6-dehydratase encoded by amphDIII, which uses GDP-mannose derived from primary
metabolism as substrate [298]. The product of the AmphDIII-catalysed dehydratase reaction is
GDP-4-keto-6-deoxy-d-mannose and not GDP-3-keto-6-deoxy-d-mannose, which is the substrate
recognised by the transaminase AmphDII. So far, no GDP-4-keto-6-deoxy-d-mannose-3,4-isomerase
has been identified in any of the polyene gene clusters and it is hypothesised that the ketoisomerisation
reaction is the result of a spontaneous, non-enzymatic reaction [298].
Export of amphotericin B has been hypothesised to be facilitated by two putative ABC transporters,
encoded by amphG and amphH. The reason why two transporters are present in the gene cluster remains
unknown. It has been speculated that ABC transporters can confer self-resistance of the producing
host [313]. Based on the high degree of sequence similarity between nystatin and amphotericin PKS
genes, it has been postulated that the genes amphRI through amphRIV are homologues of the genes
nysRI–nysRIV in nystatin and encode regulatory proteins, which act in a very similar fashion [298,315].
Since its marketing in 1957, amphotericin B (Table 1) has been used as the “gold standard” for
treatment of the most severe dimorphic fungal and yeast infections, caused by Blastomyces, Candida,
Cryptococcus, and Histoplasma spp. [307]. The MOA of amphotericin B is identical to that of nystatin.
Despite its preference for ergosterol found in fungal cellular membranes, amphotericin B also interacts
to a lesser extend with the cholesterol found in mammalian cell membranes [164]. This and the side
effects, including nephrotoxicity present a major limitation to the application of amphotericin B as
an antibiotic for human therapy. In addition to its antifungal properties, amphotericin has also been
implemented in delaying onset of prion disease in cultured cells with human immunodeficiency virus
(HIV) and in inhibition of the protozoal parasite Leishmania [313].
Although amphotericin B shows a promising spectrum of activity and potential applications,
the compound is poorly soluble in water and displays certain toxicity, which restricts its use in
intravenous therapy. Consequently, only life-threatening fungal infections are treated with amphotericin
B. Interestingly, despite its use as an antifungal drug for more than 40 years, reports of mycological
resistance development in clinical fungi isolates against amphotericin B remain relatively scarce [316].
Nonetheless, resistance occurs, as it was demonstrated by the isolation of resistant Candida spp.,
Fusarium spp., and Scedosporium apiospermum [317]. In these fungi, drug resistance is most likely
conferred by either the production of alternative ergosterols to which the amphotericin B is less efficient
or simply by decreasing the ergosterol level in the fungal cell membranes. Both mechanisms reduce
the potency of the antifungal drug [316].
The promising features of amphotericin B, such as broad-spectrum activity and low resistance
against the compound were encouraging for numerous engineering attempts in order to improve
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the properties of the antifungal drug. A great improvement in the solubility of the amphotericin B
was already achieved in the case of Fungizone, which is a mixture of amphotericin B and the bile
acid deoxycholate [165]. Additionally, reduction in the overall toxicity of amphotericin B was further
achieved through liposome encapsulation, which has resulted in the three formulations; Amphotec,
AmBisome, and Abelcet [165]. Unfortunately, the reduced toxicity of the liposome-packed amphotericin
B seems to come at a cost in antifungal efficiency.
The extensive investigations on amphotericin and polyene biosynthesis are of advantage for
targeted engineering to increase production yields and to generate new derivatives with improved
therapeutic properties. Furthermore, it should be noted that great efforts have been made in the field
of semi-synthesis and several amphotericin B analogues with improved solubility and toxicity have
been generated using different chemical approaches. Many of these have already been reviewed
elsewhere [318]. Despite the many advances in both semi-synthesis and genetic engineering for
obtaining amphotericin B analogues with improved properties, the yields of the derivatives are often
very low, and to date, none of the reported amphotericin B analogues have made it through to the
market. Consequently, the actinomycetes-derived substance amphotericin B remains one of the most
important polyketides in the sparse portfolio of antifungal drugs. This urges the need for improved
production titers in the natural producer strain. Recently, Zhang and co-workers set out to improve
yields of amphotericin B in a newly isolated strain Streptomyces spp. ZJB 2013082, which produced the
antifungal substance in low yields [319]. Using a combination of ultraviolet (UV) and NTG mutagenesis,
the mutant strain N3 was isolated, which produced 1735 mg/L, a substantially increased amount of
the product compared to the 56.2 mg/L obtained from the parent strain ZJB 2013082. Additionally,
the N3 mutant accumulated less amphotericin A than the parent strain ZJB 2013082. This could be
of industrial importance, since substance A is only allowed to account for more than five percent in
the amphotericin mixture. The genome sequence of the N3 mutant is not yet published however,
identification of the genomic architecture in the N3 mutant could help guide future engineering efforts
to obtain a stable production host for amphotericin B.
4.3. Pimaricin/Natamycin
Pimaricin (later renamed natamycin, trade names: Natacyn and E235) (Figure 9, Table 1) was
first discovered in the 1950s as the product of soil-derived Streptomyces natalensis isolated from the
South African region of Natal [166,320]. Additional producer strains have been identified, including
Streptomyces chattanoogensis [321,322] and Streptomyces lydicus [323].
The structure of pimaricin varies slightly from those of amphotericin B and nystatin A1 (Section 4.1)
owing to the smaller size of the macrolactone (Figure 9). Pimaricin is composed of a 26-membered
aglycone, containing four conjugated double bonds, to which the characteristic mycosamine sugar is
attached at the C15 atom. The tetraene polyene further contains an exocyclic carboxyl group at C12,
a functionally interestingly epoxide at C4/C5, and an internal hemiketal ring, which originates from a
spontaneous cyclisation of the C9 keto group with a hydroxyl group on C13 [167].
The elucidation of pimaricin biosynthesis has relied primarily on genome sequencing and genetic
studies of the two pimaricin-producer strains S. chattanoogensis and S. natalensis [320]. In the case of
S. natalensis, an 85 kb-large genomic region containing 16 ORFs was identified from a cosmid library
as the pimaricin gene cluster [167]. Pimaricin biosynthesis follows a logic, which is highly similar
to that governing amphotericin B and nystatin biosynthesis. Since the gene clusters identified from
S. chattanoogensis and S. natalensis are nearly identical, the following subsection will describe the studies
on S. natalensis.
The assembly of the 26-membered lactone, termed pimaricinolide, is catalysed by a type I PKS
composed of 13 (one starter and 12 extender) modules, encoded by the genes pimS0–pimS4 (Figure S9).
Chain initiation starts at PimS0 with the loading of a malonyl-CoA. Further elongation, catalysed by
PimS1 through PimS4, leads to the condensation of additional 12 acetate units and one propionate unit
to the growing polyketide precursor. In PimS4, the last domain, a TE, is responsible for the release and
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cyclisation of pimaricinolide [167]. Further examination of the pimaricin gene cluster has revealed an
additional gene pimI, which encodes an enzyme with homology to the TE found in the candicidin gene
cluster in S. griseus and to the TylO in the tylosin gene cluster in S. fradiae. It has been postulated that the
additional TE in the pimaricin gene cluster helps to remove aberrant precursors from the PKS, ensuring
continuous biosynthesis [167,204]. Upon its release from the PKS, pimaricinolide undergoes oxidation
of the methyl group on C12 resulting in the formation of a carboxylic acid. This is catalysed by PimG,
a cytochrome P450 enzyme. The resulting 12-carboxy-pimaricinolide is then glycosylated at the C15
hydroxyl group through the attachment of a mycosamine by the actions of the glycosyltransferase
PimK. The final modification of the pimaricin precursor involves another cytochrome P450 (encoded by
the gene pimD) which catalyse the oxidation leading to the spontaneous formation of an epoxy group
between C4 and C5.
Sugar biosynthesis is believed to involve only two enzymes; PimJ, a GDP-mannose-4,6-dehydratase
responsible for the conversion of GDP-mannose (from primary metabolism) to GDP-4-keto-6-deoxymannose,
and PimC, a GDP-3-keto-6-deoxymannose aminotransferase, which synthesises GDP-mycosamine from
GDP-3-keto-6-deoxymannose. Similar to what has been described for mycosamine biosynthesis in
amphotericin B and nystatin, no gene encoding an enzyme responsible for the 3,4-isomerisation required for
the conversion of GDP-4-keto-6-deoxymannose to GDP-3-keto-6-deoxymannose was found in the pimaricin
gene cluster, and the reaction is believed to occur spontaneously [298,320].
The three gene products of pimA, pimB, and pimH have been putatively assigned to proteins
ensuring the export of pimaricin in S. natalensis. While PimA and PimB group in the family of
ABC transporters, PimH might encode an efflux pump [320,324]. The functions of PimA and PimB
remain to be experimentally verified. For the homologues of PimA and PimB (ScnA and ScnB) in
S. chattanoogensis, it was reported that they are involved in primary exporters of natamycin [324].
With amino acid sequence similarities of above 95% for ScnA/ScnB and PimA/PimB, it is likely that the
later enzymes have a similar function and also act as primary transporters of pimaricin.
The regulatory mechanisms governing pimaricin biosynthesis has been studied in S. natalensis
and S. chattanoogensis. Two transcriptional regulators PimM and PimR play an important role in
pimaricin production in S. natalensis [325,326]. Furthermore, the amino acid exporter PimT and the
putative cholesterol oxidase PimE add an extra layer of regulation to the pimaricin biosynthesis.
While PimT was found to play a role in export of quorum-sensing pimaricin-inducer (PI) factor [327],
PimE could act as a signalling molecule, triggering production of pimaricin in the producer in
the presence of fungi [328,329]. The complex regulation cascade contains potential “targets” for
engineering of the producer and increasing the production of the antifungal compound. Some of the
most successful examples include overexpression of the regulator-encoding gene scnRII (homologue to
pimM) in S. chattanoogensis, deletion of sngR, a γ-butyrolactone receptor-encoding gene, in S. natalensis,
and chromosomal integration of the Vitreoscilla haemoglobin vgb gene in S. gilvosporeus, resulting in
460%, 460%, and 407% increase in pimaricin yields, respectively, in the mutant strains compared to
wild types [320,330–332].
More than 40 years after the introduction of pimaricin to the market, it remains an important
antifungal agent and it is still used in the treatment of fungal keratitis, an infection of the cornea caused
primarily by filamentous fungi Fusarium and Aspergillus, and yeast-like Candida [168]. Due to its low
water solubility and limited oral absorption, pimaricin is mainly available as a topical agent in human
medicine. Recently, an antiprotozoan activity of pimaricin was detected which makes the compound
attractive for potential treatment of keratitis caused by Acanthamoeba.
The MOA of pimaricin differs from that of nystatin and amphotericin B. While the main target of
the pimaricin is ergosterol, which is the major sterol found in fungal cells membranes, pimaricin only
binds to the lipid receptor. The interaction between pimaricin and ergosterol has been examined in
Aspergillus niger, showing that upon its binding, pimaricin blocks transport of amino acids and glucose
across the fungal plasma membrane, which leads to cell death [169]. Due to its specific interaction
with ergosterol, the development of microbial resistance towards pimaricin is seen as posing only a
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minor risk [320]. This, combined with its low oral absorption, has paved the way for pimaricin as a
food preservative. Sold under the label E235, pimaricin is approved as a protecting agent against yeast
and mould and is used for surface treatment of hard, semi-hard, and semi-soft cheeses, and of dried,
cured sausage in Europe. Other applications of pimaricin are summarised in the review by Aparicio
and co-workers [320]. Additionally, pimaricin is the only antifungal agent to date, which has gained
the generally regarded as safe (GRAS) status.
While pimaricin itself remains an important agent for treatment of fungal keratitis and as
a food preservative, efforts to engineer strains which produce novel pimaricin analogues with
improved solubility and toxicity have been undertaken. These efforts have been greatly aided
by the complete genome sequencing of S. natalensis and S. chattanoogensis, both harbouring the
BGC of pimaricin. Recently, Qi and co-workers could identify three novel pimaricin analogues
based on a single mutation of the gene scnG in S. chattanoogensis (pimG in S. natalensis) [333],
which encodes the cytochrome P450 enzyme responsible for the formation of carboxyl group at
the C12 in pimaricin. Out of the three identified derivatives, 12-decarboxy-12-methyl pimaricin and
4,5-desepoxy-12-decarboxy-12-methyl pimaricin, both displayed reduced cytotoxicity compared to
pimaricin. Additionally, 12-decarboxy-12-methyl pimaricin showed a two-fold increase in antifungal
activity against C. albicans ATCC 14,053 compared to pimaricin. Through further biochemical and
genetic analyses, 4,5-desepoxy-12-decarboxy-12-methyl pimaricin was found to be the precursor
of 12-decarboxy-12-methyl pimaricin in the reaction catalysed by the C4/C5 epoxidase encoded by
scnD (pimD). Therefore, to ensure the complete conversion of 4,5-desepoxy-12-decarboxy-12-methyl
pimaricin into 12-decarboxy-12-methyl pimaricin, scnD was overexpressed in the ΔscnG mutant,
which led to a 20% increase in production of the latter derivative. However, with an overall yield
of 268 ± 10 mg/L for 12-decarboxy-12-methyl pimaricin in the best performing mutant, the needs for
further engineering to optimise yields are necessary. In this case, the pathway-specific regulators PimM
and PimR or the PI-factor could be the next targets for improving pimaricin derivative production [333].
5. Strategies and Tools for the Discovery of Natural Products
The emergence of antibiotic resistant microbes is alarming and underlines the urgent need for
new drugs to combat the pathogens. However, the discovery and approval of new antibiotics is
more difficult than expected [334–336]. Therefore, the question arises: how to improve the chances
for finding new antimicrobial compounds? Recently, new approaches and advances of the existing
technologies within the early stage of drug discovery and development were reported.
For natural product-derived antimicrobial compounds, the “journey” starts with the identification
of the source (e.g., producer organism) and/or the bioactive molecule, responsible for the inhibition
or killing of a pathogen. Already at this stage, the re-discovery rate of known structures might be
reduced by taking samples and isolation of potential producers or compounds from undiscovered
environments [337–343]. This is often limited by the fact that organisms originating from “extreme”
habitats require special cultivation conditions and thus, many strategies were developed to overcome
this barrier (e.g., co-cultivation [344–346], iChip [347–352], or combination of both [353]).
Confirmed or potential producers of new antimicrobial agents are further analysed by diverse
“omics” approaches [342,354–357]. The downstream evaluation of the collected data sets using
bioinformatics tools enables for example the identification of the BGC for the product of interest and/or
provides an overview on the overall biosynthetic potential of target strain (genome mining) [9,358–360].
In cases where promising BGCs were identified, however, no products were found with the available
fermentation and analytic methods [361–364], the expression of the clusters and production of the
respective metabolite might be achieved by addition of elicitors [341,342,365–369] or the heterologous
expression of the BGC in optimized hosts [370–375].
In order to improve the production of relevant products, including polyketides, molecular
biology tools and methods (e.g., vectors, plasmids, recombinases, CRISPR-Cas9, promoters, and other
synthetic parts as well as methods for their delivery (conjugation, protoplast transformation, and direct
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transformation)) are used. They play an important role for engineering of both, the natural producer and
heterologous hosts. Challenges and new opportunities for the genetic manipulation of actinomycetes
were recently reviewed [376–381].
Although each one of these cutting-edge technologies and approaches already contributed to the
identification of new compounds, the interplay of the different disciplines will grant a better access to
novel natural products with valuable bioactivities.
6. Conclusions and Outlook
Actinomycetes are one of the most prolific sources of biologically active secondary metabolites,
including polyketides. In the past decades, numerous polyketide compounds were isolated
and developed to highly potent antimicrobial drugs, which have saved millions of lives.
However, rapid emergence of multidrug resistant pathogens is occurring worldwide which poses a
severe threat to human health. This calls for the discovery and development of new antibiotics and
antimicrobial strategies. Unlike drugs used in case of chronic diseases (e.g., diabetes, cardiovascular
disease, cancer, arthritis, asthma), antibiotics are taken for a short period of time and thus, they are
non-profitable and economically unattractive. This and several other obstacles such as high costs
of the research and development and insufficient investment from stakeholders has prompted the
big pharmaceutical companies to terminate the development of new antibiotics. Currently, it seems
that the screening and development of new lead structures for novel antimicrobial agents is mainly
conduced at public research and non-profit institutions.
The fact that many habitats around the globe are unexplored and poorly investigated for the
presence of antibiotic-producing microbes, such as actinomycetes, motived researchers to collect
samples from these environments and isolate the diverse producers of potentially new bioactive
compounds. The valuable knowledge obtained from the investigation of the biosynthesis, regulation
and natural resistance in the natural host of the old drugs as well as the recent developments within
screening and isolation methods, sequencing and genome mining, and analytics potentiate the platforms
for drug discovery. For example, the analysis of a relatively underexplored genus of Actinoallomurus
led to the discovery of two new spirotetronate polyketide antibiotics NAI414-A and NAI414-B [382].
As exemplified in this review (Section 3.1), the success in derivatisation and combination of
existing compound classes has enabled the continuous efficient treatment of otherwise resistant clinical
isolates. In particular, the knowledge gained from detailed MOA and SAR studies of the antimicrobials
have paved the way for the development of drugs with improved pharmacokinetic properties and
expanded spectrum of bioactivity, compared to the original substance. In the future, semi-synthesis
will continue to play an important role in drug development, of both, old and new drug candidates.
Last, but not least, support from governments and cooperation across the world e.g., public research
institutions as well as United Nations organisations, the WHO, the Food and Agriculture Organization,
and the inter-governmental World Organisation for Animal Health, combined with strategies offering
long-term incentive for the pharmaceutical companies to reinvigorate their antimicrobial drug discovery
platforms are an important political aspect that has been gaining more attention these days. The option
of the US FDA to gain a fast-track approval of drug leads which can be used to treat serious or
life-threatening conditions might further enhance the chances of taking on the expenses associated
with drug discovery by pharmaceutical companies. The combination of all these efforts may give a
competitive advantage in the never-ending race between the discovery of antimicrobials and the rise
of drug resistance in pathogens.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/8/4/157/s1,
Figure S1: The erythromycin biosynthetic pathway, Figure S2: The tylosin biosynthetic pathway, Figure S3: The
monensin biosynthetic pathway, Figure S4: The biosynthetic pathway of tiacumicin, Figure S5: The biosynthetic
pathway of rifamycin, Figure S6: The biosynthetic pathway of oxytetracycline and chlortetracycline, Figure S7:
The biosynthetic pathways of pristinamycin II and pristinamycin I, Figure S8: The biosynthetic pathways of
nystatin and amphotericin B, Figure S9: The biosynthetic pathway of pimaricin.
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A adenylation domain MBC minimum bactericidal concentration
ABC ATP-binding cassette MIC minimum inhibitory concentration
ACP acyl carrier protein MLSB macrolide–lincosamide–streptogramin B
AHBA 3-amino 5-hydroxybenzoic acid MOA mode of action
ARO aromatase MRSA methicillin-resistant Staphylococcus aureus
AT acyltransferase MT methyltransferase domain
BGC biosynthetic gene cluster NADPH nicotinamide adenine dinucleotide phosphate
C condensation domain NGST Next Generation Sequencing Technologies
CABP community-acquired bacterial pneumonia NMR nuclear magnetic resonance
CCR crotonyl-CoA carboxylase/reductase NRPS nonribosomal peptide synthetase
CDI Clostridioides difficile infection NTG N-methyl-N′-nitro-N-nitrosoguanidine
CLF chain elongation factor ORF open reading frame
CoA coenzyme A PCP peptidyl carrier protein
cryo EM cryogenic electron microscopy PCR polymerase chain reaction
CYC cyclase PKS polyketide synthase
DEBS deoxyerythronolide B synthase PTC peptidyl transferase center
DH dehydratase RNA ribonucleic acid
DNA deoxyribonucleic acid RNAP RNA polymerase
dTDP deoxythymidine diphosphate rRNA ribosomal RNA
E epimerisation domain SAM S-adenosyl methionine
ER enoyl reductase SAR structure activity relationship
ESBL extended spectrum β-lactamase SARP Streptomyces antibiotic regulatory protein
FDA Food and Drug Administration Spp. Species
GDP guanosine diphosphate TB Tuberculosis
GI gastrointestinal TDP thymidine diphosphate
Kb kilobase TE Thioesterase
KR ketoreductase tRNA transfer RNA
KS ketosynthase VRE vancomycin-resistant Enterococci
LSAP Lincosamide–streptogramin A–pleuromutilin VRSA vancomycin-resistant Staphylococcus aureus
MAC Mycobacterium avium-intracellulare complex WHO World Health Organisation
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Abstract: Antimicrobial resistance is increasing despite new treatments being employed. With a decrease
in the discovery rate of novel antibiotics, this threatens to take humankind back to a “pre-antibiotic era”
of clinical care. Bacteriophages (phages) are one of the most promising alternatives to antibiotics for
clinical use. Although more than a century of mostly ad-hoc phage therapy has involved substantial
clinical experimentation, a lack of both regulatory guidance standards and effective execution of clinical
trials has meant that therapy for infectious bacterial diseases has yet to be widely adopted. However,
several recent case studies and clinical trials show promise in addressing these concerns. With the
antibiotic resistance crisis and urgent search for alternative clinical treatments for bacterial infections,
phage therapy may soon fulfill its long-held promise. This review reports on the applications of phage
therapy for various infectious diseases, phage pharmacology, immunological responses to phages, legal
concerns, and the potential benefits and disadvantages of this novel treatment.
Keywords: bacteriophages; clinical trials; antibiotic resistance; infectious disease; phage therapy
1. Introduction
There are approximately 1030-31 bacteriophages (phages) in the biosphere [1,2], which is estimated
to be 10-fold higher than the total number of bacterial cells [3]. Phages are also an inherent part of
the human microbiome, and so are usually well-tolerated when used in phage therapy [4–6]. Phages
are one of the most promising alternatives to antibiotics, which can be used for medicine, agriculture,
and related fields [7]. The evolution of multidrug-resistant and pan-drug-resistant bacteria poses
a real threat to the control of infectious diseases globally, so it is urgent to have new therapeutic tools
available. The United States National Institutes of Health have stated that phages are promising tools
for combatting microbial resistance [8].
A post-antibiotic era in which minor injuries and common infections can kill because of the lack
of drugs or their ineffectiveness is nowadays not an apocalyptic fantasy, but a real 21st-century threat.
For example, ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) are extremely resistant to
multiple antimicrobial agents [9] and are a serious challenge in medicine today. On the other hand,
there historically has been no fit for purpose regulatory framework to deal with novel flexible and
sustainable therapeutic approaches such as phages. For phages, this includes oversight of the setup
and approval of adequate clinical trials, so as a result, there is no standard protocol for phage therapy.
In this review, we summarize the phage therapy clinical trials that have shown promising results
in patients. We cover several diseases, immunological responses to phages, phage pharmacology, legal
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concerns about phage therapy, phage genetic modification, and a description of the advantages and
disadvantages of phage therapy when compared to conventional treatments with antibiotics.
2. Phage Biology
Viruses that infect bacteria and Achaea are called phages, which have no machinery for generating
energy and no ribosomes for making proteins. They are obligate bacterial parasites that carry all the
genetic information required to undertake their reproduction in an appropriate host. The genome size
of phages varies from a few thousand base pairs up to 498 kilobase pairs in phage G, which is the
largest phage sequenced to date [10]. Most phages have a high level of host specificity (though some
are broad in range), high durability in natural systems, and the inherent potential to reproduce rapidly
in an appropriate host. They can be found associated with a great diversity of bacterial species in any
natural ecosystem [11].
Phages can be characterized by their size and shape into three general groups: icosahedron,
filamentous, and complex. Members of these groups may contain nucleic acid of various types
including single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), single-stranded RNA
(ssRNA), or double-stranded RNA (dsRNA). Phages can be further classified with respect to their
actions that follow infection of the bacterial cell. Virulent bacteriophages reproduce immediately and
induce lysis of the cell to enable progeny release, whereas temperate phages insert their genetic material
into the host genome or accessory elements, where they reproduce with the host until triggered to
enter the lytic pathway as observed for virulent phages [12].
Virulent tailed phages of the Caudovirales order have been the best described for phage
therapeutic applications. Within this group, the Myoviridae have a large capsid head and contractile
tail, the Siphoviridae have a relatively small capsid and a long flexible non-contractile tail, and the
Podoviridae have a small capsid head and short tail [13]. The virulent tailed phages follow a lytic cycle
that begins with the specific attachment of phage anti-receptors to host cell surface receptor molecules.
This interaction is often two-step, with an initial reversible phase and then irreversible phase. Once
irreversibly bound, enzymes degrade the cell wall and the genetic material is ejected into the cell with
(usually) the assistance of processive host enzymes. Once transcribed, the phage genome begins to
redirect the host cell metabolism including DNA replication and protein biosynthesis to the reproduction
of viral nucleic acid and proteins. Often, the host genome is degraded during this process. Once complete
daughter viral particles are assembled, cell lysis is initiated to release the particles. Bacterial lysis is
triggered by late encoded phage proteins including holins (to permeabilize the inner cell membrane) and
endolysins (to degrade the peptidoglycan) with the loss of cell wall integrity causing lysis due to osmotic
differential [14].
Specificity
Host specificity (range) of phages is variable, with some phages infecting multiple species and
others only growing on one known isolate. However, their specificity is much higher than that of
antibiotics. The phage host cell surface receptors and antiviral defense mechanisms (genetic and
physical) are the main properties that determine specificity. For some highly conserved species, a single
phage can kill the majority of strains (e.g., phage P100 infects >90% Listeria monocytogenes isolates
tested [15]). Phages that propagate on species with high clonal diversity (e.g., Pseudomonas aeruginosa)
typically only kill a small cohort of strains [16].
Establishment of phage banks or training (in vitro evolution) of phages to become more active and
to elicit less bacterial resistance against the infecting bacterial strain can be valid strategies to overcome
limited host specificity for targeted phage therapy [16]. This strategy likely works best for chronic
infections where the target bacterium is well characterized. In order to treat acute infections, phage
cocktails including phages that together span the whole spectrum of potential strains are proposed.
However, the research and resources needed for the production of suitable and stable multi-component
cocktails are disadvantages of this approach. An alternative approach is to use phage lytic enzymes
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(endolysins), which show broader host specificity at the genus and species level. Endolysins have been
the subject of a recent review by our group [17], so are not discussed further here.
Antibiotics typically kill a broad-spectrum of either Gram-positive and Gram-negative bacteria
including benign flora, which is increasingly considered to be non-desirable due to their adverse effects
on the whole microbiota and potential to spread antibiotic resistance [18,19]. Phage therapy meets
these challenges by its superior specificity and ability to treat drug-resistant isolates.
3. Phage Pharmacology
The pharmacology of phages necessitates the study of interactions between phages and bacteria
as well as interactions between phages and body tissues [14]. Successful and safe phage therapy
involves the effective control of phage–host interactions involving two fundamental components:
pharmacodynamics and pharmacokinetics [20].
3.1. Pharmacodynamics
Pharmacodynamics is the study of the interaction of drugs with their receptors, the transduction
systems to which they are related, and the changes in cells, organs, and the whole organism. The drugs’
impact on the body can either be positive, thus maintaining or restoring health, or negative such as
causing toxic side effects [20].
Phages can be applied via active or passive therapeutic strategies. In active treatment regimes,
phages are introduced at low concentrations relative to the bacteria concentration and therapy relies
on the production and release of progeny phages to infect all bacteria. Active treatments with phages
are considered to have features of automated dosing and to mimic the bodies’ homeostatic mechanism
better than standard pharmaceuticals through the targeted killing of bacteria and phage production at
actual sites of infection rather than systemically [21]. In contrast, passive phage treatment relies on
single, or multiple rounds of sufficient phage concentrations to infect all target bacteria.
Compared to antibiotics, only a single phage is required to kill a single bacterium and so fewer
units are required per treatment. Phages also do not dissociate from bacterial targets once irreversibly
adsorbed. However, multiple phages may adsorb to individual bacteria. For these reasons, it is
important to understand the concepts of multiplicity of infection (MOI), which is the ratio of phage
infections per bacteria, and MOI input, which is the number of phages that are administered per cell.
The killing titer is another concept that can be used to guide phage therapy and is the number of effective
bactericidal phage particles delivered (c.f. the number of plaque-based phage counts) [14,20–23].
Failure to recognize the special requirements of phage pharmacodynamics could result in compromises
to phage therapy efficacy [20].
The degradation of phages by antibodies and other aspects of the immune system do not lead to the
production and accumulation of toxic by-products. The low toxicity of phages is a consequence of their
composition which, for tailed phages, is entirely protein and nucleic acid. As a result, phage therapy can
be considered comparatively physiologically benign when compared to standard antibiotic therapies.
3.2. Pharmacokinetics
Pharmacokinetics describes the absorption, distribution, metabolism, and excretion of a drug.
Absorption and distribution of the drug require its movement throughout the body, at first to the blood
and then beyond the blood into specific tissues or compartments where the drug may accumulate
at different densities [20]. Phage pharmacokinetics are also influenced by decay and proliferation as
a result of the self-replication of bacteriophages.
The route of administration for phages will also affect in situ pharmacokinetics. In clinical cases,
phages are frequently delivered by parenteral administration with oral dosing, topical application,
and aerosolization also common. Data on the relative effectiveness of these approaches is largely
drawn from animal studies. For instance, intramuscular, intraperitoneal, and subcutaneous injection
of a phage cocktail were compared for efficacy in treating a P. aeruginosa in a murine burn model where
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intraperitoneal injection was found to be the most effective, most likely due to the delivery of higher
numbers of phages more quickly and for a greater sustained period than other routes [24]. When using
oral phage dosing in mice, the addition of 0.025% CaCO3 was found to effectively protect the phage
from stomach acids and deliver the phage to the upper and lower gastrointestinal tract where they
reduced numbers of the targeted E. coli O157:H7 [25]. When treating Burkholderia infections induced in
mice, the aerosolization of phages was found to be superior to intraperitoneal injection [26]. Some
advantages and disadvantages of the administration routes are shown in Table 1.
Table 1. Routes of administration for phage therapy.





Extent of diffusion to other sites
may be overestimated in
humans (most data from small
animals).
Multiple delivery sites.
Intramuscular Phages delivered atinfection site.





Subcutaneous Localized and systemicdiffusion. Lower dosage volumes. Multi-dose courses.
Intravenous Rapid systemic diffusion. Rapid clearing of phages by theimmune system.
In vivo selection of
low-immunogenic
phages may be possible.
Topical
High dose of phages
delivered at infection
site.
Run-off from target site if
phages suspended in liquid.
Incorporate phages into
gels and dressings.







Oral Ease of delivery. Higherdosage volumes possible.
Stomach acid reduces phage titer.
Non-specific adherence of





deliver phages to target
area.
Aerosol




High proportion of phages lost.
Delivery can be impaired by
mucus and biofilms
Use of depolymerases to
reduce mucus.
In vitro studies of phage pharmacokinetics using mathematical models do not necessarily reflect
the in vivo phage kinetics observed. For instance, phage T4 was reported to not replicate in vitro at
host concentrations below 104 per mL, but evidence suggests that this is possible in murine models [27].
Phage feeding experiments in animals and humans frequently report irregular shedding and the
passage of high percentages (up to 90% administered) of phages in feces [27]. The failure of many
phage therapy experiments has been related to a poor understanding of phage pharmacokinetics,
for instance, when dosing relies too much on the self-replicating nature of phages [20].
Phage lytic enzymes (endolysins) can also be used for therapy, but their kinetics are more similar
to conventional treatments. For example, Jun et al. [28] determined that a Staphylococcus aureus specific
endolysin had a half-life between 0.04 and 0.38 h after intravenous administration in healthy volunteers.
The decay kinetics of this endolysin is likely explained by the presence of plasma proteases. Other
endolysins have demonstrated a longer half-life such as 11.3 h for CF-301 and 5.2–5.6 h (for 30 and
60 mg/kg, respectively) for P128 [29,30].
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Toxin (e.g., endotoxin) release due to significant bacterial cell lysis could potentially trigger septic
shock during phage therapy. However, antibiotics like amikacin, cefoxitin, and imipenem have been
shown to induce higher amounts of released endotoxin than coliphages [31]. The increase in endotoxin
produced after 180 min incubation of E. coli LM33 was 3.8-fold with phage LM33_P1, 5.5-fold with
amikacin, 8.7-fold with cefoxitin, and 30-fold with imipenem. With E. coli strain 536, there was
a 19.8-fold increase in endotoxin with amikacin, 29.9-fold with phage 536_P1, 53.7-fold with imipenem,
and 125.1-fold with ceftriaxone [31].
So, whilst less of an issue than for most conventional antibiotics, high fragmentation of the cell
wall must be minimized with either phage or phage endolysin therapies to prevent an increase in
pro-inflammatory cytokines [19,32]. To address this potential issue, several groups have proposed
genetically engineering phages to prevent or reduce cell lysis, whilst still causing cell death by
mechanisms such as degrading the host genome (see Section 7 and [33]).
4. Role of the Immune Response in Phage Therapy
Phages can potentially trigger innate and adaptive immune cells that may influence the success
of phage therapy. Three major fields of phage-immune interaction can be discerned. First, involving
immune recognition via pattern recognition receptor (PRR), which is a means for the recruitment of
phagocytes to the infection site [34]. Phages can mediate the activation of innate immune cells when
PRR recognizes phage-derived DNA and RNA. The extent of immune activation will differ depending
on the phage type, the phage dose, and in vivo nucleic acid synthetic activity.
Second, promoted phage-neutralizing antibodies can hamper therapeutic success and this effect
can increase with repeated administration [35]. Antibody induction against phages is considered to be
highly variable, thus immunogenicity should be considered during phage screening prior to phage
therapy. There are several externally presenting proteins on phages such as Hoc, which can potentially
induce such an immune response [36–38]. Strategies to avoid phage-induced neutralizing antibody
formation include refining dose concentrations, the use of low-multi-dose regimes, or low-dose passive
therapy approaches.
Third, the inhibitory effect of humoral (adaptive) immunity and anti-phage antibody production on
phages in the mammalian system is broadly known. Effects seem dose-dependent, with only high doses
for long periods inducing specific responses. For instance, Majewska [39] developed a long-term study
of antibody induction (IgM, IgG, secretory IgA) in mice fed T4 phage orally at high doses (109 PFU/mL
drinking water). No effect was noted in the first two weeks, then in weeks 3–5, there was an increase
in blood serum IgG. IgM did not increase until IgG began increasing, while IgA did not increase until
days 63–79, but when it reached its maximum, no phage was found in the mouse feces. Increased IgA
concentrations antagonized the gut transit of active phage and phage resistant hosts dominated the
gut flora by day 92. However, IgA was rapidly cleared after phage withdrawal [39]. A similar study
determined the immunological response of Pseudomonas phage F8 and T4 treatment in a murine systemic
inflammatory response syndrome (SIR) model. The primary (IgM) and the secondary (IgG) responses
inhibited the phages, and phage concentration in the spleen was significantly decreased [40].
Human trials in 26 patients with immunodeficiency diseases were undertaken to evaluate
immunologic responses to phage φX174. An intravenous dose of 109 PFU/kg body weight was given,
and the phage titer measured in blood. No antibody response was detected in eight cases of infantile
X-linked agammaglobulinemia with circulating phages present for up to 11 days. The other 18 patients
produced antibodies and phages were cleared from circulation within four days. Ten of these patients
showed the IgM antibody, and eight patients produced both IgM and IgG [41]. Other work using
φX174 [42] has demonstrated that repeated (up to quaternary) dosing of phages does not lead to
serious adverse reactions.
It is currently not well understood if anti-phage antibodies could prevent bacterial resistance
development to phages and if the pre-existing immunity to natural phages could affect phage therapy.
Furthermore, there is no clear information about the impact of phage-specific factors on phage clearance
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mechanisms. There are also gaps in our understanding of the clinical relevance of the phage immune
interaction. Nevertheless, the immunogenicity of phages itself does not seem to represent a significant
safety risk for patients. Reports about immune effects in clinical studies using virulent phages are
limited. The introduction of validated in vitro and in vivo methods to determine the comparability
of immune effects of different phages and phage combinations would be indispensable. This would
allow for valid conclusions on the value of immune-based parameters for the selection of phages,
identification of responsive patient populations, exchangeability of phages, and the importance of
individualized phage cocktails [33]. The engineering of phages to make them less immunogenic is also
an area of active research (see Section 7).
5. Resistance to Phages
An important consideration for phage therapy is the potential for bacterial resistance.
Phage-resistant bacteria have been noted in up to 80% of studies targeting the intestines and 50% of
studies using sepsis models, with phage-resistant variants also observed in human studies [43].
As with resistance to classical antibiotics, spontaneous resistance to phages may occur through
a number of mechanisms. For example, the cell surface target receptor(s) may not be expressed or
become mutated, thus causing a complete loss of adsorption or decreased adsorption. This is a limitation
of both phage and conventional antibiotic therapy. For both approaches, knowing the receptor site(s),
their stability, and conservation across strains will help with the mitigation of resistance.
Acquired resistance is another area that requires investigation for both therapeutic approaches.
Accessory genetic elements such as plasmids, temperate phages, and mobile genetic islands can carry
genes coding for resistance to antibiotics. For phages, acquired resistance can encompass CRISPR-Cas
systems [33], immunity proteins produced by temperate phages (though rare) and the acquisition of
DNA restriction-modification systems.
A key advantage of phage therapy over conventional treatments for the avoidance of resistance
development is the deployment of phage cocktails. The use of several phages, each targeting different
receptors and each of a diverse genetic clade will enhance the ability to mitigate against the loss of
adsorption or host genetic protection mechanisms. Genetic engineering may also provide a means to
improve the diversity and targeting efficiency of phages for the avoidance of resistance (see Section 7).
Another consideration is that bacterial mutations that confer phage-resistance often result in fitness
costs to the resistant bacterium. Therefore, understanding and exploiting the fitness costs to resistant
pathogens during therapy is a potentially promising research avenue [43].
6. Phage Therapy Clinical Trials in Humans
To date, human phage therapy trials have largely been empirical, with routine use limited to
Georgia, Poland, and Russia [44]. In particular, the George Eliava Institute in Georgia has longstanding
experience with the selection, isolation, and preparation of monophage and phage cocktails against
a variety of bacterial pathogens for phage therapy. The therapeutic application of phages has also
been undertaken for several decades at the Institute of Immunology and Experimental Therapy in
Poland [45]. However, the experimental clinical data published in Russian and Polish journals are
difficult to access due to security and language barriers.
Although the reporting and assessment of phage therapy need to improve, particularly with
regard to efficacy and tolerability and the use of adequate patient numbers, several successful case
reports have been published. The reports do provide some evidence that the development of phage
therapy is a promising alternative to combat bacterial resistance to antibiotics.
In France, the national health regulator has authorized the first treatment of patients with extremely
drug-resistant and difficult to treat infections using phage therapy. Since then, six cases with various
bacterial infections have been successfully treated [44]. Even though several treatments were not
conducted using clinical standards suitable for drug approval in the Western world, they showed
therapeutic potential for phages and how phages can be applied [45].
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New therapeutic products must usually go through a long and comprehensive process involving
preclinical and clinical trials to gain regulatory approval for market access. In the US, the average time
for the approval of a new drug from preclinical testing is 12 years and the costs run into millions of dollars
due to the length, size, and complexity of human clinical trials. For these reasons, the number of formal
phage therapy clinical trials (as listed on www.ClinicalTrials.gov or https://globalclinicaltrialdata.com/)
is very limited [45]. However, some of the human phage therapy clinical trials underway are
summarized in Figure 1 and are described in the following case studies.
Figure 1. Human phage therapy trials and the range of target sites/infections. Image adapted from
Furfaro et al. [46].
6.1. Phage Treatment of Burns
Phage therapy was applied in wound infections in 27 patients from hospitals in France and Belgium
using a cocktail of virulent anti-Pseudomonas aeruginosa bacteriophages. Participants were randomly
assigned (1:1) to a cocktail of 12 natural virulent anti-P. aeruginosa bacteriophages (106 plaque-forming
units [PFU] per mL) or standard of care (1% sulfadiazine silver emulsion cream), and the route of
administration was topical for seven days, with 14 days of follow-up [44].
The median of the primary endpoint was 144 h in the phage treatment group and 47 h in the
standard of care group. Three (23%) of the 13 analyzable participants showed adverse events in the
phage treatment group when compared with seven (54%) out of 13 in the standard care group. Bacteria
isolated from patients of the failed phage treatment were resistant to low phage doses [44].
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This study showed that phage treatment decreased bacterial burden in burn wounds in more time
than the standard treatment. In this regard, studies increasing the phage concentration and the use of
“phagograms” (as used for antibiograms) with more patients are warranted.
6.2. Treatment of A Septicemia Patient with Acute Kidney Damage
A man in his sixties was hospitalized for Enterobacter cloacae peritonitis and severe abdominal
sepsis, dispersed intravascular coagulation, herniation, and bowel strangulation. Following prolonged
treatment for these ailments, the patient developed gangrene and pressure sores colonized by
drug-resistant P. aeruginosa. The infection developed to septicemia and colistin treatment (the only
drug sensitivity) was carried out, however, acute kidney damage was detected, and the treatment was
suspended. Subsequently, phage therapy against P. aeruginosa was conducted using a mixture of two
phages active against the isolate in vitro, under the umbrella of Article 37 (Unproven Interventions in
Clinical Practice) of the Declaration of Helsinki [46]. Following phage therapy, the patient showed
improved kidney function, which returned to normal function after a few days, and blood cultures
were negative.
However, the patient’s pressure sores remained infected with P. aeruginosa and other species and
four months later, the patient developed a refractory cardiac arrest due to blood culture-confirmed
Klebsiella pneumoniae sepsis and the patient died. In vivo studies revealed that a K. pneumoniae strain
isolated from the patient was sensitive to the antibiotics. According to historical reports, the use of
phages by intravenous route in typhoid fever and Staphylococcus aureus [47] bacteremia were efficacious,
nevertheless, this is the first contemporary report using phage monotherapy against P. aeruginosa
septicemia in humans through the intravenous route [48].
6.3. Engineered Phages for Treatment of Mycobacteria in A Cystic Fibrosis Patient
Therapeutic phage treatment for mycobacteria has been explored in several animal models [49,50],
but until recently had not been successfully used for mycobacterial infections in humans. A 15-year-old
patient with cystic fibrosis and extensive comorbidities was referred for lung transplant with a disseminated
infection of Mycobacterium abscessus. Following bilateral lung transplantation and persistent M. abscessus
infections, phage genome engineering and forward genetics were used to engineer phages to target and
kill the infectious M. abscessus strain. Therapy was conducted using an intravenous three-phage cocktail of
109 PFU of each phage every 12 h for 32 weeks [51].
Intravenous phage treatment was well tolerated, clinical improvement including sternal wound
closure, improved liver and lung function, and substantial resolution of infected skin nodules were
detected in the six months following therapy. No evidence of phage neutralization was detected in
sera, although weak antibody responses to phage proteins were identified. Weak cytokine responses
were reported for interferon-γ, interleukin-6, interleukin-10, and tumor necrosis factor-α [51]. Some
evidence was presented that indicated active in vivo phage replication was taking place. Despite
the apparent success of this therapy, the authors did caution that there was significant variation in
M. abscessus phage susceptibility, so the treatment of similar patients will require more work to be
undertaken to understand the science underlying this observation.
6.4. Phage Therapy for Respiratory Infections
There have been several pre-clinical studies describing the use of phage therapy against chronic
bacterial lung infections using murine models. Pabary et. al. [52] determined that phage treatment
reduced the infective burden and inflammatory response in the murine lung. All phage-treated
mice cleared P. aeruginosa infection at 24 h, whereas infection persisted in all of the control mice.
Phage also reduced infection and inflammation in bronchoalveolar lavage fluid when administered
prophylactically. Another study showed that intranasal treatment with phage rescued mice from
Acinetobacter baumannii-mediated pneumonia. Microcomputed tomography also indicated a reduction
in lung inflammation in mice given phage [53]. In a study using a biofilm-associated murine model
200
Antibiotics 2019, 8, 138
of chronic lung infection, phage therapy was effective seven days post-infection. Additionally, these
studies established the potential for phage therapy in established and recalcitrant chronic respiratory
tract infections [54].
Notwithstanding the reported treatment of Mycobacterium described in Section 6.3, reports of
phage therapy of human bacterial respiratory infections are rare. In a 2011 case study from Georgia,
a seven-year-old cystic fibrosis (CF) patient presented with chronic colonization of P. aeruginosa and
S. aureus with antibiotic treatments having limited effect. Phage therapy was undertaken using
a “Pyo phage” phage cocktail produced by the Eliava Institute, which reportedly contains phages
active against S. aureus, Streptococcus, Proteus, P. aeruginosa, and E. coli [55]. The Pyo phage cocktail was
delivered to the patient via nebulization at four-to-six week intervals for nine rounds of treatment.
The P. aeruginosa numbers reduced considerably, however, the treatment was not effective against
S. aureus. Consequently, Sb-1 phage (a phage targeting S. aureus) was added to the Pyo phage cocktail
and administered five times with a nebulizer. This treatment reduced the concentration of S. aureus
significantly. No adverse effects were detected in the patient upon Sb-1 phage treatment [55].
Recent advances in the spray drying of phages that have achieve increased numbers of phages
delivered to the lungs (up to 108 PFU/aspiration) may considerably improve clinical outcomes for
respiratory infections such as these [56]. Work has also shown that a cocktail of ten phages significantly
decreased P. aeruginosa numbers in sputum samples from 58 CF patients collected from hospitals in
Paris [45,57]. Forty-eight of 58 samples were positive for P. aeruginosa and the addition of phages
significantly decreased the concentrations of P. aeruginosa in the sputum. An increase in the number of
bacteriophages in 45.8% of these samples was also detected, demonstrating the potential for active
phage therapy of respiratory infections in vivo.
6.5. Phage Therapy for Urinary Tract Infections
Therapy for treating urinary tract infections (UTIs) is one of the most promising applications for
phages and one of the few that have been studied in a multi-stage clinical trial. In the first stage of
the trial, 130 patients planned for transurethral resection of the prostate were screened for UTIs and
118 patients enrolled [58]. Criteria for inclusion in the trial were having ≥104 cfu/mL of the pathogens
S. aureus, E. coli, Streptococcus, P. aeruginosa, or Proteus mirabilis in their urine culture. Initial in vitro
screening of these cultures against the Pyo phage cocktail, a commercial product produced by the
Eliava Institute, revealed that the sensitivity was 41% (48/118). Directed evolution experiments were
applied to the cocktail to select for expanded host range phages, and the sensitivity was improved to
75% (88/118).
In the second stage, nine patients who had infections caused by bacteria sensitive to the Pyo
cocktail underwent non-blinded phage therapy. Administration of 20 mL 107–109 PFU/mL phages
was via a suprapubic catheter twice every 24 h for seven days, starting the first day after surgery.
Urine from the patients was subsequently cultured seven days after surgery or at the time of adverse
indications. Prior to therapy, the patients’ urine screening revealed the presence of E. coli in four cases,
Enterococcus in two cases, Streptococcus in two cases, and P. aeruginosa in one case. Following therapy,
titers of the pathogens decreased by 1–5 log cfu/mL in six out of nine patients. One of the four E. coli
cases had no detectable pathogen, one of two Streptococcus cases had no detectable pathogen, one
of the Enterococcus cases had no pathogens, but the other case detected E. coli. The patient with the
P. aeruginosa infection required antibiotic therapy following a spike in fever and became asymptomatic;
however, P. aeruginosa was detected in his urine. No adverse effects of phage therapy were detected.
The study authors hope to further progress this work to full randomized and blinded control studies
in the future.
6.6. Phage Therapy for Diarrhea
Whilst no longer an active partnership, the Nestlé Research Centre in Switzerland and the
International Centre for Diarrhoeal Diseases Research in Bangladesh have undertaken joint research
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projects over a number of years that have explored the efficacy of phage therapy for the treatment of
diarrheal diseases. In one of the studies, 120 Bangladeshi male children (6–24 months) presenting with
acute bacterial diarrhea were given either 3.6 × 108 PFU of a T4-like coliphage cocktail (39 children),
1.4 × 109 PFU of a commercial coliphage preparation (Coliproteus from Microgen, 40 children),
or a placebo (0.9% NaCl, 41 children) suspended in oral rehydration solution.
Results of this randomized blind trial indicated no adverse effects of oral phage treatment of the
children. The phage survived the gastric passage, but there was no strong evidence of intestinal replication
occurring in patients. Neither the T4-like nor the Microgen coliphage cocktail showed a significant
clinical effect when compared to the control group for stool output or frequency, or rehydration. Likely
reasons for the lack of significant effects were the lower than expected incidence of E. coli (60%) and the
incidence of mixed species infections, the presence of non-susceptible coliforms (phage cocktail was not
optimized for local isolates), and insufficient phage titer [59,60].
6.7. Treatment of Peri-Prosthetic Joint Infection
In this case study [61], an 80-year-old female patient with obesity and a history of relapsing
prosthetic joint infection of the right hip presented with a S. aureus postoperative infection and was
treated with debridement, antibiotics, and implant retention (DAIR). Four years later, another DAIR
was performed for fluoroquinolone-resistant E. coli, following reimplantation surgery in the prior
year. Then, due to a relapse including positive E. coli cultures, another DAIR was performed three
weeks later. Antibacterial therapy with ceftriaxone was started; however, there were further signs of
relapse and antibiotic treatment was stopped. Multidrug-resistant P. aeruginosa and penicillin-resistant
S. aureus were identified in swabs of the wound discharge.
To undertake phage therapy, three phages targeted against the P. aeruginosa isolate were first
prepared by Pherecydes Pharma (France). The S. aureus isolate was lost, so three phages from the
Pherecydes Pharma phage bank were used. Phages were produced in a research environment with
the manufacture overseen by The French National Agency for Medicines and Health Products Safety
(ANSM). The final formulation of the P. aeruginosa and S. aureus phages were undertaken by the hospital
pharmacy by mixing equal volumes of 1010 PFU/mL phage stocks. During the following DAIR, 20 mL
of the phage cocktail was injected into the joint region. Co-therapy with antibiotics (daptomycin,
amoxicillin, and clindamycin) was followed for the next six months without signs of P. aeruginosa or
S. aureus infection. The patient later had a Citrobacter infection, which required DAIR, but once this was
treated with Ciprofloxacin, no further infection was found in the joint (18 months post-phage therapy).
The bespoke use of phage and antibiotic combinations to treat a patient’s infection has the potential
to be utilized to create personalized therapy for deep and persistent tissue infections such as those
found associated with peri-prosthetic joints (Figure 2).
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Figure 2. Personalized combinatorial phage therapy. Image adapted from Akanda et al. [62].
6.8. Treatment of Leg Ulcers
A Phase I trial of phage therapy with 42 patients with chronic venous leg ulcers has been
undertaken [63]. Ulcers were treated for 12 weeks with a phage cocktail (WPP-201; 8 × 107 PFU/mL) or
a control (saline). The phage cocktail targeted P. aeruginosa, S. aureus, and E. coli. Patient follow-up
continued until week 24 and no adverse events were attributed to the phage treatment. There was no
significant difference between the phage therapy group and the control group for the rate or frequency
of ulcer healing. Efficacy of the preparation will need to be evaluated in a phase II efficacy study.
6.9. Therapy of Drug-Resistant Craniectomy Infection
A previously healthy 77-year-old male who suffered assault, subdural hematoma, and traumatic
brain injury underwent a craniectomy, which was complicated by postoperative intracranial infection
with multidrug-resistant A. baumannii. The isolate was resistant to all antibiotics; however, some
isolates were sensitive to colistin [64]. An emergency investigational new drug application to use
phage therapy on the patient was approved by the US Food and Drug Administration. Phages from
the Naval Medical Research Center-Frederick were screened against the isolate and the most active
phage prepared.
The phage (2.1 × 107 PFU/mL) was administered intravenously through a central catheter line
every 2 h for eight days, with 98 total doses given. Following phage treatment, the patient initially
seemed more alert, but continued to be unresponsive. The craniotomy site and skin flap healed well,
though fevers and leukocytosis continued. There were no further signs of infection at the craniotomy
site after surgical debridement. However, bacterial cultures obtained prior to phage administration
were negative, therefore it was not possible to directly measure phage efficacy. Before the receipt of
a second phage cocktail, the patient’s family decided to withdraw care and the patient died.
The authors concluded that administration of phages through the surgical drain would likely
have had more benefit than parenteral administration, less targeted phages with broader activity may
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have been more efficacious, and a better outcome might have been possible if personalized phage
therapy had been developed more quickly and administered earlier in the course of infection.
6.10. Therapy of Ear Infections
A Phase I/II research trial was conducted in the UK to test the efficacy and safety of phages
for the treatment of chronic ear infections (otitis media), where the infection is known to harbor
antibiotic-resistant P. aeruginosa [65]. In this randomized double-blinded study, a cocktail of six phages
produced by Biocontrol Limited (BiophagePA, 6 × 105 PFU), or placebo (glycerol-PBS solution) were
administered to the ear canal of 24 patients. The follow-up to treatment was at 7, 21, and 43 days
and revealed a statistically significant improvement in both clinical condition and patient-reported
indicators for the phage treated group when compared to the control. No adverse reactions were noted
in the phage-treated group.
In vivo replication of phages in the patients was evident for up to 23 days, with the mean recovery
of phages during the trial sampling points being 200 times the input concentration. Clearance of
phages was noted when the P. aeruginosa infection was resolved in patients. Reductions in overall
P. aeruginosa numbers in the phage treatment group, whilst statistically significant, were generally
modest, but measurement was likely to be compromised by the lack of access to deep parts of the
ear canal. When P. aeruginosa was not completely cleared by phage therapy, there was an increase in
clinical scores for some patients. The study authors suggest that repeated phage therapy after three to
four weeks may be beneficial to these types of patients in any future work.
7. Engineering and Other Genetic Technologies for Phage Therapy
The advent of whole-genome sequencing and metagenomics have rapidly increased the number
of phage genomes sequenced and is unlocking new insights into phage genetics. The use of this new
knowledge for phage engineering holds great potential to increase the utility of phages for therapy,
however, there are additional considerations such as ethical, safety, and regulatory, which need to be
accounted for above that of ‘natural’ phage therapy. Engineering can be used to produce new variants
of phages with expanded host range, decreasing the number of phage strains needed to cover bacterial
diversity, and generating patentable phage variants [66–68]. For example, the host specificity of the
E. coli K12-specific phage T2 was able to be changed by swapping gene products expressed at the tip
of the long tail fiber with those of the PP01 phage, which is an E. coli O157: H7-specific phage [66].
The recombinant phage was able to infect E. coli O157: H7 and related strains, but could not infect
E. coli K12 or its derivatives. Similarly, homologous recombination was used to replace the long tail
fiber genes (genes 37 and 38) from the genome of T2 with those of the IP008 phage. The recombinant
T2 phage had a host range identical to that of IP008 [67]. Lin et. al. [68] were also able to modify
the E. coli female-specific T7 phage to overcome male exclusion by recombination with phage T3.
The recombinant phages of T3 and T7 carried altered tail fibers and had better adsorption efficiency
than T3.
Genetic engineering of phage permits the addition of novel functionality such as bacteriocins,
enzybiotics, quorum sensing inhibitors, CRISPRs, and biofilm degrading enzymes that can enhance
their killing potential [69–73]. Phages can be modified using the RNA-guided nuclease Cas9 to create
sequence-specific antimicrobials. Cas9 was reprogrammed to target virulence genes and killed virulent,
but not avirulent, strains of S. aureus in a mouse skin colonization model [65]. Another study used
CRISPR-Cas technology to create RNA-guided nucleases delivered by phages to target specific DNA
sequences in carbapenem-resistant Enterobacteriaceae and enterohemorrhagic E. coli [70]. Delivery of
the nucleases improved the survival in a Galleria mellonella infection model. Phage-borne CRISPR-Cas
systems can also be used to enable site-specific cleavage to induce cytotoxicity, activate toxin-antitoxin
systems, re-sensitize bacterial populations to antibiotics, and modulate bacterial consortia [70].
Biofilms are the major cause of persistent infections in clinical settings, thus phage treatment to
lyse bacteria in biofilms has attracted growing interest. An engineered T7 phage was constructed to
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encode a lactonase enzyme with broad-range activity for the quenching of quorum sensing molecules
necessary for biofilm formation. The T7 phage incorporating the AHL lactonase aiiA gene from Bacillus
anthracis degraded AHLs from diverse bacteria and caused the inhibition of a mixed-species biofilm
composed of P. aeruginosa and E. coli [71]. In another approach using the T7 phage, a biofilm-degrading
enzyme, DspB, produced by Actinobacillus actinomycetemcomitans, was inserted into the T7 genome and
the resultant phage reduced E. coli biofilm cell counts by an additional 2 log when compared to the
unmodified T7 [72].
As described in Section 4, components of the innate immune system can remove a significant
proportion of administered phage. Studies have shown that long-circulating phage mutants can be
isolated to address this issue. Vitiello et. al. [73] determined that a single specific substitution in the
major phage capsid (E) protein of the lambda Argo phage was enough to confer a long-circulating
phenotype that enhanced phage survival in the mouse circulatory system by more than a 1000-fold.
Merril et. al. [74] used a serial passage selection method to isolate phage mutants with a greater capacity
to remain in the circulatory system of the mouse. Lambda phage mutants with 13,000–16,000-fold better
capacity to stay in the mouse circulatory system for 24 h after intraperitoneal injection were isolated.
Many antibiotics, as well as phage therapy, can present side effects due to endotoxin release from
Gram-negative bacteria. To address this, genetic engineering was used to generate non-replicating
non-lytic phage targeting P. aeruginosa. An export protein gene of the P. aeruginosa filamentous phage
Pf3 was replaced with a restriction endonuclease gene and the variant (Pf3R) was non-replicative and
prevented the release of phage from the target cell. Endotoxin release was kept to a minimum and the
Pf3R phage efficiently killed a wild-type host in vitro. Phage therapy using Pf3R showed comparable
or increased survival rates (depending on dose) when compared to Pf3 upon challenge in the mice
model. Higher survival rates were correlated with a reduced inflammatory response when using Pf3R
treatment [75]. Matsuda et. al. [76] also produced lysis-deficient T4 phages for this purpose. Mutant t
amber A3 T4 phages were compared to wild-type T4 in mouse bacterial peritonitis model. Survival was
significantly higher in mice treated with the lysis deficient phage when compared to the wild-type, and
enterotoxin levels were significantly lower in the t A3 T4-treated mice at 12 hours after infection [76].
8. The Medicinal Regulatory Status of Phages
Phages are not specifically classified as living or chemical agents in any national medicinal
legislation (as far as we are aware). This considerably complicates the regulation of human phage
therapy clinical trials and commercialization of phage products as well-established safety, good
manufacturing practice, and efficacy benchmarks are lacking [77]. Another barrier is that in order
to prove the efficiency of phage preparations, their effectiveness and host range toward currently
circulating pathogenic strains must be constantly monitored. This is most likely why the Russian
Federation and Georgia approved phage preparations are continuously updated to target newly
emerging pathogenic strains [78]. Therefore, any specific legislation regarding phage products would
ideally permit these formulation updates as required to avoid repeated registration procedures.
A breakthrough for the regulation of phage therapy occurred in 2016, when the Belgian
Minister of Social Affairs and Public Health defined the status of therapeutic phage preparations as
industrially-prepared medicinal products (subjected to constraints related to marketing authorization)
or as magistral (compounded) preparations prepared in the pharmacies’ officinal [79]. Natural
phages and their products can be processed by a pharmacist as raw materials (active ingredients)
in magistral preparations, providing there is compliance with several provisions of the European
Directive requirements for medicinal products for human use [78].
Several jurisdictions also permit the use of phages on compassionate grounds, where all other
therapies have failed, and the condition is immediately life-threatening. These include the US FDA
Expanded Access Program (www.fda.gov/news-events/public-health-focus/expanded-access) and
Investigational Drug Program (https://www.fda.gov/drugs/types-applications/investigational-new-
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drug-ind-application) and the European Medicines Agency (https://www.ema.europa.eu/en/human-
regulatory/research-development/compassionate-use).
9. Advantages and Disadvantages of Phage Therapy
Compared to conventional antibiotic therapy for bacterial infections, phage therapy has both
a number of great advantages, but also some disadvantages. Some of these have been summarized in
Table 2 and some aspects are discussed in more detail in the following subsections.
Table 2. Advantages and disadvantages of phage vs. antibiotic therapy for the treatment of
bacterial infections.
Consideration Antibiotic Therapy Phage Therapy
Specificity Low High
Development costs High Low-moderate
Side effects Moderate-high Usually low, but yet to be fully established
Resistance Increasing incidence of multi-drugresistant isolates.
Can treat multi-drug-resistant isolates. Phage
resistant isolates generally lack fitness.
Delivery to target Moderate Moderate to good. Can penetrate the blood-brainbarrier.
Formulation Fixed Fixed or variable
Regulation Well established Underdeveloped
Kinetics Single hit Single hit or self-amplifying
Immunogenicity Variable Likely low, but not well established
Clinical validation Many trial studies Relatively few trial studies
9.1. Key Advantages
Phage therapy has several key advantages that make it an attractive alternative to antibiotics.
First, phages have high specificity to their hosts and unlike antibiotics, which have a much wider
spectrum, are unlikely to cause dysbiosis and secondary infections (e.g., fungal infections). To date,
phages have also not shown any significant side effects or risks of toxicity on mammalian cells [80].
Moreover, the process of isolation and selection of new phages is less expensive, in terms of time and
costs, than the development process required for antibiotics: it typically takes millions of dollars and
numerous years to develop an effective antibiotic drug [81].
The development of the resistance of bacteria to phage therapy is likely less significant than for
antibiotics because of the ability to adapt phage cocktails by the substitution of phages, applying
in vitro evolutionary pressure, or by genetic engineering. The variant resistant mutants are also
generally of lower fitness. Phages are also able to successfully treat multi-drug-resistant bacteria as
they use different mechanisms for targeting cells.
The ability of phages to widely spread through the body when applied by systemic administration,
along with self-replication in the presence of the host, are qualities that most antibiotics do not have.
Unlike most antibiotics, phages can also pass through the blood–brain barrier [82]. Some phages can
also infiltrate and disrupt the biofilms that many pathogens naturally inhabit [82,83].
For patients with allergies to antibiotics, their treatment options can be restricted. About 1% of
hospitalized patients have an allergy to penicillin-group drugs, the most common antibiotic allergy,
followed by sulfonamides and tetracyclines [84]. Cross-reaction of penicillin allergies to next-generation
cephalosporins and carbapenems has also been reported, but this remains controversial [85]. Phage
therapy may be a valuable option for patients with antibiotic allergies, but reports are rare. For example,
12 patients with inflammatory soft tissue shotgun wounds and allergy to antibiotics (not specified)
were reported to have been treated by polyvalent phage therapy (Staphylococcus, Streptococcus, Proteus
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vulgaris, Proteus mirabilis, P. aeruginosa, E. coli, and K. pneumoniae) for 15 days [86]. The concentrations of
bacteria and the areas of wound healing were similar in the phage treatment group when compared to
a control group of 35 patients receiving antibiotics. The authors concluded that phages were a reliable
method for reducing microbial infection and that treatment led to a rapid epithelialization of the
wound site [86].
9.2. Key Disadvantages
There are currently some key disadvantages of using phages as alternatives for antibiotics.
However, these are predominantly due to gaps in knowledge and regulations, which may be resolved
in the future. Critically, there is a lack of depth of information about the clinical application of phages
for controlling bacterial infections. Much experimental clinical data published in Russian and Polish
journals are difficult to access due to security and language barriers. There are also many more
challenges for scientists in obtaining regulatory approval for phage-based therapeutic applications
when compared to conventional therapies [80].
There is a lack of common established and validated protocols for the routes of administration,
dose, frequency, and duration of phage treatment, which hampers inter-study comparison [87]. Often,
the purity and stability of phage preparations used for clinical trials are also uncertain, with insufficient
quality control data presented.
The concentration of phages may be reduced significantly during therapy by the reticuloendothelial
system or be neutralized by antibodies, thus inhibiting their antimicrobial activity [39,88]. However,
the effect of phage-neutralizing antibodies can be mitigated by refining dosing regimens and breeding
phages to evade the immune system.
The genetic biosafety of phages is complex to assess. Phages used for therapy must not contain
toxin or virulence genes, antibiotic resistance genes, or be able to horizontally transfer genes in the
human microflora. Whilst whole-genome sequencing is a powerful tool to assist with these analyses,
there is still an incomplete understanding of the functions of all encoded phage genes. Genetic
engineering of phages will also likely invite greater scrutiny of safety which practitioners will need to
address before application.
10. Conclusions
Antimicrobial resistance is increasing globally, and new treatments are urgently needed to meet
this challenge in medical care. Whilst phage therapy for bacterial infections has been around for more
than a century, the antibiotic-resistance crisis is providing renewed impetus for phage therapy to deliver
on its long-held promise as a clinical treatment. As described here, there is an increasing number of
well-executed Phase I/II clinical trials describing the safety and efficacy of phage therapy. There is
an improved understanding of the pharmacology, immunology, safety, and potential for bacterial
resistance. Technologies such as genetic engineering, whole-genome sequencing, and metagenomics
also provide new tools to optimize phage therapeutic strategies. However, there are still data gaps on
its efficacy and a lack of standardization and suitable regulatory frameworks that need to be resolved
before phage therapy can take its place in mainstream medicine. Given the renewed interest and
impetus in the field of phage therapy, there are reasons to be optimistic that these challenges can be
met in the coming years.
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Abstract: For decades, the performance of antimicrobial stewardship programs (ASPs) has been
measured by incidence rates of hospital-onset Clostridioides difficile and other infections due to
multidrug-resistant bacteria. However, these represent indirect and nonspecific ASP metrics. They are
often confounded by factors beyond an ASP’s control, such as changes in diagnostic testing methods or
algorithms and the potential of patient-to-patient transmission. Whereas these metrics remain useful
for global assessment of healthcare systems, antimicrobial use represents a direct metric that separates
the performance of an ASP from other safety and quality teams within an institution. The evolution of
electronic medical records and healthcare informatics has made measurements of antimicrobial use a
reality. The US Centers for Disease Control and Prevention’s initiative for reporting antimicrobial use
and standardized antimicrobial administration ratio in hospitals is highly welcomed. Ultimately, ASPs
should be evaluated based on what they do best and what they can control, that is, antimicrobial use
within their own institution. This narrative review critically appraises existing stewardship metrics
and advocates for adopting antimicrobial use as the primary performance measure. It proposes novel
formulas to adjust antimicrobial use based on quality of care and microbiological burden at each
institution to allow for meaningful inter-network and inter-facility comparisons.
Keywords: Antibiotics; resistance; broad-spectrum agents; hospital epidemiology; antibiotic
utilization; infection control; infection prevention; Pseudomonas aeruginosa; Acinetobacter baumannii;
extended-spectrum beta-lactamases; carbapenem-resistant Enterobacteriaceae; methicillin-resistant
Staphylococcus aureus
1. Introduction: Importance of Antimicrobial Stewardship Metrics
It is imperative for the success of any antimicrobial stewardship program (ASP) to have objective
measures for performance evaluation. Direct measurement of ASP performance via process measures
(e.g., antimicrobial use) and/or outcome measures (e.g., Clostridioides difficile infection [CDI]) is currently
recommended by clinical guidelines to improve quality care and prevent antimicrobial resistance [1].
This process ensures that both hospital administration and ASP team members have consistent goals
and expectations. It provides ASPs with the opportunity to periodically self-reflect on their performance
and discuss long-term planning to achieve their aims. This also creates national and local standards
to compare ASPs in different healthcare systems after adjustments for potential differences across
institutions [1].
ASP metrics are often categorized by type into antimicrobial use (AU) measures, process measures,
quality measures, costs and clinical outcome measures. Expert panels assembled among adult and
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pediatric stewards were challenged to develop a set of metrics perceived as both useful and logistically
feasible for adoption by ASPs as performance metrics [2,3]. Variability in practice areas, institutions,
resources and infrastructure all impede the utility of many proposed ASP metrics. The true impact
of an ASP on quality and clinical outcome measures specifically is also debatable, given the patient
complexities and confounders present. Do these metrics actually measure ASP “performance” or
“value” or “efficiency”, a combination of these factors, or none at all?
While several quantitative measures (e.g., antimicrobial use and costs) are often considered
frontline metrics and central to ASP operations, noted expert stewards have proposed a shift in focus
to quality and patient outcomes to demonstrate enhanced program value [4–6]. Many regulatory and
quality improvement organizations (e.g., Agency for Healthcare Research and Quality) have established
infectious diseases metrics designed to measure quality which are often tied to reimbursement [4].
The changing landscape of reimbursement in the US healthcare system and growing transparency of
quality and safety measures through public reporting will likely impact ASPs and potentially influence
key metrics tied to performance evaluation. Collaboration between ASPs, healthcare administration
and quality divisions is imperative in order to maintain consistency in measured success. In this
narrative review, we discuss the landscape of proposed ASP metrics and compare their value and
utility as measures of ASP performance focusing on acute care hospitals.
2. Dynamics of Antimicrobial Stewardship and Infection Prevention and Control Programs
The re-emergence of CDI as a significant threat in the early 2000s was arguably the single most
important factor increasing awareness of risks associated with antimicrobials at both the public and
institutional level. The potential of patient-to-patient transmission of C. difficile spores make clusters or
outbreaks of CDI an imminent threat to hospitals. CDI created a common target for both Infection
Prevention and Control Programs and ASPs and facilitated a dynamic relationship between both teams.
Contact isolation of hospitalized patients with CDI and hand hygiene of healthcare workers with soap
and water have been the cornerstone of Infection Prevention and Control Program efforts to reduce
transmission of C. difficile spores within the hospital. At the same time, reduction in unnecessary use of
broad-spectrum antimicrobials may reduce the risk of hospital-onset CDI (HO-CDI). For this reason,
many Infection Prevention and Control Programs started monitoring antimicrobial use in the hospital
to enhance their CDI interventions, often utilizing the same team members. On other occasions, ASPs
emerged under the Infection Prevention and Control Program umbrella. It was convenient to use
the incidence rate of HO-CDI as a metric for both Infection Prevention and Control Programs and
ASPs. The requirement for hospitals within the United States to publicly report the incidence rate of
HO-CDI through National Healthcare Safety Network (NHSN) and paucity of other measures of ASP
performance only emphasized this existing concept.
Similarly, institutional Infection Prevention and Control Programs have been monitoring and
intervening to prevent patient-to-patient transmission of multidrug-resistant (MDR) bacteria: initially,
extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) and methicillin-resistant
Staphylococcus aureus (MRSA), then carbapenem-resistant Enterobacteriaceae (CRE). Since antimicrobial
use predisposes to colonization and infections with MDR bacteria [7,8], incidence rates of infections or
colonization with MDR bacteria were often used as a quality measure of ASP performance. Mandatory
reporting of these infections added another layer of convenience.
Over time, ASPs have evolved and have become more focused on quality of patient care, including
optimization of antimicrobial management. At the same time, C. difficile, MRSA and ESBLE have
emerged as community-onset pathogens rather than predominant causes of nosocomial infections [9–12].
Antimicrobial resistance of predominantly hospital-onset bacteria, such as Pseudomonas aeruginosa and
Acinetobacter baumannii, has become the most imminent threat to hospitals in the US [13].
Moreover, with the emergence of community-acquired MRSA, intravenous vancomycin has become
the most commonly used antimicrobial in US hospitals. The increasing use of vancomycin, by itself or
in combination with piperacillin/tazobactam, has contributed to an increase in antimicrobial-associated
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nephrotoxicity in hospitalized patients [14,15]. Monitoring the use of nephrotoxic antimicrobial agents
has been added to the daily duties of ASPs. This shifting focus has allowed a greater degree of
independence from Infection Prevention and Control Programs and has made it difficult to use the
same personnel for both Infection Prevention and Control Programs and ASPs.
3. Comparison of Various Antimicrobial Stewardship Metrics
3.1. Clostridioides difficile Infection
Prevention of CDI is one of the main benefits of antimicrobial stewardship. Current or prior
antimicrobial use contributes to CDI due to changes in intestinal microbiota and decreased competition
against C. difficile [16]. Therefore, it is intuitive to use CDI as a measure of ASP performance in
hospitals [1,2]. However, the multifactorial nature of CDI, possibility of person-to-person transmission
irrespective of antimicrobial use and site of acquisition, and changing incidence rate of CDI based on
diagnostic testing methods or algorithms, argue against its use as the primary ASP metric.
3.1.1. CDI Diagnosis
CDI can only be diagnosed based on laboratory testing. Using a highly sensitive test, such as PCR,
would increase the incidence of CDI compared to toxin A/B antibody–antigen assays [17]. An increase in
the incidence rate of HO-CDI was observed when switching from toxin A/B antibody–antigen testing to
PCR [18]. The use of diagnostic tests with varying sensitivities makes comparison of HO-CDI incidence
rates across hospitals impractical. A recent study demonstrated that only 20% of in-hospital testing
for CDI was appropriate [19]. Inappropriate testing for CDI resulted in overtreatment and inaccurate
publicly reported metrics [19]. Even when the same laboratory diagnostic test is used, a change in
institutional policy or algorithm for CDI testing influenced CDI incidence rates. An institutional
requirement for testing all hospitalized patients with liquid stools was associated with higher incidence
rate of HO-CDI in Scotland [20]. C. difficile PCR does not differentiate colonization from infection.
Given the large proportion of inappropriate CDI testing in hospitals, a clinical decision-making tool to
improve the appropriateness of testing likely has a much higher impact in reducing HO-CDI rates
than any ASP intervention. This confounding makes it difficult to correlate incidence of HO-CDI with
ASP activities aiming to optimize antimicrobial use. Instead, this argues for design of a diagnostic
stewardship metric in collaboration with microbiology, central laboratory and Infection Prevention
and Control Programs.
3.1.2. Relatively Low Incidence of CDI
Most clinical studies of CDI adopt a case-control design due to the relative infrequency of CDI
in hospitalized patients. In two cohorts, only 2–4% of hospitalized patients with gram-negative
bloodstream infections developed CDI, despite receipt of broad-spectrum antimicrobial therapy [21,22].
Although still considered a major risk, the relatively large number needed to harm constitutes a
challenge for ASPs attempting to demonstrate effectiveness of their interventions. Based on such
data, ASPs are required to streamline or discontinue 25–50 courses of broad-spectrum antimicrobials
to potentially prevent one case of CDI. Discontinuation of antimicrobial therapy is one of the most
impactful outcomes of any ASP intervention; however, it is a much less frequent intervention than
de-escalation of antimicrobial therapy or reduction in proposed treatment duration [23]. Designing
an ASP intervention to reduce the incidence rate of CDI requires a tremendous amount of time,
resources and dedication. This is likely the reason for the relatively small number of published studies
demonstrating successful reduction in CDI via ASP interventions, despite several decades of focus
in this area. To our knowledge, only early de-escalation of broad-spectrum antimicrobial therapy
(within 48 h) has been associated with a reduction in CDI risk [22]. Early de-escalation of antimicrobial
therapy requires robust ASP, rapid diagnostics, timely electronic alerts, and experienced personnel to
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act on these alerts. Conventional de-escalation of antimicrobial therapy (after 4 days) has demonstrated
non-inferiority to broad-spectrum therapy, but is yet to show a significant reduction in CDI [24].
3.1.3. Multifactorial Etiology of CDI
In addition to antimicrobials, many other independent risk factors have been associated with
development of CDI, such as chemotherapy and proton-pump inhibitors [25]. Moreover, potential for
person-to-person transmission of C. difficile spores makes Infection Prevention and Control Program
efforts far more important than those of ASPs in reducing the incidence of HO-CDI. Given the large
number of ASP interventions required to prevent CDI, a cluster of CDI in one unit of the hospital may
cancel out an entire year’s worth of ASP efforts. Another factor that has not been widely studied is the
impact of antimicrobials used prior to hospital admission on the risk of HO-CDI. Hospital admissions
secondary to community-onset CDI continue to rise and are not as intensely monitored by Infection
Prevention and Control Programs or ASPs, but may also pose similar risk to institutional outbreaks.
Most institutional ASPs have no control over antimicrobials received in ambulatory settings or other
hospitals prior to referral.
3.1.4. Difficulty of Designing a Successful ASP Intervention for CDI
Although the association between antimicrobial use and CDI is strong, it remains controversial
which antimicrobial agents/classes are more likely to contribute to CDI [26]. There is general agreement
that the broader the spectrum of antimicrobials, the higher the risk of CDI; however, there are
notable exceptions to this rule, such as clindamycin [27]. Interpretation of the literature is difficult,
due to use of different definitions and inconsistent methodology. To increase sample size and
power, community-onset and HO-CDI were merged despite vast differences in the spectrum of
activity of oral and intravenous antimicrobials used in the two respective settings [28]. Moreover,
all penicillins were classified in one category, despite the huge difference in the spectrum of
activity of piperacillin-tazobactam and penicillin G, for example [29]. Even the well-designed
interventions which have reported a reduction in the incidence rate of CDI after antimicrobial formulary
changes did not assess the collateral damage of the intervention on antimicrobial resistance [20,30].
It is worrisome that some formulary restrictions designed for reducing CDI risk may encourage the
use of antipseudomonal beta-lactams and carbapenems [30]. This contradicts recent large cohorts
demonstrating the highest odds of CDI among hospitalized patients receiving antipseudomonal
beta-lactams [22,31]. In addition, the linear increase in antimicrobial resistance of E. coli and other
Enterobacteriaceae bloodstream isolates to aminopenicillins and first-generation cephalosporins
limits de-escalation options from antipseudomonal beta-lactams to intravenous ceftriaxone or oral
fluoroquinolones on many occasions [22,32,33]. The long-term consequences of increasing antimicrobial
resistance rates to antipseudomonal beta-lactams and carbapenems secondary to excessive use may
exceed any potential early benefits from this strategy [34,35]. A subtle decline in CDI at the expense
of increasing antimicrobial resistance rates of already difficult to treat bacteria, such as P. aeruginosa
and A. baumannii, constitutes one step forward and two steps back for the longevity of the ASP and
the institution.
3.2. Incidence Rates of Infections or Colonization with MDR Bacteria
3.2.1. Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae (ESBLE)
Controlling outbreaks and reducing transmission of ESBLE in the hospital setting have been
common goals for both Infection Prevention and Control Programs and ASPs since this resistance
mechanism was first described in 1983 [36]. This is conceivable since exposure to antimicrobials,
particularly beta-lactams and fluoroquinolones, is a risk factor for infection or colonization with ESBLE [7,8].
Moreover, ESBLE may be transmitted from person-to-person within hospitals or other settings. At the
turn of the century, ESBLE emerged as community-onset bacteria likely due to availability and widespread
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use of broad-spectrum oral antimicrobials in the community, such as extended-spectrum cephalosporins
and fluoroquinolones [11,37]. The incidence rate of hospital-acquired ESBLE infections have remained
relatively stable over the past decade, due to effective Infection Prevention and Control Programs and
ASPs [12]. On the other hand, the lack of such programs in ambulatory settings and long-term care
facilities has contributed to an increase in the incidence rate of community-onset ESBLE infections [12].
It is estimated that 80% of ESBLE infections in the US are acquired outside the hospital [8,12].
Another limitation of using ESBLE as a measure of ASP performance is the lag between ESBLE
colonization and infection. Colonization with ESBLE within the past one year has been associated with
increased risk of ESBLE infections [8,38]. Patients may be colonized with ESBLE due to antimicrobial
use in the community. If a urinary culture is obtained on the fourth day of hospitalization for
appropriate or inappropriate indications, the ESBLE isolate will be classified as nosocomial, even in
the absence of any antimicrobial use during the index hospitalization [39]. This limits the utility of
ESBLE as a measure of ASP performance.
3.2.2. Methicillin-Resistant Staphylococcus aureus (MRSA)
The emergence of MRSA as community-acquired bacteria by the end of last century makes the
incidence of hospital-onset MRSA infections or colonization a less useful ASP metric. There is a
suggestion that antimicrobial use may predispose to MRSA colonization or infection. A recent study
demonstrated that the restriction of fluoroquinolone and macrolide use, among other antimicrobials,
was associated with a reduction in MRSA infection rates [40]. However, this association was temporal,
at best, and a decline in MRSA infection/colonization rates was demonstrated elsewhere without
formulary changes [41–43]. In the era of increasing antimicrobial resistance rates, class restrictions
of already limited antimicrobial treatment options for hospitalized patients with serious infections
seem counterproductive. Given the high prevalence of community-acquired MRSA strains and
widespread use of fluoroquinolones in the community, it is unrealistic to expect formulary restrictions
of fluoroquinolones in hospitals to impact overall MRSA rates. Restricting fluoroquinolone use in the
community to specific indications, such as acute pyelonephritis and community-onset pneumonia,
seems more reasonable [44].
3.2.3. Carbapenem-Resistant Enterobacteriaceae (CRE)
Carbapenem exposure is a risk factor for CRE infections or colonization [45]. Since carbapenems
are currently only available in intravenous form in the US, the incidence rate of CRE appears more
relevant to institutional ASPs than that of ESBLE and MRSA. The potential for person-to-person
transmission have made long-term care facilities reservoirs for CRE, likely due to lack of effective
Infection Prevention and Control Programs and ASPs. The lag between CRE colonization and infection,
as well as the potential for receiving carbapenems at other facilities, pose some limitations to using
CRE incidence rates to evaluate ASP performance. The potential availability of oral carbapenems in
the US in the near future may change the epidemiology of CRE infections, in an unfortunate repeat of
the community-onset ESBLE phenomenon.
3.2.4. Antimicrobial-Resistant P. aeruginosa and A. baumannii
P. aeruginosa and A. baumannii are predominantly hospital-onset pathogens [46]. They are ubiquitous
bacteria which are difficult to eliminate from hospital environments. Hospitalized patients may become
colonized with these bacteria due to either heavy exposure from prolonged hospitalization or antimicrobial
selection pressure [47,48]. The presence of open wounds, mechanical ventilation, and urinary or central
venous catheters place hospitalized patients at higher risk of infections with these bacteria [46,49,50].
Resistance to antipseudomonal beta-lactams and carbapenems among these isolates poses serious
challenges to hospitals due to the lack of safe and effective antimicrobial treatment options [35].
Outbreaks of infections due to MDR P. aeruginosa and A. baumannii are devastating to both patients
and hospitals, associated with high mortality rates and high costs of treatment. The amount of time,
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resources and personnel dedicated to the containment of such outbreaks is enormous, occasionally
requiring unit closures and massive financial burdens [51,52]. For this reason, P. aeruginosa and
A. baumannii are at the top of the World Health Organization global list of critical priority [13].
Inpatient antimicrobial use is by far the most important factor influencing antimicrobial resistance
rates of these hospital-onset isolates [53–57]. The recent increase in utilization of antipseudomonal
beta-lactams and carbapenems in US hospitals has been temporally associated with an increase in
antimicrobial resistance rates of P. aeruginosa [34,35]. Using antimicrobial resistance of P. aeruginosa
and A. baumannii as an ASP metric is logical and reasonable, but has limitations. First, changes in
referral patterns may impact antimicrobial resistance at tertiary care centers. Second, nearly one-half of
P. aeruginosa bloodstream isolates are acquired outside the hospital [48]. Community-onset P. aeruginosa
infections are particularly common among immune compromised hosts and patients who received
recent beta-lactams [48–50]. Antimicrobial resistance rates of strictly hospital-onset P. aeruginosa and
A. baumannii isolates are a more equitable measure of ASP performance. This requires stratification by
site of acquisition. If such stratification is not automated by clinical informatics, then resistance rates of
hospital-onset isolates will have to be done manually. This is unlikely to be feasible for many ASPs,
based on current resources in time and personnel.
3.3. Quality of Care
Quality of patient care is the most important antimicrobial stewardship principle [2–5]. The ultimate
goal of ASPs is to optimize both empirical and definitive antimicrobial therapy for hospitalized patients
with serious infections.
3.3.1. Appropriate Definitive Antimicrobial Therapy
Many ASPs utilize available healthcare informatics resources to identify suboptimal antimicrobial
use among individual patient cases. The objective is to ensure patients who have positive clinical
cultures, particularly from sterile sites, receive the most effective antimicrobial therapy. Appropriate
therapy is not only a matter of receiving an antimicrobial agent with in vitro susceptibility against the
microbial isolate. Rather, it is based on effectiveness as derived from large clinical studies and involves
receiving an appropriately dosed agent based on the primary source of infection, the patient’s renal
and hepatic function, and the minimal inhibitory concertation of the clinical isolate. The antimicrobial
should also be administered via the appropriate route based on severity of infection, reliability of the
enteral route, and bioavailability of the agent [58–60].
Since most currently available software for identification of bug–drug mismatches use in vitro
susceptibility as a screening measure for appropriateness, many patients receiving inappropriate
definitive therapy will not be identified. This includes patients receiving antimicrobial agents without
activity at the site of the infection (e.g., daptomycin for MRSA pneumonia or nitrofurantoin for
E. coli bloodstream infections). It would require a separate ASP intervention to review all cases of
pneumonia or bloodstream infection to identify such cases. The variety of factors associated with the
“appropriateness” of antimicrobial therapy makes it difficult to measure ASP performance based on
this metric alone.
3.3.2. Appropriate Empirical Antimicrobial Therapy
Receipt of appropriate empirical antimicrobial therapy is independently associated with survival
and shorter duration of hospitalization in patients with serious bacterial infections [58,59,61–63].
Despite the excessive use of broad-spectrum agents in hospitals, up to 30% of patients still receive
inappropriate empirical therapy [64]. As the focus of ASPs has shifted to quality, many ASPs have
invested in measuring and improving the appropriateness of empirical therapy. The art is designing
institutional management guidelines which increase the appropriateness of empirical therapy while
also reducing overall use of broad-spectrum agents [65]. Institutional management guidelines based
on local evidence, coupled with rapid microbial identification and vigorous ASP monitoring, have
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been demonstrated to successfully achieve both goals [66]. The proportion of patients receiving
appropriate empirical antimicrobial therapy for serious infections is the most important measure
for the quality of ASP performance. Many host factors, including age, comorbidities and acute
severity of illness, impact both survival and hospital length of stay in patients with serious bacterial
infections [58,63,67,68]. In reality, the only variable an ASP can directly control and modify is the
selection of empirical antimicrobial therapy. In order to use appropriateness of empirical therapy as a
metric for ASP performance, it would require identification of every patient with a particular clinical
syndrome (e.g., bloodstream infections, sepsis, or pneumonia) or a representative random sample.
Although this may be time-consuming and labor-intensive, many ASPs are currently monitoring the
appropriateness of empirical therapy, particularly in patients with bloodstream infections [66,69–72].
3.4. Cost of Healthcare
Antimicrobial cost was, for the most part, the only specific measure of ASP performance.
Nonetheless, an institutional antimicrobial budget may be influenced by changes in acquisition price
or renegotiation of institutional contracts, as dictated by supply and demand in the market.
Cost reduction has historically been used to justify the presence of an ASP, including both the
establishment of a new program and maintenance of an existing program. ASPs have demonstrated
significant reductions in hospitals’ antimicrobial budgets, mostly by targeting and restricting
unnecessary use of expensive antimicrobials (e.g., daptomycin, ceftaroline) [73–76]. However, cost
savings generally plateau after few years. The cost of the acquisition of antimicrobials varies across
institutions based on purchase volume and the ability of the healthcare system to negotiate a better deal.
Occasional price hikes of commonly used agents make cost a less attractive metric. More importantly,
the biggest cost savings institutional ASPs provide are hard to measure. These cost savings include
reduction in length of hospital stay by improving the appropriateness of empirical antimicrobial
therapy for serious infections [62,63]. Second, measurement of cost avoidance is also challenging.
An ASP’s efforts in reducing antimicrobial resistance rates of hospital-onset bacteria minimizes the
need for new and often expensive antimicrobials used for treatment of infections due to MDR bacteria
(e.g., ceftolozane/tazobactam, ceftazidime/avibactam).
3.5. Antimicrobial Use
3.5.1. Direct and Specific ASP Metric
Since ASPs manage antimicrobial therapy on a daily basis, harnessing antimicrobial use as
the primary ASP metric is intuitive. Antimicrobial use represents the most direct measure of ASP
performance. Most other metrics (e.g., CDI, MDR bacteria, and cost) provide indirect assessment of
antimicrobial use. The assumption is that the higher the antimicrobial use within a hospital, the higher
the HO-CDI and antimicrobial resistance. Contrary to incidence rates of HO-CDI and infections with
MDR bacteria, institutional antimicrobial use is not affected by antimicrobials used outside the hospital.
In addition, since the incidence of HO-CDI and infections with MDR bacteria may be reduced by
Infection Prevention and Control Program efforts, antimicrobial use remains the only metric which
differentiates the performance of ASPs from other patient safety and quality teams.
3.5.2. Antimicrobial Use of Broad-Spectrum Agents
ASP priority should be given for measuring antimicrobial use of broad-spectrum agents, such as
antipseudomonal beta-lactams and carbapenems. For long-term monitoring, it would be useful to
measure collective antimicrobial use of all antipseudomonal beta-lactams (e.g., piperacillin/tazobactam,
cefepime, meropenem). This would avoid fluctuations associated with a temporary shortage of one agent.
Monitoring intravenous vancomycin use is also important given the potential risk of nephrotoxicity [14,15].
Monitoring aminoglycosides use is equally important, particularly in institutions with frequent use
of aminoglycoside combination regimens. Measurement of antimicrobial use of commonly used
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agents for treatment of community-onset infections, such as third-generation cephalosporins and
fluoroquinolones, is also useful to ensure antipseudomonal beta-lactams and carbapenems are not
completely replaced by agents which are still associated with a high risk of CDI. It would be reasonable
to monitor institutional antimicrobial use of all agents, resources permitting, in order to ensure a
decline of overall antimicrobial use in the hospital. However, most ASPs would not be bothered if the
decline in antimicrobial use of broad-spectrum agents was accompanied by an increase in antimicrobial
use of narrower-spectrum agents (e.g., penicillin G, nafcillin, ampicillin/sulbactam, cefazolin). After all,
this is reflective of their hard work in de-escalation of broad-spectrum antimicrobial therapy.
3.5.3. Benefits of Reducing Antimicrobial Use
A reduction in antimicrobial use of antipseudomonal beta-lactams and other broad-spectrum
agents is possible through syndrome-specific and other ASP interventions [72]. In addition, monitoring
antimicrobial use is also rewarding for an ASP as a decline in antimicrobial use of broad-spectrum
agents may be observed as early as 6 months following a successful intervention [72,77,78]. In the
long-term, reduction in antimicrobial use of broad-spectrum agents will result in a decline in HO-CDI
and antimicrobial resistance assuming there are no major changes in the healthcare system (e.g., referral
patterns, outpatient antimicrobial prescription rates, clusters of HO-CDI or MDR bacteria).
3.5.4. Measurement of Antimicrobial Use
There are advantages and disadvantages of using days of therapy (DOT) or defined daily dose
(DDD) as measures of antimicrobial use which are beyond the scope of this review. However, the goal
of an ASP is to optimize, rather than minimize, antimicrobial therapy. Using DDD as a measure
of antimicrobial use may punish ASPs for optimization of antimicrobial regimens in patients who
truly need high doses of antimicrobials, such as patients with serious infections and augmented renal
clearance. Conversely, institutions with relatively high rates of acute kidney injury due to heavy use of
nephrotoxic agents may benefit from measuring DDD rather than DOT. Overall, DOT seems a fair
indicator of performance for a local ASP.
An added benefit of antimicrobial use measurement is the frequent ability to stratify antimicrobial
use by location and by time. This requires detailed knowledge of the denominator used in the
generation of the antimicrobial use measurement, i.e., patient-days or the newer standard, days-present.
Such data allows antimicrobial use to be locally compared across locations, such as hospital campus
(in a multi-campus health system) or hospital unit, and by time, such as calendar month. This, in turn,
helps ASPs identify areas within the institution where antimicrobial use appears excessive and helps
design unit-specific or other targeted interventions.
4. Proposed Novel Antimicrobial Use (AU) Metrics
4.1. Adjustment of AU by Quality of Care
AU by itself is a measure of quantity, not quality of care. It would be valuable to provide reassurance
that a reduction in AU of broad-spectrum agents is not achieved at the expense of appropriateness of
therapy. Adjusting AU of broad-spectrum agents to the proportion of patients receiving appropriate





Equation (1): Antimicrobial use adjusted by quality of care as determined by appropriateness of
empirical antimicrobial therapy.
Where AUadjustedQ is the adjusted AU by quality of care at an institution, AUlocal is the raw AU at
a particular local institution; Pappropriate is the proportion of patients receiving appropriate empirical
antimicrobial therapy at that facility.
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For example, using 100 DOT/1000 patient-days of antipseudomonal beta-lactams to provide
appropriate empirical therapy to 90% of patients with gram-negative bloodstream infections at hospital
A is better than using the same amount to cover only 80% appropriately at hospital B (100/0.9 = 111
vs. 100/0.8 = 125). This formula implies it would have taken 111 and 125 DOT/1000 patient-days,
respectively, to provide appropriate empirical therapy to virtually all patients with this clinical
syndrome at hospitals A and B, respectively (Table 1). This provides an assessment of the quantitative
(AU) and qualitative (appropriateness of empirical antimicrobial therapy) performance of ASPs.
It should be noted that antimicrobial resistance rates at an institution may influence the proportion of
patients receiving appropriate empirical therapy.




Proportion o f patients with gram–negative BSI or sepsis
receiving appropriate empirical antimicrobial therapy
Carbapenems
AUCarbapenems
Proportion o f patients with gram–negative BSI or sepsis
receiving appropriate empirical antimicrobial therapy
Anti-MRSA agents
AUAnti−MRSA agents
Proportion o f patients with gram–positive BSI or sepsis
receiving appropriate empirical antimicrobial therapy
Anti-VRE agents
AUAnti−VRE agents
Proportion o f patients with gram–positive BSI or sepsis
receiving appropriate empirical antimicrobial therapy
Note: AU: antimicrobial use; APBL: antipseudomonal beta-lactams; MRSA: methicillin-resistant Staphylococcus aureus;
VRE: vancomycin-resistant Enterococcus species; BSI: bloodstream infections.
Many ASPs are currently involved in management of bloodstream infections in order to optimize
empirical therapy. The proportion of patients with bloodstream infections receiving appropriate
empirical therapy is already available at such institutions [66,69–71]. Moreover, as institutions adopt
new bundles for improvement of survival in patients with sepsis, it would be useful to measure the
appropriateness of empirical antimicrobial therapy as part of this bundle. These bloodstream infection
and sepsis cohorts may be used as representative samples for the adjustment of AU by the quality of
care received at each institution.
4.2. Adjustment of AU by Institutional Microbiological Burden
Similar to any other ASP metric, comparisons of AU across institutions are not valuable without
taking into account the differences in patient populations and microbiological burden at these
facilities. For example, there is a wide variation in the incidence of P. aeruginosa among gram-negative
bacteria at various institutions with higher incidence at tertiary care referral centers than community
hospitals [79]. Since broad-spectrum antimicrobial agents are used to treat infections due to certain
bacteria (e.g., antipseudomonal beta-lactams for P. aeruginosa), it is reasonable to adjust for the incidence






Equation (2): Antimicrobial use adjusted by microbiological burden at the institution.
Where AUadjustedM is the adjusted AU of antipseudomonal beta-lactams by microbiological burden
at an institution, AUlocal is the raw AU of antipseudomonal beta-lactams at a particular local institution,
Ilocal is the incidence of the relevant organism(s) (i.e., P. aeruginosa) at that local institution, and Ioverall is
its average incidence within the overall network or region.
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As an example, AUlocal of antipseudomonal beta-lactams at hospitals A (tertiary care medical
center) and B (rural community hospital) are both reported as 100 DOT/1000 patient-days. The Ioverall is
0.12 (12% of all gram-negative isolates within this network or region are P. aeruginosa, for instance).
Ilocal for hospitals A and B are 0.15 and 0.09, respectively. AUadjustedM of antipseudomonal beta-lactams
at hospitals A and B could then be calculated as 100/(0.15/0.12) = 80 and 100/(0.09/0.12) = 133,
respectively. The adjustments indicate that hospitals A and B would have utilized 80 and 133 DOT/1000
patient-days of antipseudomonal beta-lactams, respectively, if the proportion of P. aeruginosa isolates at both
institutions were comparable to the overall network/regional average. Using 100 DOT/1000 patient-days
of antipseudomonal beta-lactams may be justifiable in hospital A due to high microbiological burden,
but seems excessive in hospital B.
Similar adjustments may be made for AU of anti-MRSA agents relative to the proportion of MRSA
among all gram-positive isolates and AU of carbapenems based on proportion of ESBL-producing or
ceftriaxone-resistant E. coli, Klebsiella species, and Proteus mirabilis (Table 2).




AUAPBL( Incidence o f P. aeruginosa at local institution
Average overall incidence o f P. aeruginosa in network
)
Carbapenems
AUCarbapenems( Incidence o f ESBLE at local institution
Average overall incidence o f ESBLE in network
)∗
Anti-MRSA agents
AUAnti−MRSA agents( Incidence o f MRSA at local institution
Average overall incidence o f MRSA in network
)
Anti-VRE agents
AUAnti−VRE agents( Incidence o f VRE at local institution
Average overall incidence o f VRE in network
)
Note: AU: antimicrobial use; APBL: antipseudomonal beta-lactams; ESBLE: extended-spectrum beta-lactamase-
producing Enterobacteriaceae; MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant
Enterococcus species. * If microbiology laboratories in one or more hospitals in the network do not perform
the ESBL screening test, then the incidence of ceftriaxone-resistant Enterobacteriaceae may be used alternatively to
calculate adjusted carbapenem utilization in all hospitals in the network.
To our knowledge, these novel AU metrics in Section 4 have not been proposed in prior reviews
of the literature. While their simple calculation is logical and represents a reasonable approach to AU
interpretation, further research is warranted to validate these metrics in the clinical setting.
5. NHSN Antimicrobial Use and Resistance Module
The US Centers for Disease Control and Prevention (CDC) NHSN offers an antimicrobial use and
resistance module with AU and AR options [80,81]. Facilities can participate in one or both options,
but at this time, neither is required.
5.1. Antimicrobial Use (AU) Option
The AU option facilitates risk-adjusted inter- and intra-facility benchmarking of antimicrobial
use [80]. Primarily, antimicrobial use is measured as antimicrobial DOT/1000 days-present. Antimicrobial
use is aggregated by month for each patient care location and facility-wide. Antimicrobial use is
also separated by the spectrum of the antimicrobials into 6 categories (Table 3). The data are then
analyzed, and facilities receive a Standardized Antimicrobial Administration Ratio (SAAR) for each
category and total antimicrobials in each patient care location and facility-wide. A SAAR of 1 indicates
antimicrobial use is equivalent to referent populations. A SAAR greater than 1 that achieves statistical
significance demonstrates excessive antimicrobial use, and a SAAR significantly lower than 1 may
demonstrate underuse. SAAR still does not take into account quality of care (e.g., appropriateness of
antimicrobial therapy). It does, however, attempt to control for institutional specifics, such as hospital
222
Antibiotics 2019, 8, 127
size and complexity of patient population. The ability to look specifically at the different categories of
antimicrobials is important, as ASPs are focused on decreasing broad-spectrum antimicrobials and
increasing use of narrow-spectrum agents. This still constitutes a positive change for the institution,
especially if SAAR for overall antimicrobials is equivalent to, or smaller than, 1, as it implies successful
de-escalation from broad- to narrower-spectrum agents.
Table 3. Centers for Disease Control and Prevention National Healthcare and Safety Network
antimicrobial use module categories.
Category Commonly Used Antimicrobials
Broad-spectrum agents predominantly used
for hospital-onset infections
Piperacillin/tazobactam, ceftazidime, cefepime, meropenem,
imipenem/cilastatin, aztreonam, gentamicin, tobramycin
Broad-spectrum agents predominantly used
for community-acquired infections
Ceftriaxone, cefotaxime, cefuroxime, cefdinir, ertapenem,
ciprofloxacin, levofloxacin, moxifloxacin
Agents predominantly used for resistant
gram-positive infections Vancomycin, daptomycin, linezolid, ceftaroline
Narrow-spectrum beta-lactam agents
Penicillin G, ampicillin, amoxicillin, ampicillin/sulbactam,
amoxicillin/clavulanate, nafcillin, dicloxacillin, cefazolin,
cephalexin, cefoxitin
Agents posing the highest risk for
C. difficile infection
Clindamycin, cefepime, ceftriaxone, cefdinir, ciprofloxacin,
levofloxacin, moxifloxacin
Antifungal agents predominantly used for
invasive candidiasis
Fluconazole, voriconazole, posaconazole, caspofungin,
micafungin, anidulafungin
An example of such a comparison is provided in Figure 1. Such a line graph allows for a local ASP
to evaluate their SAAR data over time. The monthly SAAR for all adult antibacterial agents facility-wide
is in bold as an overall metric for antimicrobial use. Relevant subcategories are then superimposed on
the same graph to allow for simple visual comparison and analysis by the ASP. Because subcategories
for antibacterial agents are only available from NHSN for either adult intensive care units (ICUs)
(Figure 1A) or adult wards (Figure 1B), the two line graphs are generated to assess antimicrobial use in
each unit type. In this example, the adult facility-wide SAAR for overall antimicrobials remains below 1
for the entire time period. Broad-spectrum antimicrobials in adult ICUs are also consistently under 1,
yet use of narrow-spectrum beta-lactams in adult ICUs is routinely above 1.0. This suggests that the
observed use of agents such as penicillin G, ampicillin, nafcillin, and cefazolin was significantly greater
than predicted by the NHSN model. Again, this antimicrobial use metric cannot assess quality of
care. In order to distinguish whether this narrow spectrum beta-lactam use represents an appropriate
de-escalation that an ASP can celebrate, versus an aggressive de-escalation which needs to be addressed
by the ASP, this SAAR data would have to be coupled with quality of care data from the ICUs, e.g.,
appropriateness of therapy as previously discussed. In this way, SAAR data can reveal interesting
nuances to guide local ASP assessments and subsequent initiatives.
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(A) 
(B) 
Figure 1. (A) Standardized Antimicrobial Administration Ratio (SAAR) report for all and select
categories of antibacterial agents in adult intensive care units (ICUs) at a community-teaching hospital.
(B) Standardized Antimicrobial Administration Ratio (SAAR) report for all and select categories of
antibacterial agents at adult wards at a community-teaching hospital.
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5.2. Antimicrobial Resistance (AR) Option
Facilities reporting to the AR option will receive a facility-wide antibiogram that can be stratified
by source, time period, and specific antibiotics or organisms [80]. Participating facilities will also get
a line list generated for all AR events including items such as date of birth, gender, specimen type,
and organism. The benefits of this option for tracking the success of an ASP is similar to tracking
MRSA, ESBLE, CRE, and resistance among P. aeruginosa and A. baumannii isolates. While short-term
changes may be difficult to visualize, it may be possible to show long-term success. It also allows for
benchmarking with other similar institutions. Both the AU and AR modules within the NHSN are
promising ASP metrics with different potential uses.
6. Discussion
Historically, direct measurement of antimicrobial use was not feasible for most institutions; thus,
surrogate metrics such as HO-CDI incidence and cost were derived. The assumption was that higher
incidence rates of HO-CDI and infections due to MDR bacteria reflected excessive antimicrobial use
of broad-spectrum agents at an institution. However, in the era of electronic medical records and
progressive advancements of healthcare informatics, direct measurement of antimicrobial use has
become a reality. CDC/NHSN module for reporting antimicrobial use and antimicrobial resistance
provides the tools for direct measurements of ASP daily work and overall performance. Despite some
initial hurdles, hospitals and ASPs are both determined to make this breakthrough advancement in the
field of antimicrobial stewardship by improving ASP metrics. Adjustments of antimicrobial use by
quality of care and institutional microbiological burden will evolve with time. Practical adjustment
formulas, which demonstrate validity and generalizability across a broad mix of hospital types and
geographical locations, will prove most useful.
ASP metrics may be classified into direct measures of ASP performance and global metrics for
overall healthcare system evaluation. Antimicrobial use of broad-spectrum agents represents the
primary direct ASP metric. Secondary direct metrics include incidence rate of CRE and antimicrobial
resistance of predominantly hospital-onset pathogens, such as P. aeruginosa and A. baumannii (Table 4).
Table 4. Direct antimicrobial stewardship metrics.
ASP Metrics Description





• Most direct measure of ASP performance
• Evaluates effectiveness of ASP interventions
(e.g., syndrome-specific, prospective audit and feedback,
de-escalation of therapy)
• Measures both empirical and definitive therapy
• Adjustments by quantity (facility size, patient population,
or microbiological burden) and quality (appropriateness of
therapy) at each healthcare facility are possible




• Antimicrobial resistance of hospital-onset bacteria is associated
with use of broad-spectrum antimicrobials at each institution
• Antimicrobial resistance may also be influenced by referrals,
especially at tertiary care centers
• Patient-to-patient transmission of MDR bacteria may be reduced
by effective infection prevention and control methods
Incidence rate of CRE
• Excessive use of carbapenems and other broad-spectrum
antimicrobials increases risk of CRE infections or colonization
• CRE rates may be influenced by transfers from other hospitals or
skilled nursing facilities
• Infection prevention and control programs are essential for
reducing transmission of CRE in healthcare facilities
Note: ASP: antimicrobial stewardship programs; MRSA: methicillin-resistant Staphylococcus aureus; VRE:
vancomycin-resistant Enterococcus species; MDR: multi-drug resistant; CRE: carbapenem-resistant Enterobacteriaceae.
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In addition to these direct metrics, global metrics, including rates of CDI, MRSA, ESBLE, as well
as cost of healthcare, should continue to be used in order to evaluate overall performance of healthcare
systems (Table 5).
Table 5. Global metrics of overall healthcare system performance.
Global Metrics Description
Incidence rate of hospital-onset
Clostridioides difficile infection
• Indirect assessment of quantity and spectrum of AU in
healthcare facilities
• Tool for evaluation of IPCPs, clinical decision support programs,
laboratory, and diagnostic stewardship
Incidence rate of ESBLE infections
or colonization
• ESBLE predominantly cause community-onset infections in North
America and Europe
• Better metric for ambulatory ASPs and IPCPs than inpatient ASPs
• Rates are influenced by prior colonization
Incidence rate of MRSA infections
or colonization
• MRSA has emerged as community-onset bacteria as well
• Association between MRSA and AU is not very clear
• Measures performance of IPCPs more than ASPs
Sepsis or bloodstream infection
case-fatality rate
• Evaluates clinical, diagnostic, and interventional critical care skills;
clinical decision support programs; and laboratory diagnostics,
including microbiology
• ASPs may influence only one of many variables that determine
outcome, that is, empirical antimicrobial therapy through
institutional management guidelines and other interventions
Cost of healthcare
• Antimicrobial cost is a fraction of total healthcare cost
• ASPs may indirectly contribute to reduction in healthcare cost by
reducing length of hospital stay through selection of appropriate
empirical antimicrobial therapy and reducing risk of antimicrobial
adverse events such as acute kidney injury and C. difficile infection
Note: ASP: antimicrobial stewardship programs; AU: antimicrobial utilization; ESBLE: extended-spectrum
beta-lactamase-producing Enterobacteriaceae; IPCP: infection prevention and control program.
7. Conclusions
In this new era of antimicrobial stewardship, direct measurement of ASP performance is feasible
and preferable. Antimicrobial use within an institution represents the most direct and specific
antimicrobial stewardship metric for hospital-based ASPs. Antimicrobial resistance of predominantly
hospital-onset bacteria, such as P. aeruginosa and A. baumannii, represents a secondary antimicrobial
stewardship metric. Participation of US hospitals in currently available CDC/NHSN modules for
antimicrobial use and resistance is highly encouraged and represents a valuable step to improve
antimicrobial stewardship at the national level. Novel stewardship metrics presented in this review
allow adjustment of antimicrobial use by microbiological burden and quality of care as measured by
appropriateness of empirical antimicrobial therapy at each institution. This enhances the antimicrobial
stewardship mission in improving both the quantity and quality of patient care.
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Abstract: The alarming spread of multiresistant infections has kick-started the quest for alternative
antimicrobials. In a way, given the steady increase in untreatable infectious diseases, success in this
endeavor has become a matter of life and death. Perhaps we should stop searching for an antibacterial
panacea and explore a multifaceted strategy in which a wide range of compounds are available on
demand depending on the specific situation. In the context of this novel tailor-made approach to
combating bacterial pathogens, the once forgotten phage therapy is undergoing a revival. Indeed,
the compassionate use of bacteriophages against seemingly incurable infections has been attracting
a lot of media attention lately. However, in order to take full advantage of this strategy, bacteria’s
natural predators must be taken from their environment and then carefully selected to suit our needs.
In this review, we have explored the vast literature regarding phage isolation and characterization
for therapeutic purposes, paying special attention to the most recent studies, in search of findings
that hint at the most efficient strategies to identify suitable candidates. From this information, we
will list and discuss the traits that, at the moment, are considered particularly valuable in phages
destined for antimicrobial therapy applications. Due to the growing importance given to biofilms
in the context of bacterial infections, we will dedicate a specific section to those characteristics that
indicate the suitability of a bacteriophage as an antibiofilm agent. Overall, the objective is not just to
have a large collection of phages, but to have the best possible candidates to guarantee elimination of
the target pathogens.
Keywords: bacteriophages; biofilms; novel antimicrobials
1. Phage Therapy: A Major Comeback with Minor Setbacks
The existence of viruses that can infect and kill bacterial cells, known as bacteriophages (or phages),
was discovered almost simultaneously by Frederick Twort and Félix d’Herelle about one century
ago, but it is the latter who has been credited with introducing the concept of using these entities
as antimicrobial agents [1,2]. Indeed, the French-Canadian microbiologist pioneered the so-called
phage therapy and used phages to treat patients with various infectious diseases [3]. Since that time,
the utilization of phages for therapeutic applications has remained common practice in Eastern Europe,
saving countless human lives [4]. Conversely, in other parts of the world, the introduction of antibiotics
pushed this anti-infective strategy out of center stage for many decades. After all, antibiotics were
cheaper to manufacture and exhibited a broader spectrum of activity, thereby eliminating the need
to identify the etiological agent prior to treatment prescription. However, with time, overuse and
misuse of antibiotics became widespread in different fields, such as human and veterinary medicine
or agriculture. In this context, antibiotics exerted the selective pressure that resulted in the spread of
Antibiotics 2019, 8, 126; doi:10.3390/antibiotics8030126 www.mdpi.com/journal/antibiotics233
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resistance markers and led up to the current antimicrobial resistance crisis [5]. Alarmingly, the number
of deaths associated with bacterial infections is rising and threatens to reach levels not seen since the
preantibiotic era. The reason for this is that more and more bacterial strains are acquiring multiresistance
and are, consequently, able to survive treatment with most, if not all, antibiotics commonly used
in the clinic. Given the severity of such a scenario, besides curtailing unnecessary antibiotic use,
the scientific community has started a race to find as many alternatives to conventional antibiotics as
possible [6]. Among the many options being explored, the revival of phage therapy presents itself
as an attractive strategy to substitute or complement other therapies [7]. This is especially the case
because phages, due to their unique mechanism of action, exhibit some notable differences compared
to other types of antimicrobials, some of which are particularly advantageous. These positive attributes
include their natural origin, lack of toxicity for humans or nontarget microbes (being harmless to
the normal microbiota), and their effectiveness against antibiotic-resistant bacteria, amongst others.
On the downside, phage therapy generally requires identification of the target pathogen and phage
resistance development remains a possibility, although it is not usually as easily transferable to other
microorganisms as antibiotic resistance determinants. Moreover, resistance could be easily overcome
by using combinations of different phages (phage cocktails) instead of a single phage for therapeutic
applications [8].
Nonetheless, not everything is rosy on the way toward normalizing the use of bacteriophages
against unwanted bacteria in the context of human medicine. Most notably, it will be paramount to
convince both the general public and the competent authorities that these antimicrobials are safe for
human health and the environment, as well as provide undeniable proof of their efficacy in clinical
settings. Indeed, these are two key aspects in order to surmount the current regulatory constraints
that limit the use of bacterial viruses for infection treatment in humans. Until relatively recently,
most evidence regarding the effectiveness of phage therapy was the result of direct use in patients,
but well-organized and reproducible data will be essential in order to comply with the requirements
set out for the approval of medicinal products [9]. In this regard, the growing number of completed
clinical trials will certainly be invaluable. On the other hand, the growing utilization of phages
as biocontrol agents for the disinfection of inert surfaces may also help to pave the way toward
regulatory approval [10]. As a matter of fact, the relevant authorities in different countries (USA, Israel,
Canada, Switzerland, Australia, New Zealand, and the Netherlands) have already approved this type
of applications against several pathogens in the context of the food industry [11,12]. For example,
there are several commercially available products to be used against various food pathogens, such as
Listeria monocytogenes, Salmonella, or Escherichia coli, as surface disinfectants or processing aids. Indeed,
the FDA has recognized some phage-based formulations as “generally regarded as safe” (GRAS) as
food additives. Regarding medicinal use, phage therapy is now under the scrutiny of government
agencies, which are trying to determine the most adequate regulatory framework considering the
special characteristics of phages. In the meantime, patients in many countries can have access to this
treatment as compassionate use [13]. One of the major challenges of regulating phage approval is the
diversity of phages that will be necessary to successfully implement this therapeutic strategy. Indeed,
in order to harness the full potential of phage therapy and its adaptability to changes in pathogenic
strains, there should be room for making changes to phage-based formulations without the need for a
lengthy and costly approval process. In addition to regulatory hurdles, bringing phage therapy to the
market also has the problem of not being very attractive for pharmaceutical companies. To some extent,
this is a consequence of their natural origin, as phages cannot be patented. Also, their use is aimed to
be used as an acute course of treatment rather than for chronic administration, which obviously means
that they would not be as profitable as other medicines. However, the relevant authorities can help by
designing an affordable and straightforward pathway for regulatory compliance that might perhaps
encourage the participation of smaller specialized companies.
Overall, it is apparent that phages are getting closer and closer to becoming a mainstream
antimicrobial treatment option, especially in the case of difficult-to-cure multiresistant infections.
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However, in order to get the most out of phage therapy, we will need to have an arsenal of well-chosen
effective and safe bacteriophages at our disposal. This will involve a number of steps that, if not
carefully planned, may hinder the successful development and subsequent implementation of this
strategy (Figure 1). In order to maximize speed and minimize costs, it is necessary to establish clear
guidelines indicating where and how to look for suitable therapeutic phages, as well as define the
most valuable traits in the identified candidates.
Figure 1. Steps involved in the development of phage therapy strategies. In the phage characterization
step, text in green and red respectively correspond to desirable and undesirable characteristics in a
phage for therapeutic applications. Abbreviations: SBS method, step-by-step method.
2. In Search of New Phages
One of the main advantages of using bacteriophages as antimicrobials is their sheer quantity and
diversity. As a matter of fact, even without improvement by genetic engineering, nature represents an
almost limitless source of new phage variants. It is well known that phages are the most abundant
biological entities on earth (about 1031 phages in total) [14]. On top of that, bacterial viruses evolve
at a dizzying rate and are, as a result, highly diverse. Indeed, there is evidence indicating that
bacteriophages outpace their hosts in the coevolutionary race [15]. Now, this all sounds like good news
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from the perspective of the antimicrobial development pipeline until coming to the realization that
finding the right phages for our purpose among this huge set of candidates is quite the gargantuan
task. Nevertheless, it is also worth noting that vast phage collections are already available in different
research centers and universities around the globe. As a result, this would be a good place to start once
the target microbe is identified.
It is obviously impossible to screen for phages everywhere, so a major step consists in narrowing
down the most probable reservoirs of viruses that infect and kill our target microbe. As is always the
case with predators, these reservoirs are likely to coincide with the main habitats of their prey, that
is, the target pathogen. In that sense, d’Hérelle suggested that the best source of bacterial viruses for
antimicrobial applications are samples from patients who are recovering or who have just recovered
from an infection [16]. Indeed, he first remarked the existence of “bacteria eaters” in stool samples of
patients recovering from bacillary dysentery [1]. Similarly, phages against enterohemorrhagic E. coli
(EHEC) O157:H7 were found in fecal samples from human patients and cattle [17]. Additionally, phages
infecting Cutibacterium acnes (formerly Propionibacterium acnes) and Actinobacillus have respectively
been isolated from human skin and dental plaque [18,19]. Given the prevalence of human pathogenic
bacteria in infected patients, another good reservoir of phages infecting these microorganisms is
wastewater from hospitals [20]. If clinical samples are not available, good results have also been
obtained with sewage water, which has actually become a frequent starting point for phage hunts [21].
In the case of microbes with high prevalence in diverse ecological niches, different environmental
sources like river or stream water have also been the place to isolate new bacteriophages [22,23].
Additionally, drinking water was the source of phages infecting Enterococcus and Staphylococcus [24],
while silage from dairy farms proved a good source of listeriaphages [25].
In some cases, the phage titer in these reservoirs will be high enough to allow direct isolation of the
virus after filtration of the sample; for example, by visualization of lysis plaques on plates containing the
host (double layer assay). However, this is not always the case and enrichment steps are often required
to detect the presence of the phage. Frequently, it is a good idea to collect large-volume samples in
order to increase the chances of phage isolation, especially when dealing with samples taken from
environmental sources. It must also be noted that some phages form very small plaques on a bacterial
lawn, which would hinder their identification by the double layer method. For this reason, if no plaques
are observed during the isolation step, it might be worth repeating the process but using techniques
that increase plaque size, such as addition of subinhibitory concentrations of antibiotics [26,27] or other
compounds like sodium thiosulfate, ferric ammonium citrate or 2,3,5-triphenyltetrazolium [28].
Another important aspect in the quest to find new phages with antimicrobial potential lies in
the selection of the most appropriate host strain or strains. However, this choice will also depend on
the specific goal of the search. Thus, if the objective is the identification of phages against as many
strains of a given pathogen as possible, multihost selection protocols should be used. Additionally,
the host strains should preferably be very varied in terms of their characteristics and origin so that they
are representative of the species. In this sense, Casey et al. [29] recommend using bacteria reference
collections for phage identification, as they offer a good representation of the intraspecies diversity,
together with strains of clinical relevance. However, in some cases, there may be a specific target strain
or group of strains that do not seem to be susceptible to the phages available in different collections.
Then, it will be necessary to carry out screenings using these strains as selection hosts. Nonetheless,
if finding a new virulent phage that infects our target strain proves to be very difficult, it is possible
to carry out an adaptation strategy in which coevolution rounds may allow the selection of a phage
variant that can effectively infect and kill the pathogenic strain. This protocol is called the step-by-step
(SBS) method [30]. The phenomenon of local host adaptation also plays a role in the identification of
new phages [31]. Indeed, phages are known to co-evolve very closely with their host strains. As a
result, virulent phages from a given reservoir or geographic location are oftentimes more effective at
targeting strains from that same milieu.
236
Antibiotics 2019, 8, 126
3. Desirable Traits in Phages with Antimicrobial Potential
3.1. Specific but Not Too Specific
One of the major advantages of bacteriophages as antimicrobials is their specificity. A consequence
of this characteristic is that they are not only innocuous to eukaryotic cells, but also to all prokaryotic
cells outside their host range. This would ensure that the normal microbiota remains intact during
therapy, which in turn would be expected to help prevent secondary infections and probably accelerate
recovery. Indeed, there is growing proof that the microorganisms inhabiting our bodies play very
important roles in our overall health. Antibiotic treatment, by contrast, can severely affect our normal
microbiota due to their more general, broad-range action, which often results in serious side effects [32].
Another benefit of this specific action is that we can technically try to identify viruses that only
infect certain strains within a bacterial species, distinguishing, for example, between pathogenic and
nonpathogenic isolates. Again, some microbes can potentially be helpful or harmful to their human
hosts depending on the presence of sometimes only a few genes that turn them from friend to foe.
As a result, it would be ideal to develop antimicrobials that can differentiate between commensal and
pathogenic strains of the same species.
Notwithstanding the incredible target precision that can be achieved with phage therapy, it is
generally preferable to isolate viruses able to attack a wide range of strains within a bacterial species.
In some cases, it may also be desirable that a given phage can infect different pathogenic species
within a genus. Staphylococcal phages are a good example of this, with some of them infecting the
two opportunistic pathogens Staphylococcus aureus and Staphylococcus epidermidis, such as myophages
phiIPLA-RODI and phiIPLA-C1C [33]. The polyvalent nature of staphylophages is also useful since it
allows carrying out phage propagation on nonpathogenic species, such as Staphylococcus xylosus [34].
Remarkably, there are phages capable of infecting different genera within the Enterobacteriaceae family,
including E. coli O157:H7, Salmonella enterica ser. Paratyphi, and Shigella dysenteriae [35].
At first glance, it would appear that having a broad host range would be a synonym of success for
a bacteriophage, as it would increase its likelihood of encountering a susceptible bacterial cell, which is
necessary for survival of the phage population [36]. However, this hypothesis is not supported by
the available experimental data. Thus, the ability of a given phage to infect and multiply inside a
host depends on factors from both prey and predator. As mentioned previously, some studies have
observed a very well-tuned coevolution, leading to local specificity in phage–host interactions [31].
Indeed, there is evidence that greater specialization can be linked to increased infection efficacy and
the other way around, which suggests that there is an evolutionary compromise between these two
properties [37,38]. Therefore, while it is possible to broaden the host range of a given phage, this might
lead to a “weaker virus” that cannot propagate as efficiently.
In any case, a bacteriophage used for therapeutic applications should at the very least be able
to infect the different variations of the pathogen population inside the patient. As this is not always
possible with single-phage preparations, the use of a phage cocktail, if available, is always a better
option. Interestingly, study of the coexistence dynamics between the cyanobacterium Prochlorococcus
and ten cyanophages revealed that acquisition of resistance to one phage sometimes resulted in
enhanced infection by other phages [39]. In some cases, the authors could demonstrate that this was
due to the increased adsorption of “the other phages” to the phage-resistant mutants than to the
original bacterial strain. If this phenomenon is also observed in therapeutic phages, it would be useful
in the context of phage cocktail administration, as it would manifest itself as a synergic rather than an
additive effect between the different viruses. Identification of the potential phage receptors in the host
is an important aspect of designing a phage cocktail. Evidently, it would be better to have experimental
evidence of the nature of the receptor for a specific phage. However, if this information is not available,
there are now resources to predict potential receptor molecules based on the phage genome data and
information from literature or databases [40,41]. Indeed, it would help to avoid combining phages
that can potentially exhibit cross-resistance. Moreover, it would be preferable to select phages whose
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target receptors are essential for bacterial fitness or virulence as the likelihood of phage resistance
selection will be lower or, at the very least, might lead to lesser pathogenicity. Furthermore, if there is
receptor modification, the probability of phage variants that can infect the altered receptor are much
higher than they are in cases of receptor loss, a possibility with nonessential receptor molecules [42].
Indeed, infectivity evolution in phages during therapeutic applications should be studied more in
depth. Especially, because it provides a unique opportunity of using an evolving antimicrobial that
can potentially overcome by itself bacterial resistance mechanisms during therapy [42].
Another strategy for limiting phage resistance is the selection of phages harboring modified
nucleotides, like archeosine or N6-(1-acetamido)-adenine, in their genomes. This would make the
viral DNA resistant to the activity of many restriction endonucleases, one of bacteria’s natural
antiphage defense systems [43]. A hint of this trait can be found during genome sequencing
through the identification of genes involved in the biosynthesis of these nucleotides. For instance,
recent studies showed that siphophages Vid5 and BRET, which respectively infect the enterobacteria
Pantoea agglomerans and E. coli, carry archeosine biosynthesis genes [44,45].
3.2. Virulent Phages Only, Please
In addition to the lytic cycle, which ends up with the death of the bacterial cell, some bacteriophages
can also undergo the so-called lysogenic cycle. In this case, the viral genome integrates into and
replicates with the bacterial chromosome. The viral genetic material, known as prophage, can stay in
this state for generations until an environmental signal turns on the machinery leading to its excision
from the bacterial genome and kick-starts the lytic cycle. This type of phage is called temperate and
they are known to actively contribute to the phenomenon of horizontal gene transfer, one of the
main mechanisms involved in the spread of antimicrobial resistance and virulence genes. As a result,
temperate phages are not considered good candidates for phage therapy. In contrast, phages that
can only undergo the lytic cycle, or virulent phages, are ideal for this purpose, as their multiplication
is almost always followed by lysis of the infected cell. These phages are also sometimes called
“professionally lytic” [46]. During the phage selection process, virulent and temperate phages can
tentatively be differentiated as they respectively produce clear and turbid plaques on a bacterial lawn.
In some cases, phages that can infect and kill the target organism, especially if it is a specific
strain, are scarce and utilization of virulent derivatives from temperate phages is required. This
can be achieved by selecting or constructing mutant phage variants through different protocols.
For example, phage deletion mutants can be easily isolated by exposing the phage particles to several
rounds of a chelating agent such as ethylenediaminetetraacetic acid (EDTA), sodium citrate, or sodium
pyrophosphate [47]. Chelating agents exert a destabilizing effect on the phage particles by binding the
cations located on their surface, which results in conformational defects and, ultimately, in viability
loss. However, viral particles carrying deletions in their genome are smaller and can retain their
conformation and remain viable under these conditions. From the selected deletion mutants, it would
be then possible to identify the virulent variants, as they would produce clear instead of turbid
plaques. Alternatively, phages can be genetically manipulated to obtain a virulent variant by removing
genes involved in lysogeny. Indeed, a cocktail containing engineered phages successfully eliminated
an infection by a drug-resistant strain of Mycobacterium abscessus from a cystic fibrosis patient [48].
However, the use of genetically modified organisms is still shrouded in controversy and is not even a
viable option in many countries.
Nevertheless, strictly virulent phages are not completely free from the danger of facilitating
transfer of antibiotic resistance genes. For instance, Keen et al. [49] recently described the existence of
“superspreader” virulent phages, which do not carry endonucleases in their genome and release the
bacterial DNA to the environment. This would make it possible that this now extracellular DNA can
enter other microorganisms by natural transformation and potentially spread resistance or virulence
markers. In fact, this study reported that addition of the phage to cocultures of a kanamycin-sensitive
Bacillus sp. and kanamycin-resistant E. coli strains led to a 1000-fold increase in transfer of the antibiotic
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resistance marker to Bacillus. This would not be a desirable situation so it would be important to ensure
that a phage with therapeutic potential does degrade the bacterial chromosome prior to cell lysis.
Once confirmed that a candidate phage is strictly virulent and not a superspreader, the next step
is to determine if it can propagate efficiently both in vitro and in vivo. First, it is necessary to study
propagation under in vitro conditions, for example, by performing a one-step growth curve. This
technique requires achieving the synchronous infection of all bacterial cells in a population in order
to then monitor how the number of extracellular and intracellular viable phage particles changes
throughout the lytic cycle. This data will allow calculation of valuable propagation parameters, such
as burst size (average number of new phage particles released per infected cell) and latent period
(part of the lytic cycle between virion attachment to the cell and start of new phage particle release).
In some cases, a shorter latent period has been associated with the possession of DNA-dependent RNA
polymerases in the phage genome [50]. Theoretically, this protein might shut down host transcription
and increase the efficiency of the phage replication cycle, although this phenomenon has not been
supported by experimental evidence yet. After confirming that the phage can propagate under in vitro
conditions, which is essential for phage production, in vivo experiments should be performed to
confirm that the virus can also multiply effectively at the infection site if the target host is present. This
ability to self-propagate during treatment is undoubtedly a major advantage compared to other types
of antimicrobials, whose concentration invariably decreases after administration to the patient.
3.3. Safe for Human Health and the Environment
Following the isolation of a phage with therapeutic potential, it is necessary to perform genome
sequencing and analysis. Thanks to the advances made in this field, this has become an easy and
affordable task that can actually save us a lot of time and money on additional experiments. On the
one hand, examination of the phage genome can confirm that there are no genes involved in lysogeny,
such as the lytic cycle repressor, integrases or site-specific recombinases. Identification of genes
encoding potential endonucleases can also suggest that it is not a “superspreader”. On top of that,
genomic analysis is the single most reliable way to know whether the phage genome encodes toxins or
antimicrobial resistance determinants. Indeed, if there are any such genes, the phage should never be
considered for therapeutic applications. If possible, it is also preferable to choose a propagation host (a
so-called surrogate strain) that does not carry prophages or virulence/antibiotic resistance markers [51].
Besides not being carriers of “bad genes”, bacteriophages must be innocuous when administered
to the patients. As mentioned above, one key aspect of phages as therapeutics is the fact that they
do not infect nontarget bacteria, leaving the normal microbiota largely undisturbed after therapy.
Regarding their safety for the patient, all clinical trials so far indicate that they do not exhibit significant
toxicity. Nonetheless, it is worth noting that phages need to be well purified in order to remove toxic
substances before administration. A clear example of this is endotoxin, which could lead to serious
side-effects if not thoroughly removed from the phage suspension. The importance of endotoxin
removal depends, however, on the type of application. For example, it is essential for intravenous
administration, while purification does not need to be so strict for topical or oral administration to the
patient [51,52]. In that sense, it is also important to consider the potential effect of widespread lysis of
the target bacteria inside the patient. It is worth noting, however, that studies in which filtered lysates
were administered directly to patients without further purification led to mild or, most frequently,
no symptoms [53]. Overall, the available data suggests that the doses required for bacteriophages to
trigger toxicity exceed the effective concentrations necessary for their application. This holds true
not only for the administered doses but also considering the propagation inside the patient. As such,
phages typically exhibit a high therapeutic index, a quantitative measurement of the relative safety of a
drug, which is obtained as the ratio between the dose leading to toxicity and the amount that displays
antimicrobial activity.
Due to the relative simplicity and lack of diversity of bacteriophages in terms of their chemical
composition, basically consisting of proteins and nucleic acids, their potential interactions with the
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immune system are relatively easy to study and predict in stark contrast to other types of antimicrobials.
Given that the outward structure of the viral particle consists basically of proteins, phages can be
immunogenic. This issue would be especially problematic when intravenous (i.v.) administration is
required, as it could potentially lead to an anaphylactic response. However, i.v. administration of
phages has been performed repeatedly without observing major negative side effects [52].
Widespread phage application as an antimicrobial also poses questions regarding its potential
impact on natural environments [54]. Indeed, it is very important to assess the risk of altering the
composition of natural microbial communities due to the release of phages from clinical, veterinary
or agricultural applications. These changes could be deleterious to ecosystems as they might alter
nutrient cycling. Given the structure of these communities, an impact of phages on soil ecological
dynamics (phage to bacteria ratios of 1:1) would be more expected than on aquatic communities (phage
to bacteria ratios of 1:100). However, this disruptive effect would be expected to be much lower than
that of antibiotics given the specificity of bacteriophage activity.
A key aspect to ensure the safety of phages aimed for therapeutic applications is the development
of well-defined bacteriophage production and quality control protocols that allow manufacturing
of pharmaceutical-grade phage products [55]. These methods should maximize phage yield in the
production stage followed by highly effective purification steps [55,56]. Thus, while satisfying health
and environmental concerns should be a priority, the economic viability of industrial phage production
must also be taken into account. All of these steps are also very important in order to achieve regulatory
approval of phage-based formulations [57].
3.4. Stability
As mentioned above, phage particles consist of a nucleic acid molecule inside a proteinaceous
envelope. As such, they are much more complex and labile compounds than other antimicrobials.
This fact makes them unstable outside a specific range of environmental conditions (temperature, pH,
UV-light, salt concentrations, proteases). Thorough analysis of phage particle stability is, therefore, an
integral part of the phage characterization process. For example, a very effective virulent phage that
has a very narrow stability range may not be well suited for therapy. Indeed, the viral particles must be
able to withstand the production, storage and administration stages in sufficient numbers to reach their
target. However, the conditions that allow phage stability maintenance vary enormously depending
on the specific phage [58]. In fact, it appears that neither family nor close structural similarity are
good predictors of stability range, although tailed phages generally seem to be the most stable under
adverse environmental conditions [59].
After propagation, the bacteriophage should remain viable and infective throughout storage.
As mentioned above, specific storage conditions have to be tested for each phage, as they may vary
depending on its characteristics. For example, different storage temperatures are better suited for
different phages [59]. Thus, while some are more stable at temperatures around 4 ◦C, others must be
kept at freezing temperatures of −20 ◦C or even −80 ◦C. In contrast, some phages exhibit very good
stability at room temperature or even 37 ◦C. Another important factor is the format for storing the
phage particles. For instance, some phages remain viable for longer periods of time when stored in
a liquid (which can be growth medium or a buffer). An alternative possibility is storing the phage
particles in a dry powder, which can be produced by different techniques such as lyophilization (freeze
drying) or spray drying. In this case, it is necessary to consider that the drying process itself may be
deleterious for the viral particles, which might lead to a considerable titer loss prior to storage [22,60].
Sometimes, preservation in both liquid and dry form can be improved by adding different stabilizing
agents, such as skim milk, glycerol, trehalose, or sorbitol [61]. Alternatively, the phages can be kept
as a nucleic acid inside infected cells, which can then be stored frozen at −80 ◦C [62]. The lytic cycle
would continue as soon as bacterial growth is resumed. However, González-Menéndez et al. [60]
showed that this technique does not always improve phage particle stability compared to storage
of the naked phages. Some studies have also shown that phage encapsulation in nanovesicles can
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enhance stability by protecting the particles from environmental factors, although a study showed that
this improvement was only noticeable during short-term but not during long-term storage [63].
In order to be a good candidate for phage therapy, the viral particles must be stable not only during
the production and storage stages, but also during its application, that is, it has to remain infective
from the moment of administration to the patient until it reaches the target pathogen. In that context,
the characteristics of the phage and the type of formulation used will depend on the administration
route and target organs. With regards to temperature, for example, the phage should be able to
withstand the body temperature for long enough to reach its target host. Additionally, if application is
to be carried out by topical administration, it would be desirable that the phage is not exceedingly
sensitive to UV-light exposure, so that it is not inactivated before infecting the bacterial cells. If
treatment is aimed at respiratory infections, the phage particles should be able to withstand techniques
used for the preparation of aerosols, such as freeze- or spray-drying [64–66]. In turn, the ability to
withstand an acidic pH will be very important if the phage is to be administered by the oral route.
As was the case with storage, encapsulation of the phage particles can also be helpful in order
to improve stability during treatment. For example, by facilitating skin absorption of the product so
that the phage can reach deeper layers of the epidermis, or by protecting the phage particles from
the acid in the stomach or from bile salts [67]. Encapsulation can also be suitable for inhalation of
a phage formulation that has to reach the lungs. For instance, a study by Singla et al. [68] showed
that phages in liposomes were more effective than nonencapsulated phages for treating pneumonia
caused by Klebsiella pneumoniae. Additionally, encapsulated phages displayed a greater ability to enter
eukaryotic cells than their nonencapsulated counterparts [69]. This indicates that they have greater
potential for reaching intracellular pathogens. Recent work by Nobrega et al. [70] demonstrated that
improved phage stability during oral administration could be achieved by genetically engineering the
phage particles of the E. coli phage T7 to display lipids on their surface. The authors proposed this
strategy as a good alternative to encapsulation. This high stability is very important as otherwise, oral
administration of phages requires very high phage titers (≥1011 PFU/mL) so that at least a dose of 106
PFU can reach the intestine.
Topical application of phages is the preferred form of treatment for various skin infections, ranging
from acne to serious burn wound infections. In these cases, the phage will typically be applied as
a cream. Good results for phage stability in this format have been obtained so far. For example,
phages against C. acnes remained viable for 90 days in a semisolid preparation if stored protected from
light and at 4 ◦C [18]. In the case of the staphylococcal phage K, stability for several days could be
achieved with a cream stored at room temperature, and the results were improved when using an
oil-in-water nanoemulsion [71]. The authors hypothesized that this enhanced stability may be the result
of electrostatic forces [72]. Additionally, the nanoemulsion may lead to decreased electrostatic repulsion
between the negatively charged surfaces of the phage particle and the cell. In the case of products
aimed at treating burn wound infections, Merabishvili et al. [73] examined the stability of phages
against the main causative agents (P. aeruginosa, A. baumanii, S. aureus) in different antibiotic-containing
formulations, including creams, ointments, and hydrogels. The results of this work indicate that the
pH of the product is the most limiting factor for phage stability.
Finally, the bacteriophage must be able to resist the immune response of the patient. However, it
seems that a very high dose of phage particles, much higher than that recommended for treatment,
is necessary in order to elicit a significant immune response [74]. According to a study by
Majewska et al. [74], this response is higher if the phage is applied by subcutaneous injection rather
than by oral administration. This lack of a very intense response by the immune system is probably
the result of continuous exposure to phages which are part of the human microbiome [75]. In any
case, definitively showing that phages can remain viable and be effective will come from further
studies in animal models and clinical trials. It is also important to make sure that the phage particles
are not inactivated by neutralizing antibodies. However, a humoral immune response would be
more of a problem when the phages are administered parenterally rather than after oral or topical
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application [76]. Moreover, antibody production dynamics would be expected to occur more slowly
than pathogen elimination by the phage and, as a result, phage neutralization by the immune system
should not constitute a problem during acute infection therapy. Additionally, PEGylation of the phage
particles, that is, addition of monomethoxy-polyethylene glycol (mPEG), is known to reduce their
immunogenicity and result in lesser levels of cytokine production in mice [77]. Nonetheless, these
responses still must be studied in more depth.
3.5. Antibiofilm Potential
Biofilms are the most common lifestyle of bacteria in both natural and artificial environments,
including inside the human body. As a result, it is now known that biofilms contribute to bacterial
pathogenicity, especially in the case of chronic infections [78]. These multicellular structures allow
the bacterial cells to survive under normally lethal conditions, resisting challenges by the immune
system or antimicrobial compounds thanks to a combination of multiple mechanisms [79]. This makes
biofilms very difficult to eliminate, and one of the major problems that need to be tackled in order to
combat infections. In that sense, bacteriophages may, given their special characteristics, provide an
interesting alternative to conventional disinfectants or antibiotics [80,81]. However, it is necessary to
demonstrate that a given phage is a useful antibiofilm agent. Several studies have already shown that
phage treatment of preformed biofilms can successfully reduce the amount of total attached biomass as
well as the number of viable bacterial cells attached to the surface. For instance, phage phiIPLA-RODI,
which infects different staphylococcal species, can successfully kill S. aureus cells from preformed
single-species and multispecies biofilms [33,82]. A further example was provided by Khalifa et al. [83],
who showed that an enterococcal phage could eliminate in vitro biofilms and prevent infection by
Enterococcus faecalis in an ex vivo model of root canal infection. Likewise, phages have been used
to kill biofilm cells from numerous important pathogens such as P. aeruginosa [84], A. baumanii [85],
and uropathogenic E. coli [86], amongst others. Also, some studies have demonstrated that phages
can move across these complex microbial populations (Figure 2A) and propagate if a suitable host is
present (Figure 2B) [87,88]. Remarkably, phages also seem to be able to infect the infamous persister
cells (Figure 2C) that are known to contribute to recalcitrant infections, even if they cannot proceed
with the lytic cycle until bacterial growth is resumed [89].
An interesting feature of some phages is the possession of genes coding for exopolysaccharide
depolymerases (Figure 2D) that can degrade the polysaccharidic component of the extracellular
matrix of biofilms facilitating biofilm dispersion and access of the phage into the deeper layers of this
structure [90,91]. It is clear that including at least one such phage in a therapeutic cocktail would be of
help to all the different phages. Similarly, production by phage J8-65 of a colinidase, which targets
polysaccharides in the cell envelope, was responsible for synergy between this phage and T7 in a
temperature- and media-dependent manner [92]. Alternatively, a bacteriophage of interest could be
genetically modified to encode a depolymerase in its genome, as Lu and Collins [93] demonstrated in
their proof-of-principle work with phage T7. Although this strategy would be very controversial at
the moment, if engineered phages become more widely accepted for therapy applications, this would
open the door for modification with other types of genes that may control biofilm development. A
very interesting example was provided by Pei et al. [94] who cloned a quorum-quenching enzyme
in the genome of T7 bacteriophages. While phage degradation of the extracellular matrix is a very
desirable outcome, phage inactivation by matrix components should be avoided (Figure 2E).
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Figure 2. Analysis of the antibiofilm potential of a candidate bacteriophage.
Another important aspect to examine is whether a given phage can potentially promote biofilm
formation of the target pathogen (Figure 2F). In this sense, there are examples showing that both
biofilm enhancement and inhibition are possible depending on the phage–host pair, although studies
concerning the impact of virulent phages have been so far outnumbered by those focusing on
temperate viruses [95]. For example, different studies have shown that addition of some virulent
phages leads to increased biofilm formation in strains of S. aureus, P. aeruginosa, Salmonella, and
Vibrio anguillarum [96–98]. In some cases, such as P. aeruginosa, it is known that the phenotype is due to
the selection of phage-resistant mutants with better biofilm-forming ability [97]. This could be solved
by application of a phage cocktail, as selection of mutants against all phages in the cocktail would
be less likely. In V. anguillarum, phage KVP40 promotes increased cell aggregation [98]. In contrast,
accumulation of extracellular DNA was responsible for increased attached biomass upon low-level
predation of S. aureus by phage phiIPLA-RODI [96]. Nonetheless, it is worth emphasizing the need to
understand the specific mechanisms underlying biofilm increase by phages in order to take action to
reduce or completely eliminate this undesirable phenomenon.
4. Conclusions
In the midst of a nearly apocalyptic scenario regarding our ability to cure infectious diseases,
phage therapy seems like a saving grace. Perhaps not a perfect strategy by itself, it certainly is a
good supplement to other therapies as part of a vast antimicrobial arsenal. Their specificity also fits
very nicely within the tendency toward a more personalized approach to human medicine, especially
when it comes to treatment strategies. However, it is paramount to have as much information as
possible before phage therapy use in the clinic is generalized. This will hopefully prevent some of
the errors made with antibiotics. Additionally, it is very important to have a crystal-clear view of the
characteristics that make a bacteriophage a good candidate for therapeutic use. Once it is established
where and how the search for new phages will be performed, careful analysis of the isolated phage
should ensue. Perhaps the single most important trait is the selection of strictly lytic phages, while
temperate phages should be either modified or discarded outright. In addition, phages should not
carry virulence or antibiotic resistance genes in their genomes and preferably produce endonucleases
that degrade the host chromosome prior to cell lysis, thereby preventing spread of bacterial genes to
other microbes by natural transformation. Clearly, bacteriophages will never attain the spectrum of
action of antibiotics, if only because of their particular multistep mechanism of bacterial killing, the lytic
cycle, which involves several specific interactions at the molecular level. This may not necessarily be a
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drawback, as phage specificity also allows for tightly controlled killing of pathogenic targets without
damaging eukaryotic cells or nontarget microbes. This feature is very important given the increasingly
recognized role of the microbiota in human health. Another aspect that requires attention during
phage selection is phage particle stability under different conditions, especially those occurring during
storage and, above all, during treatment. Nonetheless, strategies that allow prolonged stability such as
encapsulation should be also developed further. Last but not least, the interactions between phages
and microbial biofilms should be analyzed in depth in order to maximize the potential use of bacterial
viruses to reduce or eliminate these structures. Indeed, this might be a key step in the fight against
chronic, recalcitrant infections that do not respond to other types of antimicrobial therapy. Overall,
phage therapy seems like a viable, promising strategy that might play a major role in the antibacterial
regimes of the future, perhaps even the near future. Nonetheless, further research is still necessary to
fill in the gaps that will enable using this strategy while maximizing both efficacy and safety.
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Abstract: Carbapenem-resistant Enterobacteriaceae (CRE) have become a public health threat
worldwide. There are three major mechanisms by which Enterobacteriaceae become resistant to
carbapenems: enzyme production, efflux pumps and porin mutations. Of these, enzyme production
is the main resistance mechanism. There are three main groups of enzymes responsible for
most of the carbapenem resistance: KPC (Klebsiella pneumoniae carbapenemase) (Ambler class A),
MBLs (Metallo-ß-Lactamases) (Ambler class B) and OXA-48-like (Ambler class D). KPC-producing
Enterobacteriaceae are endemic in the United States, Colombia, Argentina, Greece and Italy. On the
other hand, the MBL NDM-1 is the main carbapenemase-producing resistance in India, Pakistan and
Sri Lanka, while OXA-48-like enzyme-producers are endemic in Turkey, Malta, the Middle-East and
North Africa. All three groups of enzymes are plasmid-mediated, which implies an easier horizontal
transfer and, thus, faster spread of carbapenem resistance worldwide. As a result, there is an urgent
need to develop new therapeutic guidelines to treat CRE infections. Bearing in mind the different
mechanisms by which Enterobacteriaceae can become resistant to carbapenems, there are different
approaches to treat infections caused by these bacteria, which include the repurposing of already
existing antibiotics, dual therapies with these antibiotics, and the development of new ß-lactamase
inhibitors and antibiotics.
Keywords: Enterobacteriaceae; carbapenem-resistant; CRE; antibiotic resistance; antimicrobials
1. Introduction
Antibiotic resistance occurs when bacteria causing an infection survive after being exposed to a
drug that, under normal conditions, would kill it or inhibit its growth [1]. As a result, these surviving
strains multiply and spread due to the lack of competition from other strains sensitive to the same
drug. Due to the inappropriate prescription and administration of antibiotics, resistant bacteria have
become a public health threat worldwide [2]. In fact, the issue of antibiotic resistant bacteria is such
that, according to the World Health Organization (WHO) predictions, if antibiotic resistance continues
to increase at this rate, infections caused by resistant bacteria will become the top cause of death
worldwide, ahead of cancer, diabetes and cardiovascular diseases [3].
In 2017, WHO published a list of antibiotic resistant bacteria against which there is an urgent
need to develop new antibiotics [4]. This list is divided into three categories depending on the urgency
with which new antibiotics are needed: critical, high and medium priority. Within the critical priority
group are carbapenem and 3rd generation cephalosporin resistant Enterobacteriaceae. These bacteria are
common pathogens causing severe infections such as bloodstream infections, pneumonia, complicated
urinary tract infections and complicated intra-abdominal infections. As a result, antibiotic resistance in
Enterobacteriaceae has significant clinical and socioeconomic consequences [5,6].
Initially, Enterobacteriaceae posed a threat to the public health due to their ability to become
resistant to antibiotics by producing extended-spectrum ß-lactamases (ESBLs) [7]. To fight this threat,
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the medical community turned to drugs such as carbapenems as first-line empirical treatments [8].
This new treatment for resistant bacteria had an unexpected result, as it led to a more serious problem,
the emergence of carbapenem-resistant Enterobacteriaceae (CRE) [9]. In particular, CRE refer to bacteria
belonging to the Enterobacteriaceae family that have the ability to survive and grow in the presence of
clinically relevant concentrations of carbapenems [10]. Specifically, the Centers for Disease Control and
Prevention (CDC) defines CRE as enterobacteria non-susceptible to any carbapenem or documented to
produce carbapenemases [11].
This review analyzes the epidemiology of CRE as well as current and future treatment options
against these increasingly resistant bacteria. Furthermore, it provides an extensive review of the
different mechanisms by which Enterobacteriaceae develop resistance against carbapenems. The presence
of these three aspects in one article could be used as a key tool for a better understanding of this
emerging problem and as guidance to elaborate plans to manage the CRE crisis and develop new
active drugs more efficiently.
2. Mechanisms of Drug Resistance
There are three major mechanisms by which Enterobacteriaceae become resistant to carbapenems:
enzyme production, efflux pumps and porin mutations [12]. Of these, enzyme production is the main
resistance mechanism. Gram-negative bacteria generally develop resistances through the production of
ß-lactam-hydrolyzing enzymes [13]. Initially, these enzymes inactivated penicillin, however, as different
types of antibiotics were introduced in the treatment of infectious diseases, their spectra extended.
Thus, cephalosporinases, ESBLs, metallo-ß-lactamases (MBLs) and other carbapenemases appeared [14].
Generally, CRE are divided into two main subgroups: carbapenemase-producing CRE (CP-CRE) and
non-carbapenemase-producing CRE (non-CP-CRE) (Figure 1) [15].
Figure 1. Classification of the different mechanisms of drug resistance in CRE. (Light
grey: Ambler class A, White: Ambler class B, Dark grey: Ambler class D) (CRE:
Carbapenem-resistant Enterobacteriaceae; CP: carbapenemase producing; KPC: Klebsiella pneumoniae
carbapenemase; IMI: Imipenem-hydrolyzing ß-lactamase; GES: Guiana extended-spectrum ß-lactamase;
MBLs: Metallo-ß-lactamase; OXA: oxacillinase; NDM: New Delhi metallo-ß-lactamase; VIM: Verona
integron-borne metallo-ß-lactamase; IMP: Imipenem-resistant Pseudomonas carbapenemase; SMP: Sao
Paulo metallo-ß-lactamase; GIM: German imipenemase; SIM: Seoul imipenemase; AmpC: Type C
ampicillinase; ESBLs: Extended-spectrum ß-lactamase).
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2.1. Carbapenemase-producing CRE
CP-CRE can produce a large variety of carbapenemases which can be divided in three groups
according to the Ambler classification: class A, class B and class D ß-lactamases [16]. There is a fourth
class, Ambler class C, however, its clinical relevance remains unknown [17].
Within class A carbapenemases is the clinically relevant Klebsiella pneumoniae carbapenemase
(KPC) [18]. This is a plasmid encoded enzyme which actively hydrolyzes carbapenems and is
partially inhibited by clavulanic acid [19]. Its clinical relevance is due to the fact that it is the most
prevalent and most widely spread worldwide [20] Enterobacteriaceae producing KPCs have acquired
multidrug resistance to ß-lactams, which limits the therapeutic options to treat infections caused by
these bacteria [21]. KPC were originally found in K. pneumoniae isolates, however, clinical isolates of
KPC-producing Escherichia coli, Klebsiella oxytoca, Salmonella enterica, Citrobacter freundii, Enterobacter
aerogenes, Enterobacter cloacae, Proteus mirabillis and Serratia marcescens have been identified [22–26]
(Table 1). According to a study by Perez et al. [27], a total of 12 blaKPC gene variants exist globally.
Table 1. Carbapenemases detected in different species belonging to the Enterobacteriaceae family.
Species Class A Class B (MBLs) Class D Ref.
Klebsiella
pneumoniae KPC-3 NDM-1, VIM-1 OXA-48
Okoche et al.
Boutal et al.
Klebsiella oxytoca OXA-48, OXA-181 Okoche et al.Boutal et al.





Proteus mirabilis KPC OXA-48 Okoche et al.Boutal et al.
Serratia marcescens KPC VIM Okoche et al.Boutal et al.





Citrobacter freundii VIM OXA-48 Okoche et al.Boutal et al.





OXA-48 Fernández et al.
Morganella morganii NDM-1 OXA-48 Boutal et al.
Providencia stuartii KPC-2 VIM-1 Abdallah et al.
Providencia rettgeri IMP-1 OXA-72 Abdallah et al.
Another major carbapenemase family belonging to class A are MBLs. These enzymes depend
on the interaction with zinc ions in the active site of the enzyme [28]. These enzymes are
particularly problematic as they have a high potential for horizontal transfer, they lack clinically
useful inhibitors, and they have broad hydrolytic properties that affect most ß-lactam antibiotics except
for monobactams [29]. However, MBL resistance is usually associated with multidrug-resistance,
with MBL-producing isolates often co-expressing ESBLs, which inactivate monobactams [13]. The most
common families of MBLs found in Enterobacteriaceae were acquired [17]. These families are the New
Delhi metallo-ß-lactamase 1 (NDM-1), Imipenem-resistant Pseudomonas (IMP)-type carbapenemases
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and the Verona integron-encoded metallo-ß-lactamases (VIM) [14]. IMP-type carbapenemases were
first detected in Japan during the 1990s and have up to 18 varieties [30]. Similarly, VIM was first isolated
in Verona, Italy, in 1997 and consists of 14 members [31]. Both MBLs originated in P. aeruginosa and
were transferred to Enterobacteriaceae. In fact, these MBLs share similarities regarding the plasmids they
are carried on and their mechanism of action, as both hydrolyze all ß-lactams except for monobactams
and are susceptible to all ß-lactam inhibitors [32]. Regarding NDM-1, it is the most recently discovered
MBL. It was isolated in India, which is considered the main reservoir of NDM-producing bacteria [33].
Since then, it has spread worldwide, reaching Europe and the United States through tourists [34].
Currently, NDM is predominant in K. pneumoniae and E. coli [34]. Studies suggest that most plasmids
containing blaNDM also harbor other resistance determinants encoding different ß-lactamases, quinolone
resistance and 16S rRNA methylases which confer resistance to aminoglycosides [35].
The third clinically relevant group of carbapenemases are OXA-48-like, which belong to Ambler
class D. Six OXA-48-like variants have been identified, OXA-48 being the most widespread [36].
The remaining variants are: OXA-162, OXA-163, OXA-181, OXA-204 and OXA-232. They are
all grouped within the OXA-48-like category because they only differ on one to five amino acid
substitutions or deletions [36]. These plasmid-mediated enzymes are primarily found in K. pneumoniae,
E. coli, C. freundii and E. cloacae [37]. A major concern with these carbapenemases is that no existing
inhibitors work against them and they have an extraordinary ability to mutate and expand their
activity spectrum [38]. These enzymes are highly active against penicillins, have low activity against
carbapenems and intermediate activity against broad-spectrum cephalosporins [17].
2.2. Non-Carbapenemase-producing CRE
Besides carbapenemase production, Enterobacteriaceae have alternative mechanisms by which they
can present carbapenem resistance. These are unspecific mechanisms which can result in multi-drug
resistance, such as the production of other ß-lactamases, porin loss and efflux pump overexpression [14].
These mechanisms generally appear paired among themselves or with carbapenemase-production [39].
In fact, while carbapenemases specifically target carbapenems and other ß-lactam antibiotics, efflux
pump expression or porin changes are associate with multi-drug resistance [40]. All three alternative
mechanisms aim to block the penetration of the antibiotic within the bacterial cell.
Firstly, Enterobacteriaceae can produce different types of ß-lactamases, such as AmpC-type
ß-lactamases. These enzymes do not degrade carbapenems [41] but they form a bond with the
carbapenem molecule, preventing it from accessing its target [42]. Specifically, the plasmid-encoded
AmpC CMY-2 is frequently found in E. coli and other Enterobacteriaceae worldwide, causing resistance
to carbapenems [43].
Secondly, resistance-nodulation-division (RND) efflux pumps are a major mechanism of multi-drug
resistance in Enterobacteriaceae [44]. Among the different efflux systems, the AcrAB-TolC RND system
is the most common [44]. This RND efflux pump, along with the CusABC efflux complex, belongs to E.
coli [45]. Similarly, Campylobacter jejuni presents multi-drug resistance through the expression of the
CmeABC complex [45]. These resistant genes can be easily transmitted from one microorganism to
another through plasmids [46].
Lastly, alterations of porin synthesis also contribute to blocking penetration of carbapenems into
the bacterial cell [47]. These alterations have been described in AmpC- and carbapenemase-producing
K. pneumoniae, which suggests that changes in porin expression play a key role in the ß-lactam resistance
displayed by multi-drug resistant bacteria [48]. Studies suggest that strains that have their porins
mutated or their expression modulated typically do not have potential for mobilization into community
settings but may proliferate locally within hospitals [49].
3. Current Resistance Status
Since the detection of the first strain of CRE in the 1980s [50], CRE has rapidly spread worldwide.
Epidemiology studies suggest that different carbapenemases predominate in different areas of the
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world. For that matter, NDM-1 is the main carbapenemase producing resistance in India, Pakistan
and Sri Lanka. On the other hand, KPC-producing Enterobacteriaceae are endemic in the United States,
Colombia, Argentina, Greece and Italy, while OXA-48-like enzyme-producers are endemic in Turkey,
Malta, the Middle-East and North Africa [51] (Figure 2).
Figure 2. Timeline representing the introduction of carbapenems and the appearance of
carbapenemases worldwide.
As mentioned earlier, the first case of CP-CRE was isolated in Japan and corresponded to an
IMP-producing Serratia marcescens [50]. This strain caused a plasmid-mediated outbreak in seven
Japanese hospitals, followed by a widespread dissemination of blaIMP-1-harboring Enterobacteriaceae
throughout Japan. Since then, 52 variants of IMP genes have been identified and have their endemicity
limited to Japan and Taiwan [52]. VIM-type MBLs were described shortly after in P. aeruginosa strains [53].
By the early 2000s, cases of VIM-producing Enterobacteriaceae were already being reported [17].
K. pneumoniae and E. coli strains producing VIM-type carbapenemases have their endemicity peak
in Greece [28]. However, the major threat of MBL-producing Enterobacteriaceae appeared with the
discovery of an ST14 K. pneumoniae strain producing the NDM enzyme from a Swedish patient who
received healthcare in New Delhi, India [54]. Bacteria producing this enzyme is endemic in the Indian
subcontinent and generally appears as sporadic cases in the rest of the world [55]. NDM-1 producing
Enterobacteriaceae have been reported both in hospital and community-acquired infections, including
urinary tract infections, septicemia, pulmonary infections, peritonitis, device-associated infections and
soft tissue infections [56]. An additional issue with NDM-producing bacteria is their ability to spread
via environmental sources in community settings of lower-income countries. In fact, studies carried out
in India found that 4% of the drinking water and 30% of seepage samples contained NDM-1-producing
bacteria [33].
KPC-producing Enterobacteriaceae are categorized as one of the most successful pandemics in
the history of Gram-negative bacteria, particularly due to K. pneumoniae ST258 [57]. This strain has
been reported as endemic in Greece, Israel, Latin America and the United States [39]. The endemic
state of KPC-producing Enterobacteriaceae is not surprising, seeing as the first case of K. pneumoniae
producing this enzyme was reported in a patient in a North Carolina hospital in 1996 [18]. Only five
years later, an outbreak of KPC-producing bacteria took place throughout northeastern United States
within hospitalized patients [58]. On the other hand, Greece has one of the highest CRE rates
worldwide. Initially, this resistance was due to VIM enzymes, however, in 2007, a rapid dissemination
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of KPC-producing bacteria made KPC the main mechanism of resistance against carbapenems in the
country [39]. Current studies suggest that around 40% of the carbapenemase-resistant K. pneumoniae
harbor blaKPC in Greece [59]. Colombia was the first country within Latin America to report an outbreak
of KPC-producing K. pneumoniae, which originated from a patient who had travelled to Israel [60].
Since then, Argentina, Chile, Mexico and Brazil have also reported the detection of KPC-producing
CRE [39].
Finally, regarding OXA-48-like-producing CRE, outbreaks caused by these bacteria have been
reported in several countries, however, only Turkey, Japan and Taiwan have reported endemicity [61].
4. Treatment Options
Carbapenems continue to be used for the treatment of infections caused by Enterobacteriaceae
as suggested by both, EUCAST (European Committee on Antimicrobial Susceptibility Testing) and
CLSI (Clinical and Laboratory Standards Institute) guidelines [62,63]. The clinical breakpoints of the
carbapenems currently used are presented in Table 2. It must be noted that doripenem has been
removed from 2019 EUCAST guidelines due to the lack of availability of this drug in most countries.
In those countries where doripenem is still available, 2018 EUCAST guidelines must be used as a
reference [64]. However, CRE are an increasingly common issue in the clinical practice, rendering
carbapenems useless.
Table 2. Breakpoints for carbapenems against Enterobacteriaceae family.
Antibiotic Guidelines Disk Content (μg)
Disk Diffusion (mm) Dilution (μg/mL)




























































1 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of minimum
inhibitory concentrations (MICs) and zone diameters. Version 9.0, 2019. Available on: http//www.eucast.org
[62]. 2 CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100.
Wayne, PA: Clinical and Laboratory Standards Institute; 2019 [63]. 3 The European Committee on Antimicrobial
Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. Available
on: http//www.eucast.org [64].
Bearing in mind the different mechanisms by which Enterobacteriaceae can become resistant to
carbapenems, there are different approaches to treat infections caused by these bacteria. These treatment
options include the repurposing of already existing antibiotics, dual therapies with these antibiotics
and the development of new ß-lactamase inhibitors and antibiotics [65] (Table 3).
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Firstly, certain “old antibiotics” which have been included in the therapeutic arsenal for years are
still effective against CRE. For example, fosfomycin, frequently used to treat urinary tract infections
(UTIs), continues to be effective against approximately 80% of CRE [66]. Similarly, aminoglycosides are
still considered first-line therapy for the treatment of carbapenem-resistant K. pneumoniae infections [6].
While gentamicin is the most frequently used aminoglycoside, studies report cases where amikacin
was the only active molecule [67]. Colistin also remains as a key drug in the treatment of CRE
infections [65]. However, CRE, and more particularly K. pneumoniae, have started to develop resistance
against this drug, decreasing its efficiency as a monotherapy treatment [68]. As a result, colistin has
been included as part of a dual therapy with meropenem, which results in a significant reduction of
mortality, especially in patients with septic shock, high mortality score or rapidly fatal underlying
diseases [69]. Moreover, polymyxins continue to be considered last resort drugs due to their adverse
effects, which include nephrotoxicity, neurotoxicity and skin pigmentation [65].
Tigecycline also remains as an option for CRE treatment in certain cases [70]. The particularity with
this drug is that it displays low serum concentrations in the approved dosing regimen for the treatment
of community-acquired and nosocomial-acquired pneumonia, which hampers clinical outcomes [71].
As a result, a high-dose tigecycline regimen has been investigated and is being used to treat CRE
infections. This therapy consists of a 200 mg initial dose and a maintenance dose of 100 mg every
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12 h [65]. This high-dose is particularly effective for the treatment of ventilator-associated pneumonia
caused by CRE [72]. Furthermore, a systematic review comprising 25 studies reporting the efficacy and
safety of tigecycline-based regimens for treating CRE infections concluded that a much lower mortality
rate resulted from high-dose tigecycline than standard-dose tigecycline [70].
Lastly, carbapenems continue to be used for the treatment of CRE infections. This is done
through the combination of two different carbapenems, which is known as “double carbapenems”.
Generally, the combination consists of an initial dose of ertapenem followed by a prolonged infusion
of meropenem or doripenem over 3 or 4 h with additional 2 g doses of meropenem every 8 h [73].
This therapy is effective against CRE because the greater affinity of ertapenem to KPC makes it play
a “sacrificial role”, meaning that it is preferentially hydrolyzed by the carbapenemase, allowing the
concomitant administration of the second carbapenem to sustain a high concentration [74]. Comparator
studies such as those by Oliva et al. [75] and Venugopalan et al. [76] confirm the efficacy of dual
carbapenem therapy, reporting clinical success rates of more than 70% in both cases.
Regarding novel antibacterial drugs, they can be differentiated in two groups: newly approved
antibiotics and molecules in development stages. The latest antibiotics approved and already
being used to treat CRE infections are ceftazidime/avibactam, meropenem/vaborbactam, plazomicin
and eravacycline.
Ceftazidime/avibactam (Allergan) is a novel ß-lactam/ß-lactamase inhibitor combination.
The novelty of this combination relies on avibactam, which is a synthetic non-ß-lactam ß-lactamase
inhibitor active against ß-lactamases from Ambler classes A, C and D [77]. Clinical studies using
this combination are still scarce, however, initial results show an improved mortality rate of
9% compared to the 32% obtained when using colistin [78]. Regardless of the promising initial
results, ceftazidime/avibactam resistant strains have already been reported during treatment [79,80].
The resistance is due to mutations in the blaKPC-2 and blaKPC-3 genes affecting omega loop D179Y,
down-regulation of ompk35/36 and increase in efflux, which could decrease meropenem activity [81].
This should be taken into account by clinicians when prescribing this treatment.
Similarly, meropenem/vaborbactam (Melinta) is also a new ß-lactam/ß-lactamase inhibitor
consisting of a carbapenem and a novel boron-containing serine-ß-lactamase inhibitor that potentiates
the activity of meropenem [65]. This combination inhibits Ambler classes A and C serine
carbapenemases [82]. There are few clinical data with this combination, however, in vivo results
showed that, out of 991 clinical isolates of KPC-producing Enterobacteriaceae, 99% were susceptible to
meropenem-vaborbactam [83]. Furthermore, results from the Tango II trial, which compared the efficacy
and safety of this combination with the best available therapy in CRE infections, showed a higher
clinical cure (65.6% vs 33.3%) and 28-day mortality (15.6% vs 33.3%) for meropenem/vaborbactam [84].
Plazomicin (Achaogen) is a next-generation semisynthetic aminoglycoside with activity against
bacteria producing aminoglycoside-modifying enzymes [85]. Studies report higher potency of
plazomicin compared to other aminoglycosides against KPC-producing Enterobacteriaceae [86].
Along these lines, Endimiani et al. [86] analyzed collections of clinically relevant KPC-producers
with resistance to aminoglycosides and observed inhibition using plazomicin, with a minimum
inhibitory concentration (MIC90) of ≤2 mg/L [87]. Plazomicin has shown broad-spectrum activity
against Gram-positive cocci and Gram-negative bacilli [87], however, MBL-producers are resistant
to this antibiotic due to the methyltransferase enzymes which are commonly found, especially in
NDM-producers [87]. Aminoglycosides are not generally used as monotherapy, however, the broad
spectrum of activity along with the low renal toxicity of plazomicin make it an option for a targeted
monotherapy against extensively-drug resistant Enterobacteriaceae causing urinary tract infections [88].
Lastly, eravacycline (Tetraphase) is a synthetic fluorocycline with broad-spectrum antimicrobial
activity against Gram-positive, Gram-negative and anaerobic bacteria, regardless of resistance to other
antibiotic classes [89]. This antibiotic has several potential advantages over tigecycline, which include
a more potent in vitro antibacterial activity, excellent oral bioavailability, lower potential for drug
interactions and superior activity in biofilm [90]. This drug was also studied in cUTI (complicated
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urinary tract infection) in two Phase 3 trials (IGNITE 2/3), failing to meet endpoints in both studies,
which could be explained by an erratic pharmacokinetic in urine [91]. However, eravacycline did meet
endpoints in the IGNITE 4 Phase 3 study, in which it demonstrated similar activity to ertapenem (100%
cure rate for eravacycline vs 92.3% for ertapenem) in the treatment of complicated intra-abdominal
infections [92].
In addition to these already approved drugs, there are six molecules in early developmental stages:
imipenem/cilastatin and relebactam (Merck), cediferocol (Shionogi), SPR741 (SperoTherapeutics),
zidebactam (Wockhardt), nacubactam (Roche) and VNRX 5133 (VenatoRx Pharmaceuticals). Firstly,
imipenem/cilastatin and relebactam shares similarities with previously discussed combinations in
that it combines an approved carbapenem with a novel ß-lactamase inhibitor. In fact, the inhibitory
mechanism of relebactam is similar to that of avibactam, as it covalently and reversibly binds to classes
A and C ß-lactamases [93]. By including relebactam, the activity of imipenem increases considerably
against carbapenemase-producing bacteria, up to >16 fold [94]. In fact, the RESTORE-IMI 1 study
proved this combination to be as effective and better tolerated than colistin/imipenem for the treatment
of infections caused by KPC-producing Enterobacteriaceae [95]. Regarding cefiderocol, it is the first
siderophore-conjugated cephalosporin antibiotic to advance into late-stage development. This drug
has a novel mechanism of action in which the cathecol substituent forms a chelating complex with
iron, acting as a trojan horse by using iron active transport systems in gram negative bacteria to
bypass the other membrane permeability barrier [96]. This molecule demonstrates potent in vitro and
in vivo activity against a variety of Gram-negative bacteria, including CRE [96]. A study analyzed the
activity of cefiderocol and comparative agents against 1,022 isolates of carbapenem-nonsusceptible
Enterobacteriaceae, obtaining MIC50 and MIC90 for cefiderocol of 1 and 4 μg/mL, respectively [97].
SPR741 is in very early stages of the development process. This molecule is a polymyxin B potentiator
that increases ceftazidime and piperazine/tazobactam activity against CRE and ESBLs including
OXA-48 [98].
The remaining molecules under development are ß-lactamase inhibitors. Firstly, zidebactam and
nacubactam have high affinity to Ambler classes A and C ß-lactamases [99]. Moreover, they also have
affinity to PBPs as well as ß-lactam enhancer activity [100]. The cefepime/zidebactam combination
is currently in phase 2 clinical trials for the treatment of Gram-negative bacteria. This combination
showed potent in vitro activity against carbapenemase-producing Enterobacteriaceae, with MIC50 of
0.25 mg/L for KPC-producers and 0.5 mg/L for MBL-producers [101]. On the other hand, nacubactam in
combination with meropenem is currently in phase 1 trials against Gram-negative bacteria causing UTI
infections [102]. Results from this study show improved MIC values for the meropenem/nacubactam
combination in comparison with meropenem alone. Furthermore, this combination was active against
ceftazidime/avibactam-resistant isolates. Lastly, VNRX 5133 is a cyclic boronate broad spectrum
ß-lactamase inhibitor in clinical development with cefepime for the treatment of multidrug-resistant
bacteria [103].
5. Conclusions
As highlighted by the Global Priority List published by WHO, carbapenem-resistant
Enterobacteriaceae pose an exponentially increasing threat for the public health worldwide. These bacteria
possess diverse and versatile mechanisms of drug resistance, which makes control and early detection
of infections caused by CRE difficult. As a result, a joint effort must be made between the scientific and
medical community to slow down the appearance of resistances. Along these lines, there is an urgent
need to develop new therapeutic guidelines to treat CRE infections. This includes the repurposing of
already existing antibiotics such as fosfomycin, aminoglycosides and colistin and the development of
novel drugs such as plazomicin, eravacycline or cefiderocol among others.
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Abstract: The threat of antimicrobial resistance has global health and economic consequences.
Medical strategies to reduce unnecessary antibiotic prescribing, to conserve the effectiveness of current
antimicrobials in the long term, inevitably result in short-term costs to health care providers.
Economic evaluations of health care interventions therefore need to consider the short-term costs
of interventions, to gain future benefits. This represents a challenge for health economists, not only
in terms of the most appropriate methods for evaluation, but also in attributing the potential budget
impact over time and considering health impacts on future populations. This commentary discusses
the challenge of accurately capturing the cost-effectiveness of health care interventions aimed at tackling
antimicrobial resistance. We reflect on methods to capture and incorporate the costs and health outcomes
associated with antimicrobial resistance, the appropriateness of the quality-adjusted-life year (QALY),
individual time preferences, and perspectives in economic evaluation.
Keywords: antimicrobial resistance; economic evaluation; cost-utility analysis; cost-effectiveness
analysis; antibiotics
1. Introduction
Antimicrobial resistance encapsulates the loss of effectiveness of any anti-infective medicine,
including antiviral, antifungal, antibacterial, and antiparasitic medicines [1,2]. The threat of antimicrobial
resistance has global health and economic consequences; resistant infections are responsible for an
estimated 700,000 deaths annually worldwide which, if no action is taken, could result in a cumulative
cost of $100 trillion by 2050 [3]. Urgent threats include Clostridioides difficile, carbapenem-resistant
Enterobacteriaceae (CRE), and drug-resistant Neisseria gonorrhoeae [4]. The current rate of Clostridioides
difficile infection in the United States (US) alone is 500,000 cases and 15,000 deaths per year. The urgency
of addressing antimicrobial resistance is recognised widely [4,5], and a range of containing strategies have
been implemented, including antimicrobial stewardship, which has become a central aspect of delivering
safe and effective health care [6]. Antimicrobial stewardship involves a coordinated approach to promote
and monitor the judicious use of antimicrobials to preserve their future effectiveness [6]. The UK’s
five-year action plan outlines three key targets for tackling antimicrobial resistance: (i) reducing need
and unintentional exposure, (ii) optimizing use, and (iii) investing in innovation, supply, and access [3].
A key strategy to achieve these aims includes more appropriate prescribing, which includes reducing
unnecessary antibiotic prescribing [7–10]. Not only is unnecessary antibiotic prescribing costly for little or
no therapeutic benefit, it places patients at risk of adverse effects [8,11] and contributes to the development
of antibiotic resistance [7–10]. The potential for improved health outcomes and lower costs are easily
recognised; however, health care strategies may also include trade-offs between short-term outcomes and
long-term gains, for example, not using the most effective anti-infective medicine, in order to preserve
future effectiveness. This represents a shift of focus of evaluation, from clinical decision making
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for an individual patient in the present, to a longer-term (intergenerational) public health agenda.
Similarly, there has been a shift of focus in the pharmaceutical industry, with strategies incentivizing
the pharmaceutical industry to develop new drugs, using funding mechanisms not linked to volume [3].
Economic evidence is central to understanding the value of competing health care strategies
to lessen the probability of resistance development [12,13]. Interventions or services are typically
evaluated using standard methods of health technology assessment, including cost-effectiveness
or cost-utility analyses. Economic evaluations inform judgements on whether the value of additional
health benefits exceed the opportunity cost; where opportunity cost is the next best alterative foregone.
As conventionally applied, health benefits relate to the effectiveness of interventions in relation
to managing infections less any adverse effects, which are typically confined to adverse drug reactions.
However, the application of such methods in the context of antimicrobial resistance poses several
unique methodological challenges, not least in quantifying the costs and externality effects (impacts on
other patients) of future reductions in antimicrobial effectiveness (Table 1).
Table 1. Examples of challenges for the economic evaluation of health care strategies to contain
antimicrobial resistance.
Item Example of Challenges Recommendations
Population
Population extends beyond those receiving
the intervention. This is also likely to extend across
health technology agency (HTA) boundaries.
Where appropriate, extend the population
beyond the cohort receiving
the intervention and consider other/future
patients who become infected by a resistant
pathogen, or who have not experienced
resistant infection but receive alternative
agents due to increased resistance
of common pathogens.
Clinical
Adequate measurement of the expected rate
of growth of antimicrobial resistance and
associated outcomes over time. Clinical parameters
in the present are more easily captured than those
associated with future global consequences.
Use both empirical data and secondary data




Resource implications most likely to be short-term.
Difficult to capture long-term resource use and
the cost of negative externalities. Cost of health
care intervention impacts different budgets
to the return, e.g., primary care cost in short-term,
for long-term secondary care gains.
Application of robust resource use data
collection methods [14]. Include costs
of treating patients not receiving
the intervention (see population).
Use threshold analysis as an alternative
to specifying attaching an actual cost
to antimicrobial resistance.
Health outcomes
Health states associated with acute infection may
be perceived as transient, which limits the validity
of trade-off exercises typically used for utility
valuation. Utility measures, such as the EQ-5D,
measure health “today” and fail to capture
the value (utility) associated with future health
gains.
Cautious interpretation
of quality-adjusted-life year (QALY) gains.
Consider alternative or multiple
frameworks for analysis,
e.g., disability-adjusted-life year (DALYs)
to assess global burden, cost-benefit
analysis, using contingent valuation.
Where appropriate include the disutility
for patients with resistant infection
and the disutility of alternative agents.
Perspective
Economic evaluations of health care intervention
are often restricted to direct health effects and costs
with the health technology program considering
the evidence. Antimicrobial resistance is a societal
issue and extends beyond individual
HTA jurisdictions.
Consider a societal perspective to reflect
the true range of costs and outcomes.
Acknowledge the limitations of HTA
by individual agencies.
Time horizon
Evaluations often adopt inadequate time horizons.
Time preference may be paradoxical
for antimicrobial consumption. Costs and
outcomes extend to future generations.
Adopt a lifetime horizon of analysis,
use appropriate discounting rates,
and conduct empirical research on time
preferences for antimicrobial preferences.
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2. Challenges
2.1. Capturing the Benefits of Strategies to Contain Antimicrobial Resistance
How best to assess the value of any intervention to reduce antimicrobial resistance is a methodological
challenge, which requires adequate measurement of the expected rate of growth of antimicrobial resistance
and associated outcomes over time [15]. Economic evaluation of health care strategies to reduce antibiotic
prescribing, for instance, ought to value their impact on antimicrobial resistance. Most economic evaluations
in this area, however, fail to consider the costs and outcomes relating to antimicrobial resistance—or
where they have, consideration has been restricted to projected financial costs and was not reflective
of population health [16,17]. In order to achieve this, data are required on the long-term health outcomes
of both current patients and future cohorts of patients who may be prescribed antimicrobial therapy
in the future. This includes the health outcome of patients who become infected by a resistant pathogen,
or who have not experienced resistant infection but receive alternative agents due to increased resistance
of common pathogens. The disutility of potentially less effective treatment represents an important
economic parameter that is required in addition to the capturing the more obvious morbidity and mortality
associated with short-term health outcomes of the patient presenting with an infection.
Measure of Health Outcome
Economic evaluations of health care interventions to tackle antimicrobial resistance may consider
different measures of health outcomes, ranging from the number of prescriptions avoided, to years of life
gained and quality-adjusted-life years (QALYs). Cost-utility analyses, which yield incremental costs
per QALY gained, measure value in terms of health utility and survival. Utility represents the value or
desirability of a given health state, most typically based on indirect, multi-attribute, preference-based
measures, such as the EQ-5D [18,19]. The appropriateness of QALYs for use in evaluation of acute
conditions, such as respiratory tract infections, a common focus of intervention aimed at tacking
antimicrobial resistance, has both measurement and evaluation problems. Health state utilities
used to calculate the QALY are typically elicited using trade-off exercises, and the issue with acute
infection is that when trading quality and quantity of life, the ill-health state may be perceived as
transient, thus questioning the reliability of this method [20]. Furthermore, health care strategies
to contain antimicrobial resistance—by design—are only unlikely to concern the outcomes of today.
The valuation of future health outcomes is also important and represents a challenge for health
economists. An alternative evaluative framework may be required to capture the complexity of health
outcomes over time.
The disability-adjusted-life year (DALY) represents an alternative health index used in cost-effectiveness
analyses. The DALY captures the number of healthy years lost, by incorporating reduction in life expectancy
with years lost to disability; as such health care interventions seek to avert the DALY (as opposed to increasing
the QALY). The DALY provides an estimate of the burden of disease, such as infectious diseases, that is
useful in global health prioritization. Cassini and colleagues reported the DALYs caused by five infections
with antibiotic-resistant bacteria across populations in Europe and found this to be substantive compare
to other infectious diseases [21]. From a global health perspective, the DALY is an oft-used measure that
can be utilised in economic evaluations.
Cost-benefit analysis (CBA) is an approach to economic evaluation that places a monetary
valuation on the consequences as well as the costs of interventions. This may be achieved using
methods such as willingness to pay, which has been suggested as an alternative to the QALY when
evaluating acute disease [20]. The willingness to pay method is based on contingent valuation to elicit
monetary value for items not typically traded, such as health, and therefore accounts for both health
and non-health effects. Whilst this is considered more comprehensive, in many jurisdictions patients
may be unfamiliar with purchasing health care directly, and this may have an impact on the reliability
of the methods. A further challenge is the potential association with ability to pay, based on income and
wealth. In the context of health care strategies to tackle antimicrobial resistance, however, cost-benefit
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analysis offers a feasible method for capturing the cost of the negative externalities, on a global scale,
to represent the true value future benefits. Where applied with robust formative work, there is potential
for this method to be used to elicit individuals’ willingness to pay to avoid an illness (resistant infection)
or obtain the benefits of a future treatment.
2.2. Perspective
Prior to conducting any economic valuation, the perspective needs to be defined [22]. The perspective
of the valuation, e.g., whether it is conducted from the point of view of the patient, health care payer,
or society, will determine the costs and outcomes that need to be included in the analysis. In the UK,
the National Institute for Health and Care Excellence (NICE) recommends the perspective on outcomes
should be all direct health effects, whether for patients or other people; and the perspective adopted on
costs within its Technology Appraisal programme should be that of the National Health Service (NHS) and
personal and social services (PSS) [23]. Benefits are the assigned general population’s valuation of health
outcome (obtained from surveys), and costs include the cost of treatment and associated health service
resource use (e.g., GP visits, hospitalisation, etc.). Whilst this provides a reference case for comparison
of different health technologies, such Technology Appraisals consider individual patients or cohorts
of patients, whereas antimicrobial resistance should consider populations. Evaluation of containment
strategies may necessitate a broader perspective, and evidence in other areas suggests that assessment
of the same strategy from different perspectives can arrive at different conclusions [24].
The broadest perspective adopted in economic evaluation is the societal perspective. This should
reflect the full range of social opportunity costs associated with different interventions [22], for example,
productivity losses due to patients’ inability to work. However, there is a paucity of evidence on
the long-term indirect impact of antimicrobial resistance on costs and outcomes [25], and this represents
a significant challenge for health economists evaluating containment strategies. Economic evaluations
with restrictive perspectives have potential to overestimate the value of interventions or services.
Where the perspective for costs is limited to hospital or health service, indirect costs to current and future
patients, such as working days lost due to resistant infection, or treatment toxicity, fail to be captured.
To fully assess the cost-effectiveness of strategies to contain antimicrobial resistance and to avoid
the inefficient allocation of scarce health service resources, decision makers require economic
evaluations that incorporate costs and outcomes beyond the patient and hospital and consider
the full ramification of antimicrobial resistance. Defining the “society” then becomes a challenge within
itself, as antimicrobial resistance impacts populations that extends across jurisdictions. Adoption of a
global multiagency perspective represents new territory and a limitation of conventional health
technology assessment (HTA) and health-economic approaches. In the absence of long-term data,
economists have taken a pragmatic approach; for example, our evaluation of C-reactive protein testing
to guide antibiotic prescribing for lower respiratory tract infection in Wales, included a sensitivity
analysis of the cost of the long term global cost of antibiotic resistance [17]. A challenge for future
economic evaluation is to incorporate more robust measurement and modelling of longer-term indirect
costs and outcomes—that go beyond today’s cohorts of patients to consider the population of tomorrow.
2.3. Capturing the Long-Term Costs of Antimicrobial Resistance
The resource implications of antimicrobial resistance are most likely to accumulate in the long-term.
Short-term, direct health effects may only include the effect of the intervention on the affected patient;
however, longer-term effects on both the patient and others are more likely. It is therefore important
that all costs are captured and incorporated into economic evaluations across adequate time-horizons.
Whilst interventions to reduce unnecessary prescribing in a clinical setting may represent a short
time horizon, e.g., prescribing outcomes and re-consultation over 28-days, the longer-term effects
of unnecessary antibiotic prescribing extend to current and future patients’ lifetimes [10,26]. Initially,
resource use and costs associated with interventions that aim to contain resistance would typically be
captured using health records and/or patient reports in the short-term. Estimating long-term direct
268
Antibiotics 2019, 8, 166
and indirect cost and the cost consequences to others, however, may present more of a challenge.
The cost impact has potential to go beyond the lifetime horizon of the patient and impact the population
of tomorrow, and in some situations the product life-cycle [27] may be more relevant than the life time
of the patients being treated.
Where long-term costs have been considered in existing economic evaluations, these have relied
on estimates of per-prescription costs of antimicrobial resistance based on rudimentary calculations
of the global costs of resistance divided by the annual number of prescriptions in each geographic
region [16]. Oppong et al. 2013 [16], reported three estimates for the cost of antibiotic resistance,
based on the annual cost of resistance in the US ($55 billion) [28], the cost of multidrug resistance
in the European Union (EU) (€1.5 billion) [29], and the cost of global resistance over a 35-year period
(US$2.8 trillion annually) [5]. This method assumes that antibiotic prescribing is the main cause
of resistance, but whilst more robust estimates are required, it is widely acknowledged that this would
require complex modelling methods [15]. Robust estimates of other long-term health conditions, such
as increased risk of Clostridioides difficile infection, also require consideration. Indirect costs are also
often difficult to estimate, as they may bias against people who are not in employment and may
fluctuate over time.
A further challenge is that both direct and indirect costs may be attributable to different systems
and payers at different time points. For example, even when restricting analysis to direct health service
costs, the initial outlay for point of care C-reactive protein testing to avoid unnecessary antibiotic
prescribing may be borne by a local health service provider; however, the longer-term cost savings are
likely to be at a secondary level. Data collection should not be restricted to a single source, such as
primary care databases, but should utilise appropriate methods (e.g., self-report, hospital episode data)
to collect comprehensive data reflective of all costs incurred [14].
2.4. Time Preference
An individual’s time preference represents the extent to which they are willing to trade between
short-term costs and/or benefits and long-term costs and/or benefits, attributable with a health-related
behaviour, such as the consumption of antimicrobials. The time preference rate (discount rate)
quantifies the difference between the perceived value of future outcomes relative to more immediate
ones. Individuals with lower time preference rates have a higher value for future utility and therefore
discount the future less; and conversely, individuals with higher time preference rates have a lower
value for future utility and so require greater future reward for their behaviour. Time preference
rates for health are typically between 3–6% per annum [30]. In the UK a consistent societal discount
rate of 3.5% per annum is applied as recommended in guidance issued by HM Treasury on how
to appraise policies, programs, and projects [31]. Variation in the choice of discount rate has a marked
effect on studies with long time horizons and is therefore an important consideration for evaluations
of strategies aimed to contain resistance—an issue defined by long-term impacts. Given the future
value of antibiotics, a lower (zero or perhaps even negative in some circumstances) discount rate may
be more relevant for health outcomes [32]. This issue also applies to vaccination, where differential
discounting in model-based cost-effectiveness evaluations is being explored [33]. Empirical evidence
on time preference rates can be estimated using stated preference techniques that rely on hypothetical
scenarios [34]. Participants are typically required to imagine a health state and choose between future
outcomes related to that hypothetical health state; this method would generate empirical evidence on
individuals time preferences to inform future economic evaluations. A further challenge that will need
to be addressed is that in the context of antimicrobial resistance, the future health state to be valued is
not that of the respondent but is more likely to be the future health of others. Sensitive analysis using
a range of discount rates is recommended.
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3. Conclusions
Ascertaining the most clinically and cost-effective interventions and services to reduce
antimicrobial resistance will require a multifaceted approach, from incentivizing pharmaceutical
companies to co-production of patient-centred acceptable interventions that maximise the utility of both
patients and society. Economic evidence is central to understanding the value of competing strategies
to lessen the probability of resistance development, although the application of such methods poses
several methodological challenges. When assessment and interpreting the results of existing economic
evaluations of health care interventions in the context of antimicrobial resistance, careful consideration
is required, of the perspective, costs, and externality effects (impacts on other patients) of future
reductions in antimicrobial effectiveness. We have presented just some of the challenges of accurately
estimating the cost-effectiveness of interventions to tackle antimicrobial resistance. Further research is
required to capture the effects of antimicrobial resistance in economic evaluations to reflect the value
of preserving effective medicines for future use. This requires appropriate consideration of the wider
externalities and methodological approaches which differ from standard “reference” case of NICE and
other HTA organizations.
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